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Abstract 
Background: The Kingdom of Saudi Arabia faces one of the highest 
prevalence rates of type 2 diabetes mellitus (T2DM) in the world. However, 
there are no credible local data on the trends and future projections of the 
disease, and the relevant international studies underestimated the true 
prevalence rates. This thesis used epidemiological modelling to study the trends 
in T2DM prevalence in Saudi Arabia, predicted its future levels, and quantified 
the impact of reducing some risk factors on the disease prevalence trends. 
Methods: This thesis developed and validated the “Saudi IMPACT Diabetes 
Forecast Model”, which integrates data on the population, obesity and smoking 
prevalence trends in Saudis aged ≥25 years to estimate the trends in T2DM 
prevalence (1992-2022) using a Markov modelling approach. The model 
considers different reasonable scenarios of future trends in obesity prevalence, 
and incorporates a number of parameters to model the disease epidemiology. 
These parameters include the estimated diabetes incidence, case-fatality, total 
mortality, relative risk of diabetes if obese, and relative risk of diabetes if a 
smoker. The model data inputs and parameters were obtained from different 
sources, including local departments, medical literature and assumptions. The 
model results were validated against local data from the STEPwise survey in 
2005, and against the model of the Global Burden of Disease study, where the 
model produced reasonably close results to both of these studies. 
Results: The prevalence of T2DM among the Saudi population aged ≥25 years 
was estimated to rise substantially during the 30-year period of 1992-2022 from 
8.5% to 39.5%, assuming some levelling off of obesity trends (capping), or to 
44.1%, assuming uncapped increasing obesity trends. In men, T2DM 
prevalence was estimated to increase from 8.7% to 39.2% with capped obesity 
trends, or to 41.3% with continuing linear increase in obesity trends. In women, 
T2DM prevalence was estimated to increase from 8.2% to 39.8% with capping 
of obesity trends, or to 47.7% without such a capping. The model showed that if 
the trends in obesity start to decline by 10% in 12 years (2010-2022), a relative 
reduction of 13% in diabetes prevalence could be achieved. If the prevalence of 
obesity was halted at the 2010 levels, a 10% relative reduction in diabetes 
prevalence could be attained by 2022. 
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Conclusion: T2DM is currently a major public health challenge in Saudi Arabia, 
and this thesis predicted that its burden will increase substantially in the next 
decade. Intensive and aggressive preventive measures directed to reduce the 
levels of risk factors, particularly obesity and smoking, can result in reasonable 
reduction of the disease prevalence, and therefore should be an urgent action. 
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Chapter 1. Introduction 
1.1. Background 
Diabetes mellitus (DM) as a disease was first recognised around 3000 years 
ago by the ancient Egyptians and Indians who described some clinical features 
very similar to what is now known as DM. The Greek word “diabetes” means “a 
siphon” referring to excessive urination, while the word “mellitus” means “honey 
sweet” referring to a sweet taste of urine. In 1776, excess sugar in blood and 
urine was first confirmed in Great Britain.1, 2  
With passage of time, an extensive understanding of DM aetiology and 
pathogenesis has been achieved. Currently, DM is defined as “a group of 
metabolic diseases characterised by hyperglycaemia resulting from defects in 
insulin secretion, insulin action or both. The chronic hyperglycaemia is 
associated with disturbances in carbohydrate, fat, and protein metabolism and 
can lead to long-term damage, dysfunction and failure of various organs, 
especially the eyes, kidney, nerves, heart and blood vessels”.3 
DM is classified into four major types based on aetiology and clinical picture: 
type 1 DM, type 2 DM (T2DM), gestational DM, and other specific types. Type 1 
DM usually results from absolute insulin deficiency and is caused by destruction 
of β cells in the pancreas mostly due to a cellular mediated autoimmune 
process. T2DM is characterised by insulin resistance and relative insulin 
deficiency. Gestational DM is a glucose intolerance of varying degrees of 
severity which starts or is first recognised during pregnancy. There are also 
many other specific types of DM which can result from specific genetic 
syndromes, surgery, drugs, malnutrition, infections, and other illnesses.4, 5 
T2DM is the most common type of the disease, accounting for around 85-95% 
of all diagnosed cases of DM.4, 6 The diagnosis of T2DM usually occurs after the 
age of 40 years,5 but can occur in younger adults and even children. People 
with T2DM can remain asymptomatic for many years and the diagnosis is often 
made incidentally or when complications occur.5, 7 In contrast to type 1 DM, 
T2DM patients are not dependent on insulin therapy and are not prone to 
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ketosis, but may require insulin for control of their hyperglycaemia if this is not 
achieved with diet alone or with oral hypoglycaemic agents.5, 6 
The aetiology of T2DM is complex, and is known to be multifactorial. T2DM is 
associated with several risk factors which influence the disease occurrence, but 
are not necessarily causal factors. These risk factors can be demographic (e.g. 
age), genetic, or behavioural (e.g. obesity, physical inactivity, diet, smoking).8 
Behavioural risk factors are often known as ‘modifiable risk factors’, as changes 
to these factors have been found to change the disease occurrence in high-risk 
individuals.8 
T2DM is now one of the most common non-communicable diseases (NCDs) 
globally, and its levels are progressively increasing. It has been estimated that 
around 366 million people worldwide, or 8.3% in the age group 20-79 years had 
T2DM in 2011.9 This number has been projected to rise to 552 million (9.9%) by 
2030.9 The disease is associated with severe complications which affect health 
and productivity. More than 50% of people with diabetes die of cardiovascular 
disease (primarily heart disease and stroke). T2DM is the single most common 
cause of end stage renal disease which requires either dialysis or kidney 
transplantation.6 People with T2DM carry a risk of lower limb amputation that 
may be more than 25 times greater than that seen in those without the disease. 
T2DM is also a major cause of adult blindness due to retinal damage.6 The 
disease (in 2011) caused around 4.6 million deaths in the 20-79 age group, and 
at least US$ 465 billion in healthcare expenditures, which was equivalent to 
11% of total healthcare expenditures in adults.10 
1.2. What is this thesis about? 
This thesis used ‘epidemiological modelling’ as a tool to examine the trends in 
prevalence of T2DM in the Kingdom of Saudi Arabia during the 30-year period 
of 1992-2022. The thesis developed the ‘Saudi IMPACT Diabetes Forecast 
Model’ which integrates information on trends in the structure of the Saudi 
population with trends in the prevalence of two risk factors for T2DM: obesity 
and smoking. Also, this thesis estimated the impact of reducing the levels of 
obesity and smoking in Saudi Arabia on the future projections of T2DM 
prevalence. 
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1.3. Why is this thesis important?  
It is now well recognised that it is the low and middle income countries that face 
the greatest burden of T2DM.11 This has been attributed mainly to the rapid and 
progressive urbanisation and socioeconomic development in these countries, 
which has resulted in great changes in the lifestyle of their populations toward 
sedentary life and consuming ‘Westernised’ diets.11 Among all low and middle 
income countries, the World Health Organisation (WHO)’s Eastern 
Mediterranean Region (EMR) has been recognised as a major hot-spot for 
T2DM, where the estimates and projections of its burden exceed those of other 
world regions. The International Diabetes Federation (IDF) has ranked the 
region of Middle East and North Africa (MENA), which comprises the largest 
part of EMR, to have the highest global prevalence of diabetes in 2011 (12.5%) 
and 2030 (14.3%).9 However, the health care systems in these countries are 
generally not yet ready to deal with such an increasingly worrisome health 
problem. Public health planners and decision makers in these countries need to 
be more aware of the current high burden posed by T2DM and its complications 
and, crucially, prepare for its most likely increase during the coming decades.10, 
12  
The Kingdom of Saudi Arabia is one of the largest and richest countries in the 
EMR. It has witnessed substantial socioeconomic development in recent 
decades, as it is a leading oil-producing country. The levels of T2DM in Saudi 
Arabia have been estimated to be among the highest in the world. The IDF has 
ranked Saudi Arabia to be among the top 10 countries globally with the highest 
projected prevalence of diabetes in 2011 (19.6%) and 2030 (22.3%).9 
Furthermore, the prevalence of some risk factors for T2DM in Saudi Arabia (e.g. 
obesity) has also been estimated to be among the highest globally.13 Although 
there are currently efforts undertaken by the Saudi Ministry of Health (MOH) 
toward creating T2DM prevention strategies, it appears that these strategies 
require further developments and more aggressive implementation. The lack of 
a structured national risk factors and morbidity surveillance systems in the 
Kingdom makes understanding past trends and making future projections of the 
diabetes burden a very urgent and difficult task. 
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Nevertheless, there are some studies that provided useful estimates and 
projections of the prevalence of T2DM in Saudi Arabia.9, 14-17 These studies 
based their estimates and projections solely on the demographic changes 
(urbanisation and ageing), and did not directly take into account major 
determinants of T2DM, such as obesity. Therefore, it is most likely that such 
studies underestimated the actual trends and future projections of T2DM 
prevalence in Saudi Arabia, and their estimates have been well surpassed by 
the ‘observed’ data from national surveys.18, 19 On the other hand, there is only 
one international study20 that attempted to incorporate the trends in body mass 
index (BMI) to inform the estimates of T2DM in Saudi Arabia. However, that 
study only provided estimates to 2008, with no future projections. Furthermore, 
all these available studies did not provide ‘what if’ policy analyses to examine 
the likely impact of reducing the levels of some risk factors on the disease future 
projections (which is an essential feature in order to engage with policy 
makers). 
Thus, this thesis uses ‘epidemiological modelling’ as a logical analytical 
framework to make inferences about past trends and future projections in T2DM 
prevalence in Saudi Arabia. These inferences are based primarily on integrating 
demographic trends, as well as the trends in two risk factors for T2DM (obesity 
and smoking). In addition, this thesis uses this framework to explore health care 
policy strategies to reduce T2DM prevalence, by providing different ‘what if’ 
analyses to estimate the likely impact of reducing obesity and smoking on the 
T2DM prevalence projections in Saudi Arabia. 
1.4. Why does this thesis use modelling? 
Modelling is being increasingly used in the fields of epidemiology and public 
health. Models are used mainly to guide policy decisions in many areas that 
affect human life and health. Since models combine data from various local 
sources with trial based effectiveness evidence, they can form a helpful tool for 
decision making process.21 Models permit policy makers to examine and 
compare between various future policy options and intervention scenarios within 
a population; hence they provide a helpful tool for appropriate planning and 
resource allocation.22, 23  
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There is a large number of published diabetes modelling studies.24-29 Most of 
these models have been related to the ‘clinical’ and ‘health economics’ aspects 
of T2DM (e.g. modelling the disease clinical progression and complications, 
modelling the health care costs of diabetes, and modelling the cost-
effectiveness of some drug treatments and interventions).24, 25 These modelling 
studies have utilised a large variety of data on the disease complications and 
health care costs from several developed countries.26, 27 There are fewer 
published diabetes models that attempted to study the trends in the prevalence 
of T2DM and forecast its future burden in specific populations.30-32 However, 
most of these models are proprietary, and all of them have been used in 
developed countries and require different types of data inputs that might not be 
available in less developed settings. 
Recently, the IMPACT Diabetes Forecast Modelling methodology was originally 
developed for use in settings with limited data, and was initially piloted in four 
developing countries of the EMR (Tunisia, Syria, Turkey, and Palestinian 
areas).33 An appealing aspect of the methodology is its focus on validation of 
the model exploring recent past trends in diabetes; a feature not often explored 
in other modelling approaches.33 This important aspect helps in creating models 
that are relevant to specific populations, each one with different demographic 
and epidemiologic characteristics. Therefore, a “Saudi version” of the IMPACT 
Diabetes Forecast Model has been created (with assistance of my supervisor; 
Dr Martin O’Flaherty, University of Liverpool) specifically for this thesis. The 
model integrates data on trends in population structure, obesity prevalence and 
smoking prevalence in order to estimate the trends in T2DM prevalence and 
predict the likely future levels of the disease in Saudi Arabia. 
In this thesis, a number of substantial improvements/ developments were 
undertaken to the original IMPACT model. First, the section of “sensitivity 
analyses” was significantly developed to involve further rigorous types of 
analyses. In the original IMPACT model, the uncertainties around the modelling 
parameters were examined by applying only the ‘analysis of extremes’ method 
(discussed in detail in chapter 4) to produce uncertainty intervals. In 
comparison, the Saudi IMPACT Diabetes Forecast Model used, in addition, the 
method of ‘scenario analysis’ to explore uncertainty in the future trends of key 
model inputs. So, all the model results were presented in different scenarios 
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and with uncertainty intervals. Second, the section of ‘what if policy analyses’ in 
the original IMPACT model was extensively developed and expanded in this 
thesis. In the original IMPACT model, there were only two policy reduction 
targets (one for obesity prevalence and another for smoking prevalence), and 
both of them were ‘theoretical’ targets. On the other hand, the Saudi IMPACT 
Diabetes Forecast Model used local policy targets, in addition to other 
international targets set by leading authorities. Hence, several policy scenarios/ 
options were analysed in this thesis, which should offer more comprehensive 
and ‘realistic’ intervention options for policy makers. The approach which I 
created and used in my thesis for the ‘what if’ policy analyses is currently being 
considered as a framework for use in the four EMR countries, in which the 
original IMPACT model is being used (personal communication, Julia Critchley 
and Martin O’Flaherty, March 2013). Third, the original IMPACT model was 
validated only by comparing its estimates to the observed national data. In 
comparison, this thesis undertook, in addition, a substantially detailed 
‘concurrent validation’ comparing the model estimates to other existing models 
of the same purpose, such as that of the most recent IDF Diabetes Atlas,9 a 
recent Global Burden of Disease (GBD) project,20 and other studies.14-17   
1.5. Why does this thesis use only obesity and smoking as risk factors 
for T2DM? 
As indicated earlier, this thesis used the trends in prevalence of obesity and 
smoking in Saudi Arabia to inform the estimates and future projections of T2DM 
prevalence. However, other important ‘modifiable’ risk factors, such as physical 
inactivity and diet, were not included in this thesis. Reliable nationwide data on 
the prevalence of obesity and smoking in Saudi Arabia at different points in time 
are available19, 34-39, and could be used to estimate the likely trends and future 
projections of these two risk factors. On the contrary, prevalence data on 
physical inactivity and dietary patterns in the Saudi population are scarce, with 
only one published national study19 measuring these two conditions. In general, 
even in more developed countries, the assessment of physical activity and 
dietary patterns in population studies is difficult, as there are variations in the 
methods of measurement of these two conditions, and most of such methods 
are of highly ‘subjective’ nature.40 
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Nevertheless, this thesis captured well the most important determinant of T2DM 
(i.e. obesity), considering different reasonable scenarios of the future obesity 
trends in Saudi Arabia, and the model was validated against both local data and 
other models. 
1.6. The overall aim of this thesis 
This thesis aims to support the Saudi Ministry of Health by providing robust 
estimates and future projections of T2DM prevalence, and providing quantified 
policy options, likely to be the most effective in reducing the disease burden in 
the Kingdom.  
1.7. Specific objectives 
1. To identify and evaluate the existing local data on prevalence of T2DM, 
obesity and smoking, as well as population and demography in Saudi 
Arabia. 
 
2. To develop and use the Saudi IMPACT Diabetes Forecast Model to estimate 
the trends and likely future projections of T2DM in Saudi Arabia. 
 
3. To conduct extensive sensitivity analyses of the modelling results to 
examine the uncertainties around the model parameters. 
 
4. To validate the Saudi IMPACT Diabetes Forecast Model against local 
observed data, and carry out detailed comparisons of the model estimates 
and projections against previous existing modelling studies.  
 
5. To conduct a series of ‘what if’ analyses to quantify the estimated reduction 
in the projected T2DM prevalence, that can be attributed to specific targeted 
reductions in the prevalence of obesity and smoking in the Kingdom. 
 
6. To make recommendations regarding the appropriate preventive 
interventions for Saudi Arabia in order to reduce the prevalence of T2DM. 
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1.8. Overview of the chapters 
This thesis contains 10 chapters, including this introduction chapter (chapter 1). 
Chapter 2 summarises the criteria used to diagnose T2DM, and provides 
definitions of the relevant terms. It also presents a detailed discussion of the 
several risk factors associated with T2DM. Also, it discusses the available 
evidence regarding the role of ‘modifying’ the two risk factors studied in this 
thesis (obesity and smoking) in the prevention of T2DM. 
Chapter 3 presents a literature review regarding the size of the problem of 
T2DM in different settings. Firstly, the chapter starts with presenting the 
different global estimates and projections of T2DM in the total world population. 
Secondly, it discusses the disease prevalence estimates in the developing 
countries, with a particular focus on the EMR. Thirdly, the chapter also presents 
a comprehensive review of the national prevalence studies of T2DM, obesity 
and smoking in the countries of Gulf Cooperation Council (GCC), which are 
neighbouring to Saudi Arabia and share similar social, cultural and economic 
characteristics. Finally, chapter 3 ends with an extensive discussion of the 
Saudi context, in terms of demography, health care system, levels of NCDs, 
diabetes care, and the national studies on the prevalence of T2DM, obesity and 
smoking.  
Chapter 4 offers a theoretical discussion on modelling in terms of definition, 
uses, types, structure, and limitations. This chapter also discusses the steps 
involved in developing a model, and the existing diabetes models in the 
literature. 
Chapter 5 provides an extensive description and discussion of the model 
developed for this thesis (the Saudi IMPACT Diabetes Forecast Model), data 
inputs used to construct the model, data sources with their strengths and 
limitations, assumptions, and methods of estimating and projecting T2DM 
prevalence in Saudi Arabia. 
Chapter 6 presents the past and current trends in T2DM prevalence in Saudi 
Arabia (for the period 1992-2013), as estimated by the Saudi IMPACT Diabetes 
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Forecast Model. All results are presented with uncertainty intervals and in 
different modelling scenarios as methods of extensive sensitivity analyses. 
Chapter 7 presents the future projections of T2DM prevalence in Saudi Arabia 
(for the period 2014-2022), as estimated by the Saudi IMPACT Diabetes 
Forecast Model. Again, all results are presented with uncertainty intervals and 
in different modelling scenarios as methods of extensive sensitivity analyses. 
Chapter 8 discusses the available local and international policy targets to 
reduce the prevalence of adult obesity and smoking. Also, this chapter presents 
the likely impact of applying such targets on the future projections of T2DM 
prevalence in Saudi Arabia, as predicted by the model. 
Chapter 9 provides detailed comparisons of the results of the Saudi IMPACT 
Diabetes Forecast Model against previous modelling studies of diabetes 
prevalence estimates for Saudi Arabia. 
Chapter 10 presents the overall discussion and conclusions. It presents a 
summary of the main findings, strengths and limitations of the thesis, 
implications of the results, recommendations for policy action and further 
research, and conclusion. 
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Chapter 2. Type 2 diabetes: diagnosis and risk factors 
In this chapter, two main topics are discussed: a) the criteria used to diagnose 
T2DM with defining some relevant terms, and b) the risk factors associated with 
the occurrence of T2DM, and the role of modifying the two risk factors studied in 
this thesis (obesity and smoking) in prevention of the disease. 
2.1. Diagnosis of type 2 diabetes (brief overview) 
Diagnosis of T2DM requires an appropriate and uniform system of classification 
to identify and differentiate the various forms and stages of glucose 
abnormalities. Such a classification is a major requirement for epidemiological 
and clinical research as well as for the clinical management of the disease.3 
However, the knowledge regarding diabetes aetiology and pathogenesis is still 
growing progressively. As a result, the criteria used to diagnose/ define T2DM 
have been repeatedly revised by leading organisations, such as the WHO and 
the American Diabetes Association (ADA), as more information relevant to the 
diagnosis has become available.3   
2.1.1. Relevant definitions 
2.1.1.1 Oral Glucose Tolerance Test (OGTT)  
OGTT refers to the measurement of blood glucose values while fasting and at 
two hours (2 h) after a 75-grams oral glucose load. For children, the oral 
glucose load is related to body weight (1.75 g/kg).6 
2.1.1.2. Impaired Glucose Tolerance (IGT) and Impaired Fasting Glucose (IFG) 
Both of these terms refer to a metabolic stage intermediate between normal 
glucose homeostasis and diabetes. This metabolic stage is often referred to as 
pre-diabetes or intermediate hyperglycaemia.3 IGT and IFG are not clinical 
entities, but rather risk factors for future diabetes and adverse outcomes.41 IGT 
is associated with muscle insulin resistance and defective insulin secretion, 
while IFG is associated with impaired insulin secretion and impaired 
suppression of hepatic glucose output.42 
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2.1.2. Diagnostic criteria 
Table  2.1 summarises the different criteria used at different time points to 
diagnose diabetes. In 1965, the WHO first published criteria for the diagnosis 
and classification of diabetes. These criteria were based on specific defined 
values for fasting blood glucose and/or OGTT, and were revised several times 
by the WHO, in 1980, 1985 and 1999.41 
In 1997, the ADA revised the available diagnostic criteria. While the threshold of 
OGTT remained unchanged (11.1 mmol/l), the ADA recommended lowering the 
threshold of fasting glucose for diagnosis of diabetes from 7.8 mmol/l (140 
mg/dl) to 7.0 mmol/l (126 mg/dl) (Table  2.1).3 Moreover, the ADA recommended 
that for epidemiological studies, estimates of diabetes prevalence and incidence 
should be based only on fasting plasma glucose (FPG) of ≥126 mg/dl. This 
recommendation was justified by the interest of standardisation and facilitating 
the field work, particularly where the OGTT may be difficult to perform and 
where the cost and demands on participants' time may be excessive.3 In 1999, 
the WHO accepted the ADA’s recommendations of using the revised threshold 
of fasting glucose to diagnose diabetes and using such a threshold alone for 
epidemiological purposes.41  
The use of OGTT for clinical purposes is an issue of continuing debate. 
Although the ADA acknowledges the OGTT as a valid method to diagnose 
diabetes, the use of the test in clinical practice is discouraged in favour of FPG. 
This is due to inconvenience, greater cost and less reproducibility. On the other 
hand, the WHO recommends that OGTT should be retained as a diagnostic test 
for diabetes in clinical practice because it has been found by various studies 
that FPG alone fails to diagnose approximately 30% of undiagnosed diabetes 
cases.41 In addition, OGTT is the only means of identifying people with IGT. 
Thus, the WHO recommended that OGTT should be used in individuals with an 
FPG of 6.1–6.9 mmol/l (110–125 mg/dl) to determine glucose tolerance status.41 
More recently, a WHO consultation report (published in 2011) recommended 
that glycated haemoglobin (HbA1c) can be used as a diagnostic test for 
diabetes.43 Normally, A certain amount of haemoglobin is glycated (to form 
HbA1c) as a result of exposure to plasma glucose. As the average amount of 
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plasma glucose increases, the fraction of HbA1c also increases, so that it serves 
as a marker for average blood glucose levels over the previous period (8-12 
weeks) prior to the measurement.43 HbA1c was introduced into clinical practice 
in the 1980s, and recently, there has been substantial interest in using it as a 
diagnostic test for diabetes and as a screening test for persons at high risk of 
the disease.43  
The recent WHO consultation report has recommended HbA1c as a diagnostic 
test “providing that stringent quality assurance tests are in place and assays are 
standardised to criteria aligned to the international reference values, and there 
are no conditions present which preclude its accurate measurement. An HbA1c 
of 6.5% is recommended as the cut point for diagnosing diabetes. A value of 
less than 6.5% does not exclude diabetes diagnosed using glucose tests”.43 
This report recommended that the previous 1999 diagnostic criteria should not 
be changed. In addition, “the diagnosis of diabetes in an asymptomatic person 
should not be made on the basis of a single abnormal plasma glucose or HbA1c 
value. At least one additional HbA1c or plasma glucose test result with a value 
in the diabetic range is required, either fasting or from the OGTT”.43 
In some laboratories, the precision of HbA1c measurement is similar to that of 
plasma glucose. In addition, evidence reviewed by the WHO consultation 
suggests that HbA1c gives equal or almost equal sensitivity and specificity to a 
fasting or OGTT measurement as a predictor of prevalent microvascular 
complications of diabetes (e.g. retinopathy).43 Furthermore, compared to 
plasma glucose and OGTT, HbA1c is more convenient, performed at any time of 
the day, does not require any special preparation such as fasting, and has no 
day-to-day variability in glucose. These advantages have made HbA1c a 
preferred test for diagnosing diabetes and for assessing glycaemic control in 
diabetic individuals in some countries. Also, these properties have implications 
for early identification and treatment which have been strongly advocated in 
recent years.43  
However, HbA1c has some limitations. First, the cost of the test is much higher 
than measuring plasma glucose. Second, there are many genetic, haematologic 
and other factors that influence the measurement of HbA1c. For instance, some 
genetic haemoglobinopathies, in addition to iron and vitamin B12 deficiency 
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may increase or decrease HbA1c levels. Third, for many countries, the test is 
unavailable, the HbA1c assay is not currently well enough standardised, or there 
are high prevalences of conditions such as haemoglobinopathies, which affect 
HbA1c measurement.43 Therefore, the WHO consultation has indicated that 
these limitations make it difficult to recommend using HbA1c as a diagnostic test 
universally at this time. It has been concluded that the choice of diabetes 
diagnostic method will depend on local considerations such as cost, availability 
of equipment, population characteristics, presence of a national quality 
assurance system, etc.43  
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Table  2.1. The WHO and ADA diagnostic criteria for diabetes and intermediate hyperglycaemia at different points in time41, 43 
 
 WHO 1965 WHO 1980 WHO 1985 ADA 1997 WHO 1999 WHO 2011 
Normal       
Fasting glucose Not specified 
 
Not defined Not defined --- < 6.1 mmol/l The WHO 1999 
criteria retained 
 
 
(HbA1c) can be 
used as a 
diagnostic test for 
diabetes with a 
recommended 
value of 6.5% as 
the cut point for 
diagnosing 
diabetes 
2 h glucose < 6.1 mmol/l   --- Not specified but <7.8 
mmol/l implied 
Diabetes      
Fasting glucose Not specified ≥ 8.0 mmol/l 
and / or 
≥ 7.8 mmol/l 
or 
≥ 7.0 mmol/l 
or 
≥ 7.0 mmol/l 
or 
2 h glucose ≥ 7.2 mmol/l ≥ 11.0 mmol/l ≥ 11.1 mmol/l 
 
≥ 11.1 mmol/l ≥ 11.1 mmol/l 
   or 
Random blood glucose: 
Plasma (venous)≥11.1 mmol/l 
Plasma (capillary) ≥12.2 mmol/l 
Whole blood (venous) ≥10.0 
;(capillary) ≥11.1 mmol/l  
  
IGT      
Fasting glucose  < 8.0 mmol/l 
and 
<7.8 mmol/l 
and 
Not required < 7.0 mmol/l 
and 
2 h glucose 6.1 – 7.1 mmol/l ≥ 8.0 and  
< 11.0 mmol/l 
≥ 7.8 and 
< 11.1 mmol/l 
≥ 7.8 and 
< 11.1 mmol/l 
≥ 7.8 and 
< 11.1 mmol/l 
IFG      
Fasting glucose Not defined Not defined Not defined 5.6  to  6.9 mmol/l ≥ 6.1 and  
<7.0 mmol/l 
and 
2 h glucose    Measurement not 
recommended (but if 
measured should be < 
11.1 mmol/l) 
< 7.8 mmol/l  
(if measured) 
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It is important to mention that in this chapter and others, a distinction was made 
between “developed” and “developing” countries. This distinction was based on 
the classification of countries by the World Economic Situation and Prospects 
(WESP), United Nations.44 WESP has classified countries as developed 
economies, economies in transition and developing countries, based on a 
combination of different criteria that reflect the living standards, industrial base, 
and other indicators. According to this classification, European countries, US, 
Canada, Japan, Australia, and New Zealand have been classified as developed 
countries, and the remaining countries (including Saudi Arabia) as developing. 
However, for some countries, the dichotomy of developed versus developing 
might be too restrictive to capture the diversity in development outcomes. 
Therefore, WESP and other organisations (e.g. the World Bank) have 
developed an additional classification of the level of development of countries, 
as measured by per capita gross national income (GNI).44 Accordingly, 
countries have been grouped as high-income (GNI per capita >$12,276), upper 
middle income (GNI per capita between $3,976 and $12,275), lower middle 
income (GNI per capita between $1,006 and $3,975) and low-income (GNI per 
capita <$1,005). According to that classification, Saudi Arabia has been 
classified among the high-income countries.44 
In this thesis, for the purpose of simplicity, the first classification of WESP 
(developed and developing countries) is used.  
2.2. Risk factors for type 2 diabetes 
T2DM is a disease with a multifactorial aetiology, and is associated with a 
variety of risk factors which influence the disease occurrence. Modifications of 
some risk factors, particularly behavioural factors (e.g. obesity, physical activity, 
diet, smoking), have been found to change the disease occurrence in high-risk 
individuals.8 However, evaluation of risk factors requires careful attention, since 
the aetiology of T2DM is complex and involves interaction between various risk 
factors. In addition, the disease is heterogeneous in different families and 
populations. 
The following sections summarise the major known risk factors for T2DM.   
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2.2.1. Demographic risk factors 
2.2.1.1. Age 
The incidence and prevalence of T2DM are generally low before age of 30 
years.6, 45-48 It has been well documented that the prevalence of T2DM rapidly 
increases with increasing age in a large number of studies conducted in 
different populations and ethnic groups.5, 49-54 However, this increase in T2DM 
levels by age has been noticed to vary between ethnic strata of a population. 
For example, in the United States (US), prevalence of diabetes in Pima Indians 
aged 25-29 years (13%) is as high as that for non-Hispanic whites aged 60-64 
years.8 Ethnicity, as a risk factor, is discussed in detail in section 2.2.1.3. 
Increasing global life expectancy, which has resulted in ageing populations, has 
been suggested as one of the most important reasons for the epidemic levels of 
T2DM in the world.5, 55 This might be more evident in developing countries 
during the last few decades. These countries have witnessed ‘demographic 
transition’56, which has taken place due to several factors. First, there has been 
a massive reduction in infant and childhood mortality due to infectious diseases, 
which has been achieved through many effective control programmes of 
communicable diseases (e.g. vaccination) that have allowed for survival during 
the early years of childhood and adolescence. Second, the extensive 
improvements in sanitation and drinking water supplies have resulted in marked 
decrease in death at all ages. Third, the socioeconomic advances in developing 
countries have led to considerable progress in health care, including preventive 
and curative services. Consequently, life expectancy has increased in most 
developing countries and placed larger proportions of population in the ≥60-year 
age group, in which chronic degenerative diseases (e.g. T2DM) become the 
major determinants of health status.56  
King et al.16 and Wild et al.15 reported marked differences in the age structure of 
the diabetic populations of developed and developing countries. For developed 
countries, the largest number of people with diabetes was in the age group of 
≥65 years in 1995 and 2000, and this age group was estimated to experience 
the greatest increase in number of cases by the year 2025 and 2030. On the 
other hand, for the developing countries, the age group of 45-64 years 
contained the largest number of people with diabetes in 1995 and 2000, and 
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this tendency is predicted to be further accentuated by the year 2025 and 2030 
(Figure  2.1).15 These differences in prevalence by age structure might be 
explained by the shorter life expectancy of individuals with diabetes in 
developing countries.16 In addition, the disease incidence has been noticed to 
be higher at younger ages in developing compared to developed countries.57 
Moreover, ethnicity might be another explanation of these differences in age of 
onset of the disease across populations as discussed in section 2.2.1.3. 
It has been suggested that people tend to exercise less, lose muscle mass and 
gain weight as they age.58 As a result, they are likely to have concomitant 
increases in insulin resistance related to obesity and physical inactivity.58 Then, 
as time passes, β-cells in the pancreas fatigue from the increased insulin 
secretion needed to compensate for increasing levels of insulin resistance. 
However, the onset of diabetes at younger ages in many developing (e.g. 
Asian) countries may be attributed to an earlier decline in metabolic 
homeostasis and/or a shorter latency to the development of diabetes.58 
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Figure  2.1. Estimated number of adults with diabetes by age group and year for the developed and 
developing countries and for the world (Wild et al.15) 
2.2.1.2. Sex 
There is now good evidence on sex differences in susceptibility to a number of 
adverse health outcomes, particularly autoimmune disorders, such as 
rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis.59 
However, there is no similar considerable evidence on sex differences in 
diabetes. This lack of evidence has been based mainly on the observation that 
the overall sex balance in diabetes is almost equal.  
Gale and Gillespie60 carried out a comprehensive review of more than 100 
studies on sex differences in diabetes. They have pointed out a pronounced 
excess of T2DM in women in the first half of the 20th century, but the disease 
has now an almost equal prevalence in both sexes, although there is still some 
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little excess in women. However, men seem more susceptible than women to 
the consequences of obesity and physical inactivity, which has been attributed 
to possible differences in insulin sensitivity and regional deposition of fat.60  
An example of old studies, included in the review by Gale and Gillespie,60 is the 
United States National Health Survey in 1935-1936.61 In that study, the sample 
was 2.5 million people from 83 cities, and it was found that prevalence of T2DM 
was higher by 20% in women than men of the age group 25-34 years. This 
excess in women increased by 60% for the age group 35-44 years and almost 
by 100% in the age group of 45-64 years.  
King et al.16 suggested that the likely explanation for such a ‘female bias’  in 
developed countries is the greater longevity of women than men. However, as 
mentioned earlier, diabetes in developing countries is more common in the 
middle-aged individuals than elderly, which makes the previous explanation less 
likely. In this case, it has been suggested that differential distribution of risk 
factors (especially diet, physical inactivity, and central obesity) in men and 
women may explain such sex differences.16 This explanation is supported by 
results of several studies from developing countries. For instance, the Turkish 
Diabetes Epidemiology Study (TURDEP)62 showed that the adult Turkish 
women have a significantly higher BMI (mean 27.45 ± 5.76 kg/m2) than men 
(mean 25.47 ± 4.58 kg/m2). Prevalence of diabetes was also significantly higher 
in women (8%) compared to men (6.2%). Authors suggested that ‘lack of 
employment outside the home’ might contribute to the higher prevalence of 
obesity in Turkish women. According to that study, physical activity of women in 
Turkey, like most of countries in the EMR, is confined to house-work and they 
have no tradition for sporting activities due to social and cultural restrictions.  
Some data currently showed that the male/female ratio started to increase 
considerably by the second half of the last century.60 For instance, in the United 
Kingdom (UK), the ratio in the age group of 35-49 years increased from 0.65 
during 1945-1949 to 1.78 during 1960-1963.60, 63 Moreover, although African 
Americans showed a clear female excess in diabetes prevalence over the 
period 1963-1985, the prevalence in black males increased more rapidly 
relative to their female counterparts over the same period.60, 64 More recently, 
the estimates of IDF for both 2011 and 2030 showed little sex difference in the 
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predicted number of people with diabetes. For 2011, it has been estimated that 
there were about four million more men than women with diabetes (185 million 
men versus 181 million women). However, this difference is expected to 
decrease to two million (277 million men versus 275 million women) by 2030.10 
2.2.1.3. Ethnicity 
As mentioned earlier in chapter 1, modernisation and adopting ‘western’ 
lifestyles have been suggested to be the major reasons for the epidemic levels 
of T2DM in the world, particularly in developing countries. Such lifestyles are 
associated with low physical activity, consuming high-caloric foods and 
increasing levels of obesity. This has been supported by many studies that 
compared the prevalence of T2DM in ethnic groups living in different 
environments/societies. For example, in South Korea, the prevalence of T2DM 
in rural and small town areas was 2% and 4% respectively, compared with 13% 
and 16% found in Seoul.65 In addition, African Americans have a prevalence of 
diabetes (12%) at least 12 times higher than that observed in Native African 
Black people (1%).65 Furthermore, Schulz et al. reported a substantially higher 
prevalence of T2DM among Pima Indians living in Arizona (38%), compared to 
those living in a ‘primitive’ rural mountain region in Mexico (6.9%) although they 
were genetically related.66  
Nevertheless, a large number of studies in multi-ethnic populations revealed 
that some ethnic groups have a higher prevalence of T2DM than other 
ethnicities living in the same environment and sharing similar lifestyles and 
dietary habits.65 These observations suggest that some ethnic groups have a 
higher predisposition/ susceptibility to develop T2DM compared with others, 
when exposed to similar adverse environmental conditions.65 In the US, for 
example, T2DM is approximately twice as common in blacks and Hispanics as 
in non-Hispanic whites.8 Another study reported a high prevalence of diabetes 
(20.1% in males and 15.5% in females) and IGT (29.7% in males and 16.8% in 
females) among the minority of Arab Americans.67 According to the authors, 
these rates were considerably higher than those reported for the white, African-
American, and Hispanic populations in the US and for rural Arab populations. 
However, they are consistent with rates reported in urban Arab populations.67 In 
South Africa, Indian immigrants were found to have higher prevalence of DM 
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(7.6% in males and 13.5% in females) and IGT (7.1% in males and 4.8% in 
females) than the original native population.68 In Singapore, DM prevalence was 
higher among citizens of Indian origin (13.3% in males and 12.3% in females) 
than their counterparts of Chinese (8.5% in males and 7.7% in females) and 
Malay origins (8.6% in males and 10.1% in females).69 
However, the previous studies did not adjust their results for some important 
potential confounders such as age, sex, obesity, etc. So, although they were 
carried out among ethnic groups within the same environments, the differences 
in diabetes prevalence can still be explained by variations in prevalence of 
obesity and other behavioural risk factors among these ethnicities.8 On the 
other hand, there are several studies that undertook adjustments for known 
demographic and behavioural risk factors, and still found a significant part of 
ethnic differences unexplained.70, 71 For instance, Haffner et al. determined 
prospectively the eight-year incidence of T2DM in 617 Mexican Americans and 
306 non-Hispanic whites. Results of this study showed that 40 Mexican 
Americans (6.5%) and 6 non-Hispanic whites (2%) developed T2DM. The age-
adjusted ethnic odds ratio (OR) [Mexican Americans/non-Hispanic whites] for 
diabetes incidence was 8.13 in men (95% confidence interval (CI): 1.10–59.9) 
and 3.62 in women (95% CI: 1.37–9.55). The authors adjusted for age, sex, 
ethnicity, BMI, and level of educational attainment with multiple logistic 
regression analyses. Again, it was found that Mexican Americans continued to 
show a statistically significant increase in diabetes incidence (OR: 2.72; 95% CI: 
1.02–7.28).70 These findings were supported by Marshall et al. who conducted a 
case-control study in Colorado among 279 cases (diabetics) and 488 controls 
(normal glucose tolerance) with almost equal ethnic distribution (183 non-
Hispanic white vs. 157 Hispanic males; and 208 non-Hispanic white vs. 219 
Hispanic females). In this study, Hispanics were found to be twice as likely as 
non-Hispanic whites to have T2DM, after adjusting for age, sex, obesity, family 
history of diabetes, education, and income.71 These observations might indicate 
existence of some genetic (discussed in the next section) or other unknown risk 
factors which differ by ethnicity.8 However, these two studies might be 
constrained by the relatively small sample sizes. 
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2.2.2. Genetic risk factors 
T2DM is a heterogeneous syndrome that appears to be composed of subtypes 
where genetic susceptibility is strongly associated with environmental factors at 
one end of the spectrum, and highly genetic forms at the other end.72 The 
hereditary basis of diabetes has been suspected for more than 2000 years, and 
since the middle of the last century, extensive research has been conducted to 
investigate the genetics of this disorder.73 The evidence of a genetic component 
in the aetiology of T2DM comes primarily from the observations of its familial 
clustering and ethnic differences.74  
Although some monogenic forms of diabetes have been identified such as 
Maturity Onset Diabetes of the Young (MODY), T2DM seems to be a polygenic 
disorder in the majority of cases.72 The disease shows a clear and reproducible 
familial aggregation, with a complex interaction between genetic defects and 
environmental factors such as obesity. Such interaction complicates the task of 
identifying any single genetic susceptibility factor to T2DM.72 
Recently, several twin studies have suggested that T2DM is highly concordant 
among monozygous (MZ) twins (who are genetically identical) and less so 
among dizygous (DZ) twins (who share on average only half their genes).8, 75 In 
their extensive literature review on the risk factors for T2DM, Rewers and 
Hamman8 have reported many twin studies that revealed such a concordance. 
In these studies, the concordance ranged between 34–100% in MZ twins, and 
16–40% in DZ twins.8 However, according to the reviewers, most studies had 
potential ascertainment biases. For example, twins in these studies were found 
because they were diabetics; not because they were twins, i.e. there were no 
systematic surveys of all twins in study areas because ‘twin registers’ were not 
available.76 Twins were referred for investigation from hospitals, other 
collaborated organisations and as self-referral after programmes in radio or 
television. This method of twin ascertainment led to a bias towards discovery of 
concordant as against discordant twin pairs as they had a double chance of 
recognition.76 In the only study which had no ascertainment bias, as indicated 
by the reviewers, concordance rate was the lowest among all reviewed studies 
(34% in MZ twins and 16% in DZ twins).8   
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In addition to the role of twin studies in identifying a possible genetic component 
in T2DM aetiology, there are also many studies of various candidate genes.8 
Candidate genes are those genes selected as having a plausible role in the 
control of glucose homeostasis.72 Reasons for candidacy are numerous: (1) 
known or presumed biological function in glucose homeostasis or energy 
balance in human; (2) gene implicated in subtypes of diabetes, such as MODY; 
(3) gene associated with diabetes or associated traits in animal models; (4) 
gene responsible for an inherited disease which includes diabetes; (5) product 
differentially expressed in diabetic and normal tissues.72 Study of candidate 
genes is the most commonly used approach to tackle the genetic determinants 
of T2DM. However, almost all identified candidate genes have only small effect 
on the polygenic forms of diabetes. No genes with major effects/ associations 
have been identified.8, 72 Possible explanations for failure to identify such genes 
include the possibility that they do not exist. Moreover, it is also possible that 
the incomplete understanding of pathophysiological mechanisms of T2DM (and 
the genes that control them) has misled the choice of candidate genes.72 
Rewers and Hamman8 reviewed more than 40 studies of 13 candidate genes in 
different populations. The majority of these studies have not resulted in positive 
association for candidate genes and T2DM. Although there were some isolated 
positive findings, most of these were not replicated on repeated analysis in 
other or larger populations. Examples of the most commonly studied candidate 
genes are the insulin gene and glucokinase (GCK) gene - (GCK is an enzyme 
that catalyses the formation of glucose-6-phosphate from glucose, and is the 
major rate limiting step in glycolysis).8 Mutations in various regions of candidate 
genes have been reported by some studies. These mutations result in defects 
in glucose homeostasis (e.g. hypoinsulinaemia due to mutations in the insulin 
gene,72 and GCK dysfunction which impairs the process of glycolysis as a result 
of mutations in the GCK gene8).  
In conclusion, it appears unlikely that candidate genes are associated with a 
substantial proportion of T2DM in the general population.8 According to Velho 
and Froguel,72 all the described genetic defects account for not more than a few 
percent of all cases of T2DM. The majority of susceptibility genes to T2DM still 
require investigation and detail description in order to improve the 
understanding of molecular mechanisms that maintain glucose homeostasis 
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and of the precise molecular defects leading to chronic hyperglycaemia. A 
nosological classification of T2DM based on primary pathophysiological 
mechanisms will then be possible. Also, this could lead to the development of 
more specifically targeted anti-diabetic drugs or even gene-based therapies.72  
2.2.3. Behavioural and environmental risk factors 
2.2.3.1. Background 
Historically, the first evidence for an environmental factor in the aetiology of 
T2DM was described by Indians in the sixth century. Three Hindu physicians 
wrote of diabetes: “It is the disease of the rich and one that is brought about by 
the gluttonous overindulgence in oil, flour and sugar”.77 Diabetes and its 
relationship to overnutrition were also described in Chinese medicine in about 
400 BC.77 One thousand years after that date, diet was implicated as an 
important risk factor for T2DM by Thomas Willis.77  
Migration studies and studies of secular trends indicate that a western lifestyle 
is associated with a higher prevalence of T2DM.78 For example, a surge in the 
prevalence of T2DM concomitant to the adoption of a western lifestyle occurred 
when Japanese people emigrated to the US during the second half of the 20th 
century. At the same period, there was a shift from traditional agriculture to a 
modern American lifestyle characterised by lack of physical activity, a western 
diet and high rates of obesity.78 Thus, it was suggested that environmental 
factors played an important role in the aetiology of T2DM and the sharp 
increase in its prevalence among this group, because genetic characteristics of 
populations are unlikely to change in such a short period of time.78  
The role of environmental/ behavioural factors in the aetiology of T2DM may be 
more obvious in populations living in transition. In the past, the disease was 
more prevalent in the industrialised countries, which were far more affluent than 
other countries. Later, when the developing countries started to witness 
progressive and rapid socio-economic developments, the levels of T2DM in 
such countries started to increase dramatically. However, this might be a 
complex issue which requires further investigations. Although early studies in 
the white US and UK populations showed that people with greater affluence, 
education and social standing had a higher risk of diabetes, recent studies 
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showed the highest rates of disease in the most deprived sections of the 
community79 (discussed in section 2.2.3.6). Some researchers now postulate 
that T2DM appears to be a disease of ‘newly’ affluent more than ‘established’ 
affluent populations.80  
Behavioural/ environmental risk factors for T2DM are often known as 
‘modifiable’ risk factors. There is now increasing evidence supporting that some 
lifestyle changes (e.g. weight loss, increased physical activity, dietary 
restrictions) are associated with changes in the occurrence of T2DM.8, 81-83 
Section 2.2.4 discusses in more detail the role of modifying the two risk factors 
studied in this thesis (obesity and smoking) in preventing T2DM.   
In the following sections, the major behavioural/ environmental risk factors for 
T2DM (obesity, physical inactivity, diet, smoking, and socioeconomic status) are 
discussed. 
2.2.3.2. Obesity A. Background and definitions 
Fat, stored in the adipose tissue, forms a normal physiological part of the body, 
and has several functions.84 It acts as storage of energy in periods of lower 
energy intake compared with energy expenditure (negative energy balance) and 
has also a function as a thermal insulator. Furthermore, adipose tissue around 
certain organs protects them against mechanical damage. The amount of body 
fat is extremely variable in different individuals. The physiologically normal 
amount of body fat depends primarily on age and sex. Newborns have 10–15% 
body fat, which increases to 25% during the first year of life. However, body fat 
starts to slowly decrease again to 15% of body weight at the age of 10 years, 
when differences between the sexes become more apparent. During sexual 
maturation, girls experience an increase in their body fat again, up to about 
25%, whereas boys keep about the same body fat. During adulthood, body fat 
increases slowly with age in both men and women.84 
Obesity results when the amount of body fat exceeds normal physiological 
values. The WHO defines obesity as the accumulation of adipose tissue to 
excess and to an extent that impairs both physical and psychosocial health and 
well-being.85, 86 There are various laboratory and imaging techniques that can 
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accurately measure the amount of body fat. For example, the use of computed 
tomography (CT) or magnetic resonance imaging (MRI) allows for three-
dimensional views of body composition, and are used to obtain information on 
body fat distribution.84 However, these methods are expensive and time-
consuming. Hence, they are not suitable for field work, epidemiological studies 
and most clinical work.86 Instead, the WHO recommends the body mass index 
(BMI) as a measure of obesity. BMI is a simple index of weight-for-height and is 
defined as the weight in kilograms divided by the square of the height in metres 
(kg/m2). It is the most widely accepted measure of obesity in populations and in 
clinical practice.86 In adult populations, it has been found that the relationship 
between morbidity/mortality and BMI is U-shaped, and the risk for adverse 
health effects increases beyond a BMI of 25 kg/m2.84 Based on this relationship, 
the WHO recommends its cut-off points for overweight and obesity in adults. 
Overweight in adults is defined as a BMI greater than or equal to 25 kg/m2, 
while obesity is defined as a BMI greater than or equal to 30 kg/m2.87 BMI 
provides the most useful population-level measure of overweight and obesity as 
it is the same for both sexes and for all ages of adults, and has been widely 
used in most studies worldwide.87  
However, BMI should be considered as a rough guide because its reliability is 
prone to some limitations in persons with extremes of age, very muscular builds 
(overestimates obesity), and extreme height.85, 87, 88 In addition, it has been 
found that in some ethnic groups, particularly Asians, the above-mentioned cut-
off values of BMI are not suitable for classification of overweight and obesity. 
The mean or median BMI in Asians is lower than that observed for non-Asian 
populations; so the BMI distribution is shifted to the left. This trend leads to the 
concern that application of the standard WHO’s BMI cut-off points will 
underestimate obesity-related risks in these populations.89 In 2002, the WHO 
has recommended different BMI cut-off points for Asian populations. An expert 
WHO consultation89 indicated that there were three specific factors which led to 
development of new cut-off points in Asians. First, there was increasing 
evidence of the emerging high prevalence of T2DM and increased 
cardiovascular risk factors in parts of Asia where the average BMI is below the 
cut-off point of 25 kg/m2. Second, there was increasing evidence that the 
associations between BMI, percentage of body fat, and body fat distribution 
26 
 
differ across populations. In particular, in some Asian populations a specific BMI 
reflects a higher percentage of body fat than in white or European populations. 
Some Pacific populations also have a lower percentage of body fat at a given 
BMI than do white or European populations. Third, there had been two previous 
attempts to interpret the WHO BMI cut-offs in Asian and Pacific populations, 
which contributed to the growing debates on whether there are possible needs 
for developing different BMI cut-off points for different ethnic groups.89 The 
WHO recommended a BMI cut-off value of 23-27.5 kg/m2 for overweight and 
≥27.5 kg/m2 for obesity in Asians.89  
Another limitation of BMI is that it only estimates the ‘total’ adiposity of the body. 
Thus, it may miss many cases of ‘central / abdominal’ obesity, in which the body 
fat accumulates mainly around the waist. Some studies revealed that central 
obesity is associated with a greater prevalence of metabolic diseases, including 
T2DM and dyslipidaemia.86 The simple clinical measure of central obesity is the 
waist circumference (WC). The WHO recommends a cut-off point of WC ≥102 
cm in men and ≥88 cm in women for definition of central obesity.90 Again, Asian 
populations, particularly people of South Asian origin (Indians, Pakistanis, 
Bangladeshis), seem more prone to carrying excess fat centrally than the White 
populations and show raised obesity-related risk although they may not be 
considered obese by conventional WC criteria. Therefore, the WHO thresholds 
for central obesity in Asians are a WC ≥90 cm in men and ≥80 cm in women.90 
In addition to WC, the waist-to-hip circumference Ratio (WHR) is another 
measure of central obesity. A WHR >1.0 in men and WHR >0.85 in women are 
used as cut-offs for identifying individuals with central obesity. However, WC is 
more commonly used than WHR for measuring the abdominal obesity.90 B. Obesity and type 2 diabetes 
According to the WHO,87 the worldwide obesity has more than doubled since 
1980. In 2008, for example, 1.5 billion adults, aged ≥20 years, were overweight. 
Of these, over 200 million men and nearly 300 million women were obese, 
which means that more than one in ten of the world’s adult population was 
obese in 2008. It has now been estimated that around 65% of the world's 
population live in countries where overweight and obesity are associated with 
more deaths than underweight. In 2010, around 43 million children under five 
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were overweight. The vast majority of these overweight children (35 million) live 
in developing countries, compared to 8 million in industrialised countries.87 The 
estimated economic burden of obesity in developed countries ranges between 
2% and 7% of health care costs, and is higher in developing countries. 
However, these figures are likely to underestimate the true burden because of 
the difficulties of attributing specific costs to associated obesity and the 
exclusion of indirect costs from most studies.91 
The association between obesity and T2DM has been reproducibly observed in 
both cross-sectional71, 92 and prospective studies,93, 94 and has been consistent 
across various populations even when using different measures of fatness and 
different diagnostic criteria for T2DM.95 The current parallel global epidemics of 
obesity and diabetes seem to be related.95 Such a relation is obviously evident 
in children, who are increasingly affected by obesity and in whom the 
prevalence of T2DM is currently approaching that of type 1 diabetes.96 
Guh et al.97 have conducted a relatively recent systematic review and meta-
analysis, which included a total of 89 large prospective cohort studies reporting 
risk estimates of any of 18 comorbidities related to overweight and obesity. The 
first reviewed comorbidity was, of course, T2DM. The systematic review 
covered studies that used BMI and/or WC to define overweight and obesity (by 
the conventional definitions stated in section A above). The reported relative 
risks (RRs) in studies were synthesised, and pooled RRs were estimated, 
comparing the risk of the comorbidity in overweight (BMI ≥25-29.9 kg/m2) and in 
obese (BMI ≥30 kg/m2) to the individuals with ‘normal weight’.  Among the total 
89 studies, there were nine studies reporting incident T2DM in overweight and 
obese individuals. The estimated pooled relative T2DM risks related to being 
overweight or obese are summarised in Table  2.2. In general, elevated BMI and 
WC were significantly associated with T2DM in both men and women. The 
association between increased WC and T2DM was similar but weaker in 
comparison with BMI. 
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Table  2.2. Pooled relative T2DM risks (with 95% CIs) related to being overweight or obese, as estimated 
by Guh et al.97 
Measure of 
overweight/ 
obesity 
Overweight Obesity 
Men Women Men Women 
BMI 2.40 (2.12–2.72) 3.92 (3.10–4.97) 6.74 (5.55–8.19) 12.41 (9.03–17.06) 
WC 2.27 (1.67–3.10) 3.40 (2.42–4.78) 5.13 (3.81–6.90) 11.10 (8.23–14.96) 
However, Guh et al.97 included studies from only western populations (countries 
in Europe or North America, Australia or New Zealand). In addition, the number 
of reviewed studies for T2DM was relatively small, and the pooled RRs were 
reported as sex-specific only (no age-specific RRs). Moreover, as with all 
systematic reviews, the reported results might be affected by potential 
publication bias.  
The biological link between obesity and T2DM relates primarily to the adipose 
tissue in the body.96 Adipose tissue is not only a passive fuel storage, but has 
been also recognised as an endocrine organ which secretes hormones and 
communicates with the central nervous system in order to regulate appetite and 
metabolism.96 The main biological/pathological pathways which link obesity and 
T2DM are briefly summarised in the following points: 
• Elevated leptin levels. Leptin is a protein produced by adipocytes. The 
main role of leptin is to regulate food intake and energy expenditure by 
reducing food intake and increasing sympathetic nervous system outflow, 
therefore inducing weight loss.91 Leptin levels are elevated in obesity and 
this has been found to positively correlate with insulin resistance. Leptin can 
impair the production of insulin and reduce the effects of insulin on the 
liver.91 
• Elevated levels of adipocyte-derived free fatty acids. In adipose tissues, 
glucose is involved in lipogenesis via its conversion to glycerol-3-phosphate, 
which is then combined with ‘non-esterified fatty acids (NEFAs)’ to form 
triglycerides. An important role of insulin is to prevent the breakdown of 
triglycerides (lipolysis), which liberates NEFAs.91 In obese individuals, the 
levels of these fatty acids are raised, which results in impairment of glucose 
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metabolism by reducing insulin-stimulated glucose uptake in skeletal 
muscle, and increasing the hepatic glucose output.91, 96 
• Elevated levels of proteins secreted by adipose tissue. In addition to 
leptin, adipose tissue secretes many other proteins that modulate glucose 
metabolism and insulin action. Examples of these proteins include 
adiponectin, adipsin and resistin. Again, studies have generally suggested 
that circulating levels of these proteins are elevated in individuals with 
T2DM.96 
• Elevated levels of adipocyte-nonspecific proteins. There are some 
proteins which are secreted by adipocytes as well as other cells and tissues. 
For instance, Cytokines such as tumour necrosis factor α (TNF α) and 
interleukin-6 are produced by macrophages and also by adipocytes.96 These 
proteins are involved in innate immunity and contribute to the process of 
inflammation, either directly through acting on inflammatory cells or indirectly 
by acting on the liver to produce acute phase proteins.91, 96 Cytokines have 
been found to induce ‘suppressor of cytokine signaling-3 (SOCS-3)’, which 
is an intracellular signalling molecule that impairs the signalling of both leptin 
and insulin. In obesity, SOCS-3 levels are elevated and thus may result in 
obesity-associated resistance to the actions of both leptin and insulin.96 
Nonetheless, not every obese individual develops diabetes and, therefore, 
obesity alone is not sufficient to cause T2DM. The relationship between obesity 
and T2DM is complicated by the effects of several modifying factors. These 
factors include duration of obesity, distribution of body fat, physical activity, 
ethnicity and genetics. The following sections concisely discuss these factors 
and their possible modifying effects. 
(i) Duration of obesity   
There is little evidence that quantifies the relationship between duration of 
obesity and risk of T2DM. Reasons for this paucity of information include the 
difficulty to measure the actual onset of obesity, which can only be obtained by 
recall or by detailed longitudinal follow up studies. Furthermore, it is also difficult 
to differentiate between the effects of degree and duration of obesity in case the 
weight is changing.95  
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Examples of studies which have reported an association include one study 
among Pima Indians, who have one of the highest levels of T2DM in the world. 
In that study, Everhart et al.98 prospectively investigated 1057 individuals for a 
total of 5975 person-years of follow up. The association of duration of obesity 
with incidence of T2DM adjusted for age, sex, and current BMI was highly 
significant. This adjusted incidence of T2DM in cases/1000 person-years of 
obesity was 24.8 for people with less than 5 years of obesity, 35.2 for people 
with 5-10 years of obesity, and 59.8 for people with at least 10 years of obesity. 
In addition, another prospective study, conducted in Japan,99 observed 1598 
men aged ≥30 years for a period of 10 years or more, and these participants 
were free from serious disease conditions with initial BMI <25.0 kg/m2. Obesity 
in this study was classified as ‘ordinary obesity’ if BMI >25.0 kg/m2 and ‘extreme 
obesity’ if BMI ≥27.8 kg/m2. Results showed that the age-adjusted ORs for 
T2DM were significantly increased among individuals who were obese for 10-
19.9 years and ≥20 years (ORs 2.10 and 2.84 for ordinary obesity and 6.14 and 
4.15 for extreme obesity, respectively). Additional adjustments for physical 
activity, smoking, alcohol consumption, family history, and observation period 
did not change the findings remarkably. 
(ii) Body fat distribution 
There is considerable evidence which suggests that both overall adiposity and 
fat distribution are independently important risk factors for T2DM in both men 
and women.100 However, both cross-sectional and longitudinal data are not 
consistent as whether the total adiposity (measured by BMI) or abdominal 
adiposity (measured by WC, WHR, etc) is a stronger predictor of T2DM. For 
example, a meta-analysis100 was conducted based on 32 published studies 
from 1966–2004, and demonstrated that the three major obesity indicators 
(BMI, WC, WHR) have similar associations with incident diabetes. The pooled 
RRs for incident diabetes in this study were 1.87 (95% CI: 1.67, 2.10), 1.87 
(95% CI: 1.58, 2.20), and 1.88 (95% CI: 1.61, 2.19) per standard deviation of 
BMI, WC, and WHR respectively. 
Nevertheless, as indicated earlier, the effect of body fat distribution in predicting 
T2DM is more evident in some particular populations, such as people of South 
Asian origin. South Asians are more prone to abdominal obesity and low muscle 
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mass with increased insulin resistance compared with white western 
individuals.57 The risk of T2DM starts at a lower BMI for Asians, and they have 
lower rates of overweight and obesity than their European counterparts, using 
conventional definitions with the previously mentioned BMI cut-offs.57 These 
observations have been supported by using the imaging technology of CT scan, 
which showed that healthy Chinese and South Asian individuals have a greater 
amount of visceral adipose tissue than Europeans with the same BMI or WC.57 
McKeigue et al.101 carried out a population survey of around 3760 men and 
women aged 40-69 years in London. The study showed that the prevalence of 
diabetes was 4.3 times higher in the South Asian than European participants 
(19% vs. 4% respectively). However, mean BMI was almost equal in European 
and South Asian men (25.9 vs. 25.7 kg/m2 respectively), and slightly higher in 
South Asian women (27.0 kg/m2) than their European counterparts (25.2 kg/m2). 
On the other hand, WHR was clearly higher in South Asians (0.98 in men and 
0.85 in women) than Europeans (0.94 in men and 0.76 in women). Within each 
ethnic group, WHR was positively correlated with glucose intolerance, which 
may confirm the existence of an insulin resistance syndrome, prevalent in South 
Asian populations and associated with a pronounced tendency to central 
obesity in this group. 
(iii) Physical activity 
Physical activity is generally defined as “bodily movement produced by the 
contraction of skeletal muscle that requires energy expenditure in excess of 
resting energy expenditure”.102 There is considerable evidence supporting that 
physical activity is an important component on long-term weight control.102-105 
Physical activity generally affects body composition and weight favourably by 
promoting fat loss. However, the rate of weight loss is positively related, in a 
dose-response manner, to the frequency and duration of the physical activity 
session/ programme.102 It has been observed by a large number of studies that 
a minimum of 150 minutes/ week of moderate-intensity physical activity (e.g. 30 
minutes of brisk walking daily) is associated with health-related benefits.103, 104 
However, higher levels of physical activity may be necessary to improve long-
term weight loss outcomes. For example, an additional 200–300 minutes/ week 
of physical activity has been reported to improve weight loss in overweight and 
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obese individuals. This is approximately equivalent to 65 minutes of moderate-
intensity physical activity per day.104 Moreover, studies have demonstrated that 
exercise alone can have a significant impact on body weight when maintained 
for ≥12 months, and that individuals who reduce their level of leisure-time 
physical activity can have weight regain after a specific period of time. Thus, for 
exercise to be effective long term, it should be maintained long term in 
overweight and previously overweight individuals.104 Another important 
observation is that weight loss resulting from increased physical activity without 
caloric restriction is relatively slow, while the combination of increased physical 
activity and dieting appears to be more effective for long-term weight regulation 
than is dieting alone102 (discussed in the next section). 
(iv) Diet 
Obesity generally results from an imbalance between energy intake and energy 
expenditure.106 Relative excessive energy intake can of course result from 
excess dietary intake of fat, carbohydrates, proteins, etc. However, progress in 
understanding the role of diet in the aetiology of obesity has been seriously 
confounded by the profound under-reporting, which is now widely recognised as 
a feature of obesity. Several studies have reported that obese individuals might 
under-report their self-reported intake by an average of 30% due to many 
reasons, such as forgetfulness, underestimation of portion size, inadequate 
knowledge of food composition, or even self-deception.107 The evidence is 
inconsistent regarding the relation between intake of individual macronutrients 
(fat, carbohydrate and protein) and obesity, with fat overconsumption being the 
most commonly suggested dietary factor to have a role in the aetiology.107, 108 
Many studies have found that each individual macronutrient exerts different 
effects on eating behaviour, predominantly due to their effects on satiety. It has 
been suggested that, in contrast to carbohydrate and protein, fat appears to 
have a weak satiating capacity, and subjects readily overeat in response to high 
fat foods. As fat has twice as much energy per gram as protein or carbohydrate, 
this may eventually result in energy density.107 On the other hand, 
carbohydrates are converted to fat only after several days’ consumption of 
considerably large amounts (more than 500 grams of carbohydrates per day). 
Thus, it has been postulated that the lipogenesis from carbohydrates does not 
represent a major metabolic route in the development of obesity.108 According 
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to the review of Vögele, several large field studies have shown a positive linear 
relationship between body weight and fat consumption, but a negative 
correlation with carbohydrate intake.108 However, the results of prospective 
studies of dietary fat intake and weight gain are clearly inconsistent, although 
most cross-sectional studies do suggest an association. For instance, Seidell 
reviewed many studies with different findings. While some studies found no 
relation between percentage of energy from fat and weight gain prospectively, 
others observed a positive association which was specific only to one sex.106 
Nevertheless, some researchers now suggest that the current epidemiologic 
methods are likely to be inadequate for performing valid studies of the relation 
between dietary intake of ‘individual’ macronutrients and obesity.106 This is 
mainly due to inaccurate estimates of energy intake and energy expenditure as 
well as of dietary fat intake measurements, in addition to biases as a result of 
under-reporting77, 106 (as previously mentioned). Rather, it is believed that the 
‘total’ energy intake is the factor which has a more obvious association in most 
studies. The strongest evidence for that might come from several intervention 
studies that compared the effects of exercise and that of reducing energy intake 
on changes in body weight.104 These interventions have reported that 
reductions in energy intake (e.g. diet) have a greater impact on body weight 
than changes in energy expenditure (e.g. exercise), although the combination of 
diet plus exercise has the greatest impact on weight loss. For example, one 
intervention study reported reductions in body weight of 11.4, 8.4, and 0.3% in 
male participants with 12 weeks of diet plus exercise, diet alone, or exercise 
alone, respectively. A similar pattern of weight losses of 7.5, 5.5, and 0.6% was 
observed in women engaging in the same study.104 
(v) Genetics and ethnicity 
Evidence from some studies suggests that obesity interacts with family history 
of diabetes in promoting T2DM risk. For example, Haffner et al.109 examined 
549 non-diabetic persons with a parental history of diabetes and 1167 non-
diabetic persons without such a history. It has been found that, compared to 
persons without a parental history of diabetes, those with such a history had a 
more atherogenic pattern of cardiovascular risk factors, including higher BMI 
and serum insulin concentrations. However, after adjustment for serum insulin 
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concentration, BMI and WHR between the two parental history groups were no 
longer statistically significant, which might suggest that the association was 
mediated through hyperinsulinaemia. 
On the other hand, several other studies have observed that the association 
between T2DM and obesity was more apparent in individuals without a family 
history of diabetes. For instance, in a study among Japanese Americans,110 a 
total of 79 non-diabetic and 78 type 2 diabetic men were investigated. Family 
history of diabetes in a sibling or parent was found in 24 normal men and 45 
type 2 diabetic men. Both general adiposity and body fat distribution were 
significantly associated with T2DM. The relationships between diabetes and 
both general adiposity and body fat distribution were more apparent in those 
men without a family history of diabetes than in those with a family history. This 
study and others111 might suggest that a higher level of obesity is required for 
the development of T2DM in individuals without a genetic predisposition to the 
disease.95 
Also, as described in detail in section 2.2.1.3, a large number of studies have 
revealed that some ethnic groups have an elevated risk of T2DM compared to 
other ethnicities.8, 65-69 In all these studies, which have not adjusted for some 
confounding variables (e.g. BMI), obesity might be a modifying factor for 
increased levels of the disease. However, it has also been discussed that some 
ethnic groups, particularly Asian Indians, appear to have an elevated risk of 
T2DM compared to other ethnic groups at similar or lower levels of BMI.101 
Asian Indians are more likely to have abdominal obesity than other ethnicities, 
and this difference in body fat distribution has been proposed to have an 
association with the risk of T2DM when adjusting for many other potential 
confounding factors.101 
2.2.3.3. Physical inactivity 
As previously indicated, early suggestions of a relationship between physical 
inactivity and diabetes emerged from the observation that societies that had 
shifted their lifestyles from traditional (which included large amounts of regular 
physical activity) to westernised sedentary habits experienced major increases 
in the prevalence of T2DM.102 The epidemiological transition (chapter 3) in 
developing countries, during the last decades, is an obvious example which 
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suggests such an association.112 Moreover, several ecologic studies have 
suggested that T2DM prevalence is consistently lower in populations with 
higher levels of habitual physical activity.8  
Also, a large number of cross-sectional as well as prospective and retrospective 
observational studies have found a significant association between physical 
inactivity and T2DM.8, 102 For example, a prospective study was carried out 
among 1728 non-diabetic individuals from the high risk population of Pima 
Indians. During an average follow-up period of 6 years, it was found that total 
activity was related to diabetes incidence in women and men after adjusting for 
age. After additional adjustment for BMI, the relation between activity and 
diabetes incidence was weakened in both men and women. When the age-
adjusted diabetes incidence rates were examined by levels of activity stratified 
by tertile of BMI, the diabetes incidence rate remained lower in more active than 
in less active men and women from all BMI groups.105 
The available evidence suggests a number of possible biological pathways for 
the protective effect of physical activity on development of T2DM. First, it has 
been suggested that physical activity increases sensitivity to insulin. In a 
comprehensive report of “Physical Activity and Health” by the US Department of 
Health and Human Services,102 an extensive literature review has indicated that 
physical activity is more likely to improve abnormal glucose tolerance when the 
abnormality is primarily caused by insulin resistance than when it is caused by 
deficient amounts of circulating insulin. Therefore, physical activity is likely to be 
most beneficial in preventing the progression of T2DM during the earlier stages 
of the disease process, before insulin therapy is required. The second 
suggested protective mechanism of physical activity is that exercise appears to 
have a synergistic effect with insulin. During a single prolonged session of 
physical activity, contracting skeletal muscle has been suggested to enhance 
glucose uptake into the cells. This effect appears to be related to both increased 
blood flow in the muscle and enhanced glucose transport into the muscle cell.102 
Third, physical activity has also been found to reduce intra-abdominal fat, which 
is a known risk factor for insulin resistance. In many studies, physical activity 
has been inversely associated with intra-abdominal fat distribution, and can 
reduce those body fat stores.102 
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2.2.3.4. Diet 
The role of diet in the aetiology of T2DM was proposed by early Indians who, as 
mentioned earlier, observed that the disease was almost confined to rich people 
who consumed oil, flour and sugar in excessive amounts.77 During the First and 
Second World Wars, declines in the diabetes mortality rates were documented 
due to food shortage and famines in the involved countries such as Germany 
and other European countries. For example, in Berlin, diabetes mortality rate 
declined from 23.1/100,000 in 1914 to 10.9 in 1919.113 In contrast, no change in 
diabetes mortality were described in other countries which had no shortage in 
food at the same time period such as Japan and North American countries.113 
Importantly, however, these observations only indicate a probable dietary 
component in the aetiology of T2DM, and do not provide absolute evidence. 
The reason is the existence of many potential confounding factors and 
competing risks such as ethnicity, genetics and others. 
Again, the epidemiological transition in developing countries has always been 
attributed to adopting a western lifestyle and high-calorie dietary habits.112 This 
has been supported by studies (previously discussed in section 2.2.1.3) that 
compared T2DM prevalence among urban societies and those societies that 
remain to adopt a traditional physical activity and dietary habits.65, 66 In the 
EMR, for example, unhealthy diet has been reported among the main causes of 
the alarming high rates of NCDs, including T2DM, in the region. The mean daily 
caloric intake among countries of EMR in 2000 was 3000 kilocalories per capita, 
and it seems there was no improvement between 1994 and 2000.114  
However, evidence on the role of diet in the aetiology of T2DM remains 
controversial. While some studies have found an association between T2DM 
and high intake of carbohydrates115 and fats116, other studies have not reported 
such an association.117, 118 For over 40 studies, reviewed by Mann and 
Toeller,77 half of them have been found to report a positive association between 
high intake of sugars and development of T2DM, and a comparable number of 
studies suggesting no association. An example of studies with a positive 
association is the study of Ludwig et al.115 which investigated 548 ethnically 
diverse schoolchildren for 19 months. It has been found that for each additional 
serving of sugar sweetened drink consumed, both BMI (mean 0.24 kg/m2) and 
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frequency of obesity (OR 1.60) increased after adjustment for anthropometric, 
demographic, dietary, and lifestyle variables. On the other hand, Peterson et 
al.117 studied 23 diabetic patients: 12 with type 1 and 11 with T2DM, with 
differing degrees of glycaemic control. Two diets, each lasting 6 weeks, were 
compared. Both diets were high in fibre and low in fat. In one diet 45 grams of 
complex carbohydrate was replaced by 45 grams of sucrose taken at 
mealtimes. There were no significant biochemical differences between the two 
diets in either type 1 or type 2 patients. In type 2 patients, the mean fasting 
plasma glucose was 9.1 mmol/l on the control diet, and 8.9 mmol/l on sucrose. 
Glycosylated haemoglobin for the type 2 patients was 9.3% on control and 9.0% 
on sucrose. Moreover, there were no differences in mean daily plasma glucose 
levels or diurnal glucose profiles. 
As with carbohydrates, the relationship between dietary fats and T2DM is also 
inconsistent. Several prospective studies have found associations between fat 
intake and subsequent risk of developing T2DM. For example, in the San Luis 
Valley Diabetes Study,119 a total of 1,317 subjects without a prior diagnosis of 
diabetes were prospectively investigated for a period of 4 years. In that study, 
24-hour diet recalls were reported prior to an oral glucose tolerance test. 
Persons with previously undiagnosed diabetes (n= 70) and impaired glucose 
tolerance (n= 171) were each compared with confirmed normal controls (n= 
1076). The adjusted ORs relating a 40 grams/day increase in fat intake to 
T2DM and impaired glucose tolerance were 1.51 (95% CI: 0.85–2.67) and 1.62 
(95% CI: 1.09–2.41) respectively. Restricting cases to diabetic persons with 
fasting glucose >140 mg/dl and persons with impaired glucose tolerance 
confirmed on follow-up, the ORs increased to 3.03 (95% CI: 1.07–8.62) and 
2.67 (95% CI: 1.33–5.36) respectively. In contrast, Colditz et al.120 prospectively 
followed up a large cohort of 84,360 US women for 6 years. They examined the 
relations of the various diet components, including fat, fibre and sucrose and the 
risk of T2DM among two groups of women (those with BMI of <29 kg/m2 and 
others with BMI ≥29 kg/m2). After controlling for BMI, previous weight change 
and alcohol intake, no associations were found between intakes of fat, sucrose, 
carbohydrate or fibre and risk of diabetes in both groups. However, as 
mentioned earlier, these association studies might suffer from different 
constraints, such as poor assessment of actual dietary intake, inability to 
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disentangle dietary and other confounding factors, in addition to over-
interpretation of data derived from observational studies.77 
2.2.3.5. Smoking 
Studying the effect of smoking on T2DM might be difficult, as those people who 
smoke are more likely to be less active (sedentary), which is a risk factor for 
T2DM. However, several studies have assessed the association between 
smoking and incidence of glucose abnormalities, suggesting that active 
smoking could be independently associated with IGT, IFG, and T2DM.121-126 
According to these studies, smoking may be a modifiable risk factor for T2DM. 
Some reviews127-129 of such studies revealed that they are generally large, 
prospective and population-based, with a follow-up period greater than 10 years 
in most studies. The results generally were presented after adjustments for 
possible confounders such as age, BMI, WC, physical activity, blood pressure, 
etc. 
For instance, Perry et al.121 conducted a large prospective cohort study among 
a sample of 7735 British men, aged 40-59 years from 24 towns in Britain. All 
subjects were non-diabetic at baseline and followed up for a mean period of 
12.8 years. Baseline values (adjusted for age and BMI) showed that current 
smoking was significantly higher among men who developed T2DM during the 
follow up period, compared to those who did not develop the disease. However, 
in the multivariable analysis, the relative risk for diabetes was higher among 
smokers (adjusted RR: 1.2; 95% CI: 0.8-1.8), but the association lost its 
significance and was not independent of other risk factors (obesity and low 
physical activity were the strongest). In the Osaka Health Survey in Japan,122 a 
total of 6250 middle-aged men were followed up for a period of 4-16 years 
(60,904 person-years). Participants were free of T2DM, IFG and hypertension 
at entry. The RR of T2DM among current smokers compared to non-smokers 
was 1.47 (95% CI: 1.14–1.92) after adjustment for many covariates, including 
age, BMI, alcohol consumption, physical activity, parental history of diabetes 
and the level of fasting plasma glucose, total cholesterol, triglycerides, high-
density lipoprotein cholesterol and haematocrit. Importantly, a ‘dose-response’ 
relationship was found for this association; the number of cigarettes smoked 
daily was significantly related to the development of T2DM. 
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There are many other examples of prospective studies which reported a 
positive association between smoking and T2DM among men. Rimm et al.123 
reported a RR of 1.94 in smokers compared to non-smokers of a large cohort of 
male health professionals across the US. Moreover, another study124 analysed 
glycaemic status and smoking habits in 3718 Chinese men, and found that 
smoking is independently associated with diabetes after adjustment for age, 
BMI, alcohol, and family history of diabetes (OR: 1.7). 
In women, not as many studies have been performed as in men. However, most 
studies in women have also produced similar results.128 One of the largest 
prospective studies is the Nurses’ Health Study in the US.125 In this cohort 
study, a total of 114,247 female nurses, who were free of diabetes at baseline, 
were followed up for 12 years (1,277,589 person-years). Current smokers were 
found to have an increased risk of diabetes, and a significant dose-response 
trend for higher risk among heavier smokers was observed. The RR of 
diabetes, adjusted for several covariates (e.g. age, BMI, alcohol consumption), 
was 1.42 among women who smoked 25 or more cigarettes per day compared 
with non-smokers. In another study, Hu et al.126 carried out a new analysis of 
results from the same cohort after 16 years of follow up. They followed 84,941 
female nurses, who were confirmed non-diabetic at baseline, from 1980 to 
1996. Overweight or obesity was the single most important predictor of diabetes 
in this study. However, other risk factors, including current smoking, were 
associated with a significantly increased risk of diabetes, even after adjustment 
for BMI. The adjusted RR for diabetes in the smokers was around 1.4 when 
compared with non-smokers. 
Willi et al.130 have carried out a relatively recent systematic review and meta-
analysis of studies of association between active smoking (in contrast to 
passive or second-hand smoking) and T2DM. They have identified 25 large 
prospective cohort studies (n= 1.2 million participants) which reported risk of 
IFG, IGT, or T2DM in relationship to smoking status and excluded persons with 
T2DM at baseline. The reported incident cases of diabetes were 45,844 during 
a study follow-up period ranging from 5 to 30 years. They found that 24 studies 
reported adjusted RRs greater than 1 (range for all studies: 0.82-3.74). The 
pooled adjusted RR of incident diabetes in smokers compared with non-
smokers was 1.44 (95% CI: 1.31-1.58). RRs in the involved studies were 
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adjusted for a number of potential confounding factors, such as age, BMI, WC, 
physical activity, alcohol consumption, heredity, education, and others. Results 
were consistent with a “dose-response phenomenon”, where the risk of T2DM 
was greater for heavy smokers (≥20 cigarettes/ day; RR: 1.61) than for lighter 
smokers (RR: 1.29) and lower for former smokers (RR: 1.23) compared with 
active smokers. However, Willi et al. have not reported sex- or age-specific 
RRs, and they have estimated only one adjusted pooled RR for both men and 
women. In addition, potential publication bias could occur and affect the 
reported results. 
The metabolic effects of smoking have been examined mainly in non-diabetic 
individuals by many studies. In these studies, insulin sensitivity has been 
determined in order to test the effect of smoking on glucose metabolism. This is 
most often performed by using the ‘euglycaemic hyperinsulinaemic clamp 
technique’.128 This technique is regarded as being the gold-standard method to 
assess and quantify insulin sensitivity in most metabolic studies, and is often 
used in clinics and laboratories to measure insulin action on glucose utilisation 
in humans and animals for clinical and basic science research.131, 132 In brief, 
the concept of this technique is measuring the steady state amount of glucose 
metabolised per unit of body weight during a whole-body exposure to a 
predetermined amount of insulin, while maintaining the plasma glucose within 
the euglycaemic range.132 After an overnight fast, insulin is infused 
intravenously at a constant rate which results in a new steady state insulin level 
that is above the fasting level (hyperinsulinaemic). Consequently, glucose 
disposal in skeletal muscle and adipose tissue is increased, whereas the 
endogenous hepatic glucose production is suppressed. Under these conditions, 
a bedside glucose analyser is used to frequently monitor blood glucose levels, 
while dextrose is given intravenously at a variable rate to “clamp” blood glucose 
concentrations in the normal range (euglycaemic).133 The quantity of exogenous 
glucose infused to maintain euglycaemia is a reflection of the amount of glucose 
metabolised in peripheral tissues, and therefore reflects the sensitivity of target 
tissues to insulin. The more glucose infused per unit of time, the more sensitive 
the individual is to insulin.132 
Eliasson et al.134 examined 57 male smokers, who were middle-aged (40-60 
years), non-obese and non-diabetic. The degree of insulin resistance in the 
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participants was quantified using the euglycaemic clamp technique. In that 
study, smoking was independently correlated with degree of insulin resistance, 
even after multivariate analysis to adjust for age, lean body mass, body fat, 
BMI, WHR and alcohol consumption. Furthermore, a review128 has reported two 
studies that compared the insulin sensitivity in smoking and non-smoking men. 
It was shown that the measures of insulin sensitivity were significantly lower 
(10% to 40%) in the smokers.  
2.2.3.6. Socioeconomic status 
The observed variations in diabetes prevalence across different levels of 
socioeconomic status (SES) might be a complex issue, as these variations have 
been attributed to several factors. In addition, SES is usually defined in studies 
using different indicators (e.g. education level, income, occupation, area of 
residence, etc). Currently, the relevant evidence often makes a distinction 
between developing and developed countries regarding the relationship of SES 
and the risk and prevalence of diabetes. Generally, in developing countries, a 
number of studies have showed a higher prevalence of diabetes in groups of 
high SES.79, 80 In contrast, in developed countries, the incidence and prevalence 
of diabetes have been found to be inversely related to SES, with the highest 
prevalence in those of lowest SES.79 The commonest suggested contributing 
factor to such variations has been the differential distribution of obesity (and 
related factors such as diet and level of physical activity) across different strata 
of SES in developed and developing countries.  
In developing countries, the observations of low levels of obesity among 
individuals with low SES versus high levels among those with higher SES have 
usually been explained by three main reasons. First, people with low SES 
usually have lack of food and higher levels of physical activity and energy 
expenditure. Second, people with higher SES are more likely to have a greater 
capacity to obtain adequate food supplies. Third, cultural values in many 
developing countries favour fat body shapes.135 Monteiro et al.135 have indicated 
that evidence from studies in the developing countries prior to 1989 strongly 
suggested that obesity in the developing world would be essentially a disease of 
the socioeconomic elite. However, between 1989 and 2003, a comprehensive 
review of relevant studies showed a different picture. The authors adopted an 
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income definition of developing countries used by the World Bank, and used 
certain defined cut-offs of the annual gross national product (GNP) per capita in 
order to classify such countries into three categories: low income countries, 
lower-middle income countries, and upper-middle income countries. 
Interestingly, they have found that the burden of obesity in a particular 
developing country tends to shift towards the groups of lower SES as that 
country’s GNP increases. The prevalence of obesity was found to be relatively 
lower among groups with lower SES in most low-income and some of the lower-
middle income developing countries. On the other hand, there was an inverse 
association between SES and obesity (especially among women), in lower-
middle income and upper-middle income developing countries.135 The reviewers 
have argued that the positive association between SES and levels of obesity in 
the ‘poorer’ countries is probably attributed to the same three reasons indicated 
above. On the other hand, the inverse association observed in the middle-
income countries could be a more complicated issue. Monteiro et al.135 have 
indicated several likely explanations for such an inverse association. It has been 
argued that food scarcity and high energy expenditure patterns are likely to be 
less common in a society after a certain stage of economic growth has been 
reached, even among its poorer social classes. Individuals with lower SES are 
more likely to have a lower level of education and health-related knowledge, in 
addition to greater difficulty in obtaining the more expensive and less energy-
dense foods. Furthermore, people with lower SES are also likely to have less 
leisure-time and recreational exercise. In contrast, people with a high SES are 
more likely to have flexible choices of ‘healthy’ food and physical activity 
patterns. Hence, such people might have environments with less ‘obesogenic’ 
factors than those with a low SES.135 These explanations have also been 
suggested to justify the inverse association between SES and obesity/ diabetes 
in the developed countries.136, 137 
2.2.4. Role of modifying the behavioural/ environmental risk factors in 
prevention of type 2 diabetes 
There is evidence from a number of studies showing that interventions with 
lifestyle changes have resulted in preventing (or at least delaying) T2DM. 
Randomised trials revealed that lifestyle changes were approximately twice as 
effective as metformin therapy in preventing the disease.83, 138 These lifestyle 
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changes included modifications of different behavioural/ environmental risk 
factors such as obesity81, physical activity81, 139, diet81, 126, and smoking140. 
Tuomilehto et al.82 reviewed a number of intervention trials81, 141-148 in different 
countries/ populations. In these trials, the incidence of T2DM was estimated in 
the intervention and control groups, and the difference in incidence between the 
two groups was quantified in each study. All these trials showed that the 
incidence of T2DM was significantly lower among those participants in the 
intervention groups, who received the lifestyle intervention (reducing weight, 
increasing physical activity, intake of low-fat diets, etc.) alone or combined with 
drugs, compared to those in the control groups.   
The following two sections focus primarily on obesity and smoking, as the only 
two risk factors studied in this thesis. 
2.2.4.1. Obesity 
Among the studies reviewed by Tuomilehto et al.,82 the Finnish Diabetes 
Prevention Study81 was the only study in which the participants were recruited 
based on being overweight/ obese with IGT at the baseline. According to the 
reviewers, the Finnish Diabetes Prevention Study is the first ‘proper’ controlled 
trial on prevention of T2DM where the study participants were individually 
randomly allocated into intervention and control groups. The first part of this 
study was conducted during the period 1992-2000 in five clinics in Finland, with 
the aim to prevent T2DM with lifestyle modification alone. A total of 522 
participants at “high risk” to develop diabetes were selected after screening for 
IGT in middle aged (40-64 years), overweight (BMI >25 kg/m2) subjects. The 
presence of IGT before randomisation was confirmed in two successive 
OGTTs.81, 82 
The participants were randomly allocated into either the “intensive intervention” 
group or the “control” group. Those in the intervention group had frequent 
consultation visits with a nutritionist, and received individual advice about how 
to achieve the intervention goals. Five goals were set for intervention, as 
follows: 1) reduction in weight of 5% or more; 2) total fat intake less than 30% of 
energy consumed; 3) saturated fat intake less than 10% of energy consumed; 
4) fibre intake of at least 15 grams/1000 kilocalories; and 5) moderate exercise 
for 30 minutes/day or more. Several dietary behaviours were recommended to 
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participants in the intervention group (e.g. frequent ingestion of wholemeal 
products, fruit and vegetables, low-fat milk and meat, etc). In addition, these 
participants were individually guided to increase their level of physical activity, 
through recommending endurance exercise (e.g. walking, jogging, swimming, 
etc), and supervised and progressive circuit-type resistance training sessions.81, 
82 On the other hand, participants in the “control” group were only given general 
verbal and written advice about healthy lifestyle at the beginning of the trial.81, 82 
All participants in both groups were followed up annually by performing a fasting 
plasma glucose test and OGTT. If either fasting or OGTT values reached 
diabetic levels, a second confirmatory OGTT was performed. Diagnosis of 
T2DM was only recorded if the second test also reached diabetic levels. 
Otherwise, the participants remained in their randomly allocated group.81, 82 
The results of the study showed that during the first year, body weight 
decreased on average 4.2 kg in the intervention group, compared to 0.8 kg in 
the control group participants (the difference was statistically significant; p= 
0.0001). It has been found that most of this weight reduction was maintained 
during the second year of the trial. Furthermore, indicators of central adiposity 
and fasting glucose and insulin, 2-hour post-challenge glucose and insulin, and 
HbA1c were also reduced significantly more in the intervention group than in the 
control group during both the first and second year.81, 82 
In 2000, a total of 86 incident cases of diabetes were diagnosed among the 522 
participants (27 in the intervention group + 59 in the control group). The 
absolute risk of diabetes was 32/1000 person-years in the intervention group, 
compared to 78/1000 person-years in the control group. Importantly, the effect 
of the intervention was found to be rapid, where the difference in incidence of 
diabetes between the two study groups was already statistically significant after 
two years (6% in the intervention group and 14% in the control group).81, 82 The 
study also showed that both sexes benefited from the lifestyle intervention. The 
incidence of diabetes was reduced by 63% in men and by 54% in women in the 
intervention group compared with the control group. All participants (in the 
intervention and control groups) who reached all the five lifestyle targets by the 
1-year visit did not develop diabetes. In contrast, around one third of those 
participants who did not reach a single one of the targets developed type 2 
diabetes.81, 82 
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2.2.4.2. Smoking 
The results have been inconsistent regarding the effect of smoking cessation on 
the risk of developing diabetes. Theoretically, the reversal of the risk of diabetes 
upon cessation of smoking supports the concept of causality. However, it has 
been suggested that there are some lifestyle factors which may complicate the 
applicability of such a concept among people who choose to quit smoking.149 
For instance, some studies have showed that smoking cessation is associated 
with weight gain and a subsequent increase in the risk of diabetes.150, 151  
Most studies have observed that current smokers and ex-smokers showed a 
higher risk for developing diabetes than non-smokers. Nevertheless, according 
to Hur et al.,140 the majority of such studies have not considered changes in 
smoking habits during the follow-up period, and, hence, the effects of smoking 
cessation on the risk of developing diabetes could not be properly assessed. In 
addition, the reported increased risks of ex-smokers in these studies have not 
been statistically significant, or have not been adjusted for some covariates 
such as age, BMI, family history, etc. Moreover, the definition of ‘ex-smokers’ 
was inconsistent across studies. Thus, in their prospective study, Hur et al. 
undertook repeated measurements of smoking status during the follow-up 
period to assess the relationship between smoking status and fasting glucose 
level changes.140 The study was started in 1990 in South Korea, with baseline 
examinations in 1990 and 1992, and continued with follow-up examinations 
every 2 years up to 1998 and 2000. A total of 27,635 non-diabetic men (aged 
35-44 years) were enrolled at the baseline. They were randomly selected from 
records of the Korea Medical Insurance Corporation, which provides health 
insurance to government and private school employees and their dependants. 
The participants were classified as non-smokers (those who reported not 
smoking consistently from 1992 to 1996), ex-smokers (those who reported 
smoking cessation at baseline or during the follow-up periods) and sustained 
smokers (those who reported current smoking consistently from 1992 to 1996), 
based on repeated self-reported questionnaires in 1992, 1994 and 1996.140 To 
explore the effect of smoking cessation, ex-smokers were further classified as 
having quit smoking before 1992, during 1992–1993 or during 1994–1995. 
Baseline fasting serum glucose level and other risk factors were measured in 
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1990 and 1992. The outcome was newly developed diabetes, defined as a 
fasting glucose level of ≥7.0 mmol/l in 1998 and 2000 (averaged).140 
When compared with non-smokers, the reported risk ratio was 0.98 (95% CI: 
0.81–1.17) for ex-smokers and 1.62 (95% CI: 1.40–1.88) for current smokers, 
when the participants were categorised based on baseline smoking status only. 
However, when smoking status was re-defined based on the repeated 
assessments at 2-year intervals, the diabetes risk ratio in ex-smokers was 
found to vary by the length of time since smoking cessation. Compared with 
non-smokers, the fully adjusted risk ratio for diabetes in participants who quit 
smoking before 1992, during 1992–1993 and during 1994–1995 was 0.95 (95% 
CI: 0.72–1.25), 1.44 (95% CI: 0.96–2.15) and 2.13 (95% CI: 1.51–3.00), 
respectively, after adjustment for age, baseline fasting serum glucose, weight 
change, baseline BMI, family history of diabetes, alcohol consumption and 
exercise status. The authors argued that there is a gradual reduction in the risk 
for diabetes over time after cessation of smoking, and that ‘early’ smoking 
cessation could decrease the risk to that of non-smokers in the long term.140 
Overall, this chapter demonstrates that T2DM is associated with several risk 
factors, which interact with each other, making the aetiology of the disease 
complex. The next chapter discusses the size of the problem of T2DM in the 
world, developing countries (particularly EMR), GCC countries, and Saudi 
Arabia.  
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Chapter 3. Size of the problem of type 2 diabetes in the world, 
developing countries, and Saudi Arabia 
This chapter presents a literature review of the estimates and projections of 
T2DM prevalence in the world. Further discussion focuses on levels of the 
disease in the developing countries, the WHO’s Eastern Mediterranean Region 
(EMR), and then, more specifically, the countries of the Gulf Cooperation 
Council (GCC). Lastly, this chapter presents a detailed discussion of the context 
of Saudi Arabia, in terms of demography, health care system, levels of NCDs, 
diabetes care, and the relevant studies on prevalence of T2DM and the two risk 
factors studied in this thesis (obesity and smoking). 
3.1. Global epidemiology of type 2 diabetes 
3.1.1. Background 
Historically, communicable diseases used to be the major threats to health 
globally until the second half of the 19th century. Several devastating epidemics 
of these diseases occurred in the past, including cholera, typhoid, smallpox, and 
diphtheria, and killed huge numbers of people all over the world. While some of 
these diseases are still epidemic in some developing countries, a very 
significant drop in their levels occurred from the beginning of the 20th century as 
a result of extensive improvements in sanitation, housing, nutrition and 
cleanliness of water supplies. In addition, the discovery of antibiotics and 
immunisation has also played a vital role.152 With all these improvements, the 
global life expectancy increased substantially. Eventually, the list of leading 
causes of morbidity and mortality shifted from infectious diseases to NCDs, 
such as cardiovascular disease, diabetes, hypertension, cancer, and stroke.153 
This phenomenon is known as the “epidemiological transition” which is typically 
defined as “the series of interrelated and complex changes in the health and 
disease patterns that occur in specific human populations over large periods of 
time”.112 In developing countries, this health transition has been attributed 
mainly to rapid urbanisation and changes in the population lifestyles which 
resulted in increased levels of various risk factors for NCDs (e.g. smoking, 
unhealthy diet, obesity, and physical inactivity).4, 154  
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T2DM is a global health problem. It affects a huge number of people globally 
and its prevalence varies by age group, ethnicity, and socioeconomic status.6 
The disease reduces both a person’s quality of life and life expectancy and 
imposes a large social and economic burden on families as well as on health 
care systems.6, 45 According to the WHO’s Global Burden of Disease (GBD) 
Study in 2004, high blood glucose is one of the 10 leading risk factors causing 
death,7 where it caused around 6% of deaths worldwide. (Table  3.1). This is 
despite the fact that the true diabetes-related mortality is greatly 
underestimated, as diabetes is frequently underreported on death certificates.45, 
155 Diabetes results also in a great financial burden on health care departments. 
The direct health care costs of the disease range from 2.5% to 15% of annual 
health care budgets153, and the indirect costs are more likely to be much higher. 
This is due to the difficult measurement of indirect cost of diabetes since it 
implicates not only patients but also the families and the society as a whole.156  
Table  3.1. Ranking of the 10 leading risk factor causes of death in the world, GBD 20047  
Rank Risk factor Deaths (millions) Percentage 
1 High blood pressure  7.5 12.8 
2 Tobacco use  5.1 8.7 
3 High blood glucose  3.4 5.8 
4 Physical inactivity 3.2 5.5 
5 Overweight and obesity 2.8 4.8 
6 High cholesterol 2.6 4.5 
7 Unsafe sex 2.4 4.0 
8 Alcohol use 2.3 3.8 
9 Childhood underweight 2.2 3.8 
10 Indoor smoke from solid fuels 2.0 3.3 
3.1.2. Global estimates and projections of type 2 diabetes prevalence 
In the last two decades, several studies of global estimates and projections of 
diabetes prevalence have been published. Generally, such estimates and 
projections are highly dependent on many factors, such as data inputs, method 
of estimation, assumptions, and variables used to inform the future projections. 
The available studies mostly tended to produce different estimates and 
projections of diabetes prevalence as a result of variations in those factors. In 
addition, the available studies were carried out in different time periods, so that 
they used different diagnostic criteria to define diabetes. As discussed in 
chapter 2, such diagnostic criteria have been revised repeatedly over time, 
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leading to different classification of people (as having diabetes or not). Table  3.2 
summarises examples of studies of global projections of diabetes prevalence. 
One of the most recent estimates is that of the IDF Diabetes Atlas 2011.9 In this 
study, the IDF estimated and projected diabetes prevalence in adults aged 20-
79 years for 2011 and 2030 in different world regions and countries. Detailed 
discussion of the methodology of this study is presented in chapter 9. In brief, 
diabetes prevalence data were obtained from country-level data sources (e.g. 
national surveys, health statistics reports, and personal communications). If no 
data were obtained for a country, data from neighbouring countries (with mostly 
similar ethnicity and socioeconomic patterns) were used. A logistic regression 
model was used to generate smoothed age-specific estimates which were 
applied to the United Nations (UN) population estimates for 2011. Estimates 
and projections were presented for each country separately, using changes in 
age, sex and urbanisation as covariates. Globally, it was estimated that there 
were 366 million people with diabetes in 2011, which was predicted to rise to 
552 million by 2030.9 
Another recent study is that of the WHO’s GBD Study, 2011 [Global Burden of 
Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood 
Glucose)].20 Again, the methodology used in this study is discussed in detail in 
chapter 9. In this study, the trends in diabetes prevalence were estimated for 
adults aged ≥25 years in 199 countries and territories around the world. Data on 
diabetes prevalence were obtained from national surveys and statistics reports, 
in addition to the WHO Global InfoBase. Trends in the diabetes prevalence 
(during 1980-2008) were modelled using a multi-level statistical approach 
(Bayesian hierarchical modelling). The estimates were age standardised to the 
WHO reference population and were informed by several country-level 
covariates: national income, urbanisation, age-standardised mean BMI, and 
national availability of multiple food types for human consumption. The global 
age-standardised adult diabetes prevalence was estimated at 8.3% in men and 
7.5% in women in 1980, predicted to rise to 9.8% and 9.2% respectively in 
2008. The number of people with diabetes was estimated to increase from153 
million in 1980 to 347 million in 2008.20 
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Shaw et al.14 used 133 population-based studies from 91 countries to estimate 
age- and sex-specific diabetes prevalence in adults aged 20-79 years in 216 
countries. Diabetes prevalence data were obtained from published national 
studies and personal communications. Smoothed age- and sex-specific 
diabetes prevalence estimates were generated by applying logistic regression 
models, and then applying such estimates to each national population 
distribution for 2010 and 2030 (UN population estimates) to estimate national 
prevalence and numbers of adults with diabetes. The world prevalence of 
diabetes among adults in 2010 was estimated at 6.4% (285 million adults), and 
predicted to increase to 7.7% (439 million adults) by 2030.14 
Wild et al.15 estimated the global prevalence of diabetes for all age groups in 
2000 (as used in the WHO GBD Study) and made projections for 2030. They 
obtained age- and sex-specific data on diabetes prevalence from population-
based prevalence studies from a limited number of countries. The diabetes 
prevalence estimates were then extrapolated to all the 191 WHO member 
states, using a combination of criteria including geographical proximity, ethnic, 
and socioeconomic similarities. Smoothed age-specific estimates of diabetes 
prevalence were produced using DISMOD 2 software. Information on DISMOD 
2 software is extensively discussed in chapter 5, as it was also used in this 
thesis. Concisely, DISMOD is a mathematical disease model designed to 
supplement data on a disease epidemiology by exploiting the causal relations 
between the various available variables that describe a disease process.157 Wild 
et al. used as inputs into DISMOD the age- and sex-specific diabetes 
prevalence (from country-specific prevalence studies), remission (assumed to 
be zero), and estimates of relative risk of mortality among people with diabetes 
(from literature). DISMOD provided as outputs estimates of prevalence, 
incidence, and mortality that are ‘internally consistent’. The prevalence 
estimates were then applied to the UN population estimates for individual 
countries for 2000 and 2030. The future projections in diabetes prevalence were 
informed by demographic changes alone. In addition, it was assumed that other 
diabetes risk factor levels (e.g. obesity and physical activity) remain constant in 
developed countries. In comparison, in developing countries, urbanisation was 
used as a proxy measure of the levels of risk factors, as urbanisation in these 
countries is associated with obesity, reduced physical activity, and changes in 
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dietary habits. The estimated worldwide prevalence of diabetes (all age groups) 
was 2.8% (171 million individuals) in 2000 and 4.4% (366 million individuals) in 
2030 with higher rates among men than women.15 
In a relatively older study, King et al.16 used age-specific diabetes prevalence 
estimates from the WHO’s diabetes database (collected from 32 countries). 
They applied these prevalence data to the UN demographic estimates for the 
world’s population, in order to predict the global prevalence of diabetes in adults 
aged ≥20 years for three points in time (1995, 2000, and 2025). As used in the 
study of Wild et al.15, for countries lacking valid prevalence estimates, data were 
extrapolated from neighbouring countries or those with most similar ethnic and 
socioeconomic characteristics. Projections in diabetes prevalence were 
informed by the trends in population size, age structure and levels of 
urbanisation. Prevalence of diabetes in adults worldwide was estimated to be 
4.0% in 1995 and was projected to rise by around 35% to reach 5.4% by 2025. 
The number of adults with diabetes in the world was predicted to rise from 135 
million in 1995 to 300 million in 2025, with the majority of this increase occurring 
in developing countries.16 
Another relatively old study is that of Amos et al.17, in which the global diabetes 
prevalence was estimated for 1995 and projected to 2010. Country-specific data 
on diabetes prevalence were obtained mainly from epidemiological studies 
published during the period 1980-1997, which used the WHO 1980 and 1985 
diagnostic criteria with OGTT to define diabetes. As with the previously 
mentioned studies, when diabetes prevalence data were not available for a 
given country, data were obtained from another country with a similar ethnic 
composition and level of economic development. The country-specific diabetes 
prevalence data were then applied to the corresponding national age 
distribution, in order to estimate diabetes prevalence for 1995 and make 
projections to 2010. The main variables used to inform projections were the 
level of economic development [Gross National Product (GNP) per capita] and 
urbanisation. The number of people with T2DM was estimated at around 115 
million in 1995 and 215 million in 2010.  
However, these estimates have some limitations, such as paucity of data, 
particularly for many developing countries.15 In addition, it is possible that 
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individual studies used for estimations and projections were not representative 
of the whole country in which they were performed. Moreover, some country-
specific estimates were extrapolated to neighbouring countries, which might 
give inaccurate estimates of DM prevalence. 
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Table  3.2. Studies of estimates and projections of the global prevalence of diabetes 
Study 
(year published) 
Main sources of data on 
diabetes prevalence Age (years) Diagnostic criteria 
Covariates used to inform 
projections 
Global estimates and 
projections (of diabetes 
prevalence and/or number 
of people with diabetes) 
year result 
Whiting et al. [9] 
(IDF Diabetes Atlas, 
2011)  
 Published prevalence 
studies (1980-2011) 
 Health statistics reports 
 Contacts with regional 
diabetes researchers 
20-79  WHO 1985 
 ADA 1997 
 HbA1c 
Demographic changes (changes 
in age, sex, and urbanisation) 
2011 
2030 
366 million 
552 million 
Danaei et al. [20] 
(WHO, 2011) 
 Published national surveys 
 Health statistics reports 
 The WHO Global Infobase 
≥25  ADA 1997   National income  
 Urbanisation  
 National availability of multiple 
food types 
 Age-standardised mean BMI 
1980 
 
2008 
8.3% (men) 
7.5% (women) 
9.8% (men) 
9.2 (women) 
Shaw et al. [14] 
(2010) 
 Published prevalence 
studies 
 Contacts with regional 
diabetes researchers 
20-79  WHO 1985 
 ADA 1997 
 Self-reported 
Demographic changes (changes 
in age, sex, and urbanisation) 
2010 
2030 
6.4% (285 million) 
7.7% (439 million) 
Wild et al. [15] 
(2004) 
Population-based prevalence 
studies 
All age 
groups (both 
type 1 and 
type 2 
diabetes) 
 WHO 1985 Demographic changes (assuming 
constant levels of risk factors, 
such as obesity and physical 
activity, in developed countries 
versus using urbanisation as a 
proxy in developing countries) 
2000 
2030 
2.8% (171 million) 
4.4% (366 million) 
King et al. [16] 
(1998) 
The WHO’s diabetes database ≥20  WHO 1985  Trends in population size, age 
structure and levels of 
urbanisation 
1995 
2025 
4.0% 
5.4% 
Amos et al. [17] 
(1997) 
 Published epidemiological 
studies (1980-1997) 
 Contacts with regional 
diabetes researchers 
All age 
groups 
 WHO 1980 
 WHO 1985 
 Level of economic 
development [Gross National 
Product (GNP) per capita] 
 Urbanisation 
1995 
2000 
2010 
115 million 
147 million 
215 million 
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3.2. Diabetes burden in developing countries 
In the past, the industrialised countries were the main focus for NCDs, and 
these diseases were known for a long time as “diseases of affluence”.4, 158 
However, in the last few decades, NCD levels (including T2DM) have increased 
globally with higher morbidity and mortality numbers and rates in developing 
countries. It has been estimated that NCDs are responsible for around 50% of 
the total disease burden in these countries.11, 55 The main reason for these 
elevated levels is the increase in the major risk factors (e.g. obesity, physical 
inactivity, smoking, changes in diet) in these countries, as a consequence of 
rapid urbanisation and changes in the population lifestyle and nutrition. In 
addition, increasing life expectancy has resulted in ageing populations and 
elevation of the rates of chronic diseases.46 It has been well documented by 
various studies that T2DM prevalence is lowest among people who still have a 
more active ‘traditional’ or ‘primitive’ lifestyle in developing countries, in spite of 
similarities in ethnicity and genetic characteristics (as discussed in chapter 2).52, 
66, 159-161 
The estimates and future projections of diabetes burden in developing countries 
are rising progressively. Over the 30-year period from 1995 to 2025, the 
increase was estimated to be around 170% in the number of adults with 
diabetes in developing countries, from 84 to 228 million, compared to 42% 
increase, from 51 to 72 million, in developed countries. Thus, by 2025, more 
than 75% of people with diabetes will reside in developing countries, as 
compared with 62% in 1995.16 Between 2000 and 2030, the estimated 
percentage change in the number of people (all ages) with diabetes in 
developing versus developed countries was estimated to range from 104-163% 
and 20-54% respectively.15 Another study estimated that between 2010 and 
2030, there will be a 69% estimated increase in the numbers of adults with 
diabetes in developing countries and a 20% estimated increase in developed 
countries.14 These great differences in the projected numbers of diabetes cases 
have been attributed to two main factors. First, the population demographic 
differences have been projected to be large between developed and developing 
countries. For developed countries, total population size has been projected to 
remain relatively stable, with an 11% increase from 1995 to 2025 of 1 billion. On 
the other hand, the population increase in developing countries will be around 
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80%, from 2.5 billion in 1995 to 4 billion in 2025.16 Second, the levels of 
diabetes risk factors (particularly obesity) in developing countries have been 
estimated to increase substantially over time. In a recent WHO study13, the 
regions of Southern Africa, North Africa and Middle East, and Central Latin 
America have been classified to have the highest prevalence rates of obesity 
(particularly in women) globally in 1980 and 2008. However, most global 
estimates and projections of diabetes prevalence did not directly account for the 
increased prevalence of risk factors (e.g. obesity) in developing countries. 
Instead, as mentioned in section 3.1.2, these global projections mainly relied on 
demographic changes and urbanisation to inform future estimates. Some of 
these studies (IDF9 and Wild et al.15) have acknowledged that the reported 
projections of diabetes burden might be higher if the observed increasing levels 
of obesity in some countries have been modelled directly. 
The age distribution of people with diabetes has also been found to be different 
in developing countries (discussed in chapter 2). While the majority of diabetes 
cases in developed countries are in the older age groups, the majority of cases 
in developing countries tend to be among young and middle-aged people.16 
This implies that the health, social, and economic burdens of the disease 
extend to even younger ages and for a longer period of an individual’s life 
span.162 
Health services in most developing countries are organised to primarily tackle 
acute communicable diseases. These services are often not ideally developed 
to promote effective care and prevention for NCDs.12 As a result, unfortunately, 
there are now many ‘poorer’ developing countries that face a double burden, 
since the levels of infectious diseases (e.g. HIV/AIDS, tuberculosis, malaria, 
etc) continue to be high, in addition to increasing levels of NCDs.48, 163 
3.3. Diabetes burden in the Eastern Mediterranean Region 
In the WHO’s Eastern Mediterranean Region (EMR) (Figure  3.1), the problem of 
T2DM is mounting. There has been a rapid increase of the disease prevalence 
rates in both sexes in the EMR.114 The majority of countries in this region have 
witnessed massive and rapid socioeconomic developments over the last four 
decades. These improvements in social and economic standards have been 
recognised as the major reason for the epidemiological transition of risk and 
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disease burden in the region.112, 164-166 The WHO has estimated that around 
47% of the EMR’s burden of disease is due to NCDs and that this figure is 
expected to rise to 60% by 2020.114 
 
 
Figure  3.1. Map of the WHO’s Eastern Mediterranean Region (EMR) 
The prevalence of major risk factors for NCDs have been estimated to be very 
high in this region.114 According to estimates of the regional WHO office in EMR 
in 2004, 14.5% of adults (≥20 year-old) in the region had diabetes, 43% were 
overweight/obese, and 40% of men were smokers (Table  3.3).114 As with most 
developing countries, many EMR countries have reported the onset of T2DM at 
the second and third decades of age in a large proportion of cases, and in some 
countries the disease is emerging in children.162  
Table  3.3. Distribution of NCD risk factors among adults (≥ 20 years-old) in the countries of the EMR114 
Risk factor Regional adjusted mean (%) Range (%) 
Smoking   
Males 40 9-82 
Females 13 - 
Hypertension 26 7-48 
Diabetes 14.5 3-36 
Overweight/ obesity 43 11-79 
Dyslipidaemia 50 4-57 
Physical inactivity 79 18-97 
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The IDF’s region of Middle East and North Africa (MENA), which is similar to the 
WHO’s EMR with inclusion of Algeria and exclusion of Somalia and Djibouti, 
has been recognised as the major hot spot for diabetes in the world. According 
to the IDF, MENA had the highest estimated prevalence of diabetes (12.5%) 
globally in 2011, and will remain to have the highest predicted prevalence 
(14.3%) by 2030. This is equivalent to 32.8 million people with diabetes in 2011 
and 60 million people in 2030.9 In 2012, diabetes has resulted in 356,586 
estimated deaths in MENA, and approximately US$ 12 billion have been spent 
on treating diabetes in the region.167 
The majority of countries in EMR were found to have national guidelines for the 
prevention and management of diabetes, and more than 50% of these countries 
reported having diabetes control plans. However, according to the WHO, 
although preventive strategies exist in many EMR countries, these strategies 
are not being rationally or widely utilised.162 
Among all countries in the EMR, the countries of the Gulf Cooperation Council 
(GCC) have the highest levels of diabetes, and are almost constantly among 
the top 10 countries with the highest diabetes prevalence globally. Therefore, 
the next section focuses on prevalence rates of diabetes and the risk factors 
studied in this thesis (obesity and smoking) in the GCC countries. 
3.4. Prevalence of diabetes, obesity and smoking in the countries of 
Gulf Cooperation Council 
3.4.1. Overview 
The Gulf Cooperation Council (GCC) was established in 1981 between six 
countries located on the coast of the Arabian Gulf (Figure  3.2). These countries 
are Saudi Arabia, Bahrain, Kuwait, Oman, Qatar, and United Arab Emirates 
(UAE). These countries declared that the GCC was established in view of the 
special relations between them, their similar political systems, and common 
objectives.168 People of these countries have many familial inter-relations, and 
share many similarities in environments, lifestyle, and social and cultural 
habits.169 
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 Figure  3.2. Map showing the GCC and neighbouring countries 
Compared to Saudi Arabia, all the remaining five countries are small and have 
small population sizes. The total area of GCC countries is 2,672,700 km2, with 
Saudi Arabia alone constituting an area of approximately 2,250,000 km2.168 In 
2002, the total population of all GCC countries has been estimated to be around 
32 million. The population of Saudi Arabia alone constituted around 22 million, 
compared to around 3.5 million in UAE, 2.5 million in Oman, 2.5 million in 
Kuwait, 685,000 in Qatar, and 672,000 in Bahrain.168 
The GCC countries are known to be the major source of oil in the world, with 
the strongest economies among countries of the EMR. The gross domestic 
product (GDP) of these countries in 2008 has been estimated to be 1060 billion 
US dollars, with an average GDP per capita of 28,300 US dollars.168 UAE has 
been ranked to have the second highest GDP per capita in the world in 2009.170 
The GCC countries have witnessed substantial social and economic 
developments in the recent decades, with great changes toward sedentary 
lifestyles and ‘western’ dietary habits of their populations.171 These countries 
are now considered a major focus for diabetes globally. According to the IDF, all 
the GCC countries, except Oman, are among the top 10 countries with the 
highest prevalence of diabetes in the world in 2011 and 2030.9 
In the next subsection, the published national population-based studies of 
prevalence of diabetes, obesity, and smoking in the GCC countries (except 
Saudi Arabia) are presented. Then, section 3.5. discusses in more detail the 
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Saudi context in terms of demography, health care system, levels of NCDs, 
diabetes care, and the relevant studies on the prevalence of diabetes, obesity 
and smoking.  
3.4.2. Published studies on the prevalence of diabetes, obesity, and smoking 
in the GCC countries 
A comprehensive literature review was conducted for the national population-
based studies that reported the prevalence of T2DM and the two risk factors 
studied in this thesis (obesity and smoking) in the GCC countries. The search 
was carried out using Medline database with relevant search terms (appendix 
1). Results of these prevalence studies are shown in Tables  3.4–3.6. 
The inclusion criteria for studies were the following: a) a nationwide population-
based cross sectional survey; b) multistage stratified random sampling 
techniques; c) both men and women were included; d) prevalence of outcome 
of interest (i.e. T2DM, obesity, and smoking) was reported; and e) diagnostic 
criteria of T2DM and definition of obesity were clearly stated.  
The exclusion criteria were a) a study that covered a subnational sample of 
population (e.g. covered only one region of the country, or only one sex); b) a 
study that reported the prevalence of self-reported diabetes or self-
measurement of weight and height; and c) duplicate papers that used the same 
data but reported the results for different age ranges (in this case, the most 
recent paper that reported the prevalence for adults was selected). 
In general, all these studies used good sampling techniques and covered large 
sample sizes of both sexes with good response rates. They used standard 
global criteria for diagnosis of T2DM (WHO and ADA criteria) and obesity (BMI 
≥30 kg/m2). Thus, the studied samples and results were most likely reliable and 
representative of each country’s population. 
Most of the selected studies excluded pregnant women, but did not differentiate 
between type 1 and type 2 diabetes. In this thesis, the reported prevalence 
rates of diabetes in adults were considered as being for T2DM, as T2DM 
constitutes around 90% of all diagnosed cases of diabetes and is the most 
common type of diabetes in adults.  
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Prevalence of T2DM in these studies ranges between 9.8–29.4%172-178 (Table 
 3.4). The highest prevalence was reported in Bahrain177 but this study covered 
an older study population (40–69 years) than other studies in the remaining 
countries (≥20 years). UAE had the second highest prevalence (21.4%),174 
while Oman reported the lowest prevalence in two studies (9.8% and 11.6%).175, 
178 The prevalence in all studies was almost equal in both sexes or was slightly 
higher in women, except in Bahrain where the prevalence in women (35.3%) 
was considerably higher than men (25.4%).177 
Studies showed very high prevalence rates of obesity in the GCC countries 
(Table  3.5). The studies were based on BMI (≥ 30 kg/m2) for diagnosis of 
obesity and none of them used other measures, such as WC or WHR. 
Prevalence of obesity ranges between 19-47.5%172-174, 179-182 with prevalence 
rates of more than 45% in Kuwait172 and Qatar173. However, one study in 
Oman180 reported a prevalence of 47.9% but that was for overweight (BMI ≥ 25 
kg/m2) and obesity combined. The lowest prevalence (19%) was reported in 
Oman, but it should be noted that data of this study were old (for year 1991), 
although the study was published in 2004.179 Prevalence of obesity in the GCC 
countries was substantially higher in women than men, as reported by almost all 
studies. 
For smoking prevalence, there were only three studies (from Oman, Bahrain 
and Kuwait) found to be conducted at national level183-185 (Table  3.6). No 
published studies were obtained for Qatar and UAE. In these three studies, the 
prevalence of ‘active’ smoking (defined as smoking at the time of survey) was 
measured. The highest overall prevalence was in Bahrain (21.2%)184 followed 
by Kuwait (17%)185, whereas it was much lower in Oman (7%)183. However, the 
study in Oman covered an older population (40–69 years) than studies in 
Bahrain (≥15 years) and Kuwait (≥18 years). In all studies, the prevalence of 
smoking in men was much higher than women. This is an expected finding, 
since female smoking in the GCC countries is not acceptable in their 
conservative social cultures. 
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Table  3.4. Studies on the prevalence of diabetes in the GCC countries 
Study (year published) Country Sample size Age (years) Diagnostic criteria 
Prevalence of diabetes (%) 
men women total men women total 
Al Rashdan et al. [172] 
2010 
 
Kuwait 918 1362 2280 20-65 ADA 1997 
FPG 
- - 18.1 
Bener et al. [173] 
2009 
 
Qatar 571 546 1117 ≥ 20 WHO 1999 
OGTT if FPG < 7 mmol/l 
15.2 18.1 16.7 
Malik et al. [174] 
2005 
 
UAE 2498 3346 5844 ≥ 20 WHO 1999 
OGTT if FPG < 7 mmol/l 
20.4 22.3 21.4 
Al-Lawati et al. [175] 
2002 
 
Oman 2905 2933 5838 ≥ 20 WHO 1999 
FPG 
11.8 11.3 11.6 
Abdella et al. [176] 
1998 
 
Kuwait 1105 1898 3003 ≥ 20 WHO 1985 
OGTT if FPG ≥ 6.1 mmol/l 
14.7 14.8 14.8 
Al-Mahroos et al. [177] 
1998 
 
Bahrain 1195 834 2029 40-69 WHO 1985 
OGTT 
25.4 35.3 29.4 
Asfour et al. [178] 
1995 
Oman 2133 2963 5096 ≥ 20 WHO 1985 
OGTT 
9.7 9.8 9.8 
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Table  3.5. Studies on the prevalence of obesity in the GCC countries 
Study (year published) Country 
Sample size Age 
(years) 
Prevalence of obesity (%) 
BMI ≥30 kg/m2 
men women total men women total 
Al Rashdan et al. [172] 
2010 
 
Kuwait 918 1362 2280 20-65 39.2 53.0 47.5 
Bener et al. [173] 
2009 
 
Qatar 571 546 1117 ≥ 20 - - 45.2 
Malik et al. [174] 
2005 
 
UAE 2498 3346 5844 ≥ 20 24.0 40.0 33.0 
Al-Lawati et al. [179] 
2004 (data for year 1991) 
 
Oman 2128 2958 5086 ≥ 20 10.5 25.1 19.0 
Al-Riyami [180]  
2003 
 
Oman 3074 3356 6430 ≥ 20 42.0* 46.0* 47.9* 
Musaiger et al. [181] 
2001 
 
Bahrain 298 216 514 30-79 21.2 48.7 35.0 
Al-Mahroos et al. [182] 
2001 Bahrain 1168 845 2013 ≥ 20 25.3 33.2 29.3 
* Prevalence estimates are for overweight and obesity combined (BMI ≥25 kg/m2) 
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Table  3.6. Studies on the prevalence of active smoking in the GCC countries 
Study (year published) Country Sample size Age (years) 
Definition of active 
smoking 
Prevalence of active smoking (%) 
men women total men women total 
 
AlRiyami et al. [183] 
2004 
 
Oman 3506 3505 7011 40-69 Smoking at the time of survey 13.4 0.5 7.0 
          
Hamadeh et al. [184] 
1992 
 
Bahrain 4785 4497 9282 ≥ 15 Smoking at the time of survey 33.1 9.2 21.2 
          
Memon et al. [185] 
2000 Kuwait 1798 2061 3859 ≥ 18 
Smoking at the time of 
survey and had smoked 
more than 100 cigarettes 
in their lifetime 
34.4 1.9 17.0 
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3.5. Prevalence of diabetes, obesity and smoking in Saudi Arabia 
3.5.1. Introduction 
The Kingdom of Saudi Arabia occupies most of the Arabian Peninsula. It is one 
of the largest countries in the Middle East Region, extending between the Red 
Sea in the west to the Arabian Gulf in the east. Saudi Arabia has diverse 
geography with coastal areas in the east and west (coastline of around 2650 
km), high rugged mountains mainly in the south and south-west, but the sandy 
desert areas remain to occupy most parts of land. Climate conditions are 
extremely hot and harsh at summer times, with temperatures reaching 50°C 
and more, and dry cold at winter with minimum temperatures of less than 0°C in 
some regions. Riyadh is the Capital City of the country, located in its centre. 
The Kingdom is divided into 13 administrative regions (provinces) as illustrated 
in Figure  3.3. 
 
Figure  3.3. Administrative regions of Saudi Arabia 
Saudi Arabia is one of the strongest economies in its region, as it is ranked the 
first in the list of oil-producing countries globally. Oil was first discovered in 
Saudi Arabia in 1930s and the country now has the largest reserves of 
petroleum in the world, and is the largest exporter. The petroleum sector 
accounts for roughly 80% of budget revenues, 45% of GDP, and 90% of export 
earnings. As a result, Saudi Arabia witnessed a massive improvement in 
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socioeconomic development in the past five decades, with great progress 
having been made in health, education, housing and the environment. There is 
now an extensive network of modern roads, highways, airports, seaports and 
huge industrial cities and complexes for petrochemical, desalination and other 
plants. The industrial sector is the dominant source of wealth, creating around 
51% of GDP with most of this from oil and gas mining; the service sector 
accounts for 43% of GDP and agriculture for 5%.186 Presence of the two Holy 
Mosques in Mecca and Medina makes Saudi Arabia one of the most popular 
destinations to all Muslims all over the world. This may also contribute to the 
Saudi economy income, as many millions of people come to visit these places 
during Hajj (the Muslim pilgrimage to Mecca) and all-round the year. 
3.5.2. Demography  
The population of Saudi Arabia was estimated in the last completed national 
census, held in 2004, to be 22,678,262. The age and sex distribution of the 
Saudi population is shown in the 2004 population pyramid in Figure  3.4. The 
Kingdom has a relatively young population, where those who aged less than 15 
years constitute 39.9% of the total Saudi population, compared to 56.6% aged 
15-64 years, and 3.5% aged ≥ 65 years.187  
 
Figure  3.4. The Saudi population pyramid, 2004187 
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Table  3.7 shows the major demographic indicators in the last few years, as 
estimated by the Saudi Ministry of Health.188 
Table  3.7. Major demographic indicators of the Saudi national population188 
Indicator 2004 2005 2006 2007 
Crude birth rate/ 1000 population 25.3 25.3 24.9 24.5 
Crude death rate/ 1000 population 3.8 3.8 4.0 3.9 
Infant mortality rate/ 1000 live births 19.1 18.5 18.6 17.4 
Maternal mortality rate/ 100,000 live births 12.0 12.0 14.6 14.6 
Life expectancy at birth (years) 73.6 72.5 73.1 73.3 
Crude birth and death rates fell from 49/1000 population and 23/1000 
population in 1960189 to 24.5/1000 population and 3.9/1000 population 
respectively, in 2007.188 Furthermore, infant mortality greatly decreased from 
170/1000 live births in 1960189 to 17.4/1000 live births in 2007.188 In contrast, life 
expectancy notably increased from 44 years in 1960189 to 73.3 years in 2007.188 
National censuses in Saudi Arabia do not account for ethnic groups of the 
Saudi-national population. However, other sources estimated that Arabs 
constitute more than 90% of them, and less than 10% are descended from Afro-
Asian origins, mainly black Africans, Turks, Iranians, Indonesians, Indians, 
Russians and others.190 These ethnic minorities primarily immigrated as pilgrims 
hundreds of years ago and then resided permanently in some regions of the 
country.190    
The population growth rate between 1992 and 2004 was estimated to be 2.5%, 
which is less than that between 1974 and 1992 (3.7%). This decrease was 
attributed to decreased birth rate, mainly due to improved level of education, 
increased access to contraceptives and older age at marriage than in the 
past.187 As a result, the population in the ≤15 year age group decreased by 
18.9% from 1992 to 2004. On the other hand, the population in the ≥65 year 
age group increased by 6.7% during the same period, due to improved health 
services and increased life expectancy of population.187 
The 2004 census also showed that around two thirds of the Saudi population 
live in the three most urbanised regions of the country (Riyadh, Mecca, and 
Eastern Province). The total Saudi population living in urban areas increased 
from 49% in 1974 to 80% in 2004. Rate of illiteracy among Saudis fell by half 
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from 28.4% in 1992 to 14.7% in 2004.187 Around 86% of Saudi families have 
one car or more, 90% of them have television, and 25% of them had internet 
access in 2004.187 According to the World Bank, the Saudi GDP per capita in 
2009 was US$ 23,429, which is one of the highest in the world.170 
Saudi Arabia (and other GCC countries) has a large population of foreign 
workers (expatriates). In the 2004 census, it has been estimated that around 
25% (6,150,922) of the Saudi population were non-Saudi nationals.187 During 
the past five decades (the post-oil era), Saudi Arabia has been highly 
dependent on foreign labour. Later, with the progressive increase in the national 
population size and the considerable improvements in education and training, a 
large proportion of foreign labour in professional, administrative and technical 
work positions have been replaced by Saudi nationals. Nevertheless, 
expatriates still comprise the majority of employees in some occupations, 
mainly agriculture, cleaning and domestic service industries. The 2004 
estimates showed that the main bulk of the foreign population is formed of 
people from South Asian origin (Indians, Pakistanis, Bangladeshis and Sri 
Lankans), Arabs (mainly Egyptians, Yemenis, Syrians and Sudanese), Turkish, 
and Pacific and Southeast Asia (mainly Indonesians and Filipinos).187 However, 
in terms of net migration, Saudi Arabia has almost a stable situation. It has been 
estimated that the net migration rate in Saudi Arabia was -0.6 migrant/ 1000 
population in 2012.191 
Also, data on the socioeconomic status of population and regional disparities/ 
inequalities are limited from Saudi Arabia. However, the 2004 census reported 
some socioeconomic indicators of population by region (e.g. level of education, 
type of housing, and main occupational groupings).187 Table  3.8 summarises 
these indicators in the three most urbanised regions (Riyadh, Mecca and 
Eastern Province) in addition to two terminal regions (Jazan and Northern 
Borders). In general, the level of education is better in the three main regions 
compared to the other two terminal regions. However, the differences in the 
main occupational groupings are small. There are slightly higher proportions of 
people working in ‘high-class’ (e.g. management and professional scientific) 
occupations in the three main regions. In contrast, proportions of people 
working in ‘lower-class’ (e.g. agriculture and manual) occupations are slightly 
higher in terminal regions. In terms of housing type, there is a higher proportion 
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of ‘villa’ households in Northern Borders Region, and a higher proportion of ‘flat’ 
households in the three main regions, but this could be mainly attributed to 
regional differences in the population density and relative costs of households. 
Table  3.8. Some socioeconomic indicators by region from the national census, 2004 
 Riyadh Mecca Eastern Province Jazan 
Northern 
Borders 
Level of education (% population aged ≥10 years) 
Illiterate  10.5 14.1 9.9 26.2 18.3 
      
University 10.9 10.4 9.1 5.9 7.1 
      
Post-graduate 0.8 1.1 0.4 0.1 0.1 
 
Main occupational groupings (% population aged ≥15 years) 
Directors & managers 11.5 11.0 9.8 6.9 8.4 
      
Specialists in professional and 
technical fields 
14.7 13.5 12.6 10.1 10.2 
      
Workers in service sector 10.7 11.6 11.6 12.8 12.0 
      
Workers in agriculture and 
manual jobs 
4.1 4.9 4.6 9.2 8.1 
      
Type of housing (% households) 
Traditional house 12.5 31.2 17.8 73.2 20.2 
      
Villa 27.7 7.9 27.6 9.5 34.4 
      
Flat  34.4 51.1 42.6 8.2 18.4 
3.5.3. Overview of the Saudi health care system 
The health care system in Saudi Arabia started in 1925 when a ‘public health 
department’ was established in Mecca and was responsible for sponsoring and 
monitoring free health care for the population and pilgrims through establishing 
a number of hospitals and dispensaries in the main cities.192, 193 The network of 
health services started to expand after the establishment of the Ministry of 
Health (MOH) in 1951. However, health services were predominantly curative 
and delivered by an extending network of dispensaries and hospitals in most 
regions of the Kingdom. Preventive health care was carried out by some 
regional ‘health offices’ while some of the common communicable diseases 
(e.g. TB, leishmaniasis, and malaria) were controlled through separate 
programmes.192 Further important development in the health care system was 
introduced when the primary health care (PHC) system was established in the 
early 1980s. Since that time, preventive care started to become a major integral 
role of PHC which currently covers all regions of the country.192, 193  
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Currently, the national health care system in Saudi Arabia is mainly run by the 
MOH, which provides free-of-charge primary, secondary, and tertiary health 
care across the whole country. MOH has a decentralised organisational and 
administrative structure.192 There are 20 health regions, each led by a Regional 
Director and having a number of health sectors. Each health sector includes at 
least one general hospital and a number of primary health care centres 
(PHCCs), school health services and health offices. The policies, plans and 
programmes of the MOH are implemented through this structure. The curative, 
preventive, and rehabilitative services are also provided by other governmental 
and private sectors.192 In the last few years, there has been a big advance in 
the size and quality of health care services in KSA. There is currently a network 
of around 2000 PHCCs and more than 200 hospitals, including tertiary and 
specialist hospitals.192 The MOH budget was approximately 3% of the total 
national budget in 1970, and this increased to 5% in 1992, 8% in 2001,189 and 
12% in 2011.194 
PHCCs represent the leading and largest component of the Saudi health care 
system, where approximately 83% of public health sector attendances occur in 
PHC clinics.195 They are distributed throughout the country and serve as the 
patient’s first point of contact with the national health system. The centres form 
a network closely linked to the general hospitals, which in turn are linked to 
tertiary care services by a referral and feedback system.192 The health centres 
implement the various aspects of PHC which include primary, secondary and 
tertiary preventive services, in addition to curative health care. Moreover, they 
carry out population and family censuses within their catchment areas, maintain 
patient health records, survey schools in their areas and conduct routine home 
visits. The essential services provided by a PHCC include maternal and child 
health, immunisation, management of chronic diseases (e.g. hypertension and 
diabetes), dental health, provision of essential drugs, environmental health (e.g. 
water safety and food hygiene), health education and disease control.192  
The MOH hospitals are also distributed all over the country and provide a wide 
range of emergency and advanced medical and surgical services. The health 
care services within hospitals vary according to their levels (secondary general 
hospitals and tertiary referral and specialist hospitals).193 During the last few 
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years, many types of complex surgical procedures have been made in the 
Saudi hospitals as first in the Middle East region. Examples include conjoint 
twins separation, liver transplantation and some advanced open heart 
surgeries.188 
In addition to PHCCs and hospitals, there are also some other health care 
institutions which provide specific health services. For instance, a number of 
chest/ TB hospitals, physiotherapy and rehabilitation centres and anti-smoking 
centres are distributed in different regions.188   
3.5.4. Non-communicable diseases in Saudi Arabia 
Because of the massive improvement of health care services along with the 
marked socio-economic advances in the past few decades, the predominant 
disease pattern in Saudi Arabia has shifted from communicable to non-
communicable diseases.192 This is consistent with the ‘epidemiological 
transition’ that has been taking place in most developing countries, as described 
in section 3.1.1. In the period of 1920s-1960s, the main health concern in Saudi 
Arabia was the control of various infectious diseases such as TB, leishmaniasis, 
schistosomiasis, malaria, measles, etc. Although some sporadic cases and 
outbreaks of these diseases remain, they are no longer the major cause of ill 
health in the Kingdom. During the last 30-40 years, there has been sharp 
elevation in the levels of several non-communicable health problems, such as 
diabetes, cardiovascular disease, cancer, and road traffic accidents (RTA).19, 188, 
195, 196 As described earlier in section 3.1.1, this increase in the burden of NCDs 
can mainly be attributed to changes in the population lifestyle and dietary habits 
toward a modern/western lifestyle with sedentary behaviours and increased 
access to high calorie and unhealthy foods.  
Prevalence of hypertension and hyperlipidaemia in Saudi Arabia has been 
estimated at 26% and 19.3% respectively according to the WHO Stepwise 
sureveillance (STEPS) in 2005.19 Of the 413 deaths per 100,000 in 2002, 144 
(35%) were due to cardiovascular disease.196 Neoplasms account for 
approximately 5% of hospital reported deaths.188 In addition, RTA is a major 
problem faced by the health care system in Saudi Arabia, and it has been 
estimated that of all the deaths that occur in the MOH hospitals, more than 80% 
71 
 
are due to road traffic crashes.195 Diabetes and its risk factors (e.g. obesity and 
smoking) have also been reported at very high levels, and this is discussed in 
detail in section 3.5.6.  
In 2003, the Saudi MOH established the “General Directorate of Non-
communicable Diseases” with a principal aim of preventing NCDs and their 
complications through various measures. These measures include, for example, 
enhancing the public awareness toward NCDs, their risk factors and 
complications, and population screening for early diagnosis of NCDs.197 The 
Directorate also initiates and coordinates national strategies, plans and 
campaigns for control and prevention of NCDs. There are several units/ 
programmes that follow the Directorate, such as the National Diabetes 
Programme (NDP), Diet and Physical Activity Programme, Cardio-vascular 
Disease Control Programme, Cancer Control Programme, Premarital Screening 
Programme and others.197 
3.5.5. Diabetes health care in Saudi Arabia 
Most diabetes health care is provided to patients within PHCCs. Each patient 
diagnosed with diabetes has to be registered in his/her PHCC for regular follow 
up, health education, and treatment by general practitioners. Each patient has a 
specific diabetes record in the PHCC. The record contains information on the 
patient’s vital signs, urine and blood investigation results, treatment and health 
education advices, all recorded regularly (usually monthly). Oral hypoglycaemic 
drugs and insulin are all available in PHCCs. Patients are referred to secondary 
or tertiary care levels if further evaluation or management is needed. In addition, 
there are 20 “Diabetic Clinics” distributed all over the 20 health regions of Saudi 
Arabia. Patients are also referred regularly to these clinics for further evaluation 
by specialist doctors. In 2007, for example, more than 400,000 visits to these 
clinics were recorded by MOH.188 Data on T2DM patients are forwarded from 
health sectors to the NDP in MOH. 
The NDP is the central unit within the General Directorate of Non-
communicable Diseases that contains the national morbidity and mortality 
statistics of patients diagnosed with diabetes (all types). In addition, the NDP 
initiates and coordinates national strategies and campaigns for diabetes control 
and prevention. Important roles of the NDP include, for example, health 
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promotion, screening of high risk groups of population, ongoing supervision of 
diabetes health services in PHCCs, hospitals and diabetes clinics (personal 
communication, Dr M. Al-Hamid, the Head of NDP, 2012). Although the 
establishment of the NDP in Saudi Arabia is an exremely important step, it 
remains a ‘young’ programme, which needs time for several future 
developments in terms of reliable population-based data on diabetes. For 
example, in relation to this thesis, cross sectional data on prevalence of T2DM 
and its risk factors could not be obtained from NDP because, as mentioned 
earlier, all data in the NDP are related to the diagnosed ‘cases’ of the disease 
only. There were no diabetes population-based surveys carried out by NDP at a 
national level. Furthermore, a national diabetes registry is not currently 
available, although development of one is now in process (personal 
communication, Dr M. Al-Hamid, the Head of NDP, 2012). 
The public health planners in Saudi Arabia (and other GCC countries) have 
started to realise the massive and progressively growing burden of diabetes in 
their countries. Currently, Saudi Arabia adopts the GCC Action Plan for 
prevention and control of diabetes, which was established by all the GCC 
countries in 2007.198 This action plan has been set for the 10-year period of 
2008-2018. It aims to achieve several objectives related to the prevention of 
diabetes (primary, secondary and tertiary prevention), in addition to improving 
the health care services offered to diabetic individuals and supporting the 
relevant research. The objective of primary prevention aims to reduce the 
prevalence of T2DM, mainly through reducing the levels of its risk factors, such 
as obesity, physical inactivity and smoking. Several strategies have been set, 
including setting policy reduction targets for obesity and smoking prevalence to 
be achieved by each member country by 2018. These policy targets are 
discussed in detail in chapter 8. 
In Saudi Arabia, the Diet and Physical Activity Programme199 has already 
developed in late 2011 a national strategy for diet and physical activity, which is 
compatible with the WHO’s Global Strategy on Diet, Physical Activity and 
Health.200 The Programme has also established in 2012 a ‘national committee’ 
for diet and physical activity, chaired by the MOH and includes a number of 
relevant departments (e.g. schools, universities, food industry, media, etc) that 
can assist in implementing the strategy. Elements of the strategy include, for 
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example, increasing the community awareness of the importance of physical 
activity and healthy diet, integrating physical activity and healthy diet in school 
curriculums and environments, and increasing and improving the outdoor and 
indoor spaces for public walking and exercise.199 
Moreover, the Tobacco Control Programme (TCP)201 in the Saudi MOH 
(established in 2002) aims to reduce the levels of active and passive tobacco 
smoking in the Kingdom. The main preventive strategies of the TCP are raising 
the awareness of people on the smoking health hazards, monitoring the 
relevant legislations (e.g. prohibition of smoking in public areas and 
workplaces), and offering free help and consultation to those who decide to quit 
smoking (through the Tobacco Control Clinics).  
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3.5.6. Published studies on the prevalence of type 2 diabetes, obesity and 
smoking in Saudi Arabia  
A comprehensive literature review was carried out on the prevalence studies of 
T2DM, obesity and smoking in Saudi Arabia through Medline database. The 
reference lists of relevant articles were checked to identify other studies. 
Moreover, personal communications were made with the head of the Saudi 
NDP to obtain more relevant information and guidance to further studies. 
The search strategy used in Medline is shown in appendix 1. Inclusion and 
exclusion criteria were similar to those used for studies from the GCC countries 
(as discussed in section 3.4.2).  
3.5.6.1. Prevalence studies of type 2 diabetes in Saudi Arabia 
Literature review identified five national population-based studies. These 
studies were carried out between 1989 and 2005 and covered both sexes of the 
Saudi population. They varied in the age groups included and diagnostic 
methods and criteria (Table  3.9).  
The most recent published study was the WHO’s STEPwise Surveillance 
(STEPS) of NCDs risk factors19 in 2005. In this study, individuals aged 15-24 
years were included, in addition to the recommended age of the WHO STEPS 
approach (25-64 years). An overall prevalence of 15.8% and 14.9% was 
reported in men and women aged 15-64 years respectively, using the ADA 
1997/ WHO 1999 diagnostic criteria (fasting plasma glucose ≥7 mmol/l). 
However, the reported overall prevalence for those aged 25-64 years was 
20.1% in men and 18.3% in women. Results showed significant increasing 
prevalence rates with increasing age in both sexes. The age-specific 
prevalence rates were very similar for men and women across all age groups, 
except for the oldest age group (55-64 years), where women had a higher 
prevalence (49.7%) than men (39.5%).  
Another study was conducted by Al-Nozha et al.18 over a five-year period 
between 1995 and 2000. They studied around 17,000 adult Saudi subjects 
aged 30-70 years. Diagnosis of diabetes was based on the ADA 1997 criteria 
with measuring only fasting blood glucose. This study showed that the overall 
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prevalence of diabetes in the Saudi population was 23.7% which was 
significantly higher among men (26.2%) than women (21.5%), and among those 
living in urban areas (25.5%) than the residents of rural areas (19.5%). Again, 
the reported prevalence of diabetes increased significantly with increasing age 
in both men and women, and there were no noticeable differences in the age-
specific prevalence for all age groups of both sexes.  
Earlier studies included relatively younger age groups and showed lower overall 
prevalence rates.35, 36, 202 In one study that was carried out  during 1992-1995,36 
the total prevalence in those aged >14 years was reported to be 5.6% and 4.5% 
among men and women respectively, using the WHO 1985 criteria with 
measuring both fasting blood glucose and OGTT to define diabetes (fasting 
blood glucose ≥7.8 mmol/l and/or 2 hour OGTT ≥11.1 mmol/l). In another  
study, Al-Nuaim202 studied a large sample of individuals aged ≥15 years and 
reported a significantly higher prevalence among residents in urban (men 5.1%, 
women 4.9%) than rural settings (men 4.5%, women 4.5%), using random (not 
fasting) blood glucose of ≥11.1 mmol/l to define diabetes. Osman et al.35 
reported a higher prevalence of 13.2%  among  subjects aged ≥18 years, with a 
fasting blood glucose of ≥7.0 mmol/l used as a cut-off value to diagnose 
diabetes. 
In general, all these studies used good sampling techniques of multistage 
stratified random sampling of all regions of the Kingdom with probability 
proportionate to population size of each region. They covered large nationwide 
sample sizes of households and considered both sexes. The reported response 
rates in these studies were excellent. With the exception of Al-Nuaim study, in 
which the response rate was 69%, the other studies reported response rates 
ranging from 92-98%. Thus, the studied samples were most likely reliable and 
representative of the total Saudi population. The studies used standardised 
methods, tools, and criteria for measuring blood glucose and diagnosis of 
diabetes. 
Nevertheless, the data periods in these studies overlap, and they covered 
different age ranges of the Saudi population, used different diagnostic criteria to 
define diabetes, and reported the prevalence rates in different age-group 
intervals. These differences may make it difficult to compare between the 
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results. However, generally, there was a rise in diabetes prevalence in Saudi 
Arabia over time, as reported by these studies. Such an observed rise could be 
mainly explained by three factors. First, the levels of risk factors for developing 
diabetes (e.g. obesity, physical inactivity, smoking, etc) had, in parallel, 
increased over time (as discussed in the next two sections). Second, the 
change in the diagnostic criteria of diabetes from the old fasting glucose and 
OGTT cut-offs to the new lower fasting values might contribute to this rise, as 
the new criteria probably classified more individuals to be diabetics compared to 
the old criteria. Third, the incidence of diabetes in the Saudi population might 
increase over time leading to this elevation in the disease prevalence. 
Osman et al.35 reported only the overall prevalence of diabetes for the total 
population without providing age- and sex-specific prevalence rates. Moreover, 
Al-Nuaim202 used ‘random’ blood glucose (no fasting glucose) measurements to 
diagnose diabetes, which might lead to missing of significant numbers of 
individuals with diabetes. However, although measuring random glucose can be 
considered a limitation by today’s standards, such a method was recommended 
by the WHO, at the time of the study, to be used in epidemiological studies.203 
As mentioned in section 3.4.2, most of diabetes prevalence studies excluded 
pregnant women from their population samples. However, these studies did not 
differentiate between type 1 and type 2 diabetes. In this thesis, the reported 
prevalence rates of diabetes in adults were considered as being for T2DM, as 
T2DM constitutes approximately 90% of all diagnosed cases of diabetes and is 
the most common type of diabetes in adults. 
3.5.6.2. Prevalence studies of obesity in Saudi Arabia 
Five nationwide population-based studies of obesity prevalence have been 
identified through literature review. All these studies used BMI to define obesity 
(BMI ≥30 kg/m2). Like the diabetes prevalence studies, these studies were also 
carried out between 1989 and 2005 and covered both sexes of Saudis (Table 
 3.10). 
The WHO STEPS study19 reported a mean BMI of 27.0 kg/m2 in men and 29.1 
kg/m2 in women aged 15-64 years. The prevalence of obesity among men and 
women in 2005 was 28.3% and 43.8% respectively. Al-Nozha et al.34 reported 
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an overall prevalence of obesity of 35.6% among those aged 30-70 years 
during 1995-2000, which was significantly higher in women (44%) than men 
(26.4%). 
In another study conducted during 1990-1993 among those aged ≥20 years, Al-
Nuaim et al.37 reported an overall obesity prevalence of 22.1%. Again, it was 
significantly higher among women (26.6%) than men (17.8%). Moreover, 
Osman et al.35 reported an overall obesity prevalence of 20.8% during 1989-
1994 (15.6% in men and 24.9% in women). Warsy and El-Hazmi36 reported an 
overall prevalence of obesity of 15.8% which was significantly higher in women 
(18.6%) than men (11.9%). 
As with the diabetes prevalence studies, these studies covered large samples 
of both sexes with excellent response rates from all regions of Saudi Arabia, 
using multistage stratified random methods and probability proportionate to 
size. They used standardised tools to measure BMI, which is recommended by 
WHO as the most useful population-level measure of obesity. However, BMI 
has its own limitations that have been described earlier in chapter 2. 
On the other hand, the data periods in these studies overlap, and they covered 
samples with different age ranges, and reported their results in different age 
group bands. In addition, Al-Nuaim37 reported only age-specific prevalence 
rates of obesity (no sex-specific).    
3.5.6.3. Prevalence studies of smoking in Saudi Arabia 
There are more than 30 published studies investigating the prevalence of 
smoking in Saudi Arabia during the last three decades. Unfortunately, the 
majority of these studies were carried out among only men from certain 
population subgroups (e.g. school students, medical students, physicians, etc) 
and were limited only to some cities or provinces. According to these studies, 
the prevalence of current smoking among Saudis ranges from 2.4-53% (median 
17.5%).204  
There are three nationwide population-based studies19, 38, 39 on current smoking 
among adults of both sexes in Saudi Arabia, conducted between 1990-2005 
(Table  3.11). The overall prevalence of active smoking in these studies ranges 
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from 11.6–12.8%. As expected, the prevalence of smoking was substantially 
higher among men than women as reported by two studies19, 39, since female 
smoking in Saudi Arabia is considered socially unacceptable and stigmatised.39 
However, recent data from subnational surveys suggested that female smoking 
prevalence in Saudi Arabia is increasing, particularly among some specific 
subgroups (e.g. university students). In these surveys, smoking prevalence 
ranges between 4.2%205 and 9.1%206, and the ‘water-pipe’ tobacco was the 
commonest type consumed, as it is often readily available, and is perceived as 
‘fashionable’.205 There are no recent surveys that measured the prevalence of 
female smoking at the national level.  
In general, these studies used representative nationwide population-based 
samples through multistage stratified random sampling techniques and 
probability proportionate to size. As with diabetes and obesity prevalence 
studies, these studies covered both sexes and different age ranges of the Saudi 
population.  
Nevertheless, it is not easy to collect information on smoking in Saudi Arabia, 
particularly among women and in some regions where smoking represents a 
social and religious stigma, even for men. Some people may hide their smoking, 
particularly during an interview or in the presence of other family members if 
they are young or female.39 Therefore, as documented by Jarallah et al.39, 
smoking prevalence in Saudi Arabia may have been underestimated in 
prevalence studies. Furthermore, the data periods in these studies overlap, and 
they used different definitions for self-reported active smoking (Table  3.11) 
through interviews or questionnaires, and none of them used biomedical 
validation of smoking status. 
In total, this chapter reveals the massive and growing global burden of T2DM 
and its risk factors, particularly on developing countries, including Saudi Arabia. 
As this thesis uses a modelling approach to estimate and predict T2DM 
prevalence trends in Saudi Arabia, the next chapter presents a comprehensive 
theoretical discussion on epidemiological modelling.  
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Table  3.9. Summary of the published national studies on type 2 diabetes prevalence in Saudi Arabia 
Study (year 
published) 
Year 
conducted 
Sample size Age 
(years) 
Diagnostic 
criteria 
T2DM prevalence (%) Age 
groups 
(years) 
Male 
prevalence 
(%) 
Female 
prevalence 
(%) 
Males Females Total Males Females Total 
WHO STEPS 
(2005) [19 ] 
2005 2312  2340  4652  15-64  WHO 1999  
FPG  
15.8 
(20.1)*  
14.9 
(18.3)*  
15.3 
(19.2)*  
15-24 2.0 2.4 
          25-34 2.8 4.5 
          35-44 13.7 14.8 
          45-54 31.0 31.1 
          55-64 39.5 49.7 
Al-Nozha et al. 
(2004) [18]  
 
1995-2000 -  -  16,917  30-70  ADA 1997  
FPG  
26.2  21.5  23.7  30-39 13.0 11.6 
          40-49 23.9 22.4 
          50-59 33.5 34.3 
          60-70 36.2 36.9 
Osman et al. 
(2000) [35]  
1989-1994 2673  3590  6253  ≥ 18  ADA 1997  
FPG  
-  -  13.2  - - - 
Warsy and El-
Hazmi (1999) 
[36]  
 
1992-1995 6162  8498  14,660  > 14  WHO 1985  
OGTT  
5.63  4.53  4.99  14-29 0.38 0.99 
          30-44 7.01 5.03 
          45-59 21.06 22.09 
          > 60 28.75 24.37 
Al-Nuaim (1997) 
[202]  
 
1990-1993 6873  6304  13,177  ≥ 15  Random Plasma 
Glucose (RPG). 
DM if RPG >11.1 
mmol/l.  
OGTT if RPG 
5.5–11.1mmol/l  
12.0 (U)**  
7.0 (R)** 
14.0 (U)  
8.0 (R)  
-  15-20 2.0(U); 1.0 (R) 2.0(U); 1.0 (R) 
          21-30 3.0(U); 2.0(R) 5.0(U); 3.0(R) 
          31-40 9.0(U); 4.0(R) 15.0(U); 8.0 (R) 
          41-50 28.0(U); 17.0(R) 36.0(U); 11.0(R) 
          51-60 39.0(U); 22.0(R) 49.0(U); 26.0(R) 
          > 60 35.0(U); 19.0 (R) 42.0(U); 29.0(R) 
* Prevalence rate for population aged 25-64 years   ** U: urban; R: rural 
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Table  3.10. Summary of the published national studies on obesity prevalence in Saudi Arabia 
Study (year 
published) 
Year 
conducted 
Sample size Age 
(years) 
Obesity prevalence (%) 
(BMI ≥ 30 kg/m2) 
Age 
groups 
(years) 
Male  
prevalence 
(%) 
Female 
prevalence 
(%) Males Females Total Males Females Total 
WHO STEPS 
(2005) [19]  
2005 2244  2345  4589  15-64  28.3 
(31.5) *  
43.8 
(50.4) *  
36.2 
(41.2) *  
15-24 17.8 19.6 
         25-34 27.1 39.5 
         35-44 34.5 54.7 
         45-54 32.9 58.8 
         55-64 31.0 53.2 
Al-Nozha et al. 
(2004) [34]  
 
1995-2000 -  -  17,232  
 
30-70  26.4  44.0  35.6  30-39 25.2 40.2 
         40-49 30.3 50.2 
         50-59 27.8 45.9 
         60-70 22.1 39.0 
            
Osman et al. 
(2000) [35]  
1989-1994 2673  3590  6253  ≥ 18  15.6  24.9  20.8  18 - <21 9.0 16.5 
         21 - <31 10.4 22.1 
         31 - <40 20.7 32.7 
         ≥ 40 20.8 33.2 
            
Warsy et al. (1999) 
[36]  
1992-1995 6646  9064  15,710  > 14  13.1  20.3  15.8  14-19 4.7 4.5 
         20-29 9.1 13.2 
         30-39 15.9 26.9 
         40-49 19.2 36.0 
         50-59 16.4 28.7 
            
Al-Nuaim (1997) 
[37] 
 
1990-1993 5407  5244  10,651  ≥ 20  17.8  26.6  22.1  20-29 14.7 (both sexes combined) 
         30-39 24.8 (both sexes combined) 
         40-49 33.2 (both sexes combined) 
         50-59 26.3 (both sexes combined) 
* Prevalence rate for population aged 25-64 years
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Table  3.11. Summary of the published national studies on smoking prevalence in Saudi Arabia 
Study (year 
published) 
Year 
conducted 
Sample size Age 
(years) 
Definition of active 
smoking 
Smoking prevalence (%) Age 
groups 
(years) 
Male 
prevalence 
(%) 
Female 
prevalence 
(%) Males Females Total Males Females Total 
             
WHO STEPS 
(2005) [19] 
 
2005 2336  2414  4750  15-64  - 24.2 
(23.6) *  
1.4 
(1.5) *  
12.6 
(12.2) *  
15-24 26.0 0.96 
          25-34 31.7 1.3 
          35-44 27.4 1.4 
          45-54 19.2 2.2 
          55-64 13.1 1.1 
             
Al-Nozha et 
al. (2004) [38] 
 
1995-2000 - -  17,232  
 
30-70  Smoking in the last one 
year before survey  
-  -  12.8  -  - - 
             
Jarallah et al. 
(1999) [39]  
 
1990-1993 - -  8,310  ≥ 15  Smoking one or more 
cigarettes daily for 6 
months or more before 
survey 
21.1 0.9  11.6  15-20 6.7 (both sexes combined) 
          21-30 13.7 (both sexes combined) 
          31-40 15.8 (both sexes combined) 
          41-50 12.2 (both sexes combined) 
          51-60 8.2 (both sexes combined) 
          61-70 8.0 (both sexes combined) 
* Prevalence rate for population aged 25-64 years
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Chapter 4. Epidemiological Modelling 
As stated in chapter 1, this thesis used the approach of modelling to study the 
trends and projections of the prevalence of T2DM in Saudi Arabia. Therefore, 
this chapter presents a theoretical discussion on modelling in terms of definition, 
uses, types, structure, and limitations. In addition, this chapter also discusses 
the steps involved in developing a model, and the existing diabetes models in 
the literature. 
4.1. What is a model? 
In brief, a model is a simplification of reality.207 The National Research 
Council208 defined a model as “… a replicable, objective sequence of 
computations used for generating estimates of quantities of concern…”.  
According to the International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) Task Force on Good Research Practices - Modelling 
Studies,22 a model is defined as “an analytic methodology that accounts for 
events over time and across populations based on data drawn from primary 
and/or secondary sources”. So, a model is a logical mathematical framework 
that permits the integration of facts and values, and that links these data to 
outcomes that are of interest to health-care decision makers. 
4.2. What are the uses of models in epidemiology and public health? 
Models have been extensively used in the fields of epidemiology and public 
health. They are used mainly to guide policy decisions in many areas that affect 
human life and health.21 For instance, models can be used to predict the trends 
in a disease prevalence and mortality under alternative health policy scenarios 
or to compare the effectiveness and cost-effectiveness of different 
treatments.209 Since models combine data from various local sources with trial 
based effectiveness evidence, they can form a helpful tool for decision making 
process.21 Models permit policy makers to examine and compare between 
various future policy options and intervention scenarios within a population; 
hence they provide a platform for appropriate planning and resource 
allocation.22, 23 
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One of the most important advantages of modelling is its ability to use different 
types of inputs from various sources and to reveal the logical connection 
between these inputs and outputs of interest.22 A model combines and 
integrates into a coherent whole different types of data from prevalence studies, 
prospective studies, controlled trials, meta-analyses, routine surveillance, expert 
opinions, and assumptions.207 However, different types of data sources are 
associated with varying data quality, and this can result in uncertainty of the 
model parameters. Thus, models and their results should be represented as 
aids to decision making, not as statements of scientific fact,22 i.e. model results 
should never be presented as unconditional claims of estimates or 
effectiveness. Rather, the model outputs should be represented as conditional 
upon the input data and assumptions.22, 23 In other words, models should 
eliminate the random noise, which exists in ‘real-world’ situations and focus 
solely on the relationship between inputs and outcomes.210 Therefore, models 
must be subjected to sensitivity analyses to identify the impact of potential 
uncertainties around the different input parameters on the results.22  
4.3. Why model type 2 diabetes? 
As mentioned in chapter 3, T2DM is a global health concern and is associated 
with substantial morbidity and mortality.45 The disease imposes enormous 
social and economic burdens on both individuals and health care budgets.6 
Such a burden is heavier in developing countries, which are facing a dramatic 
increase in T2DM levels, and where the health care systems and policies are 
not well organised to tackle the growing problem.12 
Policy makers in T2DM prevention and control programmes are required to 
make decisions and to allocate resources, which should be important and have 
lasting consequences for a large number of the population.211 Unfortunately, 
there is limited evidence regarding epidemiological studies or clinical trials that 
measured disease progression and the impact of interventions on the disease 
prevalence and longevity.28 When such information is not available, the logical 
analytical framework offered by modelling can be a helpful tool. Models can be 
used to gain insights about the likely future trends in the levels of T2DM and 
related risk factors, and to quantify the impact of reducing such risk factors in 
preventing the disease and its complications.28, 211 
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Diabetes modelling studies have been widely used to provide different types of 
useful information for policy makers. Some models have been used to forecast 
the future burden of diabetes and impact of some interventions (e.g. risk factor 
modifications, treatments) on the future disease levels.28, 212 Other models, such 
as the United Kingdom Prospective Diabetes Study (UKPDS), estimated the 
likely occurrence of major complications of diabetes (e.g. ischaemic heart 
disease, myocardial infarction, stroke, renal failure, blindness, etc) over a 
lifetime and calculated health economic outcomes, such as quality adjusted life 
expectancy.26 Moreover, other models have been intended for assessment of 
budgetary impact of diabetes in terms of the direct health care costs associated 
with the main diabetic complications.211 
One of the most common types of models used for chronic diseases (including 
T2DM) is a “Markov model”. This particular type/ class of modelling is also used 
in this thesis. Therefore, the next section presents a brief discussion of Markov 
models, their general structure and limitations.  
4.4. Overview of Markov models 
4.4.1. Background 
Based on their analytical methodology and their use of time, models can 
generally follow one of two broad classes. First, simple decision trees, which 
are very useful for modelling events or health states that do not occur 
repeatedly and the likelihood of the event does not change over time.213 This 
modelling approach fits well for acute and short-term conditions (e.g. bacterial 
infection, antibiotic therapy, adverse events in a hospitalised patient). Second, 
Recursive trees, which involve health states that can repeat over time. The 
model starts with a cohort of individuals and follows them for a specific time 
period. In each time cycle (e.g. one year), individuals have a risk (probability) of 
developing the outcome. The probability of developing the outcome may 
change every year.213, 214 Markov modelling is a logical extension of recursive 
trees for more complex events occurring over time. Hence, Markov modelling is 
ideal for chronic diseases such as T2DM.214 
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4.4.2. General structure of a Markov model 
Figure  4.1 illustrates a very simple general structure of a Markov model.215 The 
model starts with a cohort of patients/persons that are followed over some 
specified time (i.e. the time horizon of analysis). The time horizon is divided into 
equal increments of time, referred to as Markov cycles.214 A Markov model 
assumes that an individual is always in one of a finite number of discrete health 
states referred to as Markov states (illustrated in Figure  4.1 as ovals). All events 
of interest are modelled as transitions from one state to another (illustrated in 
Figure  4.1 as arrows). Therefore, a Markov model is classified as a state- 
transition model. During each Markov cycle, an individual may make a transition 
from one state to another, or may remain in the same state in consecutive 
cycles (illustrated in Figure  4.1 as arrows leading from a state to itself).214, 216, 217 
In most models, only certain transitions are allowed. For instance, an individual 
with T2DM assigned to “Diseased” health state is not allowed to make a 
transition back to “Well” state, assuming that the remission rate is zero. In 
addition, of course, a person in “Dead” state cannot make a transition to any 
other state. Thus, “Dead” state is referred to as an absorbing state, where the 
entire cohort will have been absorbed by this state after a sufficient number of 
cycles have passed.214 
The relative size of of the “starting states” can usually be determined from 
population demographic trends or prevalence studies. State transitions are 
expressed as transition probabilities (TPs), which are assumed to take place for 
each cycle of the model. Transition probabilities are abstracted from literature or 
may represent experts’ assessment.216 In the literature, state transitions are 
most commonly expressed as “rates”. Rates can, theoretically, range from zero 
to infinity and are expressed per unit time. On the other hand, probabilities 
range from zero to one and have time built into them implicitly. To  convert  
rates  into  probabilities,  the  following   formula  is  generally used:    
P[t] = 1 – e-rt, where P is transition probability; t is time units; and r is rate.216, 217 
However, this formula mostly produces probabilities of transition between 
states. The probability of staying in the same state in a given cycle will be 
simply 1 minus the probability of leaving that particular state, because the 
probability of moving to states in each cycle must sum to 1 (since an individual 
must be in one and only one state at any given time).216, 217  
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Figure  4.1. Simple illustration of the general structure of a Markov model215 
4.4.3. Limitations of Markov models 
The most important limitation of Markov models is the loss of memory of prior 
states, which is referred to as the Markovian assumption or Markov property. 
This restriction specifies that the behaviour of the process subsequent to any 
cycle depends only on its description in that cycle; and that knowing only the 
present health state of an individual is sufficient to project the future states. In 
other words, all individuals in a given state at a given time have the same 
prognosis, regardless of how they reached their present state or how long they 
spent in the previous state.214, 217 
As previously stated, data for modelling are obtained from various sources. As 
this may be considered an advantage, it can also be a limitation. Such different 
types of data sources are associated with varying data quality, and this can 
result in uncertainties of some modelling parameters. Thus, all Markov models 
should be subjected to appropriate sensitivity analyses to identify the impact of 
uncertainty of different parameters on the modelling results.22  
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4.5. What are the steps of developing a model? 
Figure  4.2 demonstrates a flow chart of the most important steps in developing 
a model.  
 
1. Identifying the research questions and objectives 
 
2. Determining and developing the model structure 
 
3. Data gathering 
 
4. Populating the model 
 
5. Data entry 
 
6. Calculation of model outcomes 
 
7. Sensitivity analysis 
 
8. Model validation 
 
9. Interpretation of results 
Figure  4.2. Flow chart for the steps of developing a model 
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Identifying the research questions and objectives is the first step in 
developing a model. The research question must be clearly stated. In addition, 
the competing interventions, target population, length of follow up and outcome 
measures must also be explicitly defined.218  
After defining the research problem, the appropriate model structure should be 
determined. This step is primarily based on understanding of the nature and 
progression of the health event of interest.218 In general, disease modelling 
(particularly chronic disease modelling) combines two major components: the 
disease natural history and different interventions in order to answer policy 
questions.209 Natural history of chronic diseases can be very complex. At the 
same time, a model structure should be as simple as possible. Therefore, the 
ISPOR Task Force recommended that “it is not necessary to model the full 
complexity of a disease if the decision can be informed by a more aggregated 
structure, in terms of disease states or population subgroups”.22  
The structure of a model should be consistent both with a coherent theory of the 
modelled disease and with available evidence regarding causal linkages 
between variables.22 However, this does not mean that all causal linkages must 
have been proven by, for example, showing that the effect size is statistically 
significant (p<0.05). Instead, it means that the linkages assumed are not 
contradicted by available evidence and are consistent with widely accepted 
theories.22  
The structure of a model should reflect the time dependence of events being 
modelled. As previously discussed, in a simple decision tree, the likelihood of a 
modelled event is mostly time-independent (i.e. does not change over time).213, 
214 On the other hand, recursive trees and Markov models fit well for chronic 
conditions with prolonged or continuous exposure to a risk.210, 217 The modelled 
disease in this thesis (T2DM) is a typical example for such chronic health 
events.  
It is important to indicate that the level of complexity (e.g. number of health 
states, number of modelled outcomes) of a chronic disease model depends on 
the amount of data available to inform the model parameters.209 Therefore, if 
the available modelling data are limited, some explicitly-justified compromises/ 
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assumptions might be needed regarding, for example, the way of modelling a 
chronic disease epidemiology and natural history.209, 219 
Data gathering is the next step after determining the suitable modelling 
structure. It was discussed earlier that models are flexible regarding the types of 
required data. Modelling data can be obtained from different sources which vary 
in terms of data amount and quality.22, 207 These data sources may be health 
records, clinical trials, literature (e.g. meta-analyses), databases, etc. If there 
are no reliable data on some variables, expert opinions and assumptions can be 
useful.22, 218 One of the recommendations of the ISPOR Task Force22 was that 
“a model should not be faulted because existing data fall short of ideal 
standards of scientific rigor. Decisions will be made, with or without the model. 
To reject the model because of incomplete evidence would imply that a decision 
with neither the data nor the model is better than a decision with the model but 
without the data. With the model, the available evidence can be used in a 
logical way to inform the decision; without the model, an opportunity to utilise 
the available evidence within the logical framework will have been forgone”. 
However, it is essential that all data sources are described with their strengths 
and limitations, and any assumptions must also be clearly addressed, since the 
modelling results are conditional upon such data inputs and assumptions.22 
Populating the model and then data entry are the stages where the collected 
data are incorporated into the model. There are two basic steps that should be 
undertaken regarding populating a model. First is setting up the transition 
probabilities (TPs) of the model. TPs represent the tendency of an individual to 
make a transition from one state to another or the likelihood that an event will 
occur in a given length of time.214 TPs are derived mainly from published 
sources, such as clinical trials and systematic reviews. Examples of information 
that can be used to set up TPs include mortality rates, RRs, incidence rates of a 
disease, and response to a treatment.217 The second important step in 
populating a model is determining the types of outcome parameters. This 
depends largely on the nature of the modelled health event. For instance, in 
some diabetes forecasting models, the major modelling outcome would be the 
projected prevalence of diabetes and the number of diabetic individuals.220 In 
comparison, models of other chronic diseases (e.g. ischaemic heart disease) 
may use different outcome parameters that consider quality of life or duration of 
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survival of patients (e.g. Quality Adjusted Life Years “QALYs”, Disability 
Adjusted Life Years “DALYs”, Deaths Prevented or Postponed “DPPs”, and Life 
Years Gained “LYG”).23,213 
After data entry, the next stage of analysis work can be started for calculation 
of model outcomes. The analysis work is an iterative process, and the key 
modelling variables should be tested using different values/ ranges 
(scenarios).209, 213, 221 This process is known as sensitivity analysis, which 
must be a vital part of all modelling studies.22 Sensitivity analysis  is essential to 
deal with the problem of uncertainty of some model variables, which can 
originate from uncertain values or subjective estimates and assumptions.21  
There are two broad types/ techniques of sensitivity analysis: one-way 
(univariate) and multi-way (multivariate). In the one-way (univariate) sensitivity 
analysis, only one variable is examined at a time. After the base-case scenario 
is estimated, the outcome variable is re-estimated holding all parameters 
constant apart from the one parameter chosen. This method can be applied 
repeatedly to as many variables in a model as desired.222 One commonly used 
subtype of univariate sensitivity analysis is the “threshold analysis”. In this type 
of analysis, the size of one input parameter is changed over a range, followed 
by determining the level above or below which the conclusions change, i.e. the 
‘threshold’ point at which there is no better alternative than others. Threshold 
analysis is commonly used in models with cost effectiveness analyses.222  
In the multi-way (multivariate) sensitivity analysis, more than one modelling 
variable are examined simultaneously. It can be two-way, three-way or n-way 
analysis.222 For example, a two-way analysis examines varying values of a 
range for two parameters at the same time. Both of these parameters should be 
common to the interventions assessed and, eventually, the impact of changes 
on the outcomes of two mutually exclusive interventions is assessed.222  
One subtype of the multi-way sensitivity analysis is referred to as “analysis of 
extremes” method. This method has been used in several modelling studies, 
including this thesis as discussed in detail in chapter 5. In this type of sensitivity 
analysis, the best and worst estimates of a variable (or a number of variables) 
are incorporated and the model is then run to produce extreme estimates of the 
output.219, 222 However, a common criticism to the ‘analysis of extremes’ method 
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is that the choice of ‘extreme values’ is mostly arbitrary,223 and it is unlikely that 
all of the extreme values of key modelling parameters will occur 
simultaneously.222  
A second subtype of multi-way sensitivity analysis is known as “probabilistic 
sensitivity analysis”, which is a relatively complex process, in which all input 
parameters are considered as random quantities and therefore are associated 
with a probability distribution.224, 225 Uncertainties in the model inputs are 
formulated by a joint probability distribution and then the induced uncertainties 
in the outputs are analysed.225 
Moreover, another example of multi-way sensitivity analysis is the “scenario 
analysis”, in which a number of interesting values for some of the modelling 
parameters are examined under different scenarios in order to evaluate the 
expected outcomes of each scenario.224 Scenario analysis was also used in this 
thesis as discussed in chapters 5,6, 7, and 8.  
Model validation is an important step in order for a model to earn the 
acceptance of decision makers and health care providers.226 The ISPOR Task 
Force grouped model validation approaches into three main categories.22 First, 
internal validation through internal testing and ‘debugging’. This type of 
validation can be performed by using null or extreme input values to check if 
they result in the expected output values.22 The second type of validation is 
between-model validation, in which a model is validated against other models 
addressing the same problem (convergent validity).22, 227 The third type is 
external validation that compares a model’s outputs with observed data. 
However, models are based on evidence available at the time they are 
constructed. Thus, as discussed earlier, models should never be regarded as 
complete, immutable or statements of scientific facts. They should be subjected 
to repeated updates as new evidence becomes available regarding their 
structure and input parameters.22 
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4.6. Existing diabetes models in the literature 
4.6.1. Background 
For many years, large-scale randomised controlled trials on diabetes clinical 
outcomes and impact of interventions have been the main data source for 
clinicians and decision makers involved in diabetes care. Nevertheless, 
although such trials remain a vital source of information, they often do not 
provide data on the long-term (>5-10 years) scale. In addition, the results of a 
clinical trial are directly applicable only to the population recruited and the 
protocol used.228, 229 Alternatively, clinicians and policy makers have traditionally 
had to rely on their own judgement. However, there are wide variations in 
practice patterns of clinicians, and it is impossible for the human mind to 
address the complexity, variability and uncertainties of health and disease.229 In 
addition, as discussed in chapter 3, the global prevalence rates of diabetes and 
its risk factors are progressively increasing, and countries need to gain insights 
on the future trends in the disease levels. Therefore, the logical analytic 
framework of modelling, as a valuable tool to provide this information, has been 
largely accepted by leading diabetes organisations, such as the American 
Diabetes Association (ADA).229 
There is now a growing utilisation of computer modelling technology to study 
various clinical and epidemiological aspects of diabetes.229 There is a large 
body of published literature that describes several diabetes models and 
presents their results.26-32 These models used different methodologies, obtained 
data from different types of sources, and reported different outcome measures.  
4.6.2. Published diabetes models 
4.6.2.1. Clinical and economic diabetes models 
As discussed earlier, this thesis aims mainly to study the past, current, and 
future trends in the prevalence of T2DM in Saudi Arabia, which has a relatively 
limited amount of data on T2DM epidemiology and risk factors. The majority of 
published diabetes models have utilised data and presented results that are 
related to the ‘clinical’ and ‘health economics’ aspects of T2DM (e.g. modelling 
the disease clinical progression and complications, modelling the health care 
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costs of diabetes, and modelling the cost-effectiveness of some drug treatments 
and interventions).24, 25 In addition, many models have not used the ‘general 
population’ or ‘total diabetic population’ as their population of interest. Rather, 
these models have studied ‘sub-samples’ of diabetics (e.g. those diabetic 
patients with a certain complication) in order to model and project certain 
outcomes, costs, intervention impact, etc.230 Table  4.1 presents a brief list of 
some examples of published diabetes models with different output parameters 
related primarily to the disease complications and health economics.    
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Table  4.1. Summary of examples of published diabetes models with their main output parameters    
 Name of model/ authors Type Setting and/or study population Main output parameter(s) 
1 The CORE Diabetes Model 
[28, 226, 231] 
Markov model (internet-
based, interactive computer 
model) 
Type 1 and type 2 
diabetic populations  
• Development of long-term diabetes complications 
• Life expectancy 
• Quality adjusted life expectancy 
• Total health care costs of patients with the complications 
2 The UKPDS Outcomes Model 
[26] 
Probabilistic discrete-time 
model (implemented in 
software) 
Consists of several sub-
models, each for one 
complication 
Type 2 diabetic 
populations 
• Estimated 1st occurrence of each of 7 diabetes-related 
complications 
• Life expectancy 
• Quality adjusted life expectancy 
• Costs of complications in people with T2DM 
3 Eastman et al. [232, 233] Markov model 
Consists of several sub-
models for complications 
United States, 
Incident T2DM cases 
aged 25-74 years 
• Occurrence of T2DM complications  
4 EAGLE [27] Markov model Type 1 and type 2 
diabetics in many 
European countries 
• Long-term effects of diabetes treatment and related costs in 
type 1 and type 2 diabetes 
5 The Global Diabetes Model 
(GDM) [29] 
Continuous, stochastic 
microsimulation model 
Individuals with diabetes 
and representative 
diabetic populations 
• Predicted complications, survival, utilities, and medical care 
costs 
6  JADE [234] Probabilistic discrete-event 
simulation model 
United Kingdom, 
Type 2 diabetic 
population (UKPDS 
participants) 
• projected long-term impacts on life expectancy and 
occurrence of complications of diabetes when using different 
HbA1c thresholds for intensifying treatment of T2DM 
7 Saaddine et al. [235] Markov model United States, 
US population with 
diagnosed diabetes, 
age ≥40 years 
• Projected number of people with diabetic eye complications 
for the years 2005-2050 
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Table 4.1 (cont.). Summary of examples of published diabetes models with their main output parameters 
 Name of model/ authors Type Setting and/or study population Main output parameter(s) 
8 The Cardiff Stochastic 
Simulation Cost-Utility Model 
(DiabForecaster) [236] 
Discrete-event simulation 
model 
Cardiff, United 
Kingdom, 
Large cohort of T2DM 
patients 
• Total costs  
• Total number of clinical events  
• Quality-adjusted life years (QALYs) 
9 The CDC Diabetes Cost-
effectiveness Group Model 
[237] 
Markov model United States, 
Cohort of newly 
diagnosed T2DM 
patients aged ≥25 years 
• Cost per QALY for multiple interventions 
10 Zhou et al. [238] Discrete-event simulation 
model 
Wisconsin, United 
States,  
Cohort of T2DM 
patients  
• Predicted mortality 
• Predicted prevalence rates of multiple complications and 
comorbidities of T2DM 
• Predicted average undiscounted total direct medical costs 
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4.6.2.2. Diabetes prevalence forecasting models 
There are fewer models that have attempted to study the trends in the 
prevalence of T2DM and forecast its future burden on specific populations. For 
the purpose of comparison with the model used in this thesis, Table  4.2 
provides a more detailed list of only those relevant models, which had a similar 
main output parameter as that used in this thesis (the projected population 
prevalence of diabetes). This list of ‘diabetes prevalence forecasting models’ 
was obtained through searching Medline (1980 - week 46 of 2012) using the 
following search strategy for titles and keywords: [‘diabetes OR type 2 diabetes’ 
AND ‘prevalence’ AND ‘model$ OR diabetes model$ OR prevalence model$ 
OR project$ OR forecast$’] and through cross referencing of relevant articles. 
The electronic search yielded a total of 2410 articles. The vast majority of 
search results (2336 articles) were excluded as being irrelevant after skimming 
of the titles. Abstract reviews of the remaining 74 articles resulted in excluding 
65 articles, leaving 9 articles for inclusion. Additional 3 articles were obtained 
through cross-referencing. Articles were included if they used modelling 
approaches, covered a defined general population or total/ large cohort of type 
2 diabetics, and reported projections (forecasts) of diabetes prevalence among 
the main modelling outputs. However, the data sources and results of these 
models are not presented in Table  4.2, as this brief list aims basically to 
compare the main structure and data input requirements of these models 
against the model in this thesis. In addition, the list does not include those 
models which were built to produce ‘global’ predictions of diabetes prevalence, 
such as the previously discussed models9, 14-17, 20 in chapter 3. 
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Table  4.2. Summary of diabetes models with ‘the projected diabetes prevalence’ as a main output parameter 
 Name of 
model / 
authors 
Type 
Setting and/or 
study 
population 
Main data inputs used to 
construct the model Main output parameter(s) 
Main variables 
used to inform 
the projections of 
T2DM prevalence 
Sensitivity 
analysis Validation 
1 Holman et 
al. [30] 
(the APHO* 
Diabetes 
Prevalence 
Model) 
-- United 
Kingdom, 
Population of 
England aged 
≥16 years with 
diagnosed and 
undiagnosed 
diabetes 
• Current and projected 
estimates of population 
structure (by age, sex 
and ethnicity) 
• Age- and sex-specific 
prevalence rates for self-
reported physician 
diagnosed diabetes 
• Undiagnosed diabetes 
prevalence based on 
HbA1c 
• Prevalence and future 
projections of obesity 
and overweight 
• Projected prevalence 
of diabetes (2010-
2030) 
• Demographic 
changes 
• Trends in the 
population 
rates of 
overweight and 
obesity 
Multi-
variate 
sensitivity 
analysis: 
95% CIs of 
diabetes 
prevalence 
estimates, 
and other 
data input 
parameters 
Results of the 
model 
compared 
with results 
from the 
general 
practitioner 
diabetes 
registers and 
the PBS 
Diabetes 
Prevalence 
Model 
2 Boyle et al. 
[31] 
Multiple 
discrete 
states 
dynamic 
models 
United States, 
US adult 
population aged 
18-79 years 
• Current and projected 
estimates of population 
structure, mortality 
rates, net migration, 
and births 
• Current and projected 
estimates of diabetes 
incidence, and 
prevalence of diabetes 
and ‘prediabetes’ 
• Projected annual 
diagnosed diabetes 
incidence (2008-2050) 
• Projected annual total 
diabetes prevalence 
(2008-2050) 
• Trends in 
diabetes 
incidence and 
mortality 
Results 
presented 
in different 
scenarios 
based on 
different 
values of 
incidence 
and 
mortality 
risk 
Not reported 
   * The Association of Public Health Observatories  
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Table 4.2 (cont.). Summary of diabetes models with ‘the projected diabetes prevalence’ as a main output parameter 
 Name of 
model / 
authors 
Type 
Setting and/or 
study 
population 
Main data inputs used to 
construct the model Main output parameter(s) 
Main variables 
used to inform 
the projections of 
T2DM prevalence 
Sensitivity 
analysis Validation 
3 Lau et al. 
[32] 
(The Alberta 
Diabetes 
Model) 
Life table 
model 
Alberta 
(Canada), 
Population of 
Alberta 
• Age- and sex-specific 
diabetes prevalence for 
the last observed year 
• Historical age- and sex-
specific incidence and 
mortality rates 
• Future projections of 
prevalence, incidence 
and mortality 
• Current and projected 
estimates of population 
structure 
• Detailed health care 
cost data 
• Projected prevalence 
of diagnosed diabetes 
(2008-2035) 
• Projected health care 
costs of diabetes 
(2008-2035) 
• Demographic 
changes 
• Changes in 
incidence and 
mortality 
 
Not reported Not reported 
4 Huang et al. 
[239] 
Markov 
model 
(consists of 
multiple 
modules) 
United States, 
Diabetic men 
and women 
aged 24-85 
years 
• Prevalence and incidence 
of diabetes for the 
baseline year 
• Total population structure 
and projections by age, 
sex and ethnicity 
• Population mortality data 
• Estimated lifetime costs 
for prevalent and incident 
cohorts (for all drugs and 
treatment options) 
• Initial distribution of BMI 
categories 
• Yearly transitions across 
BMI categories (estimated 
from longitudinal data) 
• Projected incidence 
and prevalence of 
obesity and diabetes 
(2009-2034)  
• The direct spending on 
diabetes care and 
complications (2009-
2034) 
• Demographic 
changes 
• Trends in the 
population 
rates of 
overweight and 
obesity 
Not reported Not reported 
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Table 4.2 (cont.). Summary of diabetes models with ‘the projected diabetes prevalence’ as a main output parameter 
 Name of 
model / 
authors 
Type 
Setting and/or 
study 
population 
Main data inputs used to 
construct the model Main output parameter(s) 
Main variables 
used to inform 
the projections of 
T2DM prevalence 
Sensitivity 
analysis Validation 
5 Magliano et 
al. [240] 
Multi-state 
life-tables 
Australia, 
population aged 
≥ 25 years 
• Age- and sex-specific 
incidence rates of 
diabetes 
• All-cause mortality in 
those with diabetes 
• All-cause mortality in 
those without diabetes 
• Lifetime risk of 
diabetes 
• The number of years 
lived free of, and the 
number of years lived 
with diabetes 
for the Australian adult 
population from the 
year 2000, and 
• Projected prevalence 
of diabetes to the year 
2025 
• Demographic 
changes 
• Incidence and 
mortality rates 
(assumed that 
the observed 
rates during 
2000 - 2005 
remain 
constant over 
the modelling 
period) 
95% CIs for 
the age-
specific 
diabetes 
incidence, 
diabetes 
prevalence 
and the RR 
for mortality 
associated 
with 
diabetes 
Not reported 
6 Mainous et 
al. [212] 
Multi-state 
Markov 
model 
United States, 
US population 
aged >20 years 
• Population data and 
projections 
• Prevalence of 
diagnosed 
diabetes and total 
diabetes burden 
(diagnosed and 
undiagnosed)  
• Proportion of the 
population at risk of 
developing diabetes 
• Diabetes mortality 
estimates [all-cause 
mortality among 
individuals with 
diabetes (either 
diagnosed or 
undiagnosed)] 
• Estimated future 
diabetes (diagnosed 
and undiagnosed) 
prevalence in 2011, 
2021, and 2031 
• Demographic 
factors  
• Incidence 
• Mortality  
• Migration 
• The trends in 
proportion of 
adults at high 
risk of diabetes 
(based on a 
national 
published 
multivariable 
diabetes risk 
score) 
Results 
presented 
under 
various 
assumed 
values 
(increase 
and then 
decrease 
by 10%, 
20%, 30%) 
of the 
proportion 
of adults at 
high risk of 
diabetes, 
and the 
mortality  
Not reported 
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Table 4.2 (cont.). Summary of diabetes models with ‘the projected diabetes prevalence’ as a main output parameter 
 Name of 
model / 
authors 
Type 
Setting and/or 
study 
population 
Main data inputs used to 
construct the model Main output parameter(s) 
Main variables 
used to inform 
the projections of 
T2DM prevalence 
Sensitivity 
analysis Validation 
7 Martinsen 
et al. [241] 
-- Greenland, 
Total population 
• Current and projected 
estimates of population 
structure aged ≥35 
years 
• Current and projected 
estimates of obesity 
prevalence 
• Base year’s prevalence 
of T2DM (≥35 years) 
• Base year’s prevalence 
of multiple 
complications of 
diabetes 
• Projected prevalence 
of T2DM (1999-2014) 
• Projected prevalence 
of complications 
(1999-2014) 
• Demographic 
changes 
• Temporal 
changes in 
obesity 
prevalence 
Results 
presented 
based on two 
assumed 
scenarios for 
the BMI 
distribution 
trends 
Not reported 
8 Narayan et 
al. [242] 
Markov 
model 
United States, 
Total population 
• Age-, sex-, and 
ethnicity-specific 
diabetes incidence, 
2004 
• Age-, sex-, and 
ethnicity-specific  
diabetes prevalence, 
2004 
• US population data, 
2004 
• Census projections of 
the US live births, 
mortality rates, and net 
migration 
• RR of mortality for 
people with diabetes 
• Prevalence of 
diagnosed diabetes in 
the US for 2005-2050 
• Incidence rate 
of diabetes in 
2004 
95% CIs for 
uncertainty in 
the model 
transition 
rates, 
including 
incidence 
Not reported 
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Table 4.2 (cont.). Summary of diabetes models with ‘the projected diabetes prevalence’ as a main output parameter 
 Name of 
model / 
authors 
Type 
Setting and/or 
study 
population 
Main data inputs used to 
construct the model 
Main output 
parameter(s) 
Main variables 
used to inform 
the projections of 
T2DM prevalence 
Sensitivity 
analysis Validation 
9 Honeycutt 
et al. [220] 
Markov 
model 
United States, 
US men and 
women with 
diagnosed 
diabetes 
• Estimated diagnosed 
diabetes prevalence 
and incidence 
• The relative risk of 
mortality from diabetes 
compared with no 
diabetes 
• Current and projected 
estimates of current 
population structure 
(by age, sex and 
ethnicity), live births, 
net migration 
• The mortality rate of 
the general population 
• Projected number of 
people with diagnosed 
diabetes (2000-2050) 
• Projected incidence 
and prevalence of 
diagnosed diabetes in 
the US (2000-2050) 
• Demographic 
changes 
 
Model run with 
lower and 
upper bounds 
on 95% CIs for 
2000 
prevalences, 
2000 incidence 
rates, and RRs 
Results 
compared 
to previous 
forecasts of 
the same 
population 
– this model 
resulted in 
higher 
forecasts 
10 Bagust et 
al. [211, 
243] 
Markov 
model 
(consists of 
multiple 
modules for 
outcomes 
and costs) 
United 
Kingdom, 
Type 2 diabetic 
populations 
• Total population 
structure and 
projections by age and 
sex 
• Prevalence of the 
major complications of 
diabetes 
• The annual excess 
cost of T2DM in 
population 
• Projected incidence 
and prevalence of 
T2DM 
• Long-term 
complications in 
people with T2DM 
• Health care costs of 
complications of 
T2DM 
• Demographic 
changes 
 
Results 
presented 
based on +/- 1 
standard error 
of the 
proportional 
reduction in 
cardiovascular 
mortality 
reported by 
UKPDS 
Not reported 
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Table 4.2 (cont.). Summary of diabetes models with ‘the projected diabetes prevalence’ as a main output parameter 
 Name of 
model / 
authors 
Type 
Setting and/or 
study 
population 
Main data inputs used to 
construct the model Main output parameter(s) 
Main variables 
used to inform 
the projections of 
T2DM prevalence 
Sensitivity 
analysis Validation 
11 Ruwaard et 
al. [244] 
-- Netherlands, 
Total population  
• Base year’s estimates 
and future projections 
of diabetes prevalence 
and incidence, and 
population life 
expectancy 
• Projected number of 
diabetic individuals 
(1980-2005) 
• Projected prevalence 
of diabetes (1980-
2005) 
• Trends in 
diabetes 
incidence and 
population life 
expectancy 
Results 
presented 
based on 
different 
variants of 
prevalence, 
incidence, 
and 
reduction of 
life 
expectancy 
The model 
prevalence 
estimates 
were 
compared 
with 
previous 
available 
cross-
sectional 
data for  
1980 
12 
 
 
 
 
 
Helms [245] -- United States, 
Total population  
• Age-specific 
prevalence of diabetes, 
1987 
• Age-specific incidence 
rate of diabetes 
• US population data and 
projections 
• Projected prevalence 
of diabetes, 1990-2050 
• Projected number of 
people with diabetes, 
1990-2050 
• Estimated 
incidence of 
diabetes 
Not reported Not reported 
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The diabetes prevalence forecasting models listed in Table  4.2 predicted the 
future prevalence of diabetes in different populations. However, these models 
varied in the type/ structure, data inputs used for model building, and the 
variables used to inform the projections of diabetes prevalence. For example, 
two of the most recent models in the list [the APHO Diabetes Prevalence 
Model30 (for England) and the model of Boyle et al.31 (for the US)] have some 
differences in the parameters used to project the future diabetes prevalence.  
Briefly, the APHO Diabetes Prevalence Model predicted the total diabetes 
prevalence (diagnosed and undiagnosed) for the population of England aged 
≥16 years for 2009, 2010, 2015, 2020, 2025, and 2030.30 The first main set of 
data inputs used in this model was the current and projected population data 
(by age, sex, ethnic group, and deprivation) from the Office for National 
Statistics (ONS). The population data used in the model were based on the 
ONS populations by ethnic group for 2002-2007. Trends in the proportion of the 
population in sex specific age groups during 2002-2007 were extrapolated to 
2030 using linear regression. Then, these proportions were applied to the 2006 
based population projections produced by the ONS. It was assumed that the 
changes in the population by ethnic group found in 2002-2007 would continue 
to apply from 2008 to 2030.30 The second set of data inputs was the age- and 
sex-specific prevalence rates for self-reported physician diagnosed diabetes, 
which were obtained from the Health Survey for England (HSE), 2006. 
Undiagnosed diabetes was also obtained from HSE 2006 and was defined as 
HbA1c of ≥6.5% (≥48 mmol/ mol) in the absence of a self-reported diagnosis of 
diabetes. To take account of differences in the prevalence by ethnic group, the 
model used data from HSE 2004, which included a booster sample of people 
from minority ethnic groups. Trends in the prevalence of overweight (BMI 25–
29.9 kg/ m2) and obesity (BMI ≥30 kg/ m2) were obtained from the HSEs 2003–
2008, and were assumed to continue to 2030. These trends in overweight and 
obesity were used to inform the projections in diabetes prevalence.30 Moreover, 
the model also used different RRs for estimations. For instance, sex-specific 
RRs by ethnicity were used for some ethnic minorities such as south Asian 
(Indian, Pakistani and Bangladeshi) men and women. Also, RRs of having 
diabetes if overweight or obese were incorporated in the estimation of future 
diabetes prevalence.30 The APHO Diabetes Prevalence Model estimated that 
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the diabetes prevalence in 2010 was 7.4% among those aged ≥16 years, and 
was predicted to rise to 8.0% in 2015 and 9.5% in 2030. The estimated 
prevalence of diabetes was higher in men (8.6%) than women (6.3%) and 
among people from South Asian (14.0%) and Black (9.8%) ethnic groups than 
in White, mixed and other ethnic groups (6.9%).30  
In comparison, Boyle et al.31 constructed a series of dynamic models to project 
the future burden of diabetes among US adults (18-79 years) up to 2050. A 
three-state model partitioned the US population into ‘no diabetes’, ‘undiagnosed 
diabetes’, and ‘diagnosed diabetes’. Then, a four-state model divided the state 
of ‘no diabetes’ into high-risk (prediabetes) and low-risk (normal glucose) states. 
The data inputs used for modelling included population data and projections up 
to 2050 from the US Census Bureau, initial year prevalence of diabetes in the 
US, and incidence rate estimates of diagnosed diabetes for the US adult 
population aged 18-79 years from 1980-2007 obtained from the Centres for 
Disease Control and Prevention (CDC). Projections in the incidence of diabetes 
for 2008-2050 were estimated using logistic regression. In addition, the model 
included literature-derived estimates of the rates of transition from having no 
diabetes, prediabetes, and undiagnosed diabetes to having diagnosed diabetes, 
as well as the risk of mortality associated with different glycaemic and diabetic 
states. Boyle et al. used primarily two sets of variables to inform the projected 
future diabetes prevalence. First, the trends in the incidence of diabetes, from 
which they assumed three projection scenarios (low incidence, middle 
incidence, and high incidence) for 2008-2050, based on the mean incidence 
rates from logistic regression. The second set contained the RR of death for 
individuals with undiagnosed diabetes and the RR of death for those with 
diagnosed diabetes (both versus those without diabetes). Again, the authors 
assumed two different sets of such RRs (high and low) from two different 
studies in the US. The modelling results of the future diabetes prevalence were 
presented in four scenarios: two low incidence scenarios (with high and with low 
mortality risk) and two middle incidence scenarios (with high and with low 
mortality risk). Assuming low incidence and relatively high diabetes mortality, 
the model projected the total diabetes prevalence (diagnosed and undiagnosed) 
to increase from 14% in 2010 to 21% of the US adult population by 2050. On 
the other hand, if recent increases in diabetes incidence continue and diabetes 
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mortality is relatively low, the projected prevalence will increase to 33% by 
2050. Moreover, a middle-ground scenario projected a prevalence of 25% to 
28% by 2050. The model also quantified the potential effect of a hypothetical 
preventive intervention offered to all people with impaired fasting glucose (who 
constitute a group with a high risk for future development of diabetes). The 
authors argued that if half of the people with impaired fasting glucose 
participated in an intervention and their incidence was reduced by 50%, it would 
be roughly equivalent to a 25% reduction in all people with impaired fasting 
glucose. Therefore, it was assumed that the hypothetical intervention would 
reduce by 25% the annual incidence of diabetes in people with impaired fasting 
glucose. For example, using the projected middle incidence scenario and low 
mortality risk, the model projected that nearly 3.5 million incident cases would 
be reported in 2050 with no intervention, and around 3.2 million incident cases 
would be reported with intervention. That is equivalent to a net reduction of 
approximately 345,000 incident cases of diabetes by 2050 with such a 
hypothetical intervention. 
In general, this chapter offers a theoretical background of epidemiological 
models of T2DM, their uses, structure, and limitations. It also presents a review 
of the existing diabetes models in literature. In the next chapter, the Saudi 
IMPACT Diabetes Forecast Model (used in this thesis) is described in detail, 
including data sources, assumptions used, methods, and justification of its use 
(over the other diabetes prevalence forecast models) to study diabetes 
prevalence trends and projections in Saudi Arabia. 
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Chapter 5. The Saudi IMPACT Diabetes Forecast Model: data 
inputs, data sources, and methods 
This chapter presents an extensive description and discussion of the model 
developed and used in this thesis (the Saudi IMPACT Diabetes Forecast 
Model), data inputs used to construct the model, data sources with their 
strengths and limitations, assumptions, and methods of estimating and 
projecting T2DM prevalence in Saudi Arabia.  
5.1. Introduction 
The IMPACT model was first developed in 1996, and was used in many settings 
to estimate the changes in coronary heart disease (CHD) mortality attributable 
to medical and surgical treatments, and risk factor changes.219, 246-249 The 
IMPACT model studied diabetes as one of several risk factors for CHD. Later, 
the model was further developed to study diabetes prevalence as an output, 
based on trends in some main risk factors, and to provide some policy 
scenarios to quantify the impact of reducing the levels of such risk factors on 
the projected diabetes prevalence. The ‘IMPACT Diabetes Forecast Model’ has 
been successfully used and validated in four developing countries in the EMR 
(Turkey, Syria, Tunisia, and Palestinian areas), as part of the project: 
MEDiterranean studies of Cardiovascular disease and Hyperglycaemia: 
analytical Modelling of Population Socio-economic transitions 
(MEDCHAMPS).219  
The IMPACT Diabetes Forecast Model used in MEDCHAMPS is a Markov 
model implemented in Microsoft Excel spreadsheets. It works in the same 
method of Markov modelling as that described earlier in chapter 4. The model 
integrates information on population, obesity and smoking trends. The model 
assumes that the population is divided into three distinct (discrete) pools (health 
states): those who are obese, those who are smokers, and those who are 
‘healthy’ (i.e. non-obese, non-smoker, and non-diabetic). From these health 
states, the model estimates and predicts the trends in diabetes prevalence over 
a specified time period. It also estimates the decline in the projected diabetes 
107 
 
prevalence, which might be attributed to changes in the levels of obesity and 
smoking as risk factors (Figure  5.1).219 
 
Figure  5.1.  General structure of the IMPACT Diabetes Forecast Model 
As a ‘discrete-state’ Markov model, the IMPACT Diabetes Forecast Model 
assumes that every individual in the population is in one (and only one) health 
state in each modelling cycle (one year). As illustrated in Figure  5.1, the model 
assumes that individuals make transitions from the three main health states 
(healthy, obese, and smokers), or remain in the same state during each 
modelling cycle. Individuals in these three main states can make transitions to 
the (diabetes) state (i.e. they develop diabetes), or die due to other causes. 
Individuals in the (diabetes) states can die as a result of diabetes or diabetes-
related conditions (such as cardiovascular disease) or due to other causes. 
Diabetic individuals cannot make the transition back to the three main states, 
assuming a zero remission rate. Generally, the transition from (healthy) to 
(diabetes) states is informed by the incidence of diabetes, while the transition 
from (obese) to (diabetes) states is informed by the (diabetes incidence X 
relative risk of diabetes in ‘obese’ individuals), and the transition from (smokers) 
to (diabetes) states is informed by the (diabetes incidence X relative risk of 
diabetes in ‘smokers’). Moreover, the transitions from any of the model states 
(healthy, obese, smokers and diabetes) to the state of (deaths due to other 
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causes) are informed by the total mortality rate. On the other hand, the 
transition from the (diabetes) state to the state of (diabetes-related deaths) is 
informed by the case fatality rate.  
Because the modelling was originally intended for developing countries, the 
IMPACT Diabetes Forecast Model was designed to use a relatively small 
amount of data inputs that should be obtainable from such countries with only 
limited available local data. The main data input requirements are a) cross 
sectional data on T2DM, obesity and smoking prevalence, b) population 
structure by age and sex, and c) population demographic trends. In addition, 
other data items are required, such as RRs of T2DM in obese and in smokers, 
but most of such data can be obtained from the literature, and will be subject to 
extensive sensitivity analyses, which will take in consideration the uncertainties 
around such parameters. If some data are unavailable, the model can use 
reasonable assumptions.  
However, the most crucial piece of data required is the incidence of T2DM, 
which is a key model parameter. Diabetes incidence is usually very difficult to 
obtain and is not expected to have local estimates for most countries 
worldwide,219 and is widely variable between different countries and regions. 
Thus, the model adapted Barendregt’s (DISMOD) method157, which estimates a 
baseline diabetes incidence based on the diabetes prevalence and general 
mortality, that are usually available in many developing countries. Detailed 
description of the DISMOD method, in addition to the model structure, 
assumptions made and data sources are discussed later in this chapter. The 
IMPACT Diabetes Forecast Model was validated by comparing its estimates to 
observed estimates for each participating country. The validation results were 
good for all countries, and the model estimates were reasonably close to 
observed estimates for men and women at different time points (Personal 
communication, Martin O’Flaherty, 2012). 
It is important to mention that this thesis constructed the Saudi IMPACT 
Diabetes Forecast Model based on the general structure of the original IMPACT 
model. However, as discussed in chapter 1, this thesis undertook a number of 
‘original’ substantial developments and improvements to the original IMPACT 
model, mainly to the sections of sensitivity analyses, validation and ‘what if’ 
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policy options. These developments are discussed in more detail in section 5.4 
of this chapter, chapter 6, and chapter 8. In brief, as previously mentioned in 
chapter 1, the original IMPACT model, examined the uncertainties around the 
modelling parameters by applying only the ‘analysis of extremes’ method. In 
comparison, the Saudi IMPACT Diabetes Forecast Model used, in addition, the 
method of ‘scenario analysis’ to explore uncertainties in the future trends of key 
model inputs. Also, in the original IMPACT model, there were only two policy 
reduction targets (one for obesity prevalence and another for smoking 
prevalence), and both of them were ‘theoretical/ hypothetical’ targets. On the 
other hand, the Saudi IMPACT Diabetes Forecast Model used existing local 
policy targets, in addition to other international targets set by leading authorities, 
and therefore should offer more comprehensive and ‘realistic’ intervention 
options for policy makers. Furthermore, the original IMPACT model was 
validated only by comparing its estimates to the observed data, while this thesis 
undertook, in addition, a substantially detailed ‘concurrent validation’, by 
comparing the model estimates to other existing models of the same purpose, 
such as that of the most recent IDF Diabetes Atlas,9 a recent Global Burden of 
Disease (GBD) project,20 and other studies.14-17  
Choosing the structure of the IMPACT Diabetes Forecast Model as a ‘base/ 
foundation’ for building the model in this thesis can be justified by its successful 
use and validation in four countries of the Eastern Mediterranean Region, in 
which Saudi Arabia is located. The model was originally developed for use in 
this particular region which, as discussed earlier, has alarming levels of T2DM 
and its risk factors (e.g. obesity and smoking). In addition, the model takes into 
consideration the paucity of information in such developing countries, and 
therefore the required data inputs for modelling should be attainable from them. 
The risk factors studied by the IMPACT Diabetes Forecast Model (obesity and 
smoking) are common health problems in these countries and there are 
reasonably good local population data on these risk factors. It has been 
mentioned in chapter 1 that reliable prevalence data on obesity and smoking in 
Saudi Arabia are available at different time points. Therefore, these data were 
used to estimate the likely trends and projections of the levels of these two risk 
factors over time. In contrast, there are no sufficient data on the prevalence of 
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other risk factors (physical activity and diet). Only one national study19 has 
reported the prevalence of physical activity and dietary patterns. 
The other existing diabetes models (discussed in chapter 4) were originally 
designed for use in developed populations, that have different occurrence and 
levels of T2DM and its risk factors. In addition, most of these models have 
different output parameters, and therefore require several types of data inputs, 
which are unlikely to be available from developing countries. Furthermore, none 
of these models was validated in the EMR region or any other developing 
countries. 
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5.2. Structure of the Saudi IMPACT Diabetes Forecast Model software  
The Saudi IMPACT Diabetes Forecast Model is a Markov model implemented 
in Microsoft Excel spreadsheets, specifically created for this thesis. The model’s 
workbook is structured in ‘tabs’.250 The main tabs of the model are summarised 
in Table  5.1. 
Table  5.1. Summary of the general workbook structure of the Saudi IMPACT Diabetes Forecast Model  
Name of tab(s) Description 
About General information on the model and names of the development team 
  
Data Input Data entry facility for entering country specific data 
  
Dashboard Tabular and graphical presentation of the main model outputs 
  
Outputs Tables of the model’s output numbers 
  
Validation Summary and graphical presentation of validation of the model 
       
Sensitivity Analysis Setting up different scenarios and summary of the effect of change in 
values of the important parameters on the model outputs 
  
Age and sex specific Markov 
chains 
Perform the calculations for each age group and sex in the model 
 
The ‘Data Input’ tab is the major one to be filled in by the user. Information in 
almost all the other tabs are dependent on data entered into the ‘Data Input’ 
tab. Figures 5.2-5.6 show screenshots of the sections in this tab. Cells in white 
colour (unshaded) are the only cells that must be filled in by the user. The 
starting year of the model’s time horizon must be entered and the model then 
automatically fills in all the following years (time horizon was set up for 30 years 
in the model). In the Saudi IMPACT Diabetes Forecast Model, the time horizon 
starts from 1992 and ends at 2022. The starting year of modelling (1992) was 
selected based on the timing of the earliest available local population-based 
data on diabetes prevalence, as the available population surveys from Saudi 
Arabia started at the early 1990s (as discussed in chapter 3).  
The ‘Data Input’ tab consists of two main sections. Section 1 (figure 5.2) is for 
population structure data, where the numbers of the Saudi population for each 
year, sex and age group are entered. The age groups covered by the model are 
six, starting from 25 year-old and are ordered in 10-year-intervals (i.e. 25-34, 
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35-44, 45-54, 55-64, 65-74 and 75+ years). The model calculates the total 
numbers of population for each year and sex, and for both sexes combined. 
Figure  5.2. Section 1 of the ‘Data Input’ tab of the Saudi IMPACT Diabetes Model 
Section 2 is designed for morbidity data, and is divided into four subsections. 
The first subsection (figure 5.3) is for the entry of T2DM prevalence for the 
starting year of modelling (1992). The prevalence must be entered for each sex 
and age group of population. 
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Figure  5.3. Section 2 of the ‘Data Input’ tab: Diabetes prevalence for the starting year 
The second subsection (figure 5.4) is for data on obesity prevalence trends 
which must be entered for each sex and age group and for all years (1992-
2022). The model calculates the weighted average of obesity prevalence of 
each year, for each sex and for both sexes combined, by dividing the total 
prevalence of each year on the number of population at the same period as a 
denominator.  
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Figure  5.4. Section 2 of the ‘Data Input’ tab: Obesity prevalence trends 
In the third subsection (figure 5.5), smoking prevalence trends are entered for 
each sex and age group and for all years (1992-2022). The last subsection 
(figure 5.6) is for the other essential parameters for modelling (transition 
parameters). These parameters are sex- and age-specific diabetes incidence, 
case fatality rate and total mortality, which were derived for the Saudi population 
by using the DISMOD model software (discussed in detail in section 5.3.2.5).  
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Figure  5.5. Section 2 of the ‘Data Input’ tab: Smoking prevalence trends 
Some important information (e.g. data sources, diabetes definition, etc) can be 
documented for each section in the ‘Data Input’ tab, and the features of 
Microsoft Excel also enable the user to insert comments on any particular 
section or cell in order to document or clarify any related special information. 
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Figure  5.6. Section 2 of the ‘Data Input’ tab: Data of the DISMOD-derived parameters 
5.3. Data inputs into the Saudi IMPACT Diabetes Forecast Model: 
description, sources and assumptions 
5.3.1. Introduction 
As previously mentioned in chapter 4, modelling data can be obtained from a 
wide range number of sources, which can include assumptions and expert 
opinions.  
The Saudi IMPACT Diabetes Forecast Model required various data from 
different sources, such as population structure, demographic trends, total 
mortality, prevalence of obesity and smoking, and trends in the levels of these 
two risk factors over time. Unfortunately, some required data from Saudi Arabia 
were scarce and patchy, even for population structure and mortality, which 
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should be routine data as in more developed countries. For other types of data, 
such as prevalence of T2DM and risk factors, the published national surveys 
were reliable and used validated and standardised measuring tools. However, 
these studies presented their findings in different formats. For instance, the 
‘age’ variable of study populations varied in terms of the whole age range of 
participants and the age-group intervals. 
The shortage/variations in data from Saudi Arabia made it necessary to develop 
some ‘reasonable’ assumptions and to perform some approaches such as inter- 
and extrapolation of some model parameters. However, this is not critical for the 
successful development of a valid model219 and, as described in chapter 4, it is 
natural for the majority of models to utilise a wide range of data inputs, including 
assumptions, from various sources.22 However, all assumptions and sources of 
modelling data should be explicitly stated for all modelling studies, because 
model results are conditional upon data inputs and assumptions.22, 210  
5.3.2. Description of data inputs and their sources 
The basic data required to build the Saudi IMPACT Diabetes Forecast Model 
are a) the Saudi population structure by age and sex; b) future projections in 
population structure over the time horizon of model; c) prevalence of T2DM for 
the starting year of modelling (1992); d) prevalence of obesity and smoking for 
as many time points as possible; and e) trends in prevalence of obesity and 
smoking over time. The other types of data (parameters) required to set up the 
transition probabilities between the model states are either estimated through 
some specific approaches implemented in DISMOD (incidence, case fatality, 
and total mortality) or obtained from literature (RRs of T2DM in obese and in 
smoking individuals). 
Sources of all modelling data inputs and their advantages and limitations are 
summarised in Table  5.2. Next, the following sections present a detailed 
description of the data items included in the modelling process. 
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Table  5.2. Summary of data sources for the Saudi IMPACT Diabetes Forecast Model with their strengths and limitations 
Information Data source(s) Strengths and limitations 
Population structure Central Department of Statistics and 
Information (CDSI) [251] 
Strengths: 
• Available online. 
• Population structure stratified by age group and sex. 
Limitations: 
• Available only for two years (1992 and 2004). 
Projections in population structure United Nations, Department of Economic 
and Social Affairs [252] 
Strengths: 
• Available online. 
• Population structure stratified by age group and sex. 
• Population projections estimated based on the local censuses from the 
CDSI.  
Limitations: 
• Population projections only available in 5-year period intervals. 
Prevalence of T2DM, obesity and 
smoking 
Published national surveys in the 
literature [19, 34, 36, 37, 39] 
Strengths: 
• Nationwide and population-based. 
• Large sample sizes. 
• Good sampling techniques - representative national samples from both 
sexes and all regions of the country. 
• Very good response rates. 
• Standardised methods, tools, and criteria for diagnosis of T2DM and 
obesity. 
Limitations: 
• Some studies did not report prevalence by age group, sex, or both. 
• For obesity studies, all of them relied on BMI to diagnose obesity – none 
of them used WC or WHR. 
• For smoking studies, they used different definitions for ‘active smoking’.  
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Table 5.2. (cont.). Summary of data sources for the Saudi IMPACT Diabetes Forecast Model with their strengths and limitations 
Information Data source(s) Strengths and limitations 
Projections in obesity and smoking 
prevalence 
Assumptions 
(Linear interpolation + projecting by the 
observed annual rate of increase)  
 
Strengths: 
• Observed data on obesity and smoking suggest linear trend. 
• Linear increase in obesity prevalence compatible with linear increase in 
mean BMI as estimated by WHO [13].  
Limitations: 
• Extremely high (probably implausible) projections of obesity in some age 
groups. 
 
 
T2DM incidence and case fatality  
+ total mortality 
 
DISMOD model [157] 
 
Strengths: 
• Simple concept of Markov modelling. 
• Previously validated and used for countries in EMR. 
• Used successfully by leading global studies (e.g. Global Burden of 
Disease Study) 
• Free software. 
• Supplements parameters of disease epidemiology from partial data. 
• Provides ‘internally consistent’ estimates of incidence, case fatality, and 
mortality. 
Limitations: 
• Assumes a ‘steady’ population, with stable incidence and mortality over 
time. 
• Assumes independence of the all-other-causes mortality from diabetes. 
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Table 5.2. (cont.). Summary of data sources for the Saudi IMPACT Diabetes Forecast Model with their strengths and limitations 
Information Data source(s) Strengths and limitations 
 
Relative risk of T2DM in obese 
 
Guh et al. [97] (systematic review and 
meta-analysis) 
 
Strengths: 
• Pooled RRs estimated from large prospective cohort studies. 
• Pooled RRs estimated by comparing the risk of T2DM in obese (BMI ≥30 
kg/m2) with those with ‘normal’ weight. 
Limitations: 
• The studies included were from developed countries only. 
• Pooled RRs reported as sex-specific only (no age-specific). 
• Potential publication bias. 
 
 
Relative risk of T2DM in smokers 
 
 
Willi et al. [130] (systematic review and 
meta-analysis) 
 
 
Strengths: 
• Pooled RR estimated from large prospective cohort studies. 
• Pooled RR adjusted for several covariates. 
• Included studies from developed and developing countries. 
Limitations: 
• Reported only one adjusted pooled RR for both men and women (no 
sex- or age-specific RRs). 
• Potential publication bias. 
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5.3.2.1. Population structure  
The structure of the adult Saudi population aged 25-75+ years (by age group 
and sex) was obtained from the Central Department of Statistics and 
Information (CDSI); an affiliate of the Ministry of Economy and Planning in 
Saudi Arabia. The CDSI was established around 50 years ago to be the main 
official authority for population statistics in Saudi Arabia.251   
Three completed national censuses have been conducted by CDSI to-date: in 
1974, 1992 and 2004. Detailed data of these censuses were available on the 
CDSI website (http://www.cdsi.gov.sa/english/).251 
The Saudi population structure in each census was stratified by sex and five-
year age groups (<1, 1-4, 5-9, 10-14, 15-19, up to 80+ years). Since the time 
period covered by the model in this thesis was 1992-2022, data of the 1974 
census were not used. A linear interpolation approach was used to ‘fill in the 
gaps’ between the census data for 1992 and 2004. The 'average' estimates of 
population structure were calculated between these two available time points, 
assuming a linear increase in population. For example, to calculate population 
in 1993, the formula: (11*α1+α2)/12 was used; where α1 is population in 1992 
and α2 is population in 2004. Similarly, for year 1994, the formula: 
(10*α1+2α2)/12 was used, and so on. These formula calculations were applied 
to each single age group of population for each individual year.  
5.3.2.2. Projections in population structure 
There were no available local data on the Saudi population structure from 2005 
onwards. Therefore, data were obtained from the United Nations; Department of 
Economic and Social Affairs (UN-ESA), Population Estimates and Projections 
Section.252 The UN-ESA provides “World Population Prospects”, with a wide 
range of detailed country-specific indicators of populations for most countries in 
the world. Data were available online (http://esa.un.org/wpp/) with a long list of 
available indicators and another list of countries. After selecting one indicator 
and one country from each list, the period range of interest (from 1950 up to 
2100) can also be selected. One of the listed indicators is “population by five-
year age group and sex” and the estimates of this indicator are displayed in 
five-year intervals (i.e. 1990, 1995, 2000, etc).252 
122 
 
Sources of data and method of estimation are documented on the website for 
each country, which is a strength of this particular data source.252 Estimates and 
projections of the UN-ESA for Saudi Arabia are most likely reliable, since they 
were based on the available local data and indicators. As reported in the 
website, the total Saudi population for 2010 was estimated to be consistent with 
the 1974 and 2004 censuses, taking into account the subsequent trends in 
fertility, mortality and international migration. Such trends and population 
projections were estimated using sophisticated statistical methods, such as 
‘probabilistic projections’ using Bayesian hierarchal modelling. These methods 
and related assumptions are explicitly documented in detail on the website.252  
The Department of Health Statistics in the Saudi Ministry of Health often relies 
on these UN population data for estimating different health parameters in the 
Kingdom (Personal communication, Statistics Department staff, February 2011). 
Moreover, the UN population projections were widely used by leading global 
organisations, such as the IDF9, and several other studies14-16 to estimate and 
predict diabetes prevalence in countries. 
The population structure for 2005-2009 was obtained through linear 
interpolation (similar approach as that described in section 5.3.2.1), since local 
data for 2004 were available, and the 2010 estimates were provided by the UN-
ESA. Estimated population structure was then calculated through the same 
interpolation approach for every year up to 2022. 
The Saudi population structure (1992 - 2022) that was used as an input into the 
Saudi IMPACT Diabetes Forecast Model is summarised in Table  5.3. 
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Table  5.3. Data input into the Saudi IMPACT Diabetes Forecast Model: Structure of population of Saudi Arabia, 1992-2022 (*) 
Year Men- age groups (years) Women- age groups (years) 
25-34 35-44 45-54 55-64 65-74 75+ 25-34 35-44 45-54 55-64 65-74 75+ 
1992 1988608 1265062 561736 305582 149294 97116 1158266 685776 368854 205322 110180 77585 
1993 2042141 1333903 603824 313209 154106 99411 1210719 727225 387551 215229 117693 79507 
1994 2095674 1402743 645911 320836 158918 101705 1263172 768674 406248 225135 125206 81429 
1995 2149206 1471584 687999 328464 163730 104000 1315625 810122 424945 235042 132720 83351 
1996 2202739 1540425 730086 336091 168542 106295 1368078 851571 443642 244948 140233 85273 
1997 2256272 1609265 772174 343718 173354 108589 1420531 893020 462339 254855 147746 87195 
1998 2309805 1678106 814262 351345 178166 110884 1472984 934469 481036 264762 155259 89118 
1999 2363337 1746947 856349 358972 182977 113179 1525436 975917 499732 274668 162772 91040 
2000 2416870 1815787 898437 366599 187789 115473 1577889 1017366 518429 284575 170285 92962 
2001 2470403 1884628 940524 374227 192601 117768 1630342 1058815 537126 294481 177799 94884 
2002 2523936 1953469 982612 381854 197413 120063 1682795 1100264 555823 304388 185312 96806 
2003 2577468 2022309 1024699 389481 202225 122357 1735248 1141712 574520 314294 192825 98728 
2004 2631001 2091150 1066787 397108 207037 124652 1787701 1183161 593217 324201 200338 100650 
2005 2641168 2146125 1136823 436590 217198 125043 1837418 1241468 633848 344334 209282 105375 
2006 2651334 2201100 1206858 476072 227358 125435 1887134 1299774 674478 364467 218225 110100 
2007 2661501 2256075 1276894 515554 237519 125826 1936851 1358081 715109 384601 227169 114825 
2008 2671667 2311050 1346929 555036 247679 126217 1986567 1416387 755739 404734 236113 119550 
2009 2681834 2366025 1416965 594518 257840 126609 2036284 1474694 796370 424867 245056 124275 
2010 2692000 2421000 1487000 634000 268000 127000 2086000 1533000 837000 445000 254000 129000 
2011 2701400 2450200 1569200 694400 284200 130600 2134400 1596600 895000 469800 267000 134600 
2012 2710800 2479400 1651400 754800 300400 134200 2182800 1660200 953000 494600 280000 140200 
2013 2720200 2508600 1733600 815200 316600 137800 2231200 1723800 1011000 519400 293000 145800 
2014 2729600 2537800 1815800 875600 332800 141400 2279600 1787400 1069000 544200 306000 151400 
2015 2739000 2567000 1898000 936000 349000 145000 2328000 1851000 1127000 569000 319000 157000 
2016 2790200 2573200 1949800 1007400 383800 150200 2395400 1898800 1180400 611400 336000 165400 
2017 2841400 2579400 2001600 1078800 418600 155400 2462800 1946600 1233800 653800 353000 173800 
2018 2892600 2585600 2053400 1150200 453400 160600 2530200 1994400 1287200 696200 370000 182200 
2019 2943800 2591800 2105200 1221600 488200 165800 2597600 2042200 1340600 738600 387000 190600 
2020 2995000 2598000 2157000 1293000 523000 171000 2665000 2090000 1394000 781000 404000 199000 
2021 3029200 2611200 2186600 1370400 572600 181400 2698000 2138600 1457000 836800 426800 211400 
2022 3063400 2624400 2216200 1447800 622200 191800 2731000 2187200 1520000 892600 449600 223800 
(*) Results for (1993-2003, 2005-2009, 2011-2014, 2016-2019, and 2021-2022) were obtained through interpolation. Results for 2010, 2015, and 2020 were obtained from the World 
Population Prospects, United Nations.  
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5.3.2.3. Prevalence of type 2 diabetes, obesity and smoking 
The major sources of data on prevalence of T2DM, obesity and smoking in 
Saudi Arabia were the published national surveys.19, 34, 36, 37, 39 Different sources 
were utilised for literature review, including the MEDLINE database, in addition 
to cross referencing and personal contacts. The literature review strategy is 
presented in appendix 1, and the selected surveys have been discussed earlier 
in chapter 3.  
As previously discussed in chapter 3, all studies were population-based and 
were carried out at the national level, covering all regions of Saudi Arabia, with 
good sampling sizes and techniques and high response rates. Hence, they 
were most likely representative of the population of Saudi Arabia. In addition, 
they used standard validated measuring and diagnostic tools such as the 
criteria of WHO or ADA for diagnosis of diabetes41; and BMI for definition of 
obesity.87 On the other hand, some of these studies reported only the overall 
prevalence rate without providing the age- and sex-specific rates.38 Moreover, 
all obesity studies depended only on BMI for diagnosis of obesity19, 34, 36, 37, 
which has some limitations, as discussed in chapter 2. For smoking studies, 
different definitions of active smoking were used across different studies.19, 35, 39 
However, it was assumed that these different definitions would not affect the 
prevalence results substantially. 
The Saudi IMPACT Diabetes Forecast Model requires data on the T2DM 
prevalence for each sex and age group of the population in the starting year of 
model (1992) only. In addition, the model also needs similar data on obesity and 
smoking prevalence for each single year of its time horizon (1992-2022). For 
the T2DM prevalence in 1992, the study of Warsy and El-Hazmi36 was used as 
a source of data. However, as previously described in chapter 3, the study of 
Warsy and El-Hazmi, in addition to four obesity studies34-37 and two smoking 
studies38, 39, were carried out over a “period range” – e.g. 1990-1993 and 1995-
2000, and their results were reported in age group intervals that were different 
from the model. Furthermore, one obesity study37 and one smoking study39 
provided only the age-specific prevalence rates (no sex-specific). Therefore, 
some assumptions were necessary in order to make the age group intervals 
homogeneous for all studies and to obtain ‘single year’ prevalence rates. 
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Moreover, assumptions were required to obtain sex- and age-specific rates for 
all studies. 
Firstly, it was assumed that the reported prevalence rates applied roughly to the 
midpoint of the period range. For instance, the study of Al-Nozha et al.34 on 
obesity was conducted over the period of 1995-2000, so it was assumed that 
the results apply for 1997. Similarly, the results of Jarallah et al. study39 on 
smoking, conducted during 1990-1993, were assumed to apply for 1992 and so 
on. However, the only exception to this assumption was the use of the study of 
Warsy and El-Hazmi36 for obtaining the starting year (1992) diabetes 
prevalence, although it was conducted over the period range of 1992-1995. 
Warsy and El-Hazmi used the WHO 1985 diagnostic criteria, with fasting blood 
glucose and OGTT, to define T2DM. On the other hand, there were two more 
potential studies for obtaining the 1992 diabetes prevalence35, 202, but neither 
study was used as a source for the starting year prevalence, due to limitations 
in either the diagnostic definition used or the presentation of reported results. 
The first study was that of Al-Nuaim202, which was conducted during 1990-1993. 
As mentioned in chapter 3, that study used ‘random’ blood sugar (not fasting or 
OGTT) to diagnose T2DM. The second study was that of Osman et al.35 which 
was carried out over the period of 1989-1994. Unfortunately, this study reported 
only the total population diabetes prevalence without presenting the age- and 
sex-specific prevalence rates.  
Secondly, the age group bands of studies were managed to be compatible with 
the model’s age groups. One of studies (the WHO STEPS study)19 had the 
same age bands as those of the model, however only up to 64 years (i.e. 25-34, 
35-44, 45-54, 55-64 years). For other studies, assumptions were made to 
consider the overlap between the model’s age groups and those reported by 
studies. For example, in Al-Nozha et al. study34, the prevalence rate of the age 
group 35-44 years was assumed to be the average of prevalence for the study 
age groups of 30-39 and 40-49 years, while the prevalence rate of the age 
group 45-54 years was assumed to be equal to the average of that reported for 
age groups 40-49 and 50-59 years. Similarly, in the study of Warsy and El-
Hazmi36, the prevalence rate for the age group 25-34 years was assumed to be 
the average of the reported prevalence rates for the reported age groups of 14-
29 and 30-44 years. Also, the prevalence rate of the age group 35-44 years was 
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assumed to be the average of prevalence for the reported age groups 30-44 
and 45-59 years.  
Thirdly, for studies that reported only the age-specific prevalence, the “sex ratio” 
of prevalence was calculated from other similar studies and assumed to be the 
same for them. For example, for obesity studies, the sex ratio was calculated for 
each age group in the study of Warsy and El-Hazmi36 and applied these age-
specific ratios to Al-Nuaim study37, which was the only obesity survey that did 
not report sex-specific prevalence rates. On the other hand, for smoking 
studies, the sex ratios were calculated from the WHO STEPS19 study and were 
applied to Jarallah et al. study.39 It was assumed that such sex ratios were 
unlikely to differ substantially between different studies. 
Finally, the results of one obesity study and one smoking study were excluded 
as inputs into the model, because their data were insufficient for modelling. The 
first excluded study was that of Osman et al.,35 which included relatively 
younger age groups (18-20, 21-30, 31-40 and ≥40 years) and, therefore, the 
previous assumptions could not be applied on this particular study in order to 
obtain similar age groups as the model. The second excluded study was that of 
Al-Nozha et al.,38 which originally measured the prevalence of coronary artery 
disease in Saudi Arabia for both sexes and all age groups between 30-70 
years. This study determined also the prevalence of the major modifiable risk 
factors for coronary artery disease (including smoking). However, unfortunately, 
it reported only the overall smoking prevalence without age- or sex-specific 
rates. Attempts to contact the authors (by email and telephone) to obtain any 
further data were unsuccessful. 
Therefore, four studies on obesity prevalence and two studies on smoking 
prevalence were made compatible to the model’s requirements after applying 
the previous assumptions to their reported results. They provided prevalence 
rates of obesity and smoking for the Saudi population during the period from 
1992-2005. Interpolation was performed in order to obtain results of the missing 
years within this range. However, there were significant and unexplained 
differences in the reported prevalence rates of obesity between Al-Nuaim 
study37 (results for 1992) and the study of Warsy and El-Hazmi36 (results for 
1993) across almost all age groups of both sexes, although both studies were 
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conducted at almost the same time. For example, the prevalence in men aged 
55-64 years was 9.5% in Al-Nuaim study, and 16.4% in the other study. 
Moreover, the prevalence of obesity in women aged 35-44 years was 18.6% in 
Al-Nuaim study, while it was 31.5% in Warsy study. However, no obvious 
differences were found in the quality of data of both surveys. Table  5.4 
summarises the most important features of these two studies. Although the 
response rate in Al-Nuaim study was lower than that in Warsy et al. study, this, 
alone, seems unlikely to explain such considerable differences in results. Thus, 
the average of prevalence rates from these two studies was calculated for each 
sex and age group, and was assumed to apply for 1992. 
Table  5.4. Comparison of Al-Nuaim and Warsy et al. studies on obesity prevalence in Saudi Arabia 
Study Sample 
size 
Sampling method Response 
rate 
 Definition 
of obesity 
Measurement 
method 
Al-
Nuaim37 
10,651 
(50.8% 
males and 
49.2% 
females) 
Multistage stratified 
cluster sampling of 
all regions of Saudi 
Arabia with 
probability 
proportionate to size 
69%  BMI ≥ 30 
kg/m2 
- Trained 
physicians in 
primary care 
centres 
- standardised 
measurement 
tools 
Warsy & 
El-
Hazmi36 
14,660 
(42% 
males and 
58% 
females) 
Multistage stratified 
cluster sampling of 
all regions of Saudi 
Arabia with 
probability 
proportionate to size 
95%  BMI ≥ 30 
kg/m2 
- Household 
visits of trained 
members 
- standardised 
measurement 
tools 
Another problem faced with the prevalence surveys was the highest limit of age 
groups covered, even after applying the previous assumptions. The oldest age 
group obtained from these surveys was 55-64 years. Thus, two of the model’s 
age groups were missing (65-74 and 75+ years). However, the only exception 
was the study of Warsy and El-Hazmi36, which was used to obtain the diabetes 
prevalence for 1992. In that study, the last reported age group was ‘open-
ended’ (≥60 years), and therefore, the diabetes prevalence rates for the age 
groups 65-74 and 75+ years were assumed to be equal to that reported for the 
age group ≥60 years. 
The approach to overcome the limitation of missing older age groups was to 
search for the required data from other neighbouring countries, and to 
extrapolate the prevalence for the missing two age groups. This extrapolation 
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was based on assuming a similar pattern of prevalence in these two oldest age 
groups in relation to the previous age group (55-64 years). The Gulf 
Cooperation Council (GCC) countries have similar cultures, environments and 
population characteristics in terms of lifestyle and socioeconomic status.169 
Details of the published national surveys on obesity and smoking in these 
countries have been discussed earlier in chapter 3. Again, unfortunately, almost 
all surveys from these countries did not cover older age groups of population 
(≥65 years). However, there were two good published studies from Oman (for 
obesity and smoking prevalence rates) that included older age groups, and 
were used for extrapolation.   
The first study was that of Al-Lawati et al.179, which compared two national 
surveys for prevalence of overweight (BMI 25–29.9 kg/m2) and obesity (BMI 
≥30 kg/m2) in 1991 and 2000. Both of these surveys covered nationally 
representative samples of Omanis aged ≥20 years. There were 5,086 
participants (2,128 men and 2,958 women) in the 1991 survey, and 6,400 
participants (3,069 men and 3,331 women) in the 2000 survey. The response 
rates were above 90% in both surveys. Tools and methods of measurement of 
weight and height (to calculate BMI) were well calibrated and standardised. The 
results of these two surveys were reported for each sex and in 10-year-intervals 
(20-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80+ years). Prevalence rates of 
obesity were reported separately from those of overweight. Similar previous 
assumptions were first applied to obtain similar age groups to the Saudi 
IMPACT Diabetes Forecast Model. For instance, the prevalence rate for the age 
group 25-34 years was assumed to be the average of the reported prevalence 
rates for the age groups of 20-29 and 30-39 years, etc. Table  5.5 presents an 
example of the results of the obesity prevalence among Omani men before and 
after applying these assumptions.  
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Table  5.5. The results of two Omani surveys179 on obesity prevalence in men before and after the applying 
of assumptions 
The reported results  Results with assumptions 
The 1991 survey  The 1991 survey 
Age group (yrs) Prevalence (%) Age group (yrs) Prevalence (%) 
20-29 6.60 25-34 9.55 
30-39 12.50 35-44 14.50 
40-49 16.50 45-54 14.55 
50-59 12.60 55-64 10.55 
60-69 8.50 65-74 5.15 
70-79 1.80 75+ 0.90 
80+ 0   
Overall 10.5    
   
The 2000 survey  The 2000 survey 
Age group (yrs) Prevalence (%)  Age group (yrs) Prevalence (%) 
20-29 11.00 25-34 15.35 
30-39 19.70 35-44 21.40 
40-49 23.10 45-54 21.50 
50-59 19.90 55-64 18.15 
60-69 16.40 65-74 12.20 
70-79 8.00 75+ 6.50 
80+ 5.00   
Overall 16.7    
After obtaining a similar age group pattern as the model, the available data from 
Saudi Arabia for 1992 were extrapolated using the Omani data for 1991. For 
instance, the proportion of difference between prevalence rates for the age 
groups 55-64 and 65-74 was calculated for each sex in the Omani population in 
1991, through dividing the prevalence of older age group by that of younger age 
group (e.g. for men, 5.15 / 10.55 = 0.4882). Next, this difference proportion was 
multiplied by the prevalence for the age group 55-64 of the Saudi population, to 
eventually obtain the prevalence for the age group 65-74 years in 1991 (e.g. for 
men, 0.4882 X 12.9 = 6.30). Similar methods were applied to the Omani data in 
2000 to obtain prevalence rates of obesity in the missing age groups of both 
sexes in Saudi Arabia for 2000. Data for 1993-1999 were estimated through 
linear interpolation. Figure  5.7 compares between the data from Oman and 
Saudi Arabia after applying the previous assumptions. 
130 
 
Moreover, there was only one national smoking survey from the GCC countries 
which covered older age groups. This study was again from Oman (Al Riyami et 
al.)183, carried out in 2000 and covered a nationally representative sample of 
Omanis aged ≥20 years. The total sample size was 7011 (3,506 males and 
3,505 females). The definition of current smoking was ‘smoking at the time of 
survey’. Prevalence rates were reported for each sex and age group (20-29, 30-
39, 40-49, 50-59, 60-64, and ≥65 years). First, the age groups were arranged in 
regular 10-year-intervals (20-29, 30-39, 40-49, 50-59, 60-69, 70-79 and 80+ 
years). It was assumed that the prevalence for the age group 60-69 was the 
average of that reported for 60-64 and 65+ years (For men, [7.4 + 7.9] / 2 = 
7.7% and for women, [2.2 + 0.8] / 2 = 1.5%). The prevalence rates for the age 
groups 70-79 and 80+ years were assumed to be equal to that reported for the 
age group 65+ (7.9% for men and 0.8% for women). Next, a similar approach 
was performed as with the obesity survey in order to obtain similar age groups 
as the model. Table  5.6 illustrates an example of the results in men before and 
after applying the assumptions. 
 Table  5.6. The results of an Omani survey183 on smoking prevalence in men before and after the applying 
of assumptions 
The reported results  Results with assumptions 
Age group (yrs) Prevalence (%)  Age group (yrs) Prevalence (%) 
20-29 11.50 25-34 14.50 
30-39 17.50 35-44 18.10 
40-49 18.70 45-54 16.65 
50-59 14.60 55-64 11.15 
60-69 7.70 65-74 7.80 
70-79 7.90 75+ 7.90 
80+ 7.90   
Overall 13.4    
Again, the available Saudi data for 2000 were extrapolated in the same method 
applied for the obesity survey in order to obtain prevalence of smoking for the 
missing age groups in both sexes. However, there were no other studies 
measuring smoking prevalence in the oldest age groups from neighbouring 
countries. Hence, prevalence rates for the two oldest age groups in the Saudi 
population in 1992 (starting year of the model) were extrapolated using the 
same previous study from Oman, assuming a similar prevalence pattern by age 
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to that of 2000. Linear interpolation was performed to estimate the values for 
the period 1993-1999. Figure  5.8 showed a comparison between the data from 
Oman and Saudi Arabia after applying the previous assumptions. It could be 
observed that the smoking prevalence tended to be considerably higher among 
younger age groups of men (25-34 and 35-44 years) in Saudi Arabia in 2000 
(25% and 22% respectively), compared to their Omani counterparts (14.5% and 
18.1% respectively). However, the prevalence rates were very comparable for 
older men in the age groups of 45-54 and 55-64 years (15.3% and 10.9% 
respectively in Saudi Arabia, compared to 16.7% and 11.2% respectively in 
Oman). Therefore, the two countries seem to have different smoking prevalence 
for young men, but the prevalence tends to be similar in older men. This 
observation might justify the use of the previous Omani study to extrapolate 
smoking prevalence in the two oldest age groups in Saudi Arabia. The reported 
smoking prevalence among women of all age groups in both countries was 
extremely low, despite some minor differences, and was unlikely to have a 
significant impact on the results of extrapolation for women. 
Table  5.7 summarises the diabetes prevalence data (for 1992), in addition to 
the four studies on obesity prevalence and the two studies on smoking 
prevalence in Saudi Arabia, which were used as inputs into the Saudi IMPACT 
Diabetes Forecast model. These studies also formed a basis for future 
projections in prevalence of these risk factors, as discussed in the next section. 
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Figure  5.7. Comparison of obesity prevalence (%) between Oman and Saudi Arabia for 1991, 1992 and 
2000 
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Figure  5.8. Comparison of smoking prevalence (%) between Oman and Saudi Arabia for 2000 
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 Table  5.7. Summary of the results of prevalence studies on diabetes, obesity and smoking (%) in Saudi Arabia after applying assumptions 
Year/ 
period midpoint 
Study 
Men 
age groups (years) 
Women 
age groups (years) 
25-34 35-44 45-54 55-64 65-74 75+ 25-34 35-44 45-54 55-64 65-74 75+ 
Diabetes (Starting year) 
             
              
1992 Warsy & El-Hazmi [36] 3.7 7.0 21.1 24.9 28.8 28.8 3.0 5.0 22.1 23.2 24.4 24.4 
Obesity 
 
             
1992 
 
Al-Nuaim [37] 
Warsy & El-Hazmi [36] 
10.1 14.0 14.2 12.9 6.3 1.1 16.1 25.1 25.8 22.8 12.9 2.5 
              
1997 
 
Al-Nozha et al.[34] 25.2 27.8 29.1 25.0 13.8 6.5 40.2 45.2 48.1 42.5 25.2 10.9 
2005 
 
WHO STEPS [19] 27.1 34.5 32.9 31.0 19.8 10.3 39.5 54.7 58.8 53.2 36.8 17.3 
Smoking 
 
             
1992 
 
Jarallah et al.[39] 14.2 13.3 9.2 7.5 5.2 5.3 0.6 0.7 1.0 0.7 0.7 0.5 
2005 
 
WHO STEPS [19] 31.7 27.4 19.2 13.1 7.8 7.9 1.3 1.4 2.2 1.1 0.9 0.7 
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5.3.2.4. Projections in the obesity and smoking prevalence 
For projections in the prevalence of obesity and smoking in men and women 
aged 25-64 years, a linear trend was assumed by applying the ‘observed’ 
annual rate of increase in prevalence during the period 1992-2005. However, 
for the two oldest age groups (65-74 and 75+ years), the future projections were 
estimated through applying the annual rate of increase during 1992-2000 for 
obesity and smoking prevalence. 
The annual rate of increase in prevalence was estimated by dividing the net 
difference in prevalence for each sex and age group during the time period over 
the duration (number of years) of the same time period. For example, the 
annual rate of increase during 1992-2005 was calculated as follows: 
[prevalence rate in 2005 - prevalence rate in 1992] / 13. 
The annual rates of increase for each sex and age group are summarised in 
Table  5.8. 
Table  5.8. The observed annual rates of increase in prevalence of obesity and smoking (%) for men and 
women in Saudi Arabia(*) 
 Men – age groups (years) Women – age groups (years) 
25-
34 
35-
44 
45-
54 
55-
64 
65- 
74 
75+ 25-
34 
35-
44 
45-
54 
55-
64 
65- 
74 
75+ 
Obesity 1.50 1.85 1.72 1.66 1.51 1.09 2.10 2.78 3.05 2.80 2.46 1.68 
Smoking 1.35 1.08 0.77 0.43 0.30 0.30 0.05 0.05 0.09 0.03 0.03 0.02 
(*) Rates of change in obesity and smoking prevalence for age groups 25-64 years were calculated for the 
period 1992-2005. Rates of change in obesity prevalence for age groups 65 - ≥75 years were calculated 
for the period 1991-2000. Rates of change in smoking prevalence for age groups 65 - ≥75 years were 
calculated for the period 1992-2000. 
The decision of applying a linear increasing trend in obesity and smoking 
prevalence was justified by observing the same linear trend from the available 
local data during 1992-2005 in almost all age groups of both sexes (Table 5.7). 
Furthermore, the assumed projections in obesity prevalence were also 
supported by recent estimates of trends in mean BMI by the  WHO Global 
Burden of Disease Study (GBD), 201113, which also showed a linear increasing 
trend in mean BMI in Saudi Arabia. In the GBD Study, trends and their 
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uncertainties of mean BMI were estimated for adults aged ≥20 years in 199 
countries and territories all over the world for the period 1980-2008. Data were 
obtained from published and unpublished health examination surveys and 
epidemiological studies. For Saudi Arabia, studies used19, 34-36 were similar to 
those reviewed in this thesis (chapter 3), in addition to two unpublished data 
from the WHO and one study253 with subnational sample. For each sex, a 
complex multi-level Bayesian hierarchical model was used to estimate mean 
BMI by age, country, and year. The model was based on many sophisticated 
statistical equations described in detail by the authors.13 In general, trends over 
time were modelled as non-linear, consisting of a linear trend plus a smooth 
non-linear trend, with both components were modelled hierarchically. Time-
varying country-level covariates were used to inform the estimates. The 
covariates used were national income (natural logarithm (Ln) per-head gross 
domestic product converted to international dollars in 1990), urbanisation 
(proportion of population that lived in urban areas), and national availability of 
multiple food types (from the food balance sheets of the Food and Agriculture 
Organization (FAO) of the United Nations).13 The results of mean BMI in Saudi 
Arabia (1980-2008) as estimated by the GBD Study are summarised in Table 
 5.9. 
Table  5.9. Trends in mean BMI (and uncertainty intervals) in Saudi Arabia (1980-2008) as estimated by 
the GBD Study13, 2011  
Year 
Mean BMI (kg/m2) 
Men Women 
1980 25.0 (23.8 - 26.3) 26.3 (24.8 - 27.8) 
1990 25.9 (25.6 - 26.2) 27.3 (26.9 - 27.8) 
2000 27.0 (26.6 - 27.4) 28.5 (28.0 - 29.0) 
2008 27.9 (27.2 - 28.6) 29.6 (28.7 - 30.5) 
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- Capping of the projected obesity prevalence 
The projected obesity prevalence reached very high and probably implausible 
values with the previously discussed assumption of a linear increase in 
prevalence over time, based on the observed annual rate of increase. These 
substantially high prevalence rates were more prominent in women, where the 
projected prevalence in 2022 reached 87% in women aged 35–44 years, 98% 
in those aged 45–54 years, and 85% in those aged 55–64 years. 
Capping of the projected obesity prevalence at a specific level was performed to 
overcome this limitation. This assumed capping of prevalence was based on 
recent data from the United States254 (published in 2012), which revealed that 
the total obesity prevalence (BMI ≥30 kg/m2) in the US adult men and women 
for 2009-2010 did not differ significantly from that of 2003–2008. This ‘stability’ 
or ‘slowing / levelling off’ of obesity prevalence in the US was reported after the 
observed linear increase in the previous years. All the past and current data on 
obesity prevalence were obtained from one source of information, which is the 
National Health and Nutrition Survey (NHANES). The NHANES started in 1960, 
covering nationally-representative samples, and continued to release data in 
two-year cycles since 1999.  
Moreover, several other countries also reported the same slowing / levelling off 
in the previous obesity trends. The National Obesity Observatory255 (NOO) in 
the UK (www.noo.org.uk) has published data on trends in the prevalence of 
adult obesity (BMI ≥30 kg/m2) during 1995–2009 from many developed 
countries around the world. Unfortunately, many of these countries have 
missing prevalence data for most years within that period. However, countries 
with the most complete data have also suggested a possible degree of levelling 
off of obesity prevalence during the last 10–13 years. Examples of such 
countries include England, Italy and Sweden (Table  5.10). 
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Table  5.10. Some international data on adult obesity prevalence trends (%)255 
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In addition, Rokholm et al.256 have recently reviewed 52 studies on obesity 
prevalence (BMI ≥30 kg/m2) trends from different countries around the world. 
They found that the global obesity epidemic has generally showed levelling off 
since the early 2000s. The studies reviewed were from different countries in 
Europe, North America and Asia. The regional difference in obesity prevalence 
trends was not confirmed by the review, although some countries, particularly 
Asian (e.g. Iran and Bangladesh), remained to show increasing trends in 
prevalence. However, there were concerns regarding the low quality of studies 
from these countries.256 Furthermore, stability and signs of a decrease in 
obesity prevalence were found in some other countries of the region (e.g. Hong 
Kong, China). Thus, the authors concluded that the levelling off seems fairly 
homogeneous across the world regions. Nevertheless, this review was 
constrained by some limitations. For instance, it did not include studies from 
some world regions (e.g. Africa, Middle East and South America). In addition, 
concerns about the representativeness of samples used in studies and the 
potential publication biases might have affected the findings. 
In general, the causes of such levelling off of the global obesity prevalence 
trends in recent years are not completely clear, and are likely to have complex 
roots, in spite of some attempts to attribute these changes to certain 
environmental and socioeconomic factors.254 Of course, the accelerated global 
modernisation, urbanisation and adopting ‘western’ lifestyles, with decreased 
physical activity and consuming energy dense foods, remains the first 
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suggested cause for the worldwide epidemic of obesity. Thus, based on 
assuming this as a cause, the levelling off could be the result of public health 
campaigns, which may have been able to stabilise the population’s energy 
balance by influencing food and exercise habits.256 However, this inference 
cannot be confirmed, since there is no available evidence for the effectiveness 
of the public health campaigns in many developing countries that have already 
been observed to witness levelling off of obesity prevalence trends. In addition, 
as previously discussed in chapter 2, the aetiology of obesity is complex and 
associated with several other demographic, genetic and socioeconomic factors. 
Therefore, Rokholm et al. indicated that the currently observed changes in the 
obesity trends can provide an opportunity for further investigations into the 
causes of the obesity epidemic. If the pattern of exposure to a putative cause 
over time corresponds to the change in obesity trend, the factor would qualify 
for further analysis. However, a sufficient time lag between exposure to a 
putative cause and changes in the obesity trends may be important to be 
considered.256 
The decision to perform capping of the projected obesity prevalence in Saudi 
Arabia for this thesis could be justified primarily by two reasons. First is to avoid 
the probable implausibility of reaching a point when every individual in some 
age groups of the Saudi population becomes ‘obese’ as a result of assuming a 
continuing linearity in trends over time. Second, the previously mentioned 
literature seems supportive to this decision, although there was no specific 
evidence from Saudi Arabia or Middle East, but, at least, some other developing 
countries in Asia have been observed to witness levelling off of obesity trends 
during the last years.256 However, it is important to indicate that sensitivity 
analyses, which were performed for modelling in this thesis (as presented in 
chapters 6, 7 and 8), provided uncertainty values for the output results. 
Moreover, the main model outputs were compared with and without capping, so 
that the effect of capping on the predicted prevalence of diabetes could be 
quantified. 
An important consideration in the decision of capping was the level of obesity 
prevalence at which the capping should be performed. The available evidence, 
as reviewed by Rokholm et al.256, showed that the global levelling off of obesity 
trends was fairly homogeneous for men and women, in spite of the differences 
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in the sex-specific ‘values’ of prevalence at which the levelling off occurred. 
Furthermore, the recently observed levelling off does not imply that an absolute 
biological limit / threshold has been reached in various populations around the 
world. For example, the latest observed levelling off values in the UK255 (≈ 21-
24%) and the US254 (≈ 30-40%) have been already well surpassed in Saudi 
Arabia. 
Therefore, the assumption used in this thesis was to cap the projected obesity 
trends at the highest ‘observed’ value in any age group for each sex separately. 
The trend was fixed from that cap point on, for that sex-age group. Then, the 
other age groups were allowed to reach the cap point for the sex, and when the 
cap value is reached, the trend was also fixed from that point onwards. As 
shown in Table  5.11, the highest observed value for obesity prevalence in men 
was 34.5% in those aged 35-44 years. On the other hand, the highest observed 
value in women was 58.8% in the age group 45-54 years. So, the capping point 
was assumed to be 35% in men and 60% in women. 
Prevalence rates of obesity in Saudi Arabia from 1992-2022, after applying all 
the previously discussed assumptions, are summarised in Table  5.11, while 
those of smoking are summarised in Table  5.12. 
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Table  5.11. Data input into the Saudi IMPACT model: Prevalence rates of obesity (%) in Saudi Arabia, 1992-2022 (*) 
Year Men- age groups (years) Women- age groups (years) 
25-34 35-44 45-54 55-64 65-74 75+ 25-34 35-44 45-54 55-64 65-74 75+ 
1992 10.06 14.00 14.18 12.94 6.30 1.10 16.13 25.05 25.81 22.77 12.85 2.45 
1993 13.08 16.76 17.16 15.35 7.81 2.19 20.94 29.08 30.26 26.71 15.31 4.13 
1994 16.11 19.52 20.15 17.76 9.31 3.27 25.76 33.11 34.72 30.66 17.78 5.82 
1995 19.14 22.28 23.13 20.17 10.82 4.36 30.57 37.14 39.18 34.61 20.24 7.50 
1996 22.17 25.04 26.12 22.59 12.33 5.44 35.39 41.17 43.64 38.55 22.71 9.18 
1997 25.20 27.80 29.10 25.00 13.83 6.53 40.20 45.20 48.10 42.50 25.17 10.86 
1998 25.44 28.64 29.58 25.75 15.34 7.61 40.11 46.39 49.44 43.84 27.63 12.55 
1999 25.68 29.48 30.05 26.50 16.84 8.70 40.03 47.58 50.78 45.18 30.10 14.23 
2000 25.91 30.31 30.53 27.25 18.35 9.78 39.94 48.76 52.11 46.51 32.56 15.91 
2001 26.15 31.15 31.00 28.00 18.63 9.89 39.85 49.95 53.45 47.85 33.36 16.18 
2002 26.39 31.99 31.48 28.75 18.91 9.99 39.76 51.14 54.79 49.19 34.18 16.45 
2003 26.63 32.83 31.95 29.50 19.19 10.10 39.68 52.33 56.13 50.53 35.03 16.73 
2004 26.86 33.66 32.43 30.25 19.48 10.21 39.59 53.51 57.46 51.86 35.89 17.01 
2005 27.10 34.50 32.90 31.00 19.77 10.32 39.50 54.70 58.80 53.20 36.77 17.29 
2006 27.51 35.14 33.47 31.51 20.07 10.43 40.33 56.22 60.59 54.69 37.68 17.59 
2007 27.92 35.79 34.04 32.04 20.37 10.55 41.18 57.78 62.44 56.22 38.61 17.88 
2008 28.34 36.45 34.63 32.57 20.68 10.66 42.05 59.38 64.34 57.79 39.56 18.18 
2009 28.76 37.13 35.22 33.11 20.99 10.78 42.93 61.03 66.30 59.41 40.53 18.49 
2010 29.19 37.82 35.83 33.65 21.31 10.89 43.83 62.73 68.32 61.07 41.53 18.80 
2011 29.63 38.52 36.44 34.21 21.63 11.01 44.76 64.47 70.40 62.78 42.56 19.12 
2012 30.08 39.23 37.07 34.78 21.96 11.13 45.70 66.26 72.54 64.53 43.60 19.44 
2013 30.53 39.96 37.71 35.35 22.29 11.25 46.66 68.10 74.75 66.34 44.68 19.76 
2014 30.98 40.70 38.36 35.94 22.62 11.38 47.64 69.99 77.03 68.20 45.78 20.10 
2015 31.45 41.46 39.01 36.53 22.96 11.50 48.64 71.94 79.37 70.10 46.91 20.43 
2016 31.92 42.23 39.69 37.14 23.31 11.62 49.67 73.93 81.79 72.07 48.06 20.78 
2017 32.40 43.01 40.37 37.75 23.66 11.75 50.71 75.99 84.28 74.08 49.25 21.13 
2018 32.88 43.81 41.06 38.38 24.02 11.88 51.78 78.10 86.85 76.15 50.46 21.48 
2019 33.38 44.62 41.77 39.02 24.38 12.01 52.87 80.26 89.49 78.29 51.70 21.84 
2020 33.88 45.44 42.49 39.66 24.75 12.14 53.98 82.49 92.22 80.48 52.98 22.21 
2021 34.39 46.29 43.22 40.32 25.12 12.27 55.12 84.78 95.02 82.73 54.28 22.59 
2022 34.90 47.14 43.96 40.99 25.50 12.40 56.27 87.14 97.92 85.04 55.62 22.97 
(*) prevalence rates in bold were capped at 35% in men and 60% in women 
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Table  5.12. Data input into the Saudi IMPACT model: Prevalence rates of smoking (%) in Saudi Arabia, 1992-2022 (*) 
Year Men- age groups (years) Women- age groups (years) 
25-34 35-44 45-54 55-64 65-74 75+ 25-34 35-44 45-54 55-64 65-74 75+ 
1992 14.16 13.30 9.18 7.45 5.20 5.30 0.59 0.70 1.02 0.65 0.68 0.47 
1993 15.51 14.38 9.95 7.88 5.50 5.60 0.64 0.75 1.11 0.68 0.71 0.49 
1994 16.86 15.47 10.72 8.32 5.81 5.91 0.70 0.81 1.20 0.72 0.75 0.52 
1995 18.21 16.55 11.49 8.75 6.11 6.21 0.75 0.86 1.29 0.75 0.78 0.54 
1996 19.56 17.64 12.26 9.19 6.42 6.52 0.81 0.92 1.38 0.79 0.81 0.56 
1997 20.91 18.72 13.03 9.62 6.72 6.82 0.86 0.97 1.47 0.82 0.84 0.58 
1998 22.26 19.81 13.80 10.06 7.02 7.12 0.92 1.02 1.56 0.86 0.88 0.61 
1999 23.60 20.89 14.58 10.49 7.33 7.43 0.97 1.08 1.66 0.89 0.91 0.63 
2000 24.95 21.98 15.35 10.93 7.63 7.73 1.03 1.13 1.75 0.93 0.94 0.65 
2001 26.30 23.06 16.12 11.36 7.65 7.75 1.08 1.18 1.84 0.96 0.94 0.65 
2002 27.65 24.15 16.89 11.80 7.68 7.78 1.14 1.24 1.93 1.00 0.94 0.65 
2003 29.00 25.23 17.66 12.23 7.70 7.80 1.19 1.29 2.02 1.03 0.94 0.65 
2004 30.35 26.32 18.43 12.67 7.72 7.82 1.25 1.35 2.11 1.07 0.94 0.65 
2005 31.70 27.40 19.20 13.10 7.75 7.85 1.30 1.40 2.20 1.10 0.94 0.65 
2006 32.13 27.70 19.35 13.16 7.77 7.87 1.30 1.40 2.20 1.10 0.94 0.65 
2007 32.56 28.00 19.50 13.21 7.79 7.90 1.30 1.40 2.20 1.10 0.94 0.65 
2008 33.00 28.30 19.65 13.27 7.82 7.92 1.30 1.40 2.21 1.10 0.94 0.65 
2009 33.45 28.61 19.80 13.33 7.84 7.94 1.30 1.40 2.21 1.10 0.94 0.65 
2010 33.90 28.92 19.95 13.39 7.86 7.97 1.30 1.40 2.21 1.10 0.94 0.65 
2011 34.35 29.23 20.11 13.45 7.89 7.99 1.30 1.40 2.21 1.10 0.94 0.65 
2012 34.82 29.55 20.26 13.50 7.91 8.02 1.30 1.41 2.21 1.10 0.94 0.65 
2013 35.29 29.87 20.42 13.56 7.94 8.04 1.31 1.41 2.22 1.10 0.94 0.65 
2014 35.76 30.19 20.57 13.62 7.96 8.07 1.31 1.41 2.22 1.10 0.94 0.65 
2015 36.25 30.52 20.73 13.68 7.99 8.09 1.31 1.41 2.22 1.10 0.94 0.65 
2016 36.74 30.85 20.89 13.74 8.01 8.11 1.31 1.41 2.22 1.10 0.94 0.65 
2017 37.23 31.19 21.05 13.80 8.03 8.14 1.31 1.41 2.22 1.10 0.95 0.65 
2018 37.73 31.53 21.22 13.86 8.06 8.16 1.31 1.41 2.23 1.10 0.95 0.65 
2019 38.24 31.87 21.38 13.92 8.08 8.19 1.31 1.41 2.23 1.11 0.95 0.65 
2020 38.76 32.21 21.54 13.98 8.11 8.21 1.31 1.41 2.23 1.11 0.95 0.65 
2021 39.28 32.56 21.71 14.04 8.13 8.24 1.31 1.41 2.23 1.11 0.95 0.65 
2022 39.81 32.92 21.88 14.10 8.16 8.26 1.31 1.41 2.23 1.11 0.95 0.65 
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5.3.2.5. The transition parameters (diabetes incidence, case fatality, and total 
mortality) A. Introduction 
The Saudi IMPACT Diabetes Forecast Model used the incidence of T2DM, case 
fatality, and total mortality as crucial data inputs for the modelled Saudi 
population to inform the transitions between the different health states. 
Nevertheless, reliable data on these three parameters from Saudi Arabia were 
not available. In fact, such data (particularly incidence of T2DM) are also not 
available for most countries all over the world. This lack of incidence estimates 
globally is attributed to the difficulty in describing the epidemiology and natural 
history of T2DM.157 The disease is well known for its gradual and asymptomatic 
onset. A large proportion of patients hardly experience any symptom of T2DM in 
the early stages of disease and may remain asymptomatic with an ‘occult’ 
disease for years. As a result of this complicated case definition and a high 
prevalence of undiagnosed cases, the global estimates of T2DM incidence and 
prevalence are highly variable. These estimates are often dependent on factors 
other than the true occurrence of disease (e.g. patient awareness and level of 
case finding).157 Most available studies on incidence of diabetes in some 
countries are too small to yield reliable estimates, because it is difficult and 
expensive to conduct large studies with adequate follow-up durations.157  
Moreover, the observed mortality due to T2DM (diabetes-related mortality) is 
mostly unavailable, or is presumed to be underestimated. This is because that 
mortality estimates of T2DM are mostly obtained from death certificates, which 
are mostly based on the concept of a single ‘underlying’ cause of death. 
However, in case of T2DM, death may occur as a result of several associated 
complications, such as cardiovascular disease and/or chronic renal failure, 
which are often recorded as the underlying cause of death.157 
Therefore, in this thesis, a previously validated method was used in order to 
estimate such vital modelling parameters for the Saudi population. This method 
was that proposed by Barendregt et al. to estimate diabetes incidence in 
Netherlands.157 The method is used to obtain age- and sex-specific estimate of 
T2DM incidence that is consistent with previously estimated prevalence and 
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mortality. It combines both a prevalence estimate and a mortality estimate in an 
incidence-prevalence-mortality (IPM) model, known as DISMOD, in order to 
obtain an estimate of diabetes incidence. 
IPM models of disease processes are mainly used to overcome limitations of 
empirical observed data of some diseases, including T2DM. Of course, 
empirical observed data are the gold standard for obtaining epidemiological 
information, but such data are often incomplete or of dubious validity.257 
Moreover, the validity of observed estimates tends to vary even for an individual 
disease. For example, in instances where incidence is more difficult to observe 
than mortality, more incident cases than deaths are likely to be missed. 
Consequently, incidence data will be less complete than those on mortality, 
making these two parameters internally inconsistent.257 IPM models exploit the 
causal structure of a disease process (i.e. incidence has to precede prevalence, 
and cause-specific mortality can only follow being diseased). In other words, 
any prevalent case must have become incident at some younger age, and any 
person dead with a disease must have been an incident case previously and 
have been prevalent. This causal structure is then incorporated into a 
mathematical model (DISMOD) in order to estimate data that are missing from 
an observational set. Eventually, jointly estimated incidence, prevalence, and 
mortality rates, using a causal model, are therefore internally consistent.157, 257, 
258 
The following sections discuss in detail the DISMOD model, which was used in 
this thesis to estimate the incidence of T2DM, case fatality, and total mortality in 
Saudi Arabia; its conceptual basis, data inputs, outputs, advantages and 
limitations. B. DISMOD 
(i) Conceptual basis, data inputs and outputs 
DISMOD (stands for DISease MODelling) is a multistate generic mathematical 
disease model, implemented in software, which is made available to the public 
domain by the WHO: 
(http://www.who.int/healthinfo/global_burden_disease/tools_software/en/).  
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DISMOD was used extensively by the WHO for the Global Burden of Disease 
(GBD) Study since 1990, and also by many other subsequent country studies in 
the world. It was designed to measure the causes and patterns of disease in 
populations with only partial and insufficient data, through supplementing the 
data by exploiting the causal relations between the various variables that 
describe a disease process.157, 257, 258 These ‘logical’ relations can be expressed 
as a formal model of a generic disease process. Such a formal disease model 
allows estimation of an internally consistent description of disease epidemiology 
from partial data. 
DISMOD is based on the common conceptual disease model in figure 5.9. It is 
a continuous time Markov process (discussed in chapter 4), which describes the 
population as being in different states, while transition hazards determine how 
people move from one state to another. It follows an initially disease-free cohort 
over time and applies the transition hazards.157, 258 Population is partitioned into 
two independent (discrete) main states: susceptibles and cases. Cases may die 
from their disease, while both cases and susceptibles are at risk of dying from 
all other causes. Therefore, there are four main transition hazards between 
states: incidence, case-fatality, all-other-causes mortality and remission.257 
However, mortality from all other causes poses a problem, as it is an input to 
the model, but often is not known. It can be estimated from the total mortality 
and the diabetes-specific mortality, but, again, the latter is mostly not known. 
Hence, DISMOD assumes that hazards are not affected by the presence or 
absence of other hazards that act on the same population.258 Based on this 
assumption, the mortality from all other causes is assumed to be independent of 
diabetes (i.e. it is the same for both diabetic and non-diabetic individuals in the 
population). This implies that incidence, case fatality and remission are not 
affected by value of mortality from all other causes. So, DISMOD set the value 
of mortality from all other causes to ‘zero’, leaving it out of the model’s 
equations, and estimates the disease incidence and other rates.258  
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Figure  5.9. The conceptual disease model of DISMOD257 
By assuming independence of the mortality from all other causes, the diabetes-
related mortality in DISMOD stands for all excess mortality caused by diabetes 
(which includes deaths due to diabetes-related conditions/ complications, such 
as cardiovascular disease).258 Since valid estimates on diabetes-related 
mortality are not available from most countries in the world, including Saudi 
Arabia, an alternative method to estimate it was proposed for DISMOD by Baan 
et al.259 In brief, the method was developed in order to provide an ‘adjusted’ 
relative risk estimate of mortality in diabetics as compared to the general 
population. This relative risk estimate (in this section, is abbreviated as RRadj) 
is an equivalent to the all excess mortality caused by diabetes. The method 
estimates the RRadj by using a commonly available parameter of diabetes (i.e. 
prevalence) in addition to the ‘typical’ relative mortality risk for diabetes (in this 
section, is abbreviated as RR), which is equal to: (Total mortality rate for 
diabetics / Total mortality rate for non-diabetics).  
Because the RRadj (which is equivalent to diabetes-related mortality rate) 
includes all excess mortality for diabetics, it is therefore independent from all 
other mortality. So, it can be used (unlike the specific mortality restricted to 
diabetes) in an IPM model that assumes independence from the non-diabetes-
related mortality.157 The proposed formula of the Baan et al. method is: 
RRadj =  𝑅𝑅 
𝑝𝑅𝑅+(1−𝑝)          (1) 
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Where p is the prevalence of diabetes. 
The age- and sex-specific prevalence of diabetes in Saudi Arabia (for the 
starting year of modelling; 1992) is available (Table  5.7), and the RR can be 
obtained from literature. Baan et al.259 reviewed 12 studies that reported age- 
and sex-specific relative mortality risks for diabetes (RRs) in different countries. 
In general, they compared these studies and found that the reported RRs were 
similar in spite of differences between these studies in design, population and 
time. In order to estimate the incidence of diabetes in the Netherlands, Baan et 
al. used RRs from the Verona Diabetes Study260 (population-based) from Italy, 
which used the ‘non-diabetic’ population as the reference population.  
Briefly, the Verona Diabetes Study260 aimed to determine the prevalence of 
known diabetes mellitus on the 31st December 1986, and to assess all-cause 
mortality in the subsequent 5 years (1987-1991) in Verona, a mid-size town of 
the north-east Italy. A total of 5996 diabetic patients were identified (overall 
prevalence 2.61%) mainly from Family Physicians in Verona. Mortality was 
assessed by matching all death certificates of Verona in 1987-1991 with the 
diabetic cohort. The total ‘observed’ deaths in the diabetic cohort by the 31st 
December 1991 (1260 patients) were compared with the ‘expected’ deaths at 
the same time point (863 individuals), using as a reference the non-diabetic 
population of Verona. This reference population was obtained from the Social 
Health Unit (SHU) of Verona, which is part of the National Health System. In 
Italy, all Family Physicians in a particular area follow the SHU of the same area, 
and each citizen is assigned by law to one Family Physician. Thus, the records 
of the Family Physicians were most likely complete for the population in Verona. 
By comparing the “observed / expected” mortalities, an overall standardised 
mortality ratio (SMR) of 1.46 (95% CI: 1.38–1.54) was obtained. SMRs were 
also calculated for each age group and sex of the study population.260  
Using the age- and sex-specific SMRs from the Verona Diabetes Study,260 the 
relative risk for diabetes mortality (RRadj) was estimated for the Saudi 
population in 1992 (Table  5.13), through the Baan et al. formula259 described 
above. The decision to use RRs from the Verona Diabetes Study for this thesis 
was based on a previous effective use of such RRs for countries in the same 
region of Saudi Arabia. These RRs were used for the same purpose in the 
148 
 
MEDCHAMPS project, for the four participating countries from the EMR; namely 
Turkey, Syria, Palestine and Tunisia. The RRadj was calculated specifically for 
the population of each of these countries, using the RRs from the Verona 
Diabetes Study, and the results of all models from these countries were good 
when validated against observed data (personal communication, Martin 
O’Flaherty, 2012). However, extensive sensitivity analyses were performed in 
order to assess the potential effects of uncertainty in diabetes incidence, case 
fatality and total mortality (that were estimated using these RRs) on the model 
outputs. 
Table  5.13. The estimated RRadj  for the Saudi population 
Age group 
(years) 
Sex 
RR from 
Verona 
Study260 
Diabetes 
Prevalence 
in Saudi 
Arabia36 
(1992) 
RRadj for 
Saudi 
population 
     
25-34 men 2.33 3.70% 2.22 
women 3.43 3.01% 3.20 
     
35-44 men 2.33 7.01% 2.13 
women 3.43 5.03% 3.06 
     
45-54 men 2.33 21.06% 1.82 
women 3.43 22.09% 2.23 
     
55-64 men 2.13 24.91% 1.66 
women 2.33 23.23% 1.78 
     
65-74 men 1.5 28.75% 1.31 
women 2.27 24.37% 1.73 
     
75+ men 1.13 28.75% 1.09 
women 1.32 24.37% 1.22 
 
DISMOD needs a minimum of three input variables in order to estimate the 
epidemiological parameters of a disease. In this thesis, the available variables 
for Saudi Arabia were prevalence of T2DM for 1992 (derived from the study of 
Warsy and El-Hazmi36), remission and RRadj. Remission of T2DM was assumed 
to be zero, though some evidence has emerged showing that ‘resolution’ of 
diabetes was reported after bariatric surgeries.261 In this thesis, however, it was 
assumed that the remission rate is not likely to affect the incidence estimates 
substantially.  
In addition to the previous three disease input variables, DISMOD needs total 
mortality rates and population structure for the population under study. For 
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Saudi Arabia, population structure for 1992 was available from a national 
census, as discussed in section 5.3.2.1. Local data on the sex- and age-specific 
total mortality rates were not available from Saudi Arabia. Thus, such data (for 
1992) were obtained from the life tables of the WHO Global Health Observatory 
(GHO) Data Repository (http://apps.who.int/ghodata/).262 All input variables into 
DISMOD are by age, and the estimations are performed separately for men and 
women.258 After providing data inputs, DISMOD runs its calculations based on a 
set of differential equations that describe the disease process. These equations 
were described in detail by Barendregt et al.258 DISMOD provides different 
outputs (disease parameters), that are ‘internally-consistent’ for the modelled 
population, based on the inputs provided. 
As indicated, all the input variables of the Saudi population were specific to the 
starting year of modelling (1992). DISMOD, as an IPM model, assumes that a 
modelled population is in ‘equilibrium’ or a ‘steady state’, i.e. there are no trends 
in the disease transition parameters (incidence, case fatality and total mortality), 
and these parameters remain constant over time. So, an important assumption 
used in the Saudi IMPACT Diabetes Forecast Model was that diabetes 
incidence and other parameters obtained from DISMOD were ‘stable’ for the 
Saudi population during the modelling period (1992-2022). However, sensitivity 
analysis could deal with uncertainties in the model results that might originate 
from this assumption. 
The DISMOD outputs (parameters) used in the Saudi IMPACT Diabetes 
Forecast Model are incidence of diabetes, case fatality rate for diabetes, and 
total mortality for the Saudi population with and without diabetes. Table  5.14 
summarises the data inputs into DISMOD and the outputs used for modelling. 
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Table  5.14. Summary of the data inputs and outputs of DISMOD 
Men 
Age 
groups 
(years) 
Data inputs Data outputs 
Prevalence 
rate (%) 
Remission 
rate (%) 
RRadj 
Incidence rate 
(per 1000 
population) 
Case fatality 
rate (%) 
Total 
mortality rate 
(per 1000 
population) 
25-34 3.70 0 2.22 12.90 0.15 0.10 
35-44 7.01 0 2.13 17.70 0.39 0.50 
45-54 21.06 0 1.82 18.90 0.67 1.10 
55-64 24.91 0 1.66 20.70 1.20 2.50 
65-74 28.75 0 1.31 22.40 1.35 3.30 
75+ 28.75 0 1.09 26.70 2.10 6.10 
Women 
Age 
groups 
(years) 
Data inputs Data outputs 
Prevalence 
rate (%) 
Remission 
rate (%) 
RRadj 
Incidence rate 
(per 1000 
population) 
Case fatality 
rate (%) 
Total 
mortality rate 
(per 1000 
population) 
25-34 3.01 0 3.20 12.90 0.16 0.10 
35-44 5.03 0 3.06 15.00 0.43 0.50 
45-54 22.09 0 2.23 15.90 0.62 1.00 
55-64 23.23 0 1.78 16.70 0.96 1.80 
65-74 24.37 0 1.73 19.70 1.90 4.10 
75+ 24.37 0 1.22 30.70 4.62 11.60 
 
(ii) The DISMOD computational basis for the outputs 
The total mortality for people with and without diabetes is estimated by DISMOD 
from the ‘observed’ average population total mortality, the relative risk of 
mortality for diabetics (RRadj) and diabetes prevalence using the following 
equations:157 
m = pm1 + (1 – p)m0                        (2)  and 
m1 = m0RR                                      (3) 
By substituting equation 3 in equation 2, the mortality of the non-diabetics will 
be as follows: 
m0 =  𝑚
𝑝𝑅𝑅+1−𝑝
                                   (4) 
Thus, the diabetes-related mortality rate (md) in a population with a diabetes 
prevalence of p will be calculated as follows: 
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 md = pm0 (RR – 1) = 
𝑝(𝑅𝑅−1)𝑚
𝑝𝑅𝑅+1−𝑝
        (5) -  (This is the same as the population   
                                                                  attributable risk times total mortality). 
Where p = prevalence of diabetes; RR = relative risk on total mortality, given 
exposure to diabetes; m = average total mortality rate; m0 = total mortality rate 
of non-diabetics; m1 = total mortality rate of diabetics; md = diabetes-related 
mortality rate of the mixed population. 
Given this mortality rate in the population and the prevalence of diabetes, the 
incidence at age “a” can be written as a function of prevalence at “a” and “a+1”, 
and mortality at “a”, as follows: 
ia = 
𝑝𝑎+1 �1− 𝑚𝑎𝑑�− 𝑝𝑎+𝑚𝑎𝑑
1− 𝑝𝑎                  (6) 
This method produces a “population incidence”, i.e. for both exposed and 
unexposed people to the risk factors under study in this thesis (obesity and 
smoking). However, the Saudi IMPACT Diabetes Forecast Model needs 
incidence in the unexposed population to inform the transition between the 
(healthy) and (diabetes) states. 
The incidence of a disease in a population is a weighted sum of the incidence 
among the exposed and the incidence among the unexposed to a risk factor,263 
as follows: 
𝑖𝑝 = 𝑖𝑒 × 𝑝 + 𝑖𝑢 × (1 − 𝑝)                  (7) 
Where ip is the population incidence, ie is the incidence amongst the exposed, 
iu is the incidence amongst the unexposed and p is risk factor prevalence. 
The incidence in the exposed is equal to the incidence in the unexposed times 
the RR, as follows:  
𝑖𝑒 = 𝑅𝑅 × 𝑖𝑢                                      (8) 
Replacing equation 8 in equation 7:   𝑖𝑝 = 𝑅𝑅 × 𝑖𝑢 × 𝑝 + 𝑖𝑢 × (1 − 𝑝)         (9) 
Therefore, Iu can be calculated as follows:  
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 𝑖𝑢 =  𝑖𝑝(𝑝×𝑅𝑅−𝑝)+1                             (10) 
Table  5.15 summarises the age- and sex- specific incidence rates (Iu), that were 
calculated through equation 10 and used in the Saudi IMPACT Diabetes 
Forecast Model. 
Table  5.15. Age- and sex-specific incidence rates (Iu) used in the Saudi IMPACT Diabetes Forecast Model 
Age groups (years) Diabetes incidence rate 
 Men Women 
25-34 0.0082 0.0045 
35-44 0.0098 0.0039 
45-54 0.0105 0.0040 
55-64 0.0119 0.0046 
65-74 0.0165 0.0080 
75+ 0.0251 0.0240 
(iii) Advantages and limitations of DISMOD 
As previously discussed, DISMOD was specifically designed for situations with 
insufficient data on a disease epidemiology, in order to supplement the partial 
data by exploiting the causal relations between the various variables that 
describe a disease process.257 It is based on a ‘logical’ mathematical 
description of a disease process and natural history, and it produces ‘internally-
consistent’ parameters of the disease epidemiology in the modelled population. 
DISMOD was validated by comparing its results for some types of cancers in 
Netherlands against both the ‘observed’ data and an ‘artificial/ hypothetical’ 
dataset that was internally consistent. This validation resulted in practically 
reproducible results of the two datasets.257 In addition, as mentioned earlier, 
DISMOD has been used by the WHO for the GBD Study since 1990, and also 
for many country-specific studies around the world. It is embedded in free 
software, which is accessible through the WHO website: 
( http://www.who.int/healthinfo/global_burden_disease/tools_software/en/ ). 
On the other hand, DISMOD has some limitations. As mentioned earlier, one of 
the important limitations of DISMOD is the assumption of a ‘steady’ modelled 
population with constant trends of transition hazards over time. Therefore, 
occurrence of trends in incidence, for example, might lead to discrepancies 
between the estimates of diabetes prevalence in the Saudi IMPACT Diabetes 
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Forecast Model and the actual prevalence. In other words, if the true incidence 
of T2DM has increased in Saudi Arabia since 1992, then the model projections 
of the disease prevalence would most likely be underestimated. However, as 
discussed above, the sensitivity analysis provides different results based on 
different values of incidence and mortality, and, hence, deals with the potential 
uncertainties around such parameters. A second limitation of DISMOD is the 
assumption of a “zero” value of the excess mortality from other diseases. 
Although this assumption is convenient, it might not be appropriate in the case 
of diabetes. Diabetic individuals also suffer from an increased risk of dying from 
diseases other than diabetes (e.g. cardiovascular disease). Therefore, as 
discussed earlier, the developers of DISMOD constructed a diabetes-related 
mortality rate (RRadj), which is assumed to include all excess mortality for 
diabetics, and is independent from all other mortality. 
5.3.2.6. The transition parameters (Relative risks of diabetes in obese and in 
smokers) 
The (diabetes incidence X RR of developing diabetes if ‘obese’) was used to 
inform the transition of individuals from the model’s (obese) state to the 
(diabetes) state. Similarly, the (diabetes incidence X RR of developing diabetes 
if a smoker) was used to inform the transition from (smoker) state to (diabetes) 
state. As expected, these RRs were not available from Saudi Arabia as well as 
most developing countries. Therefore, such RRs were derived from literature. 
There are several prospective studies that have assessed the association 
between obesity and incidence of T2DM97 and between smoking and incidence 
of T2DM.130 These studies were carried out in different countries/ populations 
(mostly developed countries), and provided incidence/ RR estimates of 
developing diabetes in ‘obese’ individuals and in smokers. However, there are 
two relatively recent systematic reviews97, 130 that synthesized the results of 
multiple original studies and conducted meta-analyses to estimate pooled RRs. 
These two systematic reviews/ meta-analyses have been discussed previously 
in chapter 2. The pooled RRs estimated by such reviews were used in the 
Saudi IMPACT Diabetes Forecast Model as transition parameters, as shown in 
Table  5.16. 
154 
 
Table  5.16. Relative risk estimates used to inform transitions in the Saudi IMPACT Diabetes Forecast 
Model 
 Result Used in the model to 
inform transition Reference 
Men Women from to 
RR of having diabetes if 
obese (BMI ≥ 30 kg/m2) 
 
6.74 12.41 ‘obese’ 
state 
‘diabetes’ 
state 
Guh et al.97 
RR of having diabetes if 
smoker 
1.44 1.44 ‘smokers’ 
state 
‘diabetes’ 
state 
Willi et al.130 
It is important to note that the pooled RRs estimated by Guh et al.97 were 
reported only as sex-specific (no age-specific RRs). So, these RRs were used 
for all age groups of each sex. In addition, Willi et al.130 reported only one 
adjusted pooled RR for both men and women (no sex- or age-specific RRs). 
Therefore, the reported RR was assumed to apply equally for men and for 
women of all age groups. Furthermore, the reported diabetes RRs for obese 
and for smokers were assumed to be constant over the whole modelling period 
(1992-2022).  
5.3.2.7. Setting up the transition probabilities in the Saudi IMPACT Diabetes 
Forecast Model 
The transition hazards estimated by DISMOD (incidence, case fatality, and total 
mortality) were all expressed as rates. It has been discussed in chapter 4 that 
Markov models use transition probabilities (TPs), rather than rates, to describe 
the transitions between the health states in the model. While rates can take 
values from zero to infinity and are expressed per unit time, probabilities range 
from zero to one and have time built into them implicitly.217 To convert rates into 
probabilities, the following formula is generally used:  
P[t] = 1 – e-rt                                   (11) 
Where P is transition probability; t is time units; and r is rate. However, this 
formula produces probabilities of transition between states. The probability of 
staying in the same state in a given cycle will typically be equal to 1 minus the 
probability of leaving that particular state, because the probability of moving to 
states in each cycle must sum to 1 (since individuals must be in one and only 
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one state at any given time).216, 217 Table  5.17 summarises the results of 
converting the output rates of DISMOD to TPs. 
Table  5.17. Results of converting the values of transition hazards from rates to transition probabilities 
Age group 
(years) 
Incidence Case fatality Total mortality 
Rate 
Transition 
probability 
Rate 
Transition 
probability 
Rate 
Transition 
probability 
Men       
25 – 34 0.0082 0.0082 0.0015 0.0015 0.0001 0.0001 
35 – 44 0.0098 0.0098 0.0039 0.0039 0.0005 0.0005 
45 – 54 0.0105 0.0104 0.0067 0.0067 0.0011 0.0011 
55 – 64 0.0119 0.0118 0.0120 0.0119 0.0025 0.0025 
65 – 74 0.0165 0.0163 0.0135 0.0134 0.0033 0.0033 
75+ 0.0251 0.0248 0.0210 0.0208 0.0061 0.0061 
       
Women       
25 – 34 0.0045 0.0045 0.0016 0.0016 0.0001 0.0001 
35 – 44 0.0039 0.0039 0.0043 0.0043 0.0005 0.0005 
45 – 54 0.0040 0.0040 0.0062 0.0062 0.0010 0.0010 
55 – 64 0.0046 0.0046 0.0096 0.0096 0.0018 0.0018 
65 – 74 0.0080 0.0080 0.0190 0.0188 0.0041 0.0041 
75+ 0.0240 0.0237 0.0462 0.0451 0.0116 0.0115 
 
In the Saudi IMPACT Diabetes Forecast Model, as illustrated previously in 
Figure  5.1, there are six distinct states (including two death states) and nine 
possible transitions between them. In addition, there are four probabilities of 
staying in each of the four health states: healthy (H), obese (O), smokers (S), 
and diabetics (DM). Table  5.18 illustrated a transition matrix for the ‘allowable’ 
transitions between the states of the model. 
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Table  5.18. The allowable transitions in the Saudi IMPACT Diabetes Forecast Model 
Transition 
from 
to 
H O S DM Deaths 
(no 
DM) 
Deaths 
(DM) 
H 1-TPHDM -
TPHD- 
  TPHDM TPHD-  
O  1- TPODM - 
TPOD- 
 TPODM TPOD-  
S   1- TPSDM – 
TPSD- 
TPSDM TPSD-  
DM    1- TPDMD- – 
TPDMD+ 
TPDMD- TPDMD+ 
Deaths (no 
DM) 
      
Deaths (DM)       
These allowable TPs are specific to each age group of each sex. Six of these 
TPs represent the transition hazards which were estimated through DISMOD 
and were already converted to probability values (Table  5.17). First, the TP of 
moving from the H state to the DM state (TPHDM) is equal to the incidence of 
diabetes. Second, the TP of moving from the DM state to the state of diabetes-
specific deaths (TPDMD+) is equal to the case fatality. Third, all the four TPs of 
moving from the H, O, or S states to the state of deaths for other causes (TPHD-, 
TPOD-, TPSD-, TPDMD-) are equal to the total mortality estimated by DISMOD. 
Another two TPs are estimated by incorporating the RRs of diabetes in obese 
and in smoking individuals (Table  5.16). The TP of moving from the O state to 
the DM state (TPODM) is equal to:  [incidence of diabetes X RR of diabetes in 
obese individuals]. On the other hand, the transition probability of moving from 
the S state to the DM state (TPSDM) is equal to:  [incidence of diabetes X RR of 
diabetes in smokers]. Finally, as discussed earlier, the probability of staying at 
the same state as the previous cycle is equal to 1 minus the probability of 
leaving that particular state.  
To illustrate these calculations, the transition probabilities for men aged 25–34 
years are presented here as an example. Table  5.19 summarises the transition 
parameters for this age group of men. 
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Table  5.19. Transition parameters for men aged 25-34 years 
Parameter Value for men aged 25–34 years 
Incidence 0.0082 
Case fatality 0.0015 
Mortality 0.0001 
RR of diabetes in obese 6.7 
RR of diabetes in smokers 1.44 
Based on these transition parameters, the TPs for men aged 25–34 years were 
estimated as summarised in Table  5.20. 
Table  5.20. Summary of calculations of transition probabilities for men aged 25-34 years 
Transition 
from 
Transition to 
H O S DM Deaths 
(no 
DM) 
Deaths 
(DM) 
H 
1- 0.0082 - 0 = 
0.9918 
  
0.0082 0.0001 
 
O 
 1- 0.0549 – 0 = 
0.9451 
 0.0082 X 6.7 
= 0.0549 
0.0001  
S 
  1- 0.0118 – 0 = 
0.9882 
0.0082 X 1.44 
= 0.0118 
0.0001  
DM 
   1- 0.0001 – 0.0015 
= 0.9985 0.0001 0.0015 
Deaths (no 
DM) 
      
Deaths 
(DM) 
      
However, the major output of the Saudi IMPACT Diabetes Forecast Model is 
the trends in diabetes, in terms of both the numbers of individuals with diabetes 
and the prevalence of the disease. Thus, the model used for its estimations the 
TPs of moving to the DM state from the other states, i.e. TPHDM, TPODM, TPSDM, 
and the probability of staying in the same DM state. In addition, the model also 
used the two transition hazards to the death states (i.e. case fatality and total 
mortality). The ‘typical’ TPs of staying in the same health state were not utilised 
by the model. The model used another approach to estimate the size (number 
of individuals) in each health state at every modelling cycle. This approach 
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incorporated the parameter of ‘population attributable risk’ for estimations 
(discussed in detail in the next section, which illustrates an example of the 
model calculations of sizes of states for men aged 25-34 years). 
As previously discussed, the Saudi IMPACT Diabetes Forecast Model performs 
calculations separately for each sex and age group of the Saudi population. The 
model software (Microsoft Excel) contains a number of ‘tabs’ which present 
these calculations. Each separate tab was assigned for one age group of one 
sex. For example, the calculations for men aged 25-34 years were presented in 
one tab, while that for women aged 25-34 years in another tab, and so on. The 
age- and sex-specific calculations determined the size of each model state for 
each year (cycle) of the modelling period (1992-2002).  
Table  5.21 presents the results of these calculations for men in the age group 
25-34 years, and Table  5.22 illustrates an example of the calculation methods 
for year 1994.  
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Table  5.21. Example of calculations of a Markov chain for men aged 25-34 years 
year Population Obesity  
prevalence 
Smoking 
prevalence 
H O S DM Deaths (DM) Deaths (no DM) DM prevalence 
1992 1,988,608 10.1% 12.7% 1,492,571 173,184 249,374 73,479   3.7% 1993 2,042,141 13.1% 13.5% 1,449,039 225,346 269,796 97,960 110 199 4.8% 
1994 2,095,674 16.1% 14.1% 1,403,487 277,518 289,010 125,658 257 403 6.0% 
1995 2,149,206 19.1% 14.7% 1,356,016 329,674 306,885 156,631 445 613 7.3% 
1996 2,202,739 22.2% 15.2% 1,306,734 381,782 323,294 190,929 680 828 8.7% 
1997 2,256,272 25.2% 15.6% 1,255,751 433,810 338,115 228,596 966 1,048 10.1% 
1998 2,309,805 25.4% 16.6% 1,247,234 427,960 364,943 269,667 1,309 1,273 11.7% 
1999 2,363,337 25.7% 17.5% 1,237,894 421,904 392,325 311,214 1,713 1,504 13.2% 
2000 2,416,870 25.9% 18.5% 1,227,755 415,665 420,253 353,196 2,180 1,741 14.6% 
2001 2,470,403 26.2% 19.4% 1,216,838 409,266 448,724 395,574 2,709 1,982 16.0% 
2002 2,523,936 26.4% 20.4% 1,204,961 402,348 477,679 438,948 3,302 2,229 17.4% 
2003 2,577,468 26.6% 21.3% 1,192,521 395,642 507,207 482,098 3,960 2,482 18.7% 
2004 2,631,001 26.9% 22.2% 1,179,521 389,161 537,309 525,009 4,682 2,740 20.0% 
2005 2,641,168 27.1% 23.1% 1,144,370 371,165 557,961 567,672 5,469 3,003 21.5% 
2006 2,651,334 27.5% 23.3% 1,124,009 357,494 560,910 608,921 6,320 3,267 23.0% 
2007 2,661,501 27.9% 23.5% 1,104,105 344,559 563,928 648,908 7,233 3,532 24.4% 
2008 2,671,667 28.3% 23.6% 1,084,633 332,365 567,014 687,654 8,206 3,798 25.7% 
2009 2,681,834 28.8% 23.8% 1,065,568 320,916 570,165 725,185 9,236 4,065 27.0% 
2010 2,692,000 29.2% 24.0% 1,046,883 310,212 573,377 761,528 10,323 4,333 28.3% 
2011 2,701,400 29.6% 24.2% 1,028,198 300,028 576,461 796,712 11,465 4,602 29.5% 
2012 2,710,800 30.1% 24.3% 1,009,859 290,597 579,599 830,746 12,659 4,873 30.6% 
2013 2,720,200 30.5% 24.5% 991,825 281,886 582,780 863,709 13,904 5,144 31.8% 
2014 2,729,600 31.0% 24.7% 974,082 273,913 586,005 895,600 15,199 5,416 32.8% 
2015 2,739,000 31.4% 24.8% 956,614 266,693 589,270 926,423 16,541 5,689 33.8% 
2016 2,790,200 31.9% 25.0% 957,407 273,582 603,026 956,185 17,930 5,962 34.3% 
2017 2,841,400 32.4% 25.2% 957,563 280,761 616,814 986,262 19,363 6,242 34.7% 
2018 2,892,600 32.9% 25.3% 957,079 288,248 630,626 1,016,646 20,841 6,526 35.1% 
2019 2,943,800 33.4% 25.5% 955,955 296,062 644,454 1,047,329 22,365 6,815 35.6% 
2020 2,995,000 33.9% 25.6% 954,187 304,219 658,289 1,078,305 23,935 7,109 36.0% 
2021 3,029,200 34.4% 25.8% 945,000 306,890 667,740 1,109,569 25,551 7,409 36.6% 
2022 3,063,400 34.9% 25.9% 935,532 310,174 677,194 1,140,499 27,214 7,712 37.2% 
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Table  5.22. Example showing the calculation methods used to determine the sizes of the model states, for men aged 25-34 years in 1994 
Health state/ information Source/ Method of calculation 
Population As estimated by linear interpolation (Table 5.3) = 2,095,674 
Prevalence of obesity As estimated by linear interpolation (Table 5.11)  
= 16.1%  
Prevalence of smoking = The ‘original’ smoking prevalence in 1994 as estimated by linear interpolation (Table 5.12) – [The ‘original’ smoking prevalence in 1994 as 
estimated by linear interpolation (Table 5.12) X obesity prevalence in 1994] 
= 0.169 – [0.169 X 0.161] 
= 14.1% 
Size of the H state  = Population – O state – S state – DM state 
=  2,095,674 – 277,518 – 289,010– 125,658 
= 1,403,487 
Size of the O state = [obesity prevalence X population] – [size of DM state in 1994 X ((obesity prevalence X RR of DM if obese – 1) / (obesity prevalence X RR of 
DM if obese -1) + 1))] 
= [0.161 X 2,095,674] – [125,658 X ((0.161 X 6.7 – 1) / (0.161 X 6.7 – 1) + 1))] 
= 277,518 
Size of the S state = [smoking prevalence X population] – [size of DM state in 1994 X ((smoking prevalence X RR of DM if smoker – 1) / (smoking prevalence X RR 
of DM if smoker -1) + 1))] 
= [0.141 X 2,095,674] – [125,658 X ((0.141 X 1.44 – 1) / (0.141 X 1.44 – 1) + 1))] 
= 289,010 
Size of the DM state = Size of H state in 1993 X TP(H→DM) + Size of O state in 1993 X TP(O→DM) + Size of S state in 1993 X TP(S→DM) + Size of DM state in 
1993 X TP(DM→DM) 
= 1,449,039 X 0.008 + 225,346 X 0.055 + 269,796 X 0.012 + 97,960 X 0.999 
= 125,658 
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Table  5.22 (cont.). Example showing the calculation methods used to determine the sizes of the model states, for men aged 25-34 years in 1994 
Health state/ information Source/ Method of calculation 
Size of the state of DM-related 
deaths  
= (Size of DM state in 1993 X TP of case fatality) + Size of the state of DM-related deaths in 1993 
= (97,960 X 0.0015) + 110 
= 257 
Size of the state of deaths due to 
other causes 
= Size of the state of deaths due to other causes in 1993 + [Size of H state in 1993 X TP of total mortality + Size of O state in 1993 X TP of total 
mortality + Size of S state in 1993 X TP of total mortality + Size of DM state in 1993 X TP of total mortality] 
= 199 + [1,449,039 X 0.0001 + 225,346 X 0.0001 + 269,796 X 0.0001 + 97,960 X 0.0001] 
= 403 
Diabetes prevalence = Size of the DM state / population in 1994  
= 125,658 / 2,095,674  
= 6.0% 
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As shown in Table  5.22, the model performs its calculations through the 
concept of transitions between ‘discrete’ Markov states, as discussed earlier. 
Nevertheless, the methods of calculation were different for both smoking 
prevalence and the sizes of the risk factor states (O and S states). These 
different methods of calculation were used to handle the issue of ‘overlaps’ 
between the model health states.  
Since the model states are discrete, an individual can only be in one (and only 
one) state during a modelling cycle (one year). Therefore, the presence of any 
individual in the (O) state implies that this individual is obese, but not a smoker 
and not diabetic. In other words, the size of the (O) state, for example, 
represents only those obese individuals who are not smokers and not diabetics 
at the same time.  
In order to handle such overlaps, there were three different methods of 
calculation performed by the model. The first method was to deal with the 
overlap between the (O) and (S) states. The ‘original’ prevalence of smoking, 
which was obtained through linear interpolation (Table  5.12), was multiplied by 
the obesity prevalence. This multiplication was assumed to yield the proportion 
of population who were both obese and smokers at the same time. Then, such 
a proportion was subtracted from the ‘original’ prevalence of smoking, to leave 
in the (S) state only those individuals who were smokers but not obese.  
The second method of calculation was performed to handle the overlap 
between the (O) and (DM) states. This method used the population attributable 
risk (PAR) for obesity to eliminate this potential overlap. 
PAR is one of the commonly used “measures of impact” in epidemiology. It is 
defined as the excess rate of disease in the total study population of exposed 
and non-exposed individuals that is attributable to a particular exposure, 
assuming a causal relationship between exposure and disease.264 If the 
prevalence of exposure (p) and the relative risk (RR) are available, PAR is 
conventionally calculated as follows: 
𝑃𝐴𝑅 =  𝑝 (𝑅𝑅 − 1)
𝑝 (𝑅𝑅 − 1) + 1 
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In the context of this thesis, assuming a causal relationship between obesity 
and diabetes, the calculated PAR yielded the excess rate of diabetes in the total 
population (obese and non-obese) that was attributed to obesity. The model 
calculated the number of diabetes cases (in the DM state) in whom the disease 
was assumed to be ‘caused’ by obesity, through multiplying PAR by the size of 
DM state. Then, the number of such cases was subtracted from the total obese 
individuals in population. This calculation method was assumed to leave in the 
(O) state only those obese individuals who were non-diabetics.  
The third method of calculation was applied to remove the overlap between the 
(S) and (DM) states. This method used the same previous approach of PAR, 
which was assumed to leave in the (S) states only those people who were 
smokers, but not diabetics.  
Therefore, by applying these three methods (approaches) of calculation, the 
study population was assumed to be partitioned in discrete Markov states 
without overlaps. 
5.4. Sensitivity analyses 
In chapter 4, it has been discussed that sensitivity analysis should be a vital part 
in all modelling studies.22 Modelling data are mostly obtained from different 
sources and might be of different qualities. In addition, models commonly use 
assumptions and expert opinions. Thus, modelling input parameters could be 
subject to uncertainties, which might result in uncertain outputs. Simply, 
sensitivity analysis refers to estimation and presentation of model results under 
various scenarios,209 as a way of handling the uncertainties around the key 
model parameters. In the Saudi IMPACT Diabetes Forecast Model, several 
types of sensitivity analyses have been performed. As previously mentioned, 
substantial original developments were undertaken to the section of sensitivity 
analyses in this thesis, in order to involve additional and more rigorous types 
than that used in the original IMPACT model. These types of sensitivity 
analyses are summarised in the following three sections. 
5.4.1. Analysis of extremes 
The model used the ‘analysis of extremes’ method of sensitivity analysis. As 
discussed in chapter 4, this method is commonly used in modelling studies, and 
164 
 
is a type of multi-way (multivariate) analysis. It consists of examining different 
(higher and lower) values of multiple parameters simultaneously, and 
presenting the impact of such ‘extreme’ values on the output results of the 
model. So, the ‘best’ values estimated through the base-case scenario are 
presented with ranges of minimum and maximum uncertainty limits. 
In the Saudi IMPACT Diabetes Forecast Model, all model parameters (except 
population structure) were set at 20% higher and 20% lower values than the 
base-case scenario. The model was run with this distribution of extreme values 
and the uncertainty limits were estimated accordingly. In chapters 6, 7 and 8, all 
the results are presented with such uncertainty limits (in brackets or presented 
separately in tables). 
However, it has been discussed in chapter 4 that the extreme uncertainty 
values in this method of sensitivity analysis are mostly decided arbitrarily. In this 
thesis, the range of uncertainty (20% higher and 20% lower) was decided, as it 
is relatively ‘conservative’, because it is wider (though not much wider) than the 
95% CIs of the point estimates reported in some national surveys of obesity and 
smoking prevalence.19, 34, 37, 39  
5.4.2. Modelling scenarios with capped versus uncapped projections in the 
obesity trends 
As indicated earlier, capping was performed for the assumed increasing linear 
trends in obesity prevalence in Saudi Arabia. Detailed discussion has been 
provided in section 5.3.2.4, regarding the justification and assumed levels of 
capping used in the model. There was no evidence for a specific biological 
threshold/ limit at which capping could be done, and therefore the capping 
points in this thesis (35% in men and 60% in women) were decided arbitrarily. 
So, such a decision of capping remains uncertain, although it might seem more 
realistic than reaching extremely high and probably implausible prevalence 
rates as a result of assuming linear increasing projections of obesity. Therefore, 
the modelling outputs are presented in this thesis (chapters 6, 7 and 8) with 
different scenarios of capped versus uncapped trends in obesity prevalence 
rates. The quantified effects (impact) of capping on the main modelling outputs 
are presented as a form of sensitivity analysis. 
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5.4.3. Modelling scenarios with inclusion versus exclusion of the two oldest 
age groups of population  
It has been discussed earlier that the available ‘observed’ data from Saudi 
Arabia on obesity and smoking prevalence did not cover the population age 
groups of ≥65 years. The oldest age groups reported in these surveys were in 
the range of 60-64 years. Therefore, the trends in prevalence of obesity and 
smoking for the age groups 65-74 and ≥75 years were obtained through 
extrapolating the available data using similar population-based information from 
Oman. However, again, such a method of extrapolation remains uncertain. 
Although the two countries are neighbouring and might share many similar 
population and lifestyle characteristics, there might be still some significant 
differences in the prevalence of these risk factors. Hence, in order to handle this 
type of uncertainty, modelling outputs are presented with inclusion of these two 
oldest age groups in the modelled Saudi population, and then with exclusion of 
them. 
Overall, this chapter provides an extensive description and discussion of the 
Saudi IMPACT Diabetes Forecast Model, its structure and data sources, 
assumptions, and methodology (including the different methods of sensitivity 
analyses). The next chapter presents the model results (outputs) for the past 
and current estimated T2DM prevalence (1992-2013). 
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Chapter 6. Past and current trends in the estimated prevalence of 
type 2 diabetes in Saudi Arabia 
In chapter 5, the Saudi IMPACT Diabetes Forecast Model was described, along 
with the data sources and their strengths and limitations. Also, data inputs into 
the model, methods, and the assumptions used were discussed. This chapter 
presents the results (outputs) of the model for the period 1992-2013. Minimum 
and maximum values [uncertainty intervals (UI)] of the outputs are presented in 
brackets in this chapter, chapter 7, and chapter 8 as a form of sensitivity 
analysis. As discussed earlier, these uncertainty values were estimated using 
the ‘analysis of extremes’ method, through running the model with all 
parameters set to values of 20% lower and 20% higher than the ‘best’ estimates 
of the model. This chapter also presents the results of validation of the Saudi 
IMPACT Diabetes Forecast Model against local observed data and another 
model. 
As mentioned in chapter 5, the results of the Saudi IMPACT Diabetes Forecast 
Model are presented in different scenarios as part of dealing with uncertainties 
around some parameters, particularly among obesity trends projections under 
different assumptions. These scenarios are summarised in Table  6.1. 
Table  6.1. The different four scenarios to present the results of the Saudi IMPACT Diabetes Forecast 
Model 
 Description 
Scenario 1 Modelling results for the population aged 25-64 years, with capping 
Scenario 2 Modelling results for the population aged 25-64 years, without capping 
Scenario 3 Modelling results for the population aged 25-75+ years, with capping 
Scenario 4 Modelling results for the population aged 25-75+ years, without capping 
6.1. Trends in the prevalence of type 2 diabetes in Saudi Arabia during 
1992 - 2013 
In this section, the trends in prevalence of T2DM in Saudi Arabia during the 
period of 1992–2013 are presented, as estimated by the Saudi IMPACT 
Diabetes Forecast Model. These results are presented based on the four 
scenarios discussed in Table  6.1. 
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6.1.1. The overall and sex-specific prevalence of diabetes and numbers of 
diabetic individuals in the Saudi population 
6.1.1.1. Results based on scenario 1: population aged 25-64 years, with capping 
Assuming linearly increasing trends in the prevalence of smoking and obesity in 
Saudi Arabia (obesity prevalence capped at 35% in men and 60% in women), 
the model estimated that the overall diabetes prevalence in the Saudi 
population aged 25-64 years would increase from 8.5% (UI: 6.8–10.2%) to 
30.8% (UI: 25.2–36.2%) during the period of 1992–2013 (Figure  6.1). The 
number of individuals with T2DM was estimated to increase nearly eight-fold, 
from 555,101 (UI: 355,265–799,346) in 1992 to 4,090,778 (UI: 2,669,048–
5,761,060) in 2013 (Table  6.2). 
In men, diabetes prevalence was estimated to increase substantially by 263% 
during the same period; from 8.7% (UI: 6.9–10.4%) to 31.6% (UI: 26.2–36.5%) 
(Figure  6.3). This is equivalent to an increase of 2,101,687 individuals (UI: 
1,399,606-2,896,341); from 356,567 (UI: 228,203-513,456) in 1992 to 
2,458,253 (UI: 1,627,808-3,409,797) in 2013 (Table  6.2). 
In comparison, in women, diabetes prevalence was estimated to increase also 
by 263%; from 8.2% (UI: 6.6–9.9%) in 1992 to 29.8% (UI: 23.7–35.7%) in 2013 
(Figure  6.3). The total number of women with diabetes was estimated to 
increase by 1,433,991 (UI: 914,178-2,065,373); from 198,534 (UI: 127,062-
285,890) in 1992 to 1,632,525 (UI: 1,041,240-2,351,262) in 2013 (Table  6.2).  
6.1.1.2. Results based on scenario 2: population aged 25-64 years, without 
capping 
Under the assumption that the obesity and smoking trends in Saudi Arabia 
would continue to increase by the same ‘observed’ annual rates till 2013 
(without capping of the projected obesity prevalence), the overall prevalence of 
diabetes in the Saudi population aged 25-64 years was estimated to increase to 
31.4% (UI: 25.5–37.0%) by 2013 (Figure  6.2). The total number of individuals 
with diabetes was estimated to increase to 4,161,646 (UI: 2,703,025–
5,887,412) (Table  6.3). 
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In men, the estimated relative increase in diabetes prevalence during 1992-
2013 was 267%, where the prevalence reached 31.9% (UI: 26.3–37.0%) in 
2013 (Figure  6.4). The number of men with diabetes was estimated to increase 
by a total of 2,124,221 (UI: 1,410,334-2,937,711) during the same period, and 
reached 2,480,788 (UI: 1,638,536-3,451,167) in 2013 (Table  6.3). 
On the other hand, diabetes prevalence was estimated to increase by 273% in 
women aged 25-64 years during the same period, with a prevalence reaching 
30.6% (UI: 24.3–37.0%) in 2013 (Figure  6.4). The number of women with 
diabetes increased by 1,482,323 (UI: 937,426-2,150,355), and was estimated to 
be 1,680,858 (UI: 1,064,488 - 2,436,245) in 2013 (Table  6.3).                                    
  
169 
 
 Figure  6.1. (Scenario 1) Trends in the estimated diabetes total prevalence (and uncertainty values) for 
population aged 25-64 years, with capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
[Solid line: point (best) estimates; Dotted lines: minimum and maximum uncertainty estimates. Diagnostic 
criteria: WHO 1985] 
 
 
 
 
Figure  6.2. (Scenario 2) Trends in the estimated diabetes total prevalence (and uncertainty values) for 
population aged 25-64 years, without capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
[Solid line: point (best) estimates; Dotted lines: minimum and maximum uncertainty estimates. Diagnostic 
criteria: WHO 1985]  
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Figure  6.3. (Scenario 1) Trends in the estimated diabetes prevalence (and uncertainty values) for men and 
women aged 25-64 years, with capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
[Diagnostic criteria: WHO 1985] 
 
Figure  6.4. (Scenario 2) Trends in the estimated diabetes prevalence (and uncertainty values) for men and 
women aged 25-64 years, without capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
[Diagnostic criteria: WHO 1985]
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Table  6.2. (Scenario 1) Estimated numbers of individuals with diabetes for population aged 25-64 years, with capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
Year Men Uncertainty intervals Women Uncertainty intervals Total Uncertainty intervals 
 best estimate minimum maximum best estimate minimum maximum best estimate minimum maximum 
1992 356,567 228,203 513,456 198,534 127,062 285,890 555,101 355,265 799,346 
1993 408,141 263,675 580,974 223,907 144,786 319,582 632,047 408,462 900,556 
1994 467,098 303,390 660,351 255,030 165,718 362,454 722,128 469,108 1,022,805 
1995 533,753 347,522 752,099 292,164 190,015 414,860 825,917 537,536 1,166,960 
1996 608,378 396,230 856,623 335,532 217,821 477,096 943,910 614,051 1,333,719 
1997 691,204 449,663 974,229 385,328 249,268 549,398 1,076,532 698,930 1,523,628 
1998 782,428 507,950 1,105,147 441,714 284,474 631,952 1,224,142 792,424 1,737,098 
1999 876,174 568,323 1,238,508 499,184 320,653 715,520 1,375,358 888,976 1,954,029 
2000 972,353 630,739 1,374,194 557,746 357,800 800,153 1,530,098 988,538 2,174,346 
2001 1,070,872 695,152 1,512,085 617,405 395,908 885,882 1,688,277 1,091,060 2,397,967 
2002 1,172,669 762,283 1,653,293 678,039 434,987 972,392 1,850,709 1,197,270 2,625,685 
2003 1,276,966 831,325 1,797,526 742,248 476,108 1,064,869 2,019,214 1,307,433 2,862,396 
2004 1,383,668 902,232 1,944,626 809,890 519,239 1,162,872 2,193,558 1,421,471 3,107,499 
2005 1,492,677 974,955 2,094,423 880,746 564,326 1,265,759 2,373,423 1,539,281 3,360,181 
2006 1,605,155 1,050,040 2,249,187 957,051 612,612 1,377,025 2,562,206 1,662,652 3,626,212 
2007 1,720,653 1,127,290 2,408,033 1,039,602 664,582 1,497,682 2,760,255 1,791,872 3,905,715 
2008 1,838,481 1,206,386 2,569,629 1,127,634 719,947 1,626,100 2,966,115 1,926,334 4,195,729 
2009 1,958,525 1,287,282 2,733,720 1,220,878 778,651 1,761,594 3,179,403 2,065,933 4,495,315 
2010 2,080,436 1,369,825 2,899,594 1,318,305 840,233 1,902,341 3,398,741 2,210,058 4,801,934 
2011 2,203,645 1,453,763 3,066,126 1,418,010 903,900 2,044,620 3,621,654 2,357,662 5,110,747 
2012 2,329,163 1,539,553 3,235,404 1,521,141 970,272 2,190,658 3,850,304 2,509,825 5,426,062 
2013 2,458,253 1,627,808 3,409,797 1,632,525 1,041,240 2,351,262 4,090,778 2,669,048 5,761,060 
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Table  6.3. (Scenario 2) Estimated numbers of individuals with diabetes for population aged 25-64 years, without capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
Year Men Uncertainty intervals Women Uncertainty intervals Total Uncertainty intervals 
 best estimate minimum maximum best estimate minimum maximum best estimate minimum maximum 
1992 356,567 228,203 513,456 198,534 127,062 285,890 555,101 355,265 799,346 
1993 408,141 263,675 580,975 223,907 144,787 319,584 632,048 408,462 900,559 
1994 467,096 303,389 660,349 255,029 165,717 362,452 722,125 469,106 1,022,801 
1995 533,749 347,520 752,096 292,161 190,013 414,856 825,910 537,532 1,166,952 
1996 608,370 396,226 856,612 335,528 217,818 477,090 943,898 614,044 1,333,701 
1997 691,195 449,658 974,216 385,321 249,263 549,387 1,076,516 698,921 1,523,603 
1998 782,414 507,943 1,105,125 441,705 284,469 631,937 1,224,119 792,411 1,737,061 
1999 876,159 568,315 1,238,485 499,173 320,647 715,504 1,375,332 888,962 1,953,989 
2000 972,336 630,729 1,374,168 557,737 357,794 800,139 1,530,072 988,524 2,174,307 
2001 1,070,848 695,139 1,512,048 617,390 395,900 885,859 1,688,238 1,091,039 2,397,907 
2002 1,172,638 762,266 1,653,243 678,020 434,976 972,362 1,850,658 1,197,243 2,625,605 
2003 1,276,932 831,307 1,797,472 742,228 476,096 1,064,838 2,019,160 1,307,403 2,862,310 
2004 1,383,630 902,212 1,944,567 809,871 519,228 1,162,844 2,193,501 1,421,440 3,107,411 
2005 1,492,630 974,930 2,094,349 880,719 564,310 1,265,716 2,373,349 1,539,240 3,360,065 
2006 1,605,099 1,050,010 2,249,098 957,018 612,594 1,376,974 2,562,118 1,662,604 3,626,072 
2007 1,720,752 1,127,333 2,408,229 1,039,836 664,693 1,498,091 2,760,587 1,792,027 3,906,320 
2008 1,839,500 1,206,867 2,571,515 1,129,087 720,651 1,628,613 2,968,587 1,927,518 4,200,129 
2009 1,961,243 1,288,576 2,738,706 1,224,641 780,482 1,768,079 3,185,884 2,069,058 4,506,785 
2010 2,085,865 1,372,417 2,909,527 1,326,372 844,193 1,916,147 3,412,237 2,216,610 4,825,674 
2011 2,213,241 1,458,340 3,083,702 1,434,154 911,775 2,072,572 3,647,395 2,370,116 5,156,273 
2012 2,344,381 1,546,811 3,263,282 1,550,214 984,363 2,241,392 3,894,596 2,531,174 5,504,673 
2013 2,480,788 1,638,536 3,451,167 1,680,858 1,064,488 2,436,245 4,161,646 2,703,025 5,887,412 
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6.1.1.3. Results based on scenario 3: population aged 25-75+ years, with 
capping 
Assuming capped trends in obesity prevalence, the model estimated that the 
overall diabetes prevalence increased by 223% during the period of 1992-2013; 
from 9.6% (UI: 7.7–11.6%) to 31.0% (UI: 25.4–36.2%) in the Saudi population 
aged 25-75+ years (Figure  6.5). There was an estimated increase of 3,712,624 
diabetic individuals (UI: 2,446,983-5,181,753) during the same period; from 
671,702 (UI: 429,890-967,251) in 1992 to 4,384,326 (UI: 2,876,872-6,149,005) 
in 2013 (Table  6.4). 
In men, diabetes prevalence increased by 217% during the same period; from 
9.8% (UI: 7.8–11.7%) in 1992 to 31.1% (UI: 25.8–35.8%) in 2013 (Figure  6.7). 
The number of men with diabetes was estimated to increase by 2,174,619 (UI: 
1,459,838-2,974,891); from 427,410 (UI: 273,542-615,470) in 1992 to 
2,602,029 (UI: 1,733,380-3,590,360) in 2013 (Table  6.4). 
In women, between 1992 and 2013, there was an estimated relative increase of 
220% in the diabetes prevalence; from 9.4% (UI: 7.5–11.2%) to 30.1% (UI: 
24.1–36.0%) (Figure  6.7). This was equivalent to an increase in the number of 
diabetic women by 1,538,005 (UI: 987,145-2,206,863); from 244,293 (UI: 
156,347-351,782) in 1992 to 1,782,297 (UI: 1,143,493-2,558,644) in 2013 
(Table  6.4). 
6.1.1.4. Results based on scenario 4: population aged 25-75+ years, without 
capping 
The total diabetes prevalence during 1992-2013 was estimated to increase by 
228%, and to reach 31.5% (UI: 25.7–36.9%) in 2013 (Figure  6.6). The 
estimated increase in the number of individuals with diabetes was 3,783,491 
(UI: 2,480,960-5,308,106), with an estimated total of 4,455,194 (UI: 2,910,849-
6,275,357) individuals with diabetes in 2013 (Table  6.5). 
In men, the estimated diabetes prevalence increased by 219%, and reached 
31.3% (UI: 25.9 – 36.2%) in 2013 (Figure  6.8). The number of men with 
diabetes increased by 2,197,154 (UI: 1,470,566-3,016,260), with an estimated 
total of 2,624,564 (UI: 1,744,108-3,631,730) in 2013 (Table  6.5). 
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In comparison, the estimated diabetes prevalence in women increased by 229% 
(UI: 17.1–25.9%); with a prevalence of 30.9% (UI: 24.6–37.2%) in 2013 (Figure 
 6.8). The estimated number of women with diabetes increased by 1,586,337 
(UI: 1,010,394-2,291,845), and reached 1,830,630 (UI: 1,166,741-2,643,627) in 
2013 (Table  6.5). 
 
 
Figure  6.5. (Scenario 3) Trends in the estimated diabetes total prevalence (and uncertainty values) for 
population aged 25-75+ years, with capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
[Solid line: point (best) estimates; Dotted lines: minimum and maximum uncertainty estimates. Diagnostic 
criteria: WHO 1985] 
 
 
Figure  6.6. (Scenario 4) Trends in the estimated diabetes total prevalence (and uncertainty values) for 
population aged 25-75+ years, without capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
[Solid line: point (best) estimates; Dotted lines: minimum and maximum uncertainty estimates. Diagnostic 
criteria: WHO 1985] 
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Figure  6.7. (Scenario 3) Trends in the estimated diabetes prevalence (and uncertainty values) for men and 
women aged 25-75+ years, with capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
[Diagnostic criteria: WHO 1985] 
 
Figure  6.8. (Scenario 4) Trends in the estimated diabetes prevalence (and uncertainty values) for men and 
women aged 25-75+ years, without capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
[Diagnostic criteria: WHO 1985]
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Table  6.4. (Scenario 3) Estimated numbers of individuals with diabetes for population aged 25-75+ years, with capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
Year Men Uncertainty intervals Women Uncertainty intervals Total Uncertainty intervals 
 best estimate minimum maximum best estimate minimum maximum best estimate minimum maximum 
1992 427,410 273,542 615,470 244,293 156,347 351,782 671,702 429,890 967,251 
1993 480,805 310,902 683,444 269,273 174,883 381,670 750,077 485,785 1,065,115 
1994 541,673 352,607 763,251 300,341 196,836 421,599 842,014 549,443 1,184,849 
1995 610,379 398,839 855,614 338,068 222,439 472,854 948,448 621,278 1,328,468 
1996 687,238 449,766 961,114 382,894 251,902 536,146 1,070,133 701,669 1,497,260 
1997 772,519 505,543 1,080,196 435,145 285,407 611,806 1,207,664 790,950 1,692,002 
1998 866,446 566,306 1,213,188 495,045 323,111 699,910 1,361,490 889,417 1,913,099 
1999 963,169 629,291 1,349,290 557,086 362,250 790,999 1,520,256 991,541 2,140,289 
2000 1,062,616 694,458 1,488,415 621,235 402,831 884,835 1,683,852 1,097,289 2,373,250 
2001 1,164,707 761,764 1,630,456 687,419 444,845 981,156 1,852,126 1,206,610 2,611,611 
2002 1,270,219 831,880 1,776,066 754,928 488,167 1,078,031 2,025,148 1,320,047 2,854,097 
2003 1,378,180 903,886 1,924,607 825,413 533,393 1,179,207 2,203,593 1,437,279 3,103,814 
2004 1,488,504 977,740 2,075,946 898,939 580,529 1,285,043 2,387,443 1,558,268 3,360,989 
2005 1,601,101 1,053,394 2,229,935 975,441 629,549 1,395,359 2,576,542 1,682,943 3,625,295 
2006 1,717,348 1,131,504 2,389,244 1,057,638 681,906 1,514,627 2,774,986 1,813,409 3,903,870 
2007 1,836,780 1,211,866 2,552,931 1,146,313 738,079 1,643,739 2,983,093 1,949,945 4,196,669 
2008 1,958,689 1,294,158 2,719,619 1,240,693 797,778 1,781,000 3,199,382 2,091,937 4,500,619 
2009 2,082,949 1,378,328 2,889,019 1,340,504 860,946 1,925,690 3,423,453 2,239,274 4,814,709 
2010 2,209,197 1,464,217 3,060,389 1,444,713 927,120 2,075,965 3,653,910 2,391,337 5,136,355 
2011 2,336,857 1,551,572 3,232,584 1,551,415 995,507 2,228,102 3,888,271 2,547,079 5,460,686 
2012 2,467,399 1,641,095 3,408,502 1,662,389 1,067,016 2,385,555 4,129,788 2,708,111 5,794,058 
2013 2,602,029 1,733,380 3,590,360 1,782,297 1,143,493 2,558,644 4,384,326 2,876,872 6,149,005 
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Table  6.5. (Scenario 4) Estimated numbers of individuals with diabetes for population aged 25-75+ years, without capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
Year Men Uncertainty intervals Women Uncertainty intervals Total Uncertainty intervals 
 best estimate minimum maximum best estimate minimum maximum best estimate minimum maximum 
1992 427,410 273,542 615,470 244,293 156,347 351,782 671,702 429,890 967,251 
1993 480,805 310,902 683,445 269,273 174,883 381,672 750,078 485,785 1,065,117 
1994 541,671 352,605 763,249 300,340 196,835 421,597 842,011 549,441 1,184,846 
1995 610,376 398,837 855,610 338,065 222,438 472,850 948,441 621,274 1,328,460 
1996 687,231 449,762 961,103 382,890 251,900 536,140 1,070,121 701,662 1,497,243 
1997 772,510 505,538 1,080,183 435,138 285,403 611,795 1,207,647 790,941 1,691,978 
1998 866,432 566,299 1,213,166 495,035 323,105 699,896 1,361,467 889,404 1,913,062 
1999 963,154 629,283 1,349,266 557,076 362,244 790,983 1,520,230 991,527 2,140,249 
2000 1,062,600 694,449 1,488,389 621,226 402,825 884,821 1,683,826 1,097,274 2,373,210 
2001 1,164,683 761,752 1,630,418 687,404 444,837 981,132 1,852,087 1,206,589 2,611,551 
2002 1,270,188 831,863 1,776,015 754,909 488,157 1,078,002 2,025,098 1,320,020 2,854,017 
2003 1,378,146 903,868 1,924,552 825,392 533,382 1,179,175 2,203,538 1,437,250 3,103,728 
2004 1,488,467 977,719 2,075,887 898,920 580,518 1,285,015 2,387,386 1,558,237 3,360,902 
2005 1,601,054 1,053,369 2,229,862 975,414 629,534 1,395,317 2,576,468 1,682,902 3,625,179 
2006 1,717,293 1,131,474 2,389,155 1,057,605 681,888 1,514,576 2,774,898 1,813,361 3,903,731 
2007 1,836,879 1,211,909 2,553,127 1,146,547 738,190 1,644,148 2,983,425 1,950,100 4,197,275 
2008 1,959,708 1,294,639 2,721,506 1,242,146 798,482 1,783,514 3,201,854 2,093,121 4,505,020 
2009 2,085,667 1,379,622 2,894,005 1,344,266 862,777 1,932,175 3,429,933 2,242,398 4,826,180 
2010 2,214,627 1,466,810 3,070,323 1,452,780 931,080 2,089,772 3,667,407 2,397,890 5,160,095 
2011 2,346,453 1,556,150 3,250,159 1,567,560 1,003,383 2,256,053 3,914,012 2,559,532 5,506,212 
2012 2,482,617 1,648,353 3,436,381 1,691,462 1,081,106 2,436,289 4,174,079 2,729,459 5,872,670 
2013 2,624,564 1,744,108 3,631,730 1,830,630 1,166,741 2,643,627 4,455,194 2,910,849 6,275,357 
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6.1.2. Age- and sex-specific prevalence of diabetes and numbers of diabetic 
individuals 
6.1.2.1. Results based on scenario 1: population aged 25-64 years, with capping 
Table  6.6 summarises the estimated prevalence rates of diabetes during 1992-
2013 for each age group in men and women aged 25-64 years, assuming 
capped trends in the projected obesity prevalence. The highest relative increase 
in the estimated diabetes prevalence was in men aged 25-34 years, where it 
increased substantially by 759%; from 3.7% (UI: 3.0–4.4%) in 1992 to 31.8% 
(UI: 26.5–36.2%) in 2013. The second highest relative increase in the estimated 
diabetes prevalence was in women aged 25-34 years (717%), followed by 
women aged 35-44 years (468%) and men aged 35-44 years (360%). On the 
other hand, the lowest relative increase was in men aged 55-64 years, where 
the diabetes prevalence increased by 27%; from 24.9% (UI: 19.9–29.9%) in 
1992 to 31.7% (UI: 25.9–37.6%) in 2013. In 2013, the highest estimated 
diabetes prevalence was 48.6% (UI: 37.2–60.1%) in women aged 55-64 years, 
followed by a prevalence of 34.0% (UI: 26.8–41.3%) in women aged 45-54 
years, while the lowest prevalence was estimated to be 24.5% (UI: 20.1–28.8%) 
in women aged 25-34 years. 
6.1.2.2. Results based on scenario 2: population aged 25-64 years, without 
capping 
The results based on this scenario are presented in Table  6.7. The highest 
relative increase in the estimated diabetes prevalence remained as with 
scenario 1, where men aged 25-34 years had a relative increase of 759%. The 
second highest relative increase (717%) was also in women aged 25-34 years, 
in whom the estimated prevalence increased from 3.0% (UI: 2.4–3.6%) in 1992 
to 24.5% (UI: 20.1–28.8%) in 2013. The lowest estimated relative increase was 
again identical to that in scenario 1 (27%) in men aged 55-64 years. In 2013, 
women aged 55-64 years had the highest estimated diabetes prevalence of 
50.2% (UI: 38.0–62.7%), followed by women aged 45-54 years, who had a 
prevalence of 36.9% (UI: 28.6–45.4%). The lowest estimated diabetes 
prevalence in 2013 was the same as that estimated through scenario 1, i.e. in 
women aged 25-34 years [24.5% (UI: 20.1–28.8%)]. 
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Table  6.8 and Table  6.9 present the lower and higher uncertainty values of the 
estimated diabetes prevalence for each age group in men and women aged 25-
64 years, based on scenario 1 and scenario 2. Moreover, Figure  6.9 and Figure 
 6.10 illustrate a graphical presentation of the trends in the estimated diabetes 
prevalence over the time period of 1992-2013 for men and women by age 
group, based on these two scenarios.   
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Table  6.6. (Scenario 1) Estimated prevalence of diabetes per age group (years) in men and women aged 25-64 years, with capping of projected obesity prevalence, Saudi Arabia 
(1992-2013) 
Year 
25-34 35-44 45-54 55-64 
Men Women Men Women Men Women Men Women 
1992 3.7% 3.0% 7.0% 5.0% 21.1% 22.1% 24.9% 23.2% 
1993 4.8% 4.0% 8.1% 6.0% 20.5% 21.6% 25.0% 22.6% 
1994 6.0% 5.1% 9.3% 7.0% 20.2% 21.3% 25.2% 22.2% 
1995 7.3% 6.4% 10.5% 8.1% 20.2% 21.3% 25.6% 22.1% 
1996 8.7% 7.7% 11.8% 9.3% 20.4% 21.6% 26.1% 22.4% 
1997 10.1% 9.2% 13.1% 10.6% 20.7% 22.1% 26.8% 22.9% 
1998 11.7% 10.7% 14.5% 12.0% 21.3% 22.7% 27.6% 23.8% 
1999 13.2% 12.1% 15.8% 13.3% 21.9% 23.4% 28.4% 24.8% 
2000 14.6% 13.3% 17.1% 14.6% 22.5% 24.2% 29.2% 25.8% 
2001 16.0% 14.5% 18.3% 15.9% 23.1% 25.0% 30.1% 26.9% 
2002 17.4% 15.5% 19.5% 17.1% 23.8% 25.9% 31.0% 28.2% 
2003 18.7% 16.4% 20.7% 18.3% 24.5% 26.8% 32.0% 30.0% 
2004 20.0% 17.3% 21.9% 19.5% 25.3% 27.9% 33.0% 32.0% 
2005 21.5% 18.2% 23.2% 20.5% 25.5% 28.1% 31.6% 33.3% 
2006 23.0% 19.0% 24.4% 21.4% 25.9% 28.6% 30.8% 35.0% 
2007 24.4% 19.8% 25.6% 22.4% 26.4% 29.3% 30.4% 37.0% 
2008 25.7% 20.6% 26.7% 23.4% 27.0% 30.2% 30.5% 39.3% 
2009 27.0% 21.4% 27.8% 24.5% 27.7% 31.1% 30.8% 41.6% 
2010 28.3% 22.1% 28.8% 25.6% 28.5% 32.0% 31.4% 44.1% 
2011 29.5% 22.9% 30.0% 26.5% 29.1% 32.4% 31.1% 45.9% 
2012 30.6% 23.7% 31.1% 27.4% 29.8% 32.9% 31.3% 47.5% 
2013 31.8% 24.5% 32.2% 28.4% 30.5% 34.0% 31.7% 48.6% 
Relative difference in prevalence +759% +717% +360% +468% +45% +54% +27% +109% 
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Table  6.7. (Scenario 2) Estimated prevalence of diabetes per age group (years) in men and women aged 25-64 years, without capping of projected obesity prevalence, Saudi Arabia 
(1992-2013) 
Year 
25-34 35-44 45-54 55-64 
Men Women Men Women Men Women Men Women 
1992 3.7% 3.0% 7.0% 5.0% 21.1% 22.1% 24.9% 23.2% 
1993 4.8% 4.0% 8.1% 6.0% 20.5% 21.6% 25.0% 22.6% 
1994 6.0% 5.1% 9.3% 7.0% 20.2% 21.3% 25.2% 22.2% 
1995 7.3% 6.4% 10.5% 8.1% 20.2% 21.3% 25.6% 22.1% 
1996 8.7% 7.7% 11.8% 9.3% 20.4% 21.6% 26.1% 22.4% 
1997 10.1% 9.2% 13.1% 10.6% 20.7% 22.1% 26.8% 22.9% 
1998 11.7% 10.7% 14.5% 12.0% 21.3% 22.7% 27.6% 23.8% 
1999 13.2% 12.1% 15.8% 13.3% 21.9% 23.4% 28.4% 24.8% 
2000 14.6% 13.3% 17.1% 14.6% 22.5% 24.2% 29.2% 25.8% 
2001 16.0% 14.5% 18.3% 15.9% 23.1% 25.0% 30.1% 26.9% 
2002 17.4% 15.5% 19.5% 17.1% 23.8% 25.9% 31.0% 28.2% 
2003 18.7% 16.4% 20.7% 18.3% 24.5% 26.8% 32.0% 30.0% 
2004 20.0% 17.3% 21.9% 19.5% 25.3% 27.9% 33.0% 32.0% 
2005 21.5% 18.2% 23.2% 20.5% 25.5% 28.1% 31.6% 33.3% 
2006 23.0% 19.0% 24.4% 21.4% 25.9% 28.6% 30.8% 35.0% 
2007 24.4% 19.8% 25.6% 22.4% 26.4% 29.4% 30.4% 37.0% 
2008 25.7% 20.6% 26.8% 23.4% 27.0% 30.4% 30.5% 39.3% 
2009 27.0% 21.4% 27.9% 24.5% 27.7% 31.5% 30.8% 41.6% 
2010 28.3% 22.1% 29.0% 25.6% 28.5% 32.9% 31.4% 44.1% 
2011 29.5% 22.9% 30.3% 26.7% 29.2% 33.8% 31.1% 46.1% 
2012 30.6% 23.7% 31.6% 27.8% 29.9% 34.9% 31.3% 48.3% 
2013 31.8% 24.5% 32.9% 29.0% 30.8% 36.9% 31.7% 50.2% 
Relative difference in prevalence +759% +717% +370% +480% +46% +67% +27% +116% 
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Table  6.8. (Scenario 1) Sensitivity analysis: lower (L) and higher (H) uncertainty values of the estimated diabetes prevalence (%) per age group (years) in men and women aged 25-64 
years, with capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
Year 
25-34 35-44 45-54 55-64 
Men Women Men Women Men Women Men Women 
L H L H L H L H L H L H L H L H 
1992 3.0 4.4 2.4 3.6 5.6 8.4 4.0 6.0 16.8 25.3 17.7 26.5 19.9 29.9 18.6 27.9 
1993 3.9 5.7 3.2 4.8 6.5 9.6 4.8 7.1 16.6 24.3 17.4 25.7 20.3 29.5 18.3 26.7 
1994 4.8 7.2 4.1 6.1 7.5 11.0 5.6 8.3 16.5 23.6 17.4 25.2 20.8 29.3 18.2 26.1 
1995 5.8 8.7 5.1 7.6 8.5 12.4 6.5 9.6 16.6 23.4 17.5 25.1 21.3 29.4 18.3 25.8 
1996 6.9 10.4 6.1 9.3 9.5 13.9 7.5 11.1 16.8 23.5 17.8 25.3 21.9 29.7 18.6 26.0 
1997 8.0 12.2 7.2 11.1 10.6 15.5 8.5 12.7 17.2 23.9 18.2 25.8 22.6 30.2 19.1 26.7 
1998 9.2 14.1 8.4 13.0 11.7 17.1 9.6 14.4 17.7 24.5 18.7 26.6 23.3 31.0 19.7 27.7 
1999 10.4 15.9 9.5 14.7 12.7 18.7 10.6 16.0 18.2 25.2 19.3 27.5 24.1 31.9 20.5 28.9 
2000 11.6 17.6 10.5 16.2 13.7 20.2 11.6 17.5 18.7 25.9 19.9 28.4 24.9 32.8 21.3 30.2 
2001 12.7 19.2 11.4 17.5 14.7 21.7 12.6 19.1 19.3 26.6 20.5 29.4 25.7 33.7 22.1 31.7 
2002 13.8 20.8 12.2 18.7 15.7 23.1 13.6 20.5 19.8 27.3 21.2 30.4 26.5 34.8 23.1 33.3 
2003 14.9 22.3 13.0 19.7 16.7 24.5 14.6 22.0 20.4 28.2 22.0 31.6 27.4 35.9 24.3 35.6 
2004 16.0 23.7 13.8 20.7 17.7 25.8 15.5 23.5 21.1 29.1 22.8 33.0 28.2 37.0 25.7 38.5 
2005 17.3 25.4 14.6 21.7 18.7 27.3 16.3 24.6 21.2 29.4 22.9 33.3 27.0 35.5 26.4 40.6 
2006 18.6 27.0 15.3 22.6 19.8 28.7 17.0 25.7 21.5 29.8 23.2 34.0 26.2 34.7 27.5 43.1 
2007 19.8 28.5 16.0 23.5 20.8 30.1 17.8 26.9 21.9 30.5 23.6 35.0 25.8 34.6 28.7 46.1 
2008 21.0 30.0 16.7 24.4 21.8 31.3 18.6 28.2 22.4 31.3 24.2 36.1 25.7 35.0 30.2 49.2 
2009 22.2 31.4 17.3 25.3 22.7 32.5 19.5 29.5 22.9 32.2 24.8 37.3 25.8 35.6 31.8 52.4 
2010 23.3 32.7 18.0 26.1 23.6 33.5 20.3 30.7 23.5 33.2 25.5 38.5 26.1 36.5 33.5 55.5 
2011 24.4 33.9 18.7 27.0 24.6 34.8 21.1 31.8 24.0 34.0 25.7 39.0 25.8 36.4 34.8 57.5 
2012 25.5 35.1 19.4 27.9 25.7 36.0 21.8 32.9 24.5 34.8 26.1 39.7 25.7 36.9 36.1 59.1 
2013 26.5 36.2 20.1 28.8 26.7 37.1 22.6 34.1 25.0 35.7 26.8 41.3 25.9 37.6 37.2 60.1 
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Table  6.9. (Scenario 2) Sensitivity analysis: lower (L) and higher (H) uncertainty values of the estimated diabetes prevalence (%) per age group (years) in men and women aged 25-64 
years, without capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
Year 
25-34 35-44 45-54 55-64 
Men Women Men Women Men Women Men Women 
L H L H L H L H L H L H L H L H 
1992 3.0 4.4 2.4 3.6 5.6 8.4 4.0 6.0 16.8 25.3 17.7 26.5 19.9 29.9 18.6 27.9 
1993 3.9 5.7 3.2 4.8 6.5 9.6 4.8 7.1 16.6 24.3 17.4 25.7 20.3 29.5 18.3 26.8 
1994 4.8 7.2 4.1 6.1 7.5 11.0 5.6 8.3 16.5 23.6 17.4 25.2 20.8 29.3 18.2 26.1 
1995 5.8 8.7 5.1 7.6 8.5 12.4 6.5 9.6 16.6 23.4 17.5 25.1 21.3 29.4 18.3 25.8 
1996 6.9 10.4 6.1 9.3 9.5 13.9 7.5 11.1 16.8 23.5 17.8 25.3 21.9 29.7 18.6 26.0 
1997 8.0 12.2 7.2 11.1 10.6 15.5 8.5 12.7 17.2 23.9 18.2 25.8 22.6 30.2 19.1 26.7 
1998 9.2 14.1 8.4 13.0 11.7 17.1 9.6 14.4 17.7 24.5 18.7 26.6 23.3 31.0 19.7 27.7 
1999 10.4 15.9 9.5 14.7 12.7 18.7 10.6 16.0 18.2 25.2 19.3 27.5 24.1 31.9 20.5 28.9 
2000 11.6 17.6 10.5 16.2 13.7 20.2 11.6 17.5 18.7 25.9 19.9 28.4 24.9 32.8 21.3 30.2 
2001 12.7 19.2 11.4 17.5 14.7 21.7 12.6 19.0 19.3 26.6 20.5 29.4 25.7 33.7 22.1 31.7 
2002 13.8 20.8 12.2 18.7 15.7 23.1 13.6 20.5 19.8 27.3 21.2 30.4 26.5 34.8 23.1 33.3 
2003 14.9 22.3 13.0 19.7 16.7 24.5 14.6 22.0 20.4 28.2 22.0 31.6 27.4 35.9 24.3 35.6 
2004 16.0 23.7 13.8 20.7 17.7 25.8 15.5 23.5 21.1 29.1 22.8 33.0 28.2 37.0 25.7 38.5 
2005 17.3 25.4 14.6 21.7 18.7 27.3 16.3 24.6 21.2 29.4 22.9 33.3 27.0 35.5 26.4 40.6 
2006 18.6 27.0 15.3 22.6 19.8 28.7 17.0 25.7 21.5 29.8 23.2 34.0 26.2 34.7 27.5 43.1 
2007 19.8 28.5 16.0 23.5 20.8 30.1 17.8 26.9 21.9 30.5 23.7 35.0 25.8 34.6 28.7 46.1 
2008 21.0 30.0 16.7 24.4 21.8 31.4 18.6 28.2 22.4 31.3 24.3 36.4 25.7 35.0 30.2 49.2 
2009 22.2 31.4 17.3 25.3 22.7 32.6 19.5 29.5 22.9 32.2 25.1 37.9 25.8 35.6 31.8 52.4 
2010 23.3 32.7 18.0 26.1 23.7 33.8 20.4 30.8 23.5 33.3 26.1 39.8 26.1 36.5 33.5 55.5 
2011 24.4 33.9 18.7 27.0 24.8 35.3 21.2 32.1 24.0 34.1 26.6 41.0 25.8 36.4 34.9 57.9 
2012 25.5 35.1 19.4 27.9 26.0 36.7 22.0 33.4 24.6 35.0 27.3 42.5 25.7 36.9 36.5 60.5 
2013 26.5 36.2 20.1 28.8 27.1 38.2 23.0 35.0 25.2 36.2 28.6 45.4 25.9 37.6 38.0 62.7 
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Figure  6.9. (Scenario 1) Trends in the estimated prevalence of diabetes per age group 
(years) in men and women aged 25-64 years, with capping of projected obesity 
prevalence, Saudi Arabia (1992-2013) [Diagnostic criteria: WHO 1985] 
 
 
 
Figure  6.10. (Scenario 2) Trends in the estimated prevalence of diabetes per age 
group (years) in men and women aged 25-64 years, without capping of projected 
obesity prevalence, Saudi Arabia (1992-2013) [Diagnostic criteria: WHO 1985] 
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6.1.2.3. Results based on scenario 3: population aged 25-75+ years, with 
capping 
As shown in Table  6.10, inclusion of the two oldest age groups (65-74 and 75+ 
years) resulted in an estimated relative increase of 60% in the diabetes 
prevalence among women aged 65-74 years; from 24.4% (UI: 19.5–29.2%) in 
1992 to 39.0% (UI: 32.1–46.1%) in 2013. On the other hand, women aged 75+ 
years showed minor fluctuations in the results of diabetes prevalence during the 
same period, with no difference in the estimated prevalence for 1992 and 2013. 
6.1.2.4. Results based on scenario 4: population aged 25-75+ years, without 
capping 
The assumption of continuing uncapped linearity in obesity trends had no effect 
on the results for the two oldest age groups. As presented in Table  6.11, 
scenario 4 produced similar results to that obtained by assuming scenario 3. 
Table  6.12 and Table  6.13 summarise the minimum and maximum uncertainty 
values in the estimated diabetes prevalence for each sex and age group, based 
on scenarios 3 and 4. In addition, Figure  6.11 and Figure  6.12 presented the 
trend lines of prevalence obtained by these two scenarios for each age group in 
men and women.  
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Table  6.10. (Scenario 3) Estimated prevalence of diabetes per age group (years) in men and women aged 25-75+ years, with capping of projected obesity prevalence, Saudi Arabia 
(1992-2013) 
Year 
25-34 35-44 45-54 55-64 65-74 75+ 
Men Women Men Women Men Women Men Women Men Women Men Women 
1992 3.7% 3.0% 7.0% 5.0% 21.1% 22.1% 24.9% 23.2% 28.8% 24.4% 28.8% 24.4% 
1993 4.8% 4.0% 8.1% 6.0% 20.5% 21.6% 25.0% 22.6% 28.4% 22.7% 29.0% 23.4% 
1994 6.0% 5.1% 9.3% 7.0% 20.2% 21.3% 25.2% 22.2% 28.2% 21.6% 29.2% 22.5% 
1995 7.3% 6.4% 10.5% 8.1% 20.2% 21.3% 25.6% 22.1% 28.1% 21.0% 29.4% 21.7% 
1996 8.7% 7.7% 11.8% 9.3% 20.4% 21.6% 26.1% 22.4% 28.1% 20.9% 29.6% 21.1% 
1997 10.1% 9.2% 13.1% 10.6% 20.7% 22.1% 26.8% 22.9% 28.3% 21.4% 29.7% 20.9% 
1998 11.7% 10.7% 14.5% 12.0% 21.3% 22.7% 27.6% 23.8% 28.6% 22.3% 29.9% 21.0% 
1999 13.2% 12.1% 15.8% 13.3% 21.9% 23.4% 28.4% 24.8% 29.0% 23.7% 30.1% 21.2% 
2000 14.6% 13.3% 17.1% 14.6% 22.5% 24.2% 29.2% 25.8% 29.5% 25.4% 30.3% 21.7% 
2001 16.0% 14.5% 18.3% 15.9% 23.1% 25.0% 30.1% 26.9% 30.1% 27.4% 30.5% 22.4% 
2002 17.4% 15.5% 19.5% 17.1% 23.8% 25.9% 31.0% 28.2% 30.7% 29.5% 30.7% 23.0% 
2003 18.7% 16.4% 20.7% 18.3% 24.5% 26.8% 32.0% 30.0% 31.3% 31.1% 30.9% 23.4% 
2004 20.0% 17.3% 21.9% 19.5% 25.3% 27.9% 33.0% 32.0% 31.9% 32.5% 31.1% 23.8% 
2005 21.5% 18.2% 23.2% 20.5% 25.5% 28.1% 31.6% 33.3% 31.6% 33.4% 31.8% 23.5% 
2006 23.0% 19.0% 24.4% 21.4% 25.9% 28.6% 30.8% 35.0% 31.5% 34.3% 32.4% 23.4% 
2007 24.4% 19.8% 25.6% 22.4% 26.4% 29.3% 30.4% 37.0% 31.5% 35.1% 32.9% 23.4% 
2008 25.7% 20.6% 26.7% 23.4% 27.0% 30.2% 30.5% 39.3% 31.5% 36.0% 33.4% 23.5% 
2009 27.0% 21.4% 27.8% 24.5% 27.7% 31.1% 30.8% 41.6% 31.6% 36.8% 33.8% 23.7% 
2010 28.3% 22.1% 28.8% 25.6% 28.5% 32.0% 31.4% 44.1% 31.8% 37.6% 34.2% 23.9% 
2011 29.5% 22.9% 30.0% 26.5% 29.1% 32.4% 31.1% 45.9% 31.4% 37.9% 33.7% 24.0% 
2012 30.6% 23.7% 31.1% 27.4% 29.8% 32.9% 31.3% 47.5% 31.1% 38.3% 33.3% 24.2% 
2013 31.8% 24.5% 32.2% 28.4% 30.5% 34.0% 31.7% 48.6% 31.0% 39.0% 33.0% 24.4% 
Relative difference in prevalence +759% +717% +360% +468% +45% +54% +27% +109% +8% +60% +15% +0% 
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Table  6.11. (Scenario 4) Estimated prevalence of diabetes per age group (years) in men and women aged 25-75+ years, without capping of projected obesity prevalence, Saudi 
Arabia (1992-2013) 
Year 
25-34 35-44 45-54 55-64 65-74 75+ 
Men Women Men Women Men Women Men Women Men Women Men Women 
1992 3.7% 3.0% 7.0% 5.0% 21.1% 22.1% 24.9% 23.2% 28.8% 24.4% 28.8% 24.4% 
1993 4.8% 4.0% 8.1% 6.0% 20.5% 21.6% 25.0% 22.6% 28.4% 22.7% 29.0% 23.4% 
1994 6.0% 5.1% 9.3% 7.0% 20.2% 21.3% 25.2% 22.2% 28.2% 21.6% 29.2% 22.5% 
1995 7.3% 6.4% 10.5% 8.1% 20.2% 21.3% 25.6% 22.1% 28.1% 21.0% 29.4% 21.7% 
1996 8.7% 7.7% 11.8% 9.3% 20.4% 21.6% 26.1% 22.4% 28.1% 20.9% 29.6% 21.1% 
1997 10.1% 9.2% 13.1% 10.6% 20.7% 22.1% 26.8% 22.9% 28.3% 21.4% 29.7% 20.9% 
1998 11.7% 10.7% 14.5% 12.0% 21.3% 22.7% 27.6% 23.8% 28.6% 22.3% 29.9% 21.0% 
1999 13.2% 12.1% 15.8% 13.3% 21.9% 23.4% 28.4% 24.8% 29.0% 23.7% 30.1% 21.2% 
2000 14.6% 13.3% 17.1% 14.6% 22.5% 24.2% 29.2% 25.8% 29.5% 25.4% 30.3% 21.7% 
2001 16.0% 14.5% 18.3% 15.9% 23.1% 25.0% 30.1% 26.9% 30.1% 27.4% 30.5% 22.4% 
2002 17.4% 15.5% 19.5% 17.1% 23.8% 25.9% 31.0% 28.2% 30.7% 29.5% 30.7% 23.0% 
2003 18.7% 16.4% 20.7% 18.3% 24.5% 26.8% 32.0% 30.0% 31.3% 31.1% 30.9% 23.4% 
2004 20.0% 17.3% 21.9% 19.5% 25.3% 27.9% 33.0% 32.0% 31.9% 32.5% 31.1% 23.8% 
2005 21.5% 18.2% 23.2% 20.5% 25.5% 28.1% 31.6% 33.3% 31.6% 33.4% 31.8% 23.5% 
2006 23.0% 19.0% 24.4% 21.4% 25.9% 28.6% 30.8% 35.0% 31.5% 34.3% 32.4% 23.4% 
2007 24.4% 19.8% 25.6% 22.4% 26.4% 29.4% 30.4% 37.0% 31.5% 35.1% 32.9% 23.4% 
2008 25.7% 20.6% 26.8% 23.4% 27.0% 30.4% 30.5% 39.3% 31.5% 36.0% 33.4% 23.5% 
2009 27.0% 21.4% 27.9% 24.5% 27.7% 31.5% 30.8% 41.6% 31.6% 36.8% 33.8% 23.7% 
2010 28.3% 22.1% 29.0% 25.6% 28.5% 32.9% 31.4% 44.1% 31.8% 37.6% 34.2% 23.9% 
2011 29.5% 22.9% 30.3% 26.7% 29.2% 33.8% 31.1% 46.1% 31.4% 37.9% 33.7% 24.0% 
2012 30.6% 23.7% 31.6% 27.8% 29.9% 34.9% 31.3% 48.3% 31.1% 38.3% 33.3% 24.2% 
2013 31.8% 24.5% 32.9% 29.0% 30.8% 36.9% 31.7% 50.2% 31.0% 39.0% 33.0% 24.4% 
Relative difference in prevalence +759% +717% +370% +480% +46% +67% +27% +116% +8% +60% +15% +0% 
188 
 
Table  6.12. (Scenario 3) Sensitivity analysis: lower (L) and higher (H) uncertainty values of the estimated diabetes prevalence (%) per age group (years) in men and women aged 25-
75+ years, with capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
Year 
25-34 35-44 45-54 55-64 65-74 75+ 
Men Women Men Women Men Women Men Women Men Women Men Women 
L H L H L H L H L H L H L H L H L H L H L H L H 
1992 3.0 4.4 2.4 3.6 5.6 8.4 4.0 6.0 16.8 25.3 17.7 26.5 19.9 29.9 18.6 27.9 23.0 34.5 19.5 29.2 23.0 34.5 19.5 29.2 
1993 3.9 5.7 3.2 4.8 6.5 9.6 4.8 7.1 16.6 24.3 17.4 25.7 20.3 29.5 18.3 26.7 23.1 33.3 18.7 26.5 23.5 34.2 19.7 25.8 
1994 4.8 7.2 4.1 6.1 7.5 11.0 5.6 8.3 16.5 23.6 17.4 25.2 20.8 29.3 18.2 26.1 23.3 32.4 18.1 24.6 24.1 33.7 19.9 22.8 
1995 5.8 8.7 5.1 7.6 8.5 12.4 6.5 9.6 16.6 23.4 17.5 25.1 21.3 29.4 18.3 25.8 23.6 31.6 17.9 23.4 24.6 33.2 20.0 20.6 
1996 6.9 10.4 6.1 9.3 9.5 13.9 7.5 11.1 16.8 23.5 17.8 25.3 21.9 29.7 18.6 26.0 23.9 31.1 18.1 23.2 25.0 32.6 20.3 19.5 
1997 8.0 12.2 7.2 11.1 10.6 15.5 8.5 12.7 17.2 23.9 18.2 25.8 22.6 30.2 19.1 26.7 24.3 30.8 18.5 23.9 25.5 32.1 20.5 19.2 
1998 9.2 14.1 8.4 13.0 11.7 17.1 9.6 14.4 17.7 24.5 18.7 26.6 23.3 31.0 19.7 27.7 24.8 30.8 19.1 25.3 26.0 31.7 20.8 19.5 
1999 10.4 15.9 9.5 14.7 12.7 18.7 10.6 16.0 18.2 25.2 19.3 27.5 24.1 31.9 20.5 28.9 25.3 31.0 20.1 27.3 26.5 31.4 21.2 20.2 
2000 11.6 17.6 10.5 16.2 13.7 20.2 11.6 17.5 18.7 25.9 19.9 28.4 24.9 32.8 21.3 30.2 25.9 31.5 21.2 29.8 26.9 31.2 21.7 21.3 
2001 12.7 19.2 11.4 17.5 14.7 21.7 12.6 19.1 19.3 26.6 20.5 29.4 25.7 33.7 22.1 31.7 26.5 32.2 22.6 32.6 27.4 31.2 22.2 22.5 
2002 13.8 20.8 12.2 18.7 15.7 23.1 13.6 20.5 19.8 27.3 21.2 30.4 26.5 34.8 23.1 33.3 27.1 32.9 24.1 35.3 27.8 31.1 22.6 23.4 
2003 14.9 22.3 13.0 19.7 16.7 24.5 14.6 22.0 20.4 28.2 22.0 31.6 27.4 35.9 24.3 35.6 27.8 33.5 25.4 37.1 28.2 31.1 23.0 24.0 
2004 16.0 23.7 13.8 20.7 17.7 25.8 15.5 23.5 21.1 29.1 22.8 33.0 28.2 37.0 25.7 38.5 28.4 34.1 26.5 38.5 28.6 31.2 23.4 24.5 
2005 17.3 25.4 14.6 21.7 18.7 27.3 16.3 24.6 21.2 29.4 22.9 33.3 27.0 35.5 26.4 40.6 28.2 33.8 27.3 39.4 29.4 31.7 23.1 24.2 
2006 18.6 27.0 15.3 22.6 19.8 28.7 17.0 25.7 21.5 29.8 23.2 34.0 26.2 34.7 27.5 43.1 28.1 33.6 28.1 40.3 30.2 32.1 22.9 24.2 
2007 19.8 28.5 16.0 23.5 20.8 30.1 17.8 26.9 21.9 30.5 23.6 35.0 25.8 34.6 28.7 46.1 28.1 33.6 28.9 41.3 30.9 32.5 22.8 24.4 
2008 21.0 30.0 16.7 24.4 21.8 31.3 18.6 28.2 22.4 31.3 24.2 36.1 25.7 35.0 30.2 49.2 28.2 33.7 29.6 42.2 31.6 32.8 22.8 24.6 
2009 22.2 31.4 17.3 25.3 22.7 32.5 19.5 29.5 22.9 32.2 24.8 37.3 25.8 35.6 31.8 52.4 28.3 33.9 30.4 43.2 32.2 33.1 22.9 24.9 
2010 23.3 32.7 18.0 26.1 23.6 33.5 20.3 30.7 23.5 33.2 25.5 38.5 26.1 36.5 33.5 55.5 28.5 34.2 31.1 44.2 32.7 33.4 23.0 25.2 
2011 24.4 33.9 18.7 27.0 24.6 34.8 21.1 31.8 24.0 34.0 25.7 39.0 25.8 36.4 34.8 57.5 28.1 33.8 31.3 44.5 32.5 32.8 23.0 25.4 
2012 25.5 35.1 19.4 27.9 25.7 36.0 21.8 32.9 24.5 34.8 26.1 39.7 25.7 36.9 36.1 59.1 27.9 33.6 31.7 45.2 32.2 32.3 23.0 25.6 
2013 26.5 36.2 20.1 28.8 26.7 37.1 22.6 34.1 25.0 35.7 26.8 41.3 25.9 37.6 37.2 60.1 27.7 33.6 32.1 46.1 32.1 32.0 23.1 25.9 
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Table  6.13. (Scenario 4) Sensitivity analysis: lower (L) and higher (H) uncertainty values of the estimated diabetes prevalence (%) per age group (years) in men and women aged 25-
75+ years, without capping of projected obesity prevalence, Saudi Arabia (1992-2013) 
Year 
25-34 35-44 45-54 55-64 65-74 75+ 
Men Women Men Women Men Women Men Women Men Women Men Women 
L H L H L H L H L H L H L H L H L H L H L H L H 
1992 3.0 4.4 2.4 3.6 5.6 8.4 4.0 6.0 16.8 25.3 17.7 26.5 19.9 29.9 18.6 27.9 23.0 34.5 19.5 29.2 23.0 34.5 19.5 29.2 
1993 3.9 5.7 3.2 4.8 6.5 9.6 4.8 7.1 16.6 24.3 17.4 25.7 20.3 29.5 18.3 26.8 23.1 33.3 18.7 26.5 23.5 34.2 19.7 25.8 
1994 4.8 7.2 4.1 6.1 7.5 11.0 5.6 8.3 16.5 23.6 17.4 25.2 20.8 29.3 18.2 26.1 23.3 32.4 18.1 24.6 24.1 33.7 19.9 22.8 
1995 5.8 8.7 5.1 7.6 8.5 12.4 6.5 9.6 16.6 23.4 17.5 25.1 21.3 29.4 18.3 25.8 23.6 31.6 17.9 23.4 24.6 33.2 20.0 20.6 
1996 6.9 10.4 6.1 9.3 9.5 13.9 7.5 11.1 16.8 23.5 17.8 25.3 21.9 29.7 18.6 26.0 23.9 31.1 18.1 23.2 25.0 32.6 20.3 19.5 
1997 8.0 12.2 7.2 11.1 10.6 15.5 8.5 12.7 17.2 23.9 18.2 25.8 22.6 30.2 19.1 26.7 24.3 30.8 18.5 23.9 25.5 32.1 20.5 19.2 
1998 9.2 14.1 8.4 13.0 11.7 17.1 9.6 14.4 17.7 24.5 18.7 26.6 23.3 31.0 19.7 27.7 24.8 30.8 19.1 25.3 26.0 31.7 20.8 19.5 
1999 10.4 15.9 9.5 14.7 12.7 18.7 10.6 16.0 18.2 25.2 19.3 27.5 24.1 31.9 20.5 28.9 25.3 31.0 20.1 27.3 26.5 31.4 21.2 20.2 
2000 11.6 17.6 10.5 16.2 13.7 20.2 11.6 17.5 18.7 25.9 19.9 28.4 24.9 32.8 21.3 30.2 25.9 31.5 21.2 29.8 26.9 31.2 21.7 21.3 
2001 12.7 19.2 11.4 17.5 14.7 21.7 12.6 19.0 19.3 26.6 20.5 29.4 25.7 33.7 22.1 31.7 26.5 32.2 22.6 32.6 27.4 31.2 22.2 22.5 
2002 13.8 20.8 12.2 18.7 15.7 23.1 13.6 20.5 19.8 27.3 21.2 30.4 26.5 34.8 23.1 33.3 27.1 32.9 24.1 35.3 27.8 31.1 22.6 23.4 
2003 14.9 22.3 13.0 19.7 16.7 24.5 14.6 22.0 20.4 28.2 22.0 31.6 27.4 35.9 24.3 35.6 27.8 33.5 25.4 37.1 28.2 31.1 23.0 24.0 
2004 16.0 23.7 13.8 20.7 17.7 25.8 15.5 23.5 21.1 29.1 22.8 33.0 28.2 37.0 25.7 38.5 28.4 34.1 26.5 38.5 28.6 31.2 23.4 24.5 
2005 17.3 25.4 14.6 21.7 18.7 27.3 16.3 24.6 21.2 29.4 22.9 33.3 27.0 35.5 26.4 40.6 28.2 33.8 27.3 39.4 29.4 31.7 23.1 24.2 
2006 18.6 27.0 15.3 22.6 19.8 28.7 17.0 25.7 21.5 29.8 23.2 34.0 26.2 34.7 27.5 43.1 28.1 33.6 28.1 40.3 30.2 32.1 22.9 24.2 
2007 19.8 28.5 16.0 23.5 20.8 30.1 17.8 26.9 21.9 30.5 23.7 35.0 25.8 34.6 28.7 46.1 28.1 33.6 28.9 41.3 30.9 32.5 22.8 24.4 
2008 21.0 30.0 16.7 24.4 21.8 31.4 18.6 28.2 22.4 31.3 24.3 36.4 25.7 35.0 30.2 49.2 28.2 33.7 29.6 42.2 31.6 32.8 22.8 24.6 
2009 22.2 31.4 17.3 25.3 22.7 32.6 19.5 29.5 22.9 32.2 25.1 37.9 25.8 35.6 31.8 52.4 28.3 33.9 30.4 43.2 32.2 33.1 22.9 24.9 
2010 23.3 32.7 18.0 26.1 23.7 33.8 20.4 30.8 23.5 33.3 26.1 39.8 26.1 36.5 33.5 55.5 28.5 34.2 31.1 44.2 32.7 33.4 23.0 25.2 
2011 24.4 33.9 18.7 27.0 24.8 35.3 21.2 32.1 24.0 34.1 26.6 41.0 25.8 36.4 34.9 57.9 28.1 33.8 31.3 44.5 32.5 32.8 23.0 25.4 
2012 25.5 35.1 19.4 27.9 26.0 36.7 22.0 33.4 24.6 35.0 27.3 42.5 25.7 36.9 36.5 60.5 27.9 33.6 31.7 45.2 32.2 32.3 23.0 25.6 
2013 26.5 36.2 20.1 28.8 27.1 38.2 23.0 35.0 25.2 36.2 28.6 45.4 25.9 37.6 38.0 62.7 27.7 33.6 32.1 46.1 32.1 32.0 23.1 25.9 
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Figure  6.11. (Scenario 3) Trends in the estimated prevalence of diabetes per age 
group (years) in men and women aged 25-75+ years, with capping of projected obesity 
prevalence, Saudi Arabia (1992-2013) [Diagnostic criteria: WHO 1985] 
 
 
 
 
Figure  6.12. (Scenario 4) Trends in the estimated prevalence of diabetes per age 
group (years) in men and women aged 25-75+ years, without capping of projected 
obesity prevalence, Saudi Arabia (1992-2013) [Diagnostic criteria: WHO 1985] 
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6.1.3. Quantified effects of the assumed capping of obesity on the modelling 
results for 2013 
Table  6.14 presents the main results of the Saudi IMPACT Diabetes Forecast 
Model for 2013 based on the different four scenarios described earlier, and 
provides a summary of the changes in diabetes prevalence estimates due to 
using different scenarios. The overall estimated population prevalence of 
diabetes in 2013 was 30.8% based on scenario 1, which calculated the results 
for the population aged 25-64 years and assumed capped trends in obesity at 
35% in men and 60% in women. With scenario 2, the overall population 
prevalence in 2013 increased by 1.9% to reach 31.4%, by assuming continuous 
uncapped linear trends in obesity. 
Also, the effects of shifting from scenario 1 to scenario 2 were minimal 
regarding the results of the overall estimated prevalence of diabetes in men and 
women. In men, the estimated prevalence in 2013 was 31.6% under scenario 1 
and 31.9% under scenario 2. On the other hand, diabetes prevalence in women 
in 2013 was estimated at 29.8% under scenario 1, increasing by 2.7% to reach 
30.6% under scenario 2. 
Similarly, shifting from scenario 1 to scenario 2 resulted in no or minor relative 
increases in the estimated diabetes prevalence for each sex and age group. 
The highest relative increase was 8.5% for women aged 45-54, where the 
prevalence was 34.0% under scenario 1 and 36.9% under scenario 2. 
In scenarios 3 and 4, estimates were calculated after the inclusion of the two 
age groups of 65-74 and 75+ years, with capped obesity trends in scenario 3 
and uncapped trends in scenario 4. Again, shifting from scenario 3 to scenario 4 
resulted in minor relative increases of the 2013 diabetes prevalence in the 
overall population (+1.6%), men (+0.6%) and women (+2.7%). Moreover, this 
shifting produced similar results of estimated prevalence in the two oldest age 
groups in men and women. 
In general, capping of the assumed linear obesity trends in men and women of 
the Saudi population resulted in only minor reduction in the estimated 
prevalence of diabetes during the period of 1992-2013. The most prominent 
impact of capping was observed in women aged 45-54 years, who had the 
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highest ‘observed’ and ‘projected’ prevalence of obesity. The estimated 
prevalence of diabetes in this particular age group showed a relative decrease 
by around 8% with capping. 
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Table  6.14. Summary of the main modelling results (2013) for each scenario and the quantified changes as a result of shifting between different scenarios 
 
Scenario 1 Scenario 2 
Quantified relative 
change (%) as a result of 
shifting from scenario 1 
to scenario 2 
Scenario 3 Scenario 4 
Quantified relative change (%) 
as a result of shifting from 
scenario 3 to scenario 4 
Overall population diabetes 
prevalence (%) in 2013 30.8 31.4 + 1.9 31.0 31.5 + 1.6 
       
Overall diabetes prevalence (%) in 
men in 2013 31.6 31.9 + 0.9 31.1 31.3 + 0.6 
       
Overall diabetes prevalence (%) in 
women in 2013 29.8 30.6 + 2.7 30.1 30.9 + 2.7 
       
Estimated prevalence of diabetes 
(%) per sex and age group in 2013:       
       
Men 25-34 years 31.8 31.8 No change 31.8 31.8 No change 
Men 35-44 years 32.2 32.9 + 2.2 32.2 32.9 + 2.2 
Men 45-54 years 30.5 30.8 + 1.0 30.5 30.8 + 1.0 
Men 55-64 years 31.7 31.7 No change 31.7 31.7 No change 
Men 65-74 years - - - 31.0 31.0 No change 
Men 75+ years - - - 33.0 33.0 No change 
       
Women 25-34 years 24.5 24.5 No change 24.5 24.5 No change 
Women 35-44 years 28.4 29.0 + 2.1 28.4 29.0 + 2.1 
Women 45-54 years 34.0 36.9 + 8.5 34.0 36.9 + 8.5 
Women 55-64 years 48.6 50.2 + 3.3 48.6 50.2 + 3.3 
Women 65-74 years - - - 39.0 39.0 No change 
Women 75+ years - - - 24.4 24.4 No change 
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6.2. Validation of the Saudi IMPACT Diabetes Forecast Model 
As mentioned in chapter 4, validation is a very important step to test the degree 
of accuracy/ credibility of a model and to gain the acceptance of health care 
planners, decision makers and other potential users.226, 265 
In this thesis, two types of validation were undertaken: a) validation against 
existing local ‘observed’ data; and b) concurrent (between-model) validation, 
where the model results were validated against another model estimating the 
same output parameter (the GBD model). Results of validation of the Saudi 
IMPACT Diabetes Forecast Model are discussed in the following two sections.   
6.2.1. Validation against local observed data 
The results of diabetes prevalence as estimated by the model were compared 
with the ‘observed’ results from the WHO STEPS survey19 in Saudi Arabia in 
2005. Selection of this particular survey for validation purposes can be justified 
by two main reasons. First, it was the only available local survey that was not 
conducted over a ‘range’ of years. The results of the survey applied for 2005 
only, and, therefore, there was no need to use the previously discussed 
assumption of the ‘period midpoint’ which was used for data from obesity and 
smoking surveys. Second, the study population in the WHO STEPS survey was 
as that covered by the Saudi IMPACT Diabetes Forecast Model (men and 
women aged 25-64 years). In the other surveys (summarised in Table  3.8, 
chapter 3), results were reported using different population denominators with 
different age ranges (e.g. ≥14 years, ≥18 years, etc), which were not 
comparable to the model’s age limits. 
It is important to mention that the model results for 2005 were the same with 
and without capping of the obesity trends. Therefore, there was no difference in 
using scenario 1 or scenario 2 of the model for the purpose of validation against 
the STEPS survey. 
Figure  6.13 illustrates the results of validation. The model estimated a diabetes 
prevalence of 23.0% (UI: 15.0–33.0%) in men aged 25-64 years in 2005, 
compared to 20.1% (95% CI: 16.9–23.2%) in the STEPS survey. In women, the 
estimated prevalence by the model was 21.7% (UI: 13.9–31.2%), compared to 
18.3% (95% CI: 15.4–21.3%). The total population diabetes prevalence in 2005 
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was estimated by the model to be 22.8% (UI: 14.8–32.3%), compared to 19.2% 
(95% CI: 16.1–22.2%) by the STEPS survey.  
In general, the model estimates of diabetes prevalence for 2005 were 
reasonably close to that of the WHO STEPS survey. However, the model 
tended to slightly overestimate the diabetes prevalence in men (by 2.9 
percentage points), women (by 3.4 percentage points) and total population (by 
3.6 percentage points), compared to the STEPS survey. The point estimates of 
the WHO STEPS survey lie within the UIs of the model in this thesis.
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Figure  6.13. Results of the model validation against the WHO STEPS survey (2005) for men, women and total population aged 25-64 years
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6.2.2. Validation against another model 
The Saudi IMPACT Diabetes Forecast Model produced reasonably comparable 
estimates of the diabetes prevalence in Saudi Arabia for years 2000 and 2008 
to that estimated recently by the WHO Global Burden of Disease (GBD) study, 
2011.20 The GBD model estimated the trends and uncertainties in mean fasting 
plasma glucose (FPG) and diabetes prevalence during 1980-2008 in adults 
aged ≥25 years in around 200 countries and territories globally. It used complex 
multi-level methods of modelling, and incorporated several covariates (including 
the mean BMI) to inform the estimates of diabetes prevalence. Detailed 
description and discussion of the methodology and results of the GBD model 
are presented in chapter 9. 
Data sources used by the GBD model for Saudi Arabia included three national 
population-based surveys.18, 19, 36 One of these surveys was that of Warsy and 
El-Hazmi,36 which was used by the Saudi IMPACT Diabetes Forecast Model to 
obtain the diabetes prevalence for the starting year of modelling. Another 
survey was the WHO STEPS survey,19 which was used in this thesis for 
validation as discussed earlier. The model results for population aged 25-64 
years in 2000 and 2008 were validated against the GBD model, as shown in 
Figure  6.14. The model results for 2000 and 2008 did not show any differences 
by assuming capped obesity trends (scenario 1) or continuing linear trends 
(scenario 2). Therefore, both scenarios can be used for validation against the 
GBD model.  
The uncertainty intervals reported by the GBD study represented the 2.5–97.5 
percentiles of the estimated means of diabetes prevalence. The Saudi IMPACT 
Diabetes Forecast Model estimated the diabetes prevalence in men at 17.7% 
(UI: 14.3 – 20.8%) in 2000, compared to 17.5% (UI: 13.6–21.9%) by the GBD 
study. In women, the estimated prevalence in 2000 was 16.4% (UI: 13.2–
19.6%) by the Saudi model and 17.7% (UI: 13.8–21.9%) by the GBD study. On 
the other hand, the estimated prevalence in 2008 for men was 26.7% (UI: 21.9–
31.1%) by the Saudi model, compared to 22.0% (UI: 14.8–30.2%) by the GBD 
study. For women in 2008, the estimated prevalence was 24.7% (UI: 19.7–
29.7%) by the Saudi model, and 21.7% (UI: 14.6–29.9%) by the GBD study.  
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Generally, the results of the two models in 2000 for men were very similar, 
whereas for women, the GBD study resulted in a slightly higher (by 1.3 
percentage points) estimate than the Saudi IMPACT Diabetes Forecast Model. 
However, for 2008, the Saudi IMPACT Diabetes Forecast Model tended to 
produce higher estimates than the other model, in both men (by 4.7 percentage 
points) and women (by 3.0 percentage points). The point estimates of the GBD 
model lie within the UIs of the model in this thesis. 
In total, in this chapter, the past and current (1992-2013) trends in the diabetes 
prevalence in Saudi Arabia have been reported, as estimated by the Saudi 
IMPACT Diabetes Forecast Model. Also, the results of validation of the model 
against observed data and the recent GBD model have been discussed. The 
next chapter presents the model outputs of the predicted future diabetes 
prevalence for the period 2014-2022. 
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Figure  6.14. Results of the model validation against the GBD study for men and women aged 25-64 years (2000 and 2008)
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Chapter 7. Using the Saudi IMPACT Diabetes Forecast Model to 
predict the future trends in diabetes prevalence in Saudi 
Arabia 
This chapter presents the future trends in diabetes prevalence during 2014-
2022, as predicted by the model. In addition, this chapter provides a brief 
overview of the main results for the whole modelling period (1992-2022). 
Moreover, this chapter discusses the impact of adjusting the modelling outputs 
of diabetes prevalence to the more recent diagnostic criteria of T2DM (ADA 
1997/ WHO 1999).  
7.1. Trends in the prevalence of type 2 diabetes in Saudi Arabia during 
2014–2022 
The results of the model predictions of the estimated diabetes prevalence in 
Saudi Arabia during 2014-2022 are presented in this section, based on the four 
scenarios discussed earlier in chapter 6. 
7.1.1. The overall and sex-specific prevalence of diabetes and numbers of 
diabetic individuals in the Saudi population 
7.1.1.1. Results based on scenario 1: population aged 25-64 years, with capping 
Diabetes prevalence is estimated to increase by 24% in the Saudi population 
aged 25-64 years during the nine-year period of 2014-2022, assuming capped 
obesity trends; from 31.8% (UI: 26.0–37.4%) to 39.5% (UI: 32.5–45.9%) (Figure 
 7.1). The estimated number of individuals with diabetes will increase by 
2,239,448 (UI: 1,508,444-3,067,650) during the same period; from 4,342,064 
(UI: 2,834,922-6,113,433) to 6,581,511 (UI: 4,343,367-9,181,082) (Table  7.1). 
In men, the predicted diabetes prevalence will increase by 21% during the same 
period; from 32.5% (UI: 27.0–37.6%) in 2014 to 39.2% (UI: 33.2-44.4%) in 2022 
(Figure  7.3). This will be equivalent to an estimated increase of 1,076,527 (UI: 
764,029-1,398,513) individuals in the number of men with diabetes; from 
2,590,085 (UI: 1,718,194–3,587,497) to 3,666,613 (UI: 2,482,223–4,986,010) 
(Table  7.1). 
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In women, the estimated diabetes prevalence is predicted to increase by 29%; 
from 30.8% (UI: 24.6–37.1%) in 2014 to 39.8% (UI: 31.7–47.7%) in 2022 
(Figure  7.3). The number of women with diabetes during the same period is 
predicted to increase by 1,162,920 (UI: 744,416-1,669,136) individuals; from 
1,751,978 (UI: 1,116,728–2,525,936) to 2,914,899 (UI: 1,861,144–4,195,073) 
(Table  7.1). 
7.1.1.2. Results based on scenario 2: population aged 25-64 years, without 
capping 
Assuming continuing uncapped linear trends in obesity prevalence, the 
estimated overall diabetes prevalence in the total Saudi population aged 25-64 
years is predicted to increase by 35% during 2014–2022; from 32.6% (UI: 26.4–
38.5%) to 44.1% (UI: 35.4–52.5%) (Figure  7.2). There is a predicted increase of 
2,904,901 (UI: 1,837,274-4,209,704) in the total number of individuals with 
diabetes; from 4,448,546 (UI: 2,885,782–6,303,886) in 2014 to 7,353,447 (UI: 
4,723,056–10,513,591) in 2022 (Table  7.2). 
In men, the predicted diabetes prevalence will increase by 26%; from 32.9% 
(UI: 27.2–38.2%) in 2014 to 41.3% (UI: 34.4–47.6%) in 2022 (Figure  7.4). The 
number of men with diabetes is predicted to increase by 1,236,955 (UI: 
840,481-1,691,082) individuals during the same period; from 2,622,048 (UI: 
1,733,362–3,646,407) to 3,859,003 (UI: 2,573,843–5,337,489) (Table  7.2). 
In comparison, the predicted diabetes prevalence in women aged 25-64 years 
during 2014-2022 will increase by 48%; from 32.2% (UI: 25.4–39.0%) to 47.7% 
(UI: 36.6–58.8%) (Figure  7.4). The number of diabetic women is predicted to 
increase by a total of 1,667,946 (UI: 996,793-2,518,622) individuals; from 
1,826,498 (UI: 1,152,419–2,657,480) to 3,494,444 (UI: 2,149,212–5,176,102) 
(Table  7.2). 
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 Figure  7.1. (Scenario 1) Trends in the predicted diabetes total prevalence (and uncertainty values) for 
population aged 25-64 years, with capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
[Solid line: point (best) estimates; Dotted lines: minimum and maximum uncertainty estimates. Diagnostic 
criteria: WHO 1985] 
 
 
Figure  7.2. (Scenario 2) Trends in the predicted diabetes total prevalence (and uncertainty values) for 
population aged 25-64 years, without capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
[Solid line: point (best) estimates; Dotted lines: minimum and maximum uncertainty estimates. Diagnostic 
criteria: WHO 1985] 
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 Figure  7.3. (Scenario 1) Trends in the predicted diabetes prevalence (and uncertainty values) for men and 
women aged 25-64 years, with capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
[Diagnostic criteria: WHO 1985] 
 
Figure  7.4. (Scenario 2) Trends in the predicted diabetes prevalence (and uncertainty values) for men and 
women aged 25-64 years, without capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
[Diagnostic criteria: WHO 1985]  
0.0% 
10.0% 
20.0% 
30.0% 
40.0% 
50.0% 
60.0% 
2014 2015 2016 2017 2018 2019 2020 2021 2022 
Pr
ed
ic
te
d 
 D
ia
be
te
s  
Pr
ev
al
en
ce
 
Year 
Men Women 
0.0% 
10.0% 
20.0% 
30.0% 
40.0% 
50.0% 
60.0% 
2014 2015 2016 2017 2018 2019 2020 2021 2022 
Pr
ed
ic
te
d 
 D
ia
be
te
s  
Pr
ev
al
en
ce
 
Year 
Men Women 
204 
 
Table  7.1. (Scenario 1) Predicted numbers of individuals with diabetes for population aged 25-64 years, with capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
Year Men Uncertainty values Women Uncertainty values Total Uncertainty values 
 best estimate minimum maximum best estimate minimum maximum best estimate minimum maximum 
2014 2,590,085 1,718,194 3,587,497 1,751,978 1,116,728 2,525,936 4,342,064 2,834,922 6,113,433 
2015 2,723,952 1,810,411 3,767,053 1,878,845 1,196,542 2,712,675 4,602,797 3,006,953 6,479,727 
2016 2,859,395 1,904,248 3,947,630 2,012,150 1,280,392 2,908,692 4,871,544 3,184,640 6,856,322 
2017 2,995,265 1,999,174 4,127,062 2,153,212 1,368,973 3,116,090 5,148,477 3,368,147 7,243,152 
2018 3,131,126 2,094,965 4,304,632 2,299,815 1,461,579 3,329,275 5,430,941 3,556,545 7,633,907 
2019 3,266,611 2,191,420 4,479,834 2,450,178 1,557,549 3,544,687 5,716,790 3,748,969 8,024,521 
2020 3,401,421 2,288,352 4,652,344 2,602,917 1,656,277 3,760,227 6,004,338 3,944,629 8,412,571 
2021 3,535,315 2,385,594 4,821,987 2,757,005 1,757,225 3,974,841 6,292,321 4,142,819 8,796,828 
2022 3,666,613 2,482,223 4,986,010 2,914,899 1,861,144 4,195,073 6,581,511 4,343,367 9,181,082 
Table  7.2. (Scenario 2) Predicted numbers of individuals with diabetes for population aged 25-64 years, without capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
Year Men Uncertainty values Women Uncertainty values Total Uncertainty values 
 best estimate minimum maximum best estimate minimum maximum best estimate minimum maximum 
2014 2,622,048 1,733,362 3,646,407 1,826,498 1,152,419 2,657,480 4,448,546 2,885,782 6,303,886 
2015 2,767,766 1,831,135 3,848,122 1,986,995 1,248,283 2,903,682 4,754,761 3,079,417 6,751,804 
2016 2,917,540 1,931,691 4,055,448 2,161,764 1,352,079 3,172,313 5,079,303 3,283,770 7,227,760 
2017 3,070,062 2,034,447 4,265,798 2,352,699 1,464,860 3,466,164 5,422,761 3,499,307 7,731,962 
2018 3,224,862 2,139,189 4,478,273 2,557,692 1,586,135 3,779,143 5,782,554 3,725,324 8,257,415 
2019 3,381,594 2,245,742 4,692,318 2,775,043 1,715,436 4,107,350 6,156,637 3,961,178 8,799,669 
2020 3,539,964 2,353,942 4,907,540 3,003,393 1,852,315 4,448,422 6,543,357 4,206,257 9,355,962 
2021 3,699,696 2,463,625 5,123,613 3,241,789 1,996,388 4,801,271 6,941,485 4,460,013 9,924,884 
2022 3,859,003 2,573,843 5,337,489 3,494,444 2,149,212 5,176,102 7,353,447 4,723,056 10,513,591 
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7.1.1.3. Results based on scenario 3: population aged 25-75+ years, with 
capping 
Assuming capped trends in the obesity trends, the overall diabetes prevalence 
in the Saudi population aged 25-75+ years is predicted to increase by 22% 
during 2014-2022; from 31.9% (UI: 26.2–37.3%) to 38.9% (UI: 32.2–45.2%) 
(Figure  7.5). There will be a predicted increase in the number of individuals with 
diabetes by 2,422,105 (UI: 1,626,531-3,332,590) during the same period; from 
4,650,710 (UI: 3,052,901–6,522,822) in 2014 to 7,072,814 (UI: 4,679,432–
9,855,412) in 2022 (Table  7.3). 
The predicted diabetes prevalence in men will increase by 18%; from 31.9% 
(UI: 26.6–36.8%) in 2014 to reach 37.8% (UI: 32.0–42.8%) by 2022 (Figure 
 7.7). The number of diabetic men is predicted to increase by a total of 
1,158,015 (UI: 818,455-1,514,613) over the same period; from 2,739,864 (UI: 
1,828,072–3,776,219) to 3,897,879 (UI: 2,646,527–5,290,833) (Table  7.3). 
In women, the predicted diabetes prevalence will increase by 28%; from 31.1% 
(UI: 24.9–37.3%) in 2014 to 39.7% (UI: 31.7–47.5%) by 2022 (Figure  7.7). This 
will be equivalent to an estimated increase of 1,264,090 (UI: 808,076-
1,817,977) individuals in the number of women with diabetes; from 1,910,846 
(UI: 1,224,829–2,746,602) to 3,174,935 (UI: 2,032,905–4,564,579) (Table  7.3). 
7.1.1.4. Results based on scenario 4: population aged 25-75+ years, without 
capping 
The predicted diabetes prevalence for the total Saudi population (25-75+ 
years), assuming continuous uncapped linear trends in obesity, will increase by 
33%; from 32.6% (UI: 26.6–38.4%) in 2014 to 43.2% (UI: 34.8–51.3%) in 2022 
(Figure  7.6). The number of individuals with diabetes during the same period is 
predicted to increase by a total of 3,087,558 (UI: 1,955,361-4,474,645); from 
4,757,192 (UI: 3,103,760–6,713,275) to reach 7,844,750 (UI: 5,059,121–
11,187,920) (Table  7.4). 
In men, the prevalence of diabetes is predicted to increase by 23%; from 32.3% 
(UI: 26.8–37.4%) in 2014 to 39.7% (UI: 33.1–45.7%) by 2022 (Figure  7.8). The 
number of diabetic men is predicted by the model to increase by 1,318,443 (UI: 
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894,907-1,807,182); from 2,771,827 (UI: 1,843,240–3,835,129) in 2014 to 
4,090,269 (UI: 2,738,147–5,642,311) by 2022 (Table  7.4). 
On the other hand, the diabetes prevalence in women is predicted to increase 
by 45% between 2014 and 2022; from 32.3% (UI: 25.7–39.1%) to 46.9% (UI: 
36.2–57.7%) (Figure  7.8). The predicted number of women with diabetes will 
increase by 1,769,115 (UI: 1,060,454-2,667,463); from 1,985,366 (UI: 
1,260,520–2,878,146) in 2014 to 3,754,481 (UI: 2,320,974–5,545,609) in 2022 
(Table  7.4). 
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 Figure  7.5. (Scenario 3) Trends in the predicted diabetes total prevalence (and uncertainty values) for 
population aged 25-75+ years, with capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
[Solid line: point (best) estimates; Dotted lines: minimum and maximum uncertainty estimates. Diagnostic 
criteria: WHO 1985] 
 
 
Figure  7.6. (Scenario 4) Trends in the predicted diabetes total prevalence (and uncertainty values) for 
population aged 25-75+ years, without capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
[Solid line: point (best) estimates; Dotted lines: minimum and maximum uncertainty estimates. Diagnostic 
criteria: WHO 1985] 
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 Figure  7.7. (Scenario 3) Trends in the predicted diabetes prevalence (and uncertainty values) for men and 
women aged 25-75+ years, with capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
[Diagnostic criteria: WHO 1985] 
 
Figure  7.8. (Scenario 4) Trends in the predicted diabetes prevalence (and uncertainty values) for men and 
women aged 25-75+ years, without capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
[Diagnostic criteria: WHO 1985]  
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Table  7.3. (Scenario 3) Predicted numbers of individuals with diabetes for population aged 25-75+ years, with capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
Year Men Uncertainty values Women Uncertainty values Total Uncertainty values 
 best estimate minimum maximum best estimate minimum maximum best estimate minimum maximum 
2014 2,739,864 1,828,072 3,776,219 1,910,846 1,224,829 2,746,602 4,650,710 3,052,901 6,522,822 
2015 2,880,151 1,924,855 3,964,527 2,047,302 1,310,802 2,947,281 4,927,453 3,235,658 6,911,807 
2016 3,022,391 2,023,503 4,154,363 2,190,639 1,401,101 3,157,820 5,213,030 3,424,604 7,312,183 
2017 3,166,556 2,124,068 4,345,577 2,342,982 1,496,789 3,381,925 5,509,538 3,620,857 7,727,502 
2018 3,312,045 2,226,273 4,537,021 2,501,876 1,597,088 3,613,331 5,813,920 3,823,361 8,150,352 
2019 3,458,346 2,329,862 4,727,842 2,665,373 1,701,279 3,848,112 6,123,719 4,031,141 8,575,954 
2020 3,605,036 2,434,602 4,917,436 2,831,976 1,808,712 4,083,972 6,437,012 4,243,315 9,001,408 
2021 3,751,764 2,540,283 5,105,401 3,000,585 1,918,813 4,319,758 6,752,349 4,459,096 9,425,159 
2022 3,897,879 2,646,527 5,290,833 3,174,935 2,032,905 4,564,579 7,072,814 4,679,432 9,855,412 
 
Table  7.4. (Scenario 4) Predicted numbers of individuals with diabetes for population aged 25-75+ years, without capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
Year Men Uncertainty values Women Uncertainty values Total Uncertainty values 
 best estimate minimum maximum best estimate minimum maximum best estimate minimum maximum 
2014 2,771,827 1,843,240 3,835,129 1,985,366 1,260,520 2,878,146 4,757,192 3,103,760 6,713,275 
2015 2,923,965 1,945,579 4,045,596 2,155,451 1,362,543 3,138,288 5,079,416 3,308,122 7,183,884 
2016 3,080,536 2,050,945 4,262,181 2,340,253 1,472,789 3,421,440 5,420,789 3,523,734 7,683,622 
2017 3,241,353 2,159,341 4,484,313 2,542,469 1,592,676 3,731,999 5,783,822 3,752,018 8,216,312 
2018 3,405,780 2,270,496 4,710,662 2,759,753 1,721,644 4,063,199 6,165,533 3,992,140 8,773,861 
2019 3,573,329 2,384,184 4,940,326 2,990,237 1,859,167 4,410,775 6,563,566 4,243,350 9,351,102 
2020 3,743,578 2,500,192 5,172,632 3,232,452 2,004,751 4,772,167 6,976,031 4,504,943 9,944,799 
2021 3,916,145 2,618,314 5,407,028 3,485,368 2,157,976 5,146,187 7,401,513 4,776,290 10,553,215 
2022 4,090,269 2,738,147 5,642,311 3,754,481 2,320,974 5,545,609 7,844,750 5,059,121 11,187,920 
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7.1.2. Age- and sex-specific prevalence of diabetes and numbers of diabetic 
individuals 
7.1.2.1. Results based on scenario 1: population aged 25-64 years, with capping 
Assuming the previously discussed capped projected obesity trends in men and 
women aged 25-64 years, the highest predicted relative increase in the 
prevalence of diabetes during 2014-2022 will be in women aged 45-54 years. 
The prevalence in this age group is predicted to increase by 39%; from 35.6% 
(UI: 27.8–43.6%) in 2014 to 49.6% (UI: 38.3–60.9%) in 2022. The second 
highest increase in the diabetes prevalence (34%) is predicted in women aged 
35-44 years; from 29.4% (UI: 23.4–35.3%) to 39.4% (UI: 31.5–47.1%). On the 
other hand, women aged 55-64 years will show relatively stable predicted 
prevalence rates during this period (Table  7.5). 
7.1.2.2. Results based on scenario 2: population aged 25-64 years, without 
capping 
If the projected trends in obesity continue to increase without capping, the 
predicted diabetes prevalence during 2014-2022 will show more significant 
relative increases than that predicted by scenario 1. In women aged 45-54 
years, the predicted diabetes prevalence will increase by 75%; from 39.5% (UI: 
30.1–49.4%) in 2014 to 69.3% (UI: 50.4–88.9%) in 2022. Moreover, the 
predicted relative increase in diabetes prevalence during the same period is 
55% in women aged 35-44 years, 38% in men aged 45-54 years and 35% in 
men aged 35-44 years. Women in the age group of 55-64 years, who show 
stable predicted prevalence of diabetes by scenario 1, are predicted to have a 
relative increase of 17%; from 52.0% (UI: 39.5–64.8%) in 2014 to reach 61.0% 
(UI: 45.8–76.8%) by 2022. However, men and women in the youngest age 
group (25-34 years) will show no difference in the predicted prevalence of 
diabetes, using both scenarios (Table  7.6). 
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Table  7.7 and Table  7.8 present the lower and higher uncertainty values of the 
predicted diabetes prevalence for the age groups, based on scenarios 1 and 2 
respectively. In addition, Figure  7.9 and Figure  7.10 illustrate a graphical 
comparison of the predicted prevalence in all age groups, using these two 
scenarios.  
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Table  7.5. (Scenario 1) Predicted prevalence of diabetes per age group (years) in men and women aged 25-64 years, with capping of projected obesity prevalence, Saudi Arabia 
(2014-2022) 
Year 
25-34 35-44 45-54 55-64 
Men Women Men Women Men Women Men Women 
2014 32.8% 25.3% 33.3% 29.4% 31.3% 35.6% 32.2% 49.5% 
2015 33.8% 26.1% 34.3% 30.5% 32.1% 37.4% 32.7% 50.1% 
2016 34.3% 26.7% 35.7% 31.9% 33.5% 39.5% 33.0% 49.2% 
2017 34.7% 27.3% 36.9% 33.2% 34.8% 41.6% 33.3% 48.9% 
2018 35.1% 28.0% 38.1% 34.6% 36.1% 43.7% 33.7% 48.8% 
2019 35.6% 28.7% 39.3% 35.9% 37.2% 45.6% 34.2% 49.0% 
2020 36.0% 29.4% 40.4% 37.1% 38.2% 47.3% 34.7% 49.3% 
2021 36.6% 30.5% 41.3% 38.3% 39.6% 48.5% 35.1% 48.8% 
2022 37.2% 31.6% 42.2% 39.4% 40.8% 49.6% 35.5% 48.7% 
Relative difference in prevalence +13% +25% +27% +34% +30% +39% +10% -2% 
Table  7.6. (Scenario 2) Predicted prevalence of diabetes per age group (years) in men and women aged 25-64 years, without capping of projected obesity prevalence, Saudi Arabia 
(2014-2022) 
Year 
25-34 35-44 45-54 55-64 
Men Women Men Women Men Women Men Women 
2014 32.8% 25.3% 34.2% 30.5% 31.8% 39.5% 32.2% 52.0% 
2015 33.8% 26.1% 35.5% 32.0% 32.8% 42.7% 32.9% 53.7% 
2016 34.3% 26.7% 37.1% 34.0% 34.5% 46.4% 33.2% 53.8% 
2017 34.7% 27.3% 38.7% 36.0% 36.0% 50.3% 33.7% 54.6% 
2018 35.1% 28.0% 40.3% 38.2% 37.6% 54.3% 34.4% 55.8% 
2019 35.6% 28.7% 41.8% 40.4% 39.1% 58.4% 35.1% 57.3% 
2020 36.0% 29.4% 43.3% 42.6% 40.5% 62.4% 35.8% 58.9% 
2021 36.6% 30.5% 44.7% 44.9% 42.3% 65.8% 36.4% 59.7% 
2022 37.2% 31.6% 46.0% 47.2% 44.0% 69.3% 37.1% 61.0% 
Relative difference in prevalence +13% +25% +35% +55% +38% +75% +15% +17% 
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Table  7.7. (Scenario 1) Sensitivity analysis: lower (L) and higher (H) uncertainty values of the predicted diabetes prevalence (%) per age group (years) in men and women aged 25-64 
years, with capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
Year 
25-34 35-44 45-54 55-64 
Men Women Men Women Men Women Men Women 
L H L H L H L H L H L H L H L H 
2014 27.5 37.3 20.8 29.7 27.7 38.2 23.4 35.3 25.7 36.7 27.8 43.6 26.2 38.3 38.1 60.7 
2015 28.5 38.3 21.5 30.6 28.6 39.3 24.2 36.6 26.3 37.7 28.9 46.3 26.6 39.0 38.9 61.2 
2016 29.0 38.6 22.0 31.3 29.8 40.7 25.3 38.3 27.4 39.4 30.3 49.3 26.7 39.3 38.4 59.8 
2017 29.5 39.0 22.5 32.0 31.0 42.1 26.4 39.9 28.5 40.9 31.8 52.1 27.0 39.7 38.3 59.3 
2018 30.0 39.4 23.1 32.8 32.2 43.3 27.5 41.5 29.6 42.2 33.3 54.7 27.3 40.2 38.3 59.4 
2019 30.4 39.7 23.7 33.6 33.3 44.5 28.5 43.0 30.6 43.4 34.7 56.9 27.7 40.7 38.5 59.6 
2020 30.9 40.1 24.3 34.4 34.3 45.5 29.5 44.5 31.5 44.5 36.1 58.7 28.1 41.2 38.7 59.9 
2021 31.5 40.7 25.2 35.7 35.3 46.4 30.5 45.8 32.8 45.9 37.2 59.8 28.4 41.5 38.4 59.3 
2022 32.2 41.3 26.1 37.0 36.2 47.2 31.5 47.1 33.9 47.1 38.3 60.9 28.8 41.9 38.4 59.3 
Table  7.8. (Scenario2) Sensitivity analysis: lower (L) and higher (H) uncertainty values of the predicted diabetes prevalence (%) per age group (years) in men and women aged 25-64 
years, without capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
Year 
25-34 35-44 45-54 55-64 
Men Women Men Women Men Women Men Women 
L H L H L H L H L H L H L H L H 
2014 27.5 37.3 20.8 29.7 28.2 39.6 24.1 36.7 25.9 37.4 30.1 49.4 26.2 38.4 39.5 64.8 
2015 28.5 38.3 21.5 30.6 29.3 41.1 25.2 38.7 26.7 38.8 32.1 54.2 26.6 39.3 40.9 66.8 
2016 29.0 38.6 22.0 31.3 30.7 42.9 26.7 41.2 28.0 40.9 34.4 59.6 26.8 39.8 41.0 66.8 
2017 29.5 39.0 22.5 32.0 32.1 44.7 28.2 43.8 29.2 42.8 37.0 65.1 27.2 40.4 41.5 68.0 
2018 30.0 39.4 23.1 32.8 33.5 46.5 29.8 46.5 30.4 44.7 39.6 70.5 27.6 41.2 42.3 69.7 
2019 30.4 39.7 23.7 33.6 34.8 48.2 31.4 49.2 31.6 46.4 42.4 75.7 28.1 42.1 43.3 71.7 
2020 30.9 40.1 24.3 34.4 36.1 49.9 33.1 52.1 32.8 48.1 45.2 80.7 28.7 43.0 44.4 73.9 
2021 31.5 40.7 25.2 35.7 37.3 51.4 34.8 54.9 34.3 50.1 47.8 84.8 29.2 43.7 44.9 75.0 
2022 32.2 41.3 26.1 37.0 38.5 52.9 36.5 57.9 35.7 52.0 50.4 88.9 29.7 44.5 45.8 76.8 
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Figure  7.9. (Scenario 1) Trends in the predicted prevalence of diabetes per age group 
(years) in men and women aged 25-64 years, with capping of projected obesity 
prevalence, Saudi Arabia (2014-2022) [Diagnostic criteria: WHO 1985] 
 
 
Figure  7.10. (Scenario 2) Trends in the predicted prevalence of diabetes per age group 
(years) in men and women aged 25-64 years, without capping of projected obesity 
prevalence, Saudi Arabia (2014-2022) [Diagnostic criteria: WHO 1985]
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7.1.2.3. Results based on scenario 3: population aged 25-75+ years, with 
capping 
When the two oldest age groups (65-74 and 75+ years) were included in the 
modelling process (with obesity trends in these age groups extrapolated using 
Omani data), the model predicted that the diabetes prevalence in women aged 
65-74 years will increase by 14%; from 39.7% (UI: 32.6–47.1%) in 2014 to 
45.2% (UI: 36.2–54.7%) in 2022. Women aged 75+ years will show relatively 
stable trends in the predicted diabetes prevalence. On the other hand, men in 
these two oldest age groups have relative decreasing trends in the predicted 
diabetes prevalence during the same period, by around 10% (Table  7.9). 
7.1.2.4. Results based on scenario 4: population aged 25-75+ years, without 
capping 
The results of the predicted diabetes prevalence in the two oldest age groups, 
assuming continuing uncapped linear trends in obesity (Table  7.10), were 
similar to that obtained through scenario 3 (with capped obesity trends).  
The uncertainty values of the predicted diabetes prevalence based on scenarios 
3 and 4 are presented in Table  7.11 and Table  7.12. Moreover, Figure  7.11 and 
Figure  7.12 demonstrate graphically the trends in the diabetes prevalence for 
each sex and age group, as predicted by applying these two scenarios. 
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Table  7.9. (Scenario 3) Predicted prevalence of diabetes per age group (years) in men and women aged 25-75+ years, with capping of projected obesity prevalence, Saudi Arabia 
(2014-2022) 
Year 
25-34 35-44 45-54 55-64 65-74 75+ 
Men Women Men Women Men Women Men Women Men Women Men Women 
2014 32.8% 25.3% 33.3% 29.4% 31.3% 35.6% 32.2% 49.5% 31.1% 39.7% 32.8% 24.6% 
2015 33.8% 26.1% 34.3% 30.5% 32.1% 37.4% 32.7% 50.1% 31.2% 40.6% 32.6% 24.9% 
2016 34.3% 26.7% 35.7% 31.9% 33.5% 39.5% 33.0% 49.2% 29.9% 40.9% 32.1% 24.8% 
2017 34.7% 27.3% 36.9% 33.2% 34.8% 41.6% 33.3% 48.9% 29.1% 41.5% 31.7% 24.8% 
2018 35.1% 28.0% 38.1% 34.6% 36.1% 43.7% 33.7% 48.8% 28.8% 42.3% 31.4% 24.9% 
2019 35.6% 28.7% 39.3% 35.9% 37.2% 45.6% 34.2% 49.0% 28.7% 43.2% 31.2% 25.2% 
2020 36.0% 29.4% 40.4% 37.1% 38.2% 47.3% 34.7% 49.3% 28.8% 44.2% 31.1% 25.5% 
2021 36.6% 30.5% 41.3% 38.3% 39.6% 48.5% 35.1% 48.8% 28.3% 44.5% 30.1% 25.3% 
2022 37.2% 31.6% 42.2% 39.4% 40.8% 49.6% 35.5% 48.7% 28.1% 45.2% 29.4% 25.3% 
Relative difference in prevalence +13% +25% +27% +34% +30% +39% +10% -2% -10% +14% -10% +3% 
 
Table  7.10. (Scenario 4) Predicted prevalence of diabetes per age group (years) in men and women aged 25-75+ years, without capping of projected obesity prevalence, Saudi Arabia 
(2014-2022) 
Year 
25-34 35-44 45-54 55-64 65-74 75+ 
Men Women Men Women Men Women Men Women Men Women Men Women 
2014 32.8% 25.3% 34.2% 30.5% 31.8% 39.5% 32.2% 52.0% 31.1% 39.7% 32.8% 24.6% 
2015 33.8% 26.1% 35.5% 32.0% 32.8% 42.7% 32.9% 53.7% 31.2% 40.6% 32.6% 24.9% 
2016 34.3% 26.7% 37.1% 34.0% 34.5% 46.4% 33.2% 53.8% 29.9% 40.9% 32.1% 24.8% 
2017 34.7% 27.3% 38.7% 36.0% 36.0% 50.3% 33.7% 54.6% 29.1% 41.5% 31.7% 24.8% 
2018 35.1% 28.0% 40.3% 38.2% 37.6% 54.3% 34.4% 55.8% 28.8% 42.3% 31.4% 24.9% 
2019 35.6% 28.7% 41.8% 40.4% 39.1% 58.4% 35.1% 57.3% 28.7% 43.2% 31.2% 25.2% 
2020 36.0% 29.4% 43.3% 42.6% 40.5% 62.4% 35.8% 58.9% 28.8% 44.2% 31.1% 25.5% 
2021 36.6% 30.5% 44.7% 44.9% 42.3% 65.8% 36.4% 59.7% 28.3% 44.5% 30.1% 25.3% 
2022 37.2% 31.6% 46.0% 47.2% 44.0% 69.3% 37.1% 61.0% 28.1% 45.2% 29.4% 25.3% 
Relative difference in prevalence +13% +25% +35% +55% +38% +75% +15% +17% -10% +14% -10% +3% 
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Table  7.11. (Scenario 3) Sensitivity analysis: lower (L) and higher (H) uncertainty values of the predicted diabetes prevalence (%) per age group (years) in men and women aged 25-
75+ years, with capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
Year 
25-34 35-44 45-54 55-64 65-74 75+ 
Men Women Men Women Men Women Men Women Men Women Men Women 
L H L H L H L H L H L H L H L H L H L H L H L H 
2014 27.5 37.3 20.8 29.7 27.7 38.2 23.4 35.3 25.7 36.7 27.8 43.6 26.2 38.3 38.1 60.7 27.7 33.8 32.6 47.1 31.9 31.7 23.3 26.3 
2015 28.5 38.3 21.5 30.6 28.6 39.3 24.2 36.6 26.3 37.7 28.9 46.3 26.6 39.0 38.9 61.2 27.8 34.0 33.2 48.2 31.8 31.6 23.5 26.6 
2016 29.0 38.6 22.0 31.3 29.8 40.7 25.3 38.3 27.4 39.4 30.3 49.3 26.7 39.3 38.4 59.8 26.6 32.7 33.4 48.7 31.4 31.1 23.3 26.5 
2017 29.5 39.0 22.5 32.0 31.0 42.1 26.4 39.9 28.5 40.9 31.8 52.1 27.0 39.7 38.3 59.3 25.8 32.1 33.8 49.6 31.1 30.8 23.2 26.7 
2018 30.0 39.4 23.1 32.8 32.2 43.3 27.5 41.5 29.6 42.2 33.3 54.7 27.3 40.2 38.3 59.4 25.3 31.9 34.3 50.7 30.8 30.6 23.2 26.9 
2019 30.4 39.7 23.7 33.6 33.3 44.5 28.5 43.0 30.6 43.4 34.7 56.9 27.7 40.7 38.5 59.6 25.1 32.0 34.9 51.9 30.6 30.5 23.3 27.3 
2020 30.9 40.1 24.3 34.4 34.3 45.5 29.5 44.5 31.5 44.5 36.1 58.7 28.1 41.2 38.7 59.9 25.0 32.3 35.6 53.1 30.5 30.5 23.5 27.7 
2021 31.5 40.7 25.2 35.7 35.3 46.4 30.5 45.8 32.8 45.9 37.2 59.8 28.4 41.5 38.4 59.3 24.4 31.9 35.8 53.7 29.5 29.6 23.3 27.6 
2022 32.2 41.3 26.1 37.0 36.2 47.2 31.5 47.1 33.9 47.1 38.3 60.9 28.8 41.9 38.4 59.3 24.1 31.9 36.2 54.7 28.7 29.0 23.2 27.7 
Table  7.12. (Scenario 4) Sensitivity analysis: lower (L) and higher (H) uncertainty values of the predicted diabetes prevalence (%) per age group (years) in men and women aged 25-
75+ years, without capping of projected obesity prevalence, Saudi Arabia (2014-2022) 
Year 
25-34 35-44 45-54 55-64 65-74 75+ 
Men Women Men Women Men Women Men Women Men Women Men Women 
L H L H L H L H L H L H L H L H L H L H L H L H 
2014 27.5 37.3 20.8 29.7 28.2 39.6 24.1 36.7 25.9 37.4 30.1 49.4 26.2 38.4 39.5 64.8 27.7 33.8 32.6 47.1 31.9 31.7 23.3 26.3 
2015 28.5 38.3 21.5 30.6 29.3 41.1 25.2 38.7 26.7 38.8 32.1 54.2 26.6 39.3 40.9 66.8 27.8 34.0 33.2 48.2 31.8 31.6 23.5 26.6 
2016 29.0 38.6 22.0 31.3 30.7 42.9 26.7 41.2 28.0 40.9 34.4 59.6 26.8 39.8 41.0 66.8 26.6 32.7 33.4 48.7 31.4 31.1 23.3 26.5 
2017 29.5 39.0 22.5 32.0 32.1 44.7 28.2 43.8 29.2 42.8 37.0 65.1 27.2 40.4 41.5 68.0 25.8 32.1 33.8 49.6 31.1 30.8 23.2 26.7 
2018 30.0 39.4 23.1 32.8 33.5 46.5 29.8 46.5 30.4 44.7 39.6 70.5 27.6 41.2 42.3 69.7 25.3 31.9 34.3 50.7 30.8 30.6 23.2 26.9 
2019 30.4 39.7 23.7 33.6 34.8 48.2 31.4 49.2 31.6 46.4 42.4 75.7 28.1 42.1 43.3 71.7 25.1 32.0 34.9 51.9 30.6 30.5 23.3 27.3 
2020 30.9 40.1 24.3 34.4 36.1 49.9 33.1 52.1 32.8 48.1 45.2 80.7 28.7 43.0 44.4 73.9 25.0 32.3 35.6 53.1 30.5 30.5 23.5 27.7 
2021 31.5 40.7 25.2 35.7 37.3 51.4 34.8 54.9 34.3 50.1 47.8 84.8 29.2 43.7 44.9 75.0 24.4 31.9 35.8 53.7 29.5 29.6 23.3 27.6 
2022 32.2 41.3 26.1 37.0 38.5 52.9 36.5 57.9 35.7 52.0 50.4 88.9 29.7 44.5 45.8 76.8 24.1 31.9 36.2 54.7 28.7 29.0 23.2 27.7 
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Figure  7.11. (Scenario 3) Trends in the predicted prevalence of diabetes per age group 
(years) in men and women aged 25-75+ years, with capping of projected obesity 
prevalence, Saudi Arabia (2014-2022) [Diagnostic criteria: WHO 1985] 
 
 
Figure  7.12. (Scenario 4) Trends in the predicted prevalence of diabetes per age group 
(years) in men and women aged 25-75+ years, without capping of projected obesity 
prevalence, Saudi Arabia (2014-2022) [Diagnostic criteria: WHO 1985] 
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7.1.3. Quantified effects of the assumed capping of obesity on the modelling 
results for 2022 
Unlike the modelling results for 2013 which have been discussed in chapter 6, 
the results for 2022 were found to be affected significantly by shifting between 
different scenarios. As summarised in Table  7.13, the estimated overall 
diabetes prevalence for the population aged 25-64 years was 39.5% under 
scenario 1 (with capped obesity trends), but 44.1% under scenario 2 (with 
increasing uncapped obesity). Also, the results due to shifting from scenario 1 
to scenario 2 showed a relative increase by 5.3% in men and 19.8% in women. 
The estimated diabetes prevalence for men and women in the age group 25-34 
years was not affected by capping, as the results were similar by shifting from 
scenario 1 to scenario 2. In the other age groups of men, the quantified relative 
changes as a result of such a shifting were 9.0% in the age group 35-44 years, 
7.8% in the age group 45-54 years and 4.5% in the age group 55-64 years. 
Importantly, these quantified relative changes were much more prominent in 
women. Shifting from scenario 1 to scenario 2 resulted in relative increases in 
the estimated diabetes prevalence by 19.8% in women aged 35-44 years, 
39.7% in those aged 45-54 years and 25.3% in the age group 55-64 years. 
Adding the two oldest age groups to the model resulted in an estimated 
population diabetes prevalence of 38.9% in 2022 by scenario 3 (with capped 
obesity), which increased to 43.2% by scenario 4 (without capping of obesity). 
In addition, shifting from scenario 3 to scenario 4 resulted in relative increases 
of diabetes prevalence by 5.0% in men and 18.1% in women. 
However, capping had no effect on the estimated results for men and women in 
the two oldest age groups (65-74 and 75+ years). By shifting from scenario 3 to 
scenario 4, the estimated diabetes prevalence remained at 28.1% for men aged 
65-74 years, 29.4% for men aged 75+ years, 45.2% for women aged 65-74 
years and 25.3% in women aged 75+ years.    
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Table  7.13. Summary of the main modelling results (2022) for each scenario and the quantified changes as a result of shifting between different scenarios 
 
Scenario 1 Scenario 2 
Quantified relative 
change (%) as a result of 
shifting from scenario 1 
to scenario 2 
Scenario 3 Scenario 4 
Quantified relative change (%) 
as a result of shifting from 
scenario 3 to scenario 4 
Overall population diabetes 
prevalence (%) in 2022  39.5 44.1 + 11.6 38.9 43.2 + 11.1 
       
Overall diabetes prevalence (%) in 
men in 2022 39.2 41.3 + 5.3 37.8 39.7 + 5.0 
       
Overall diabetes prevalence (%) in 
women in 2022 39.8 47.7 + 19.8 39.7 46.9 + 18.1 
       
Estimated prevalence of diabetes 
(%) per sex and age group in 2022:       
       
Men 25-34 years 37.2 37.2 No change 37.2 37.2 No change 
Men 35-44 years 42.2 46.0 + 9.0 42.2 46.0 + 9.0 
Men 45-54 years 40.8 44.0 + 7.8 40.8 44.0 + 7.8 
Men 55-64 years 35.5 37.1 + 4.5 35.5 37.1 + 4.5 
Men 65-74 years - - - 28.1 28.1 No change 
Men 75+ years - - - 29.4 29.4 No change 
       
Women 25-34 years 31.6 31.6 No change 31.6 31.6 No change 
Women 35-44 years 39.4 47.2 + 19.8 39.4 47.2 + 19.8 
Women 45-54 years 49.6 69.3 + 39.7 49.6 69.3 + 39.7 
Women 55-64 years 48.7 61.0 + 25.3 48.7 61.0 + 25.3 
Women 65-74 years - - - 45.2 45.2 No change 
Women 75+ years - - - 25.3 25.3 No change 
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7.2. Overview of the main results for the whole modelling period 
(1992-2022) 
7.2.1. Comparison of the main results based on scenario 1 and scenario 2 
During the 30-year-period of 1992-2022, the estimated diabetes prevalence in 
the Saudi men and women aged 25-64 years will increase substantially from 
8.5% (UI: 6.8–10.2%) to 39.5% (UI: 32.5–45.9%), assuming capped linear 
trends in obesity prevalence, and to 44.1% (UI: 35.4–52.5%), assuming 
continuing uncapped linear obesity trends (Figure  7.13 and Figure  7.14). In 
men, the diabetes prevalence is estimated to increase from 8.7% (UI: 6.9–
10.4%) to 39.2% (UI: 33.2–44.4%) with capped obesity trends, and to 41.3% 
(UI: 34.4–47.6%) with continuing linearity in obesity trends. On the other hand, 
in women, diabetes prevalence is estimated to increase from 8.2% (UI: 6.6–
9.9%) to 39.8% (UI: 31.7–47.7%) with capping of obesity trends, and to 47.7% 
(UI: 36.6–58.8%) without such a capping (Figure  7.15 and Figure  7.16). 
Among the population age groups, the assumed capping of the obesity levels 
had no effect on diabetes prevalence trends in men and women aged 25-34 
years, where the estimated relative increases were 905% in men and 953% in 
women under both scenarios 1 and 2. In comparison, there was a significant 
effect of capping on the results of the other age groups, particularly among 
women. For instance, in women aged 45-54 years, diabetes prevalence is 
estimated to increase by 124% if the obesity trends were capped, and by 214% 
if such trends were not capped. Similarly, the estimated diabetes prevalence in 
women aged 55-64 years will increase by 110% with capping, and by 163% 
with continuing uncapped obesity levels (Figure  7.17, Figure  7.18, and Table 
 7.14).  
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 Figure  7.13. (Scenario 1) Trends in the estimated diabetes total prevalence (and uncertainty values) for 
population aged 25-64 years, with capping of projected obesity prevalence, Saudi Arabia (1992-2022) 
[Solid line: point (best) estimates; Dotted lines: minimum and maximum uncertainty estimates. Diagnostic 
criteria: WHO 1985] 
 
 
Figure  7.14. (Scenario 2) Trends in the estimated diabetes total prevalence (and uncertainty values) for 
population aged 25-64 years, without capping of projected obesity prevalence, Saudi Arabia (1992-2022) 
[Solid line: point (best) estimates; Dotted lines: minimum and maximum uncertainty estimates. Diagnostic 
criteria: WHO 1985] 
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 Figure  7.15. (Scenario 1) Trends in the estimated diabetes prevalence (and uncertainty values) for men 
and women aged 25-64 years, with capping of projected obesity prevalence, Saudi Arabia (1992-2022) 
[Diagnostic criteria: WHO 1985] 
 
Figure  7.16. (Scenario 2) Trends in the estimated diabetes prevalence (and uncertainty values) for men 
and women aged 25-64 years, without capping of projected obesity prevalence, Saudi Arabia (1992-2022) 
[Diagnostic criteria: WHO 1985]  
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Figure  7.17. (Scenario 1) Trends in the estimated prevalence of diabetes per age 
group (years) in men and women aged 25-64 years, with capping of projected obesity 
prevalence, Saudi Arabia (1992-2022) [Diagnostic criteria: WHO 1985] 
 
 
Figure  7.18. (Scenario 2) Trends in the estimated prevalence of diabetes per age 
group (years) in men and women aged 25-64 years, without capping of projected 
obesity prevalence, Saudi Arabia (1992-2022) [Diagnostic criteria: WHO 1985]
Table  7.14. Summary of the diabetes prevalence rates (%) per sex and age group (years) for the first and last years of modelling, based on the four scenarios  
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Scenario Year 
25-34 35-44 45-54 55-64 65-74 75+ 
Men Women Men Women Men Women Men Women Men Women Men Women 
1 
1992 3.7 3.0 7.0 5.0 21.1 22.1 24.9 23.2     
2022 37.2 31.6 42.2 39.4 40.8 49.6 35.5 48.7     
Relative difference +905% +953% +502% +688% +93% +124% +43% +110%     
2 
1992 3.7 3.0 7.0 5.0 21.1 22.1 24.9 23.2     
2022 37.2 31.6 46.0 47.2 44.0 69.3 37.1 61.0     
Relative difference +905% +953% +557% +844% +109% +214% +49% +163%     
3 
1992 3.7 3.0 7.0 5.0 21.1 22.1 24.9 23.2 28.8 24.4 28.8 24.4 
2022 37.2 31.6 42.2 39.4 40.8 49.6 35.5 48.7 28.1 45.2 29.4 25.3 
Relative difference +905% +953% +502% +688% +93% +124% +43% +110% -2% +85% +2% +4% 
4 
1992 3.7 3.0 7.0 5.0 21.1 22.1 24.9 23.2 28.8 24.4 28.8 24.4 
2022 37.2 31.6 46.0 47.2 44.0 69.3 37.1 61.0 28.1 45.2 29.4 25.3 
Relative difference +905% +953% +557% +844% +109% +214% +49% +163% -2% +85% +2% +4% 
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7.2.2. Comparison of the main results based on scenario 3 and scenario 4 
When the two oldest age groups of the population (65-74 and 75+ years) were 
included in the modelling, the overall population prevalence of diabetes by 2022 
is estimated to reach 38.9% (UI: 32.2–45.2%), assuming capped obesity trends, 
and 43.2% (UI: 34.8–51.3%) if such trends continue to increase without capping 
(Figure  7.19 and Figure  7.20).  
In men, the estimated diabetes prevalence in 2022 is 37.8% (UI: 32.0–42.8%) 
with the assumption of capped obesity, and 39.7% (UI: 33.1–45.7%) with the 
other assumption of continuing uncapped linearity in obesity. In comparison, 
women in 2022 will have an estimated diabetes prevalence of 39.7% (UI: 31.7–
47.5%) with capping and 46.9% (UI: 36.2–57.7%) without such a capping of 
obesity levels (Figure  7.21 and Figure  7.22).  
As shown in Figure  7.23, Figure  7.24, and Table  7.14, men and women aged 
75+ years would show almost stable pattern of the trends in diabetes 
prevalence during the modelling period. Also, similar stability is predicted in 
men aged 65-74 years with a relative difference of -2% in the estimated 
diabetes prevalence in 1992 and 2022. However, women aged 65-74 years 
would have a large estimated relative increase in diabetes prevalence (85%) 
during this period. The results in the two oldest age groups were similar using 
both scenario 3 (with assumed capped obesity) and scenario 4 (with ongoing 
increasing obesity). 
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 Figure  7.19. (Scenario 3) Trends in the estimated diabetes total prevalence (and uncertainty values) for 
population aged 25-75+ years, with capping of projected obesity prevalence, Saudi Arabia (1992-2022) 
[Solid line: point (best) estimates; Dotted lines: minimum and maximum uncertainty estimates. Diagnostic 
criteria: WHO 1985] 
 
 
Figure  7.20. (Scenario 4) Trends in the estimated diabetes total prevalence (and uncertainty values) for 
population aged 25-75+ years, without capping of projected obesity prevalence, Saudi Arabia (1992-2022) 
[Solid line: point (best) estimates; Dotted lines: minimum and maximum uncertainty estimates. Diagnostic 
criteria: WHO 1985] 
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 Figure  7.21. (Scenario 3) Trends in the estimated diabetes prevalence (and uncertainty values) for men 
and women aged 25-75+ years, with capping of projected obesity prevalence, Saudi Arabia (1992-2022) 
[Diagnostic criteria: WHO 1985] 
 
Figure  7.22. (Scenario 4) Trends in the estimated diabetes prevalence (and uncertainty values) for men 
and women aged 25-75+ years, without capping of projected obesity prevalence, Saudi Arabia (1992-
2022) 
[Diagnostic criteria: WHO 1985]  
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Figure  7.23. (Scenario 3) Trends in the estimated prevalence of diabetes per age 
group (years) in men and women aged 25-75+ years, with capping of projected obesity 
prevalence, Saudi Arabia (1992-2022) [Diagnostic criteria: WHO 1985] 
 
 
Figure  7.24. (Scenario 4) Trends in the estimated prevalence of diabetes per age 
group (years) in men and women aged 25-75+ years, without capping of projected 
obesity prevalence, Saudi Arabia (1992-2022) [Diagnostic criteria: WHO 1985]  
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7.3. Impact of adjusting the modelling results of diabetes prevalence to 
the more recent diagnostic criteria 
7.3.1. Background 
The results of predicted diabetes prevalence in Saudi Arabia as estimated by 
the model were based on the local observed prevalence data in 1992 from the 
study of Warsy and El-Hazmi.36 As indicated in chapter 3, that study used the 
WHO 1985 diagnostic criteria (fasting glucose ≥7.8 mmol/l and/or OGTT 
glucose ≥11.1 mmol/l) to define diabetes. However, the WHO STEPS survey19 
(2005) and the GBD model20 (2011), which were used for validation (as 
discussed in chapter 6) used the more recent ADA criteria (only fasting glucose 
≥7.0 mmol/l) to define diabetes. Therefore, the reported results of diabetes 
prevalence by Warsy and El-Hazmi36 for 1992 were adjusted to the ADA criteria 
in order to investigate the impact of such an adjustment on the model’s 
predictions of diabetes prevalence in Saudi Arabia. 
When the new diagnostic fasting threshold was first recommended by the ADA 
in 1997 to be used alone in epidemiological studies, the ADA reported that 
changing from the WHO threshold (with OGTT) to the new one would lead to a 
minimal reduction in the overall population prevalence of diabetes.3 The ADA 
reported supporting data from the US, where diabetes prevalence fell from 
14.3% to 12.3% with shifting from the threshold of WHO to that of ADA.3 This 
fall in prevalence was equivalent to an absolute reduction of 2 percentage 
points and a relative reduction of around 14.0%. 
Moreover, Shaw et al.266 further investigated the impact of such a change in 
diagnostic thresholds on the prevalence of diabetes in some other populations. 
They used previously collected data from nine southern hemisphere population-
based studies, in which the OGTT was used for diagnosis of diabetes. The 
settings of these studies include Nauru, Western Samoa, Rodrigues, New 
Caledonia and Wallis Islands, Cook Islands, Fiji, Kiribati, Mauritius, and Papua 
New Guinea. These studies covered different ethnic groups such as 
Micronesian, Polynesian, Melanesian, Asian Indian, Chinese, African, 
European, and Malagasy ancestry. Diabetes in these surveys was diagnosed 
as ‘known’ diabetes mellitus (KDM) if subjects were on oral hypoglycaemic 
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drugs or insulin. These subjects had only a fasting plasma glucose measured, 
whereas all other subjects had an OGTT. To compare prevalence estimates 
according to the ADA (1997) and WHO (1985) diagnostic criteria, diabetes was 
determined in all non-KDM subjects according to the ADA criteria irrespective of 
OGTT, and according to WHO criteria, irrespective of fasting plasma glucose.266 
The authors found that changing the diagnostic criteria had variable effects on 
diabetes prevalence in these different populations. The relative difference in 
prevalence ranged from +30% to -19%, and the absolute difference ranged 
from +4.1 percentage points to -2.8 percentage points. Some countries (Fiji and 
Cook Islands) were found to have a 0% difference in diabetes prevalence with 
changing the diagnostic criteria. Shaw et al. reported that the logistic regression 
analysis showed that the interaction term between survey site and diabetes 
criteria (ADA or WHO) was a highly significant predictor of diabetes status (p< 
0.0001), which could confirm that the variability in performance of the two sets 
of criteria between populations was not due to chance.266 
Nevertheless, Shaw et al. did not include countries from the EMR, in which 
Saudi Arabia is located. The reported results for the countries included in the 
study might not be applicable to populations in this region. In the literature, 
there is a study from Oman (a neighbouring country to Saudi Arabia) which 
assessed the impact of applying the ADA diagnostic criteria on the reported 
diabetes prevalence based on the WHO criteria (fasting glucose and OGTT) 
from the National Diabetes Survey (1991).267 The authors used the database 
generated by that survey, which involved 4,682 subjects with no missing data 
on fasting and 2-hour (OGTT) glucose. To compare the two diagnostic criteria, 
all individuals were classified on the basis of the ADA’s versus WHO’s threshold 
values of venous fasting plasma glucose and OGTT. It was found that applying 
the ADA criteria on the Omani population resulted in an overall reduction of 
diabetes prevalence from 10.5% to 8.3%. This is equivalent to a relative 
reduction of approximately 21%, and an absolute reduction of 2.2 percentage 
points. 
There are no obvious reasons for the large variations in the effects of changing 
the diagnostic criteria (from the WHO to ADA) between countries. Shaw et al.266 
concluded that such variations are unpredictable and seemed to be related to 
various factors. To investigate the influence of some potential contributing 
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factors, they categorised the diabetic individuals from the nine countries in their 
study based on sex, age and BMI. It has been found that obesity (BMI ≥30 
kg/m2) was the most important factor in determining on which criterion diabetes 
was diagnosed. Obese diabetic subjects were much less likely than lean 
diabetic subjects to have low fasting and high OGTT levels, but more likely to 
have both elevated fasting and OGTT (p< 0.00001). Thus, diabetic subjects 
defined by the ADA criteria were found to be more obese than those identified 
by the WHO criteria.266 Among all the studies from the nine countries, the two 
studies from Nauru and Western Samoa (which had the highest mean 
population BMI) had the highest proportion of diabetic subjects with FPG ≥7.0 
mmol/l. However, this finding was not consistent among all the populations 
included, which might suggest that there are other important factors. However, 
the influence of other factors, such as age, was not clear-cut.266   
7.3.2. Results of adjustment 
In this thesis, the results of diabetes prevalence in Saudi Arabia for the starting 
year of modelling (1992), as obtained from the study of Warsy and El-Hazmi,36 
were adjusted to the ADA diagnostic threshold. Three values were used for this 
adjustment. First, the diabetes prevalence in Saudi Arabia for 1992 was 
assumed to vary by the first extreme value found by Shaw et al.266 (relative 
difference of +30%) when the diagnostic criteria are changed from WHO 
threshold to that of ADA. Second, it was assumed that the diabetes prevalence 
for the starting year of modelling would vary by the second extreme value of 
Shaw et al. (relative difference of -19%) with a similar change in diagnostic 
criteria. Third, diabetes prevalence in 1992 was assumed to show a relative 
reduction of -21% (as that found in Oman267) with changing the diagnostic 
thresholds. Table  7.15 summarises the model results of the predicted diabetes 
prevalence before and after adjustment for the starting year (1992), in addition 
to years 2000, 2005 and 2008 (years used for validation against the WHO 
STEPS survey19 and the GBD model20 as discussed in chapter 6). 
In general, the variations in the estimated diabetes prevalence in Saudi Arabia 
were small, assuming that the ‘observed’ diabetes prevalence in 1992 would 
change by any of the three adjustment values mentioned above. For instance, 
with scenario 1, using the adjustment value of Shaw et al.266 (relative difference 
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of +30%), the ‘adjusted’ prevalence of diabetes was estimated to increase by 
2.5 percentage points in 1992, 1.2 percentage points in 2000, 0.7 percentage 
points in 2005, and 0.5 percentage points in 2008. Similarly, using the 
adjustment value of Al-Lawati et al.267 (relative difference of -21%), the 
‘adjusted’ prevalence showed an estimated reduction by 1.8 percentage points 
in 1992, 0.8 percentage points in 2000, 0.5 percentage points in 2005, and 0.3 
percentage points in 2008. 
Overall, this chapter reports the model predictions of T2DM prevalence in Saudi 
Arabia during 2014-2022, and discusses the potential impact of adjusting the 
older diabetes diagnostic criteria (used for measuring T2DM prevalence in 
1992) to the more recent criteria on the modelling outputs. The next chapter 
presents the methods and results of the ‘what if’ policy analyses, using local 
and international policy reduction targets of adult obesity and smoking.      
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Table  7.15. Summary of the model results for selected years after applying assumed adjustments of the starting year diabetes prevalence  
Modelling scenario Year Baseline predicted diabetes prevalence (%) 
Predicted diabetes prevalence (%) after adjustment of the starting year results 
(using assumed values of relative difference) 
+30% (Shaw et al.) [266] -19% (Shaw et al.) [266] -21% (Al-Lawati et al.) [267] 
Scenario 1 
1992 8.5 11.0 6.9 6.7 
2000* 17.2 18.4 16.4 16.4 
2005* 22.8 23.5 22.3 22.3 
2008* 25.9 26.4 25.6 25.5 
Scenario 2 
1992 8.5 11.0 6.9 6.7 
2000* 17.2 18.4 16.4 16.4 
2005* 22.8 23.5 22.3 22.3 
2008* 25.9 26.4 25.6 25.6 
Scenario 3 
1992 9.6 12.5 7.8 7.6 
2000* 17.8 19.1 17.0 16.9 
2005* 23.3 24.0 22.8 22.7 
2008* 26.3 26.8 25.9 25.9 
Scenario 4 
1992 9.6 12.5 7.8 7.6 
2000* 17.8 19.1 17.0 16.9 
2005* 23.3 24.0 22.8 22.7 
2008* 26.3 26.8 26.0 25.9 
* years used for validation of the model [as discussed in chapter 6]
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Chapter 8. Using the Saudi IMPACT Diabetes Forecast Model for 
“What if” analyses: quantifying the impact of the targeted 
reduction of obesity and smoking prevalence in Saudi Arabia 
In chapters 6 and 7, results for past, current and predicted future prevalence 
rates of diabetes in Saudi Arabia have been presented. In this chapter, local 
and international population targets to reduce the prevalence of adult obesity 
and smoking are discussed. Also, this chapter presents the impact of applying 
such targets on the prevalence of T2DM in Saudi Arabia, as predicted by the 
Saudi IMPACT Diabetes Forecast Model.  
8.1. Background 
The available evidence (discussed in chapter 2) showed that the diabetes 
incidence among adults can be reduced through some lifestyle interventions, 
including weight reduction82 and/ or smoking cessation.140 However, at the 
overall population (e.g. national) level, no evidence is available to investigate 
the impact of reducing the prevalence of adult obesity and smoking on the 
population diabetes burden. 
The structure of the Saudi IMPACT Diabetes Forecast Model (discussed in 
detail in chapter 5) cannot adapt to directly simulate the lifestyle interventions 
reported in literature. Alternatively, the model structure can adapt to simulate 
specific ‘reduction targets’ for the prevalence of adult obesity and smoking in 
Saudi Arabia over a specific period, and then estimate the impact of applying 
such targets on the overall diabetes prevalence. Setting up such policy targets 
to reduce adult obesity and smoking prevalence has been supported and used 
by some international authorities, as discussed in detail in the next section. 
8.2. Local and international policy targets for adult obesity and 
smoking prevalence 
In 2007, the Ministries of Health in the GCC countries have set an action plan 
(for the period 2008-2018) for prevention and control of diabetes198, as a 
response from these countries to the massive and growing burden of the 
disease on their populations and health care systems. The first objective in this 
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action plan was to apply “primary prevention” measures to reduce the 
prevalence of T2DM. To achieve this objective, policy targets were set to 
reduce obesity prevalence by 10% and current smoking prevalence by 5% in 
each individual member country during 2008-2018.198 However, currently, there 
are no available data on monitoring the progress toward achieving such 
reduction targets.  
Internationally, there are some few examples of setting national targets for adult 
obesity and smoking. A first example is from England, where the Department of 
Health (in 1992) set specific targets to reduce obesity prevalence rates in 
England for men from 7% in 1986-1987 to 6% by 2005 and for women for the 
same period from 12% to 8%.268 However, those specific targets were not 
attained, and the obesity prevalence in England increased substantially in men 
and women over time, and reached more than 20% for each sex in 2005.255 
A second example is the objectives set by “Healthy People 2020” in the United 
States. Healthy People (HP) is a national health strategy, where the national 
public health objectives in the United States are set 10 years into the future and 
published as health objectives for the nation. These objectives define specific 
numerical targets for reductions in most major health problems as well as for 
increases in the prevalence of health-promoting behaviours.269 So far, three 
HPs have been published: HP 2000, HP 2010 and HP 2020. In HP 2020, one of 
the objectives was “to reduce the proportion of adults (aged ≥20 years) who are 
obese”. The target obesity prevalence was set at 30.6%, which is equivalent to 
a 10% reduction of the prevalence in 2005-2008 (34.0%).270 However, it is 
important to note that the target in HP 2020 is relatively conservative, since the 
previous targets set for HP 2000 and HP 2010 were not attainable. For 
instance, the objective in HP 2000 was to reduce the overweight prevalence in 
adults (20-74 years) from 26% in 1987 to 20% by 2000.271 The observed 
prevalence in 2000 moved around 150% away from the target, and the adult 
overweight prevalence exceeded 30% by 2000.272 Similarly, the target in HP 
2010 was to reduce the proportion of adults (aged ≥20 years) who are obese 
from 23% in 1988-1994 to 15% by 2010.273 The reported prevalence of adult 
obesity in the US adults in 2010 was 35.7%, which was more than double the 
target.274 
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A third example is the targets recommended by a “WHO Technical Working 
Group on Non-communicable Disease Targets” in July 2011.275 This working 
group, composed of international experts in NCD surveillance and WHO staff 
members, recommended, through several technical meetings, a number of 
proposed targets to monitor progress in reducing the burden of NCDs. These 
targets have been set to achieve major reductions in NCDs and their risk factors 
by 2025, and the baseline for all targets is 2010. According to the WHO, targets 
were established following scientific review of the current situation and trends, 
combined with a critical assessment of feasibility based upon demonstrated 
country achievement. For obesity, the target was “to halt the rise in obesity 
prevalence among persons aged 25+ years”.275 Interim targets for 2015 and 
2020 will be set at a later date to assess progress and achievement towards the 
target. However, there are no available data so far on such progress 
assessment. 
Moreover, there are four examples of recent national policy targets for adult 
smoking. First, HP 2020 set a target to reduce the prevalence of cigarette 
smoking in adults aged ≥18 years from 20.6% in 2008 to 12.0% in 2020, which 
is equivalent to a 41.7% relative reduction.276 Second, the WHO technical 
working group (2011) set a target of a 40% relative reduction in the prevalence 
of current daily tobacco smoking among persons aged ≥15 years by 2025, 
using 2010 as a baseline.275 Third, the “Healthy Lives, Healthy People”, which is 
a strategy setting out the Government's long-term vision for the future of public 
health in England, set a target to reduce adult (aged ≥18 years) smoking 
prevalence in England from 21.2% in 2009-2010 to 18.5% in 2015,277 and this is 
equivalent to approximately 12.7% relative reduction. Fourth, the Australian 
Government set a target to reduce the rate of daily smoking in those aged ≥14 
years from 16.6% in 2010 to 10% in 2018,278 which is equal to around 40% 
relative reduction. 
238 
 
8.3. Impact of reducing the prevalence of obesity and smoking on the 
burden of type 2 diabetes in Saudi Arabia 
8.3.1. Methods 
The targets used in this thesis for the ‘What if’ policy assumptions are those of 
the GCC Action Plan, in addition to the international targets (HP 2020 and 
WHO), which have been mentioned in the previous section. However, the final 
year of modelling in the Saudi IMPACT Diabetes Forecast Model is 2022, 
whereas the target years for the GCC Action Plan, HP 2020 and WHO are 
2018, 2020 and 2025 respectively. Therefore, these international targets were 
incorporated into the model assuming that they will be achieved by 2022. The 
baseline year was set at 2008 for targets of the GCC Action Plan, and at 2010 
for the targets of HP 2020 and WHO. 
The ‘What if’ policy assumptions quantified the impact of reducing the 
prevalence of adult obesity alone (as the major and powerful risk factor in this 
thesis) on the burden of T2DM in Saudi Arabia. In addition, the impact of 
reducing the prevalence of both risk factors in this thesis (obesity and smoking) 
was also investigated. Hence, in total, six ‘What if’ policy assumptions/ 
questions were studied in this thesis, as summarised in Table  8.1. 
All six assumptions were applied to each of the four modelling scenarios 
discussed in chapters 6 and 7. For the targets of HP 2020 and WHO, for 
example, the trends in the prevalence of obesity (presented in chapter 5) were 
kept unchanged, as estimated by each scenario, till 2010 (baseline). Then, from 
2011 onwards, the ‘what if’ targets were incorporated into the model. For 
example, to apply the target of HP 2020 for obesity, the obesity prevalence 
rates were assumed to start an annual relative reduction by approximately 
0.83% from 2011 onwards. So, after 12 years from the baseline, the obesity 
prevalence was assumed to decrease by 10% (0.83 X 12) from that in 2010. 
Similarly, to apply the target of HP 2020 for smoking, an annual relative 
reduction of the estimated smoking prevalence by around 3.33% was assumed 
to start from 2011 onwards, so that by 2022, a 40% relative reduction of 
smoking prevalence (3.33 X 12) was assumed to be achieved. Furthermore, the 
WHO target for obesity (halt the rise in obesity prevalence with 2010 as a 
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baseline) was applied to the model by assuming that the estimated obesity 
prevalence for 2011-2022 would be the same as that in 2010. 
Table  8.1. The ‘What if’ policy questions investigated in this chapter 
 ‘What if’ policy question  Reference 
1 What will be the impact of a 10% relative reduction in obesity 
prevalence by 2022 (baseline 2008) on diabetes burden in Saudi 
Arabia? 
 GCC Action Plan 
[198] 
    
2 What will be the impact of a 10% relative reduction in obesity 
prevalence and a 5% reduction in smoking prevalence by 2022 
(baseline 2008) on diabetes burden in Saudi Arabia? 
 GCC Action Plan 
[198] 
    
3 What will be the impact of a 10% relative reduction in obesity 
prevalence by 2022 (baseline 2010) on diabetes burden in Saudi 
Arabia? 
 HP 2020 [270] 
    
4 What will be the impact of a 10% relative reduction in obesity 
prevalence and a 40% reduction in smoking prevalence by 2022 
(baseline 2010) on diabetes burden in Saudi Arabia? 
 HP 2020 [270] 
    
5 What will be the impact of halting the rise in obesity prevalence 
by 2022 (baseline 2010) on diabetes burden in Saudi Arabia? 
 WHO [275] 
    
6 What will be the impact of halting the rise in obesity prevalence 
and a 40% reduction in smoking prevalence by 2022 (baseline 
2010) on diabetes burden in Saudi Arabia? 
 WHO [275] 
After incorporating each target into each of the four modelling scenarios, the 
model was run to obtain the results of ‘what if’ trends in the predicted diabetes 
prevalence and the number of diabetic individuals. 
8.3.2. Results 
8.3.2.1. Results for the total population 
Table  8.2 summarises the results of impact of applying the different ‘what if’ 
assumptions on the diabetes burden in the total Saudi population, as estimated 
by the Saudi IMPACT Diabetes Forecast Model. A. Modelling scenario 1 – population aged 25-64 years with capped obesity trends 
The model estimated that the diabetes prevalence in Saudi Arabia in 2022 can 
show a 6.0% relative reduction (equivalent to a reduction of 383,399 individuals) 
if the obesity target of the GCC Action Plan (10% relative reduction in obesity 
prevalence from that in 2008) would be achieved. The reduction in diabetes 
prevalence by 2022 is estimated to show a minimal improvement if the GCC 
Action Plan’s smoking target (5% relative reduction in smoking prevalence from 
that in 2008) is added to the obesity target. 
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Diabetes prevalence could be reduced by 4.8% (312,765 individuals), assuming 
that the target of HP 2020 (10% relative reduction in obesity prevalence from 
that in 2010) could be applied in Saudi Arabia. The reduction in diabetes 
prevalence by 2022 is estimated to show a minimal improvement if the HP 2020 
smoking target (40% relative reduction in smoking prevalence from that in 2010) 
is added to the obesity target. Such a relative reduction is estimated to be 5% 
(331,627 individuals). 
With applying the WHO target for adult obesity (halt the rise in obesity 
prevalence from 2011 onwards), the relative reduction in diabetes prevalence in 
2022 is estimated at 1.6% (107,394 individuals). If the WHO smoking target 
(40% relative reduction in smoking prevalence from that in 2010) is added, the 
diabetes prevalence in 2022 is estimated to be reduced by 1.9% (125,507 
individuals). B. Modelling scenario 2 – population aged 25-64 years without capping of obesity trends  
With scenario 2, the ‘what if’ values for reduction in diabetes prevalence and the 
number of diabetic individuals would be higher than that estimated with scenario 
1. The estimated relative reductions of diabetes prevalence in 2022 are 14.9% 
(1,098,449 individuals) using the obesity target of the GCC Action Plan, and 
15.1% (1,107,027 individuals) using both obesity and smoking targets of the 
GCC Action Plan. 
Relative reductions of diabetes prevalence are estimated at 12.7% (935,741 
individuals) using the HP 2020 target for obesity, and 13.0% (954,239 
individuals) using the HP 2020 target for obesity and smoking combined. 
If the WHO target for obesity is applied, a 9.8% reduction in diabetes 
prevalence in 2022 (718,855 individuals) is estimated to be achieved. This 
estimated reduction would show a minimal improvement to reach 10.0% 
(736,586 individuals) if the WHO targets for both obesity and smoking are 
applied. 
On the other hand, if the assumed ‘conservative’ target for obesity is used, a 
reduction of 11.3% in diabetes prevalence (829,431 individuals) in 2022 is 
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estimated. If both ‘conservative’ targets for obesity and smoking are used, the 
reduction is predicted to be 11.6% (841,354 individuals). C. Modelling scenario 3 – population aged 25-75+ years with capped obesity trends  
If the obesity target of the GCC Action Plan is used, a 6.3% reduction in 
diabetes prevalence (448,760 individuals) could be achieved by 2022. However, 
if the smoking target is added, the reduction could increase to 6.5% (457,567 
individuals). 
Using the HP 2020 target for obesity could result in a 5.2% reduction of 
diabetes prevalence (369,701 individuals) in 2022. In comparison, using the HP 
2020 targets for both obesity and smoking would show an estimated reduction 
of 5.5% in diabetes prevalence (389,183 individuals) in 2022. 
Applying the WHO target of obesity could produce an estimated reduction in 
diabetes prevalence of 2.1% (149,929 individuals) by 2022. Using a 
combination of the WHO targets for obesity and smoking could result in a 2.4% 
reduction in prevalence (168,646 individuals). D. Modelling scenario 4 – population aged 25-75+ years without capping of obesity trends 
The model estimated that a 14.8% reduction in diabetes prevalence (1,163,810 
individuals) could be achieved by 2022 if the obesity target of the GCC Action 
Plan is used. Adding the smoking target could result in a 14.9% reduction of 
diabetes prevalence (1,172,546 individuals) in 2022. 
The estimated reductions in diabetes prevalence by 2022 could reach 12.7% 
(992,677 individuals) if the HP 2020 target for obesity is used. If the HP 2020 
target for smoking is added, a 12.9% reduction of diabetes prevalence 
(1,011,795 individuals) in 2022 could be attained. 
Using the WHO target for obesity could produce a reduction of 9.7% in diabetes 
prevalence (761,389 individuals) in 2022. This estimated reduction could 
increase to 9.9% (779,725 individuals) if the WHO targets for both obesity and 
smoking are used. 
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Figures  8.1-  8.4 present graphical illustrations of the ‘what if’ policy assumptions 
applied to the total Saudi population in each of the four modelling scenarios. 
However, since the addition of smoking targets produced only minimal effects 
on the reduction of diabetes burden (as discussed in the previous sections), 
these figures show the results of applying the obesity targets only. 
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Table  8.2. Results of the impact of reducing obesity (or obesity and smoking) on the diabetes burden in Saudi Arabia (total population) using different targets 
 Baseline burden of T2DM (2022) Burden of T2DM (2022) with the “What if” policy assumption Reduction of burden of T2DM (2022) Target (What if 
assumption)* Prevalence 
(%) Number (T2DM cases) 
Prevalence 
(%) Number (T2DM cases) 
Prevalence 
(%) Number (T2DM cases) 
Sc
en
ar
io
 1
 
39.5 6,581,511 
37.2 6,198,112 -6.0 -383,399 10% O (Baseline 2008) 
37.1 6,189,463 -6.0 -392,049 10% O + 5% S (Baseline 2008) 
37.6 6,268,746 -4.8 -312,765 10% O (Baseline 2010) 
37.5 6,249,884 -5.0 -331,627 10% O + 40% S (Baseline 2010) 
38.8 6,474,117 -1.6 -107,394 Halt O (Baseline 2010) 
38.7 6,456,004 -1.9 -125,507 Halt O + 40% S (Baseline 2010) 
Sc
en
ar
io
 2
 
44.1 7,353,447 
37.5 6,254,998 -14.9 -1,098,449 10% O (Baseline 2008) 
37.4 6,246,420 -15.1 -1,107,027 10% O + 5% S (Baseline 2008) 
38.5 6,417,706 -12.7 -935,741 10% O (Baseline 2010) 
38.4 6,399,208 -13.0 -954,239 10% O + 40% S (Baseline 2010) 
39.8 6,634,593 -9.8 -718,855 Halt O (Baseline 2010) 
39.7 6,616,861 -10.0 -736,586 Halt O + 40% S (Baseline 2010) 
Sc
en
ar
io
 3
 
38.9 7,072,814 
36.5 6,624,054 -6.3 -448,760 10% O (Baseline 2008) 
36.4 6,615,247 -6.5 -457,567 10% O + 5% S (Baseline 2008) 
36.9 6,703,114 -5.2 -369,701 10% O (Baseline 2010) 
36.8 6,683,632 -5.5 -389,183 10% O + 40% S (Baseline 2010) 
38.1 6,922,885 -2.1 -149,929 Halt O (Baseline 2010) 
38.0 6,904,168 -2.4 -168,646 Halt O + 40% S (Baseline 2010) 
Sc
en
ar
io
 4
 
43.2 7,844,750 
36.8 6,680,941 -14.8 -1,163,810 10% O (Baseline 2008) 
36.7 6,672,205 -14.9 -1,172,546 10% O + 5% S (Baseline 2008) 
37.7 6,852,074 -12.7 -992,677 10% O (Baseline 2010) 
37.6 6,832,956 -12.9 -1,011,795 10% O + 40% S (Baseline 2010) 
39.0 7,083,361 -9.7 -761,389 Halt O (Baseline 2010) 
38.9 7,065,025 -9.9 -779,725 Halt O + 40% S (Baseline 2010) 
(*)10% O: 10% relative reduction of Obesity prevalence by 2022;  10% O + 5% S: 10% relative reduction of Obesity prevalence & 5% relative reduction of Smoking prevalence by 2022; 
10% O + 40% S: 10% relative reduction of Obesity prevalence & 40% relative reduction of Smoking prevalence by 2022;  
Halt O: halt the rise in Obesity prevalence by 2022; Halt O + 40% S: halt the rise in Obesity prevalence & 40% relative reduction of Smoking prevalence by 2022 
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 Figure  8.1. (Scenario 1) Results of the impact of reducing obesity on the diabetes burden in Saudi Arabia (total population) using different targets 
(Scenario 1: population aged 25-64 years with capped obesity trends)  
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 Figure  8.2. (Scenario 2) Results of the impact of reducing obesity on the diabetes burden in Saudi Arabia (total population) using different targets 
(Scenario 2: population aged 25-64 years without capped obesity trends)  
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 Figure  8.3. (Scenario 3) Results of the impact of reducing obesity on the diabetes burden in Saudi Arabia (total population) using different targets 
(Scenario 3: population aged 25-75+ years with capped obesity trends)  
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 Figure  8.4. (Scenario 4) Results of the impact of reducing obesity on the diabetes burden in Saudi Arabia (total population) using different targets 
(Scenario 4: population aged 25-75+ years without capped obesity trends)  
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8.3.2.2. Results for men and women 
In this section, the results of applying the ‘what if’ targets are compared in men 
and women of the Saudi population, as estimated by each of the four modelling 
scenarios. Table  8.3 provides a summary of the results for the ‘what if’ policy 
assumptions/ targets in men, while Table  8.4 summarises the results in women. A. Modelling scenario 1 – population aged 25-64 years with capped obesity trends 
By scenario 1, the GCC Action Plan’s target for obesity could result in an 
estimated reduction in diabetes prevalence in 2022 by 4.1% (148,532 
individuals) and 8.1% (234,868 individuals) in men and women respectively. 
Applying both targets for obesity and smoking could produce a small 
improvement in such a reduction among men [4.3% (157,141 individuals)], with 
almost no effect on the results for women. 
The estimated diabetes prevalence in 2022 could be reduced by 3.3% (120,925 
individuals) and 6.8% (191,840 individuals) in men and women respectively, if 
the HP 2020 target for obesity is used. If both HP 2020 targets for obesity and 
smoking are used, such reductions are estimated to slightly improve in men to 
reach 3.8% (139,567 individuals), with almost no change in the results for 
women. 
If the WHO target for obesity is used, the estimated reduction in diabetes 
prevalence would be 1.0% (42,487 individuals) in men and 2.3% (64,908 
individuals) in women. With using the WHO targets for both obesity and 
smoking, this reduction is again estimated to show a minimal improvement in 
men only [1.5% (60,401 individuals)]. B. Modelling scenario 2 – population aged 25-64 years without capping of obesity trends 
If the GCC Action Plan’s target for obesity is used, the estimated reductions in 
diabetes prevalence in 2022 would be 8.4% (323,458 individuals) in men and 
22.2 % (774,991 individuals) in women. Moreover, if both targets for obesity and 
smoking are applied, the reduction in men is estimated to minimally improve to 
8.6% (331,998 individuals), with nearly no effect on the results for women. 
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Using the HP 2020 target for obesity could result in an estimated reduction of 
7.0% (271,324 individuals) and 19.1% (664,416 individuals) in diabetes 
prevalence in men and women respectively by 2022. Adding the HP 2020 target 
for smoking could increase such an estimated reduction in men to 7.5% 
(289,624 individuals) with almost no change in women. 
Applying the WHO target for obesity, the reduction in diabetes prevalence in 
2022 is estimated at 5.1% (189,822 individuals) in men and 15.1% (529,032 
individuals) in women. If the WHO target for smoking is also added, the 
reduction is estimated to improve to 5.6% (207,378 individuals) in men and 
15.3% (529,208 individuals) in women. C. Modelling scenario 3 – population aged 25-75+ years with capped obesity trends 
By scenario 3, if the GCC Action Plan’s target for obesity is used, the estimated 
potential reduction in diabetes prevalence would be 2.7% (161,511 individuals) 
in men and 9.0% (287,249 individuals) in women. Applying both assumed 
targets for obesity and smoking could result in an inconsiderable improvement 
of reduction results [3.0% (170,274 individuals)] in men, and nearly no effect on 
the results for women. 
The model estimated that the reduction in diabetes prevalence in 2022 
respectively in men and women could reach 2.1% (132,065 individuals) and 
7.6% (237,636 individuals) with using the HP 2020 target for obesity. If both 
obesity and smoking targets of HP 2020 are used, the reduction in diabetes 
prevalence in men is estimated to be 2.4% (151,300 individuals), with almost no 
change among women. 
Using the WHO targets for obesity and smoking would not produce any 
significant reduction in diabetes prevalence in 2022 among men. However, 
using such targets among women could result in an estimated reduction of 
3.3% (100,212 individuals) by 2022. D. Modelling scenario 4 – population aged 25-75+ years without capping of obesity trends 
By using the GCC Action Plan’s target for obesity, the reduction in diabetes 
prevalence in 2022 among men and women is estimated respectively at 6.9% 
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(336,437 individuals) and 22.0% (827,372 individuals). However, again, using 
both targets for obesity and smoking could produce a slight increase in the 
reduction results among men [7.2% (345,131 individuals)], with nearly no 
impact on women. 
The estimated reductions in diabetes prevalence in 2022 which could be 
achieved as a result of applying the HP 2020 target for obesity are 5.5% 
(282,464 individuals) in men and 19.0% (710,213 individuals) in women. This 
estimated reduction could increase to 6.0% (301,357 individuals) among men 
only with using both HP 2020 targets for obesity and smoking. 
Using the WHO target for obesity could result in an estimated reduction of 3.5% 
(197,276 individuals) in men and 14.9% (564,113 individuals) in women. Adding 
the WHO target for smoking could slightly increase the estimated reduction in 
men to 4.0% (215,411 individuals), with, again, almost no effect on the results 
for women. 
Figures  8.5- 8.12 illustrate the results of impact of using the ‘what if’ policy 
targets on the diabetes prevalence among men and women, based on each of 
the four modelling scenarios. Because of the minimal impact of smoking targets 
on the results (as discussed in the previous sections), these figures show only 
the ‘what if’ results of the obesity targets. 
In sum, this chapter presents extensive analyses of the potential impacts of 
reducing the adult obesity and smoking in Saudi Arabia (using local and 
international policy targets) on the predicted T2DM prevalence. The next 
chapter provides detailed comparisons of the model outputs against other 
existing modelling estimates, such as those produced recently by the IDF9 and 
the GBD project.20 
 
251 
 
Table  8.3. Results of the impact of reducing obesity (or obesity and smoking) on the diabetes burden in Saudi Arabia (men) using different targets 
 Baseline burden of T2DM (2022) Burden of T2DM (2022) with the “What if” policy assumption Reduction of burden of T2DM (2022) Target (What if policy 
assumption)* Prevalence 
(%) Number (T2DM cases) 
Prevalence 
(%) Number (T2DM cases) 
Prevalence 
(%) Number (T2DM cases) 
Sc
en
ar
io
 1
 
39.2 
 
3,666,613 
 
37.6 3,518,081 -4.1 -148,532 10% O (Baseline 2008) 
37.5 3,509,472 -4.3 -157,141 10% O + 5% S (Baseline 2008) 
37.9 3,545,688 -3.3 -120,925 10% O (Baseline 2010) 
37.7 3,527,046 -3.8 -139,567 10% O + 40% S (Baseline 2010) 
38.8 3,624,126 -1.0 -42,487 Halt O (Baseline 2010) 
38.6 3,606,212 -1.5 -60,401 Halt O + 40% S (Baseline 2010) 
Sc
en
ar
io
 2
 
41.3 3,859,003 
37.8 3,535,545 -8.4 -323,458 10% O (Baseline 2008) 
37.7 3,527,005 -8.6 -331,998 10% O + 5% S (Baseline 2008) 
38.4 3,587,679 -7.0 -271,324 10% O (Baseline 2010) 
38.2 3,569,379 -7.5 -289,624 10% O + 40% S (Baseline 2010) 
39.2 3,669,181 -5.1 -189,822 Halt O (Baseline 2010) 
39.0 3,651,625 -5.6 -207,378 Halt O + 40% S (Baseline 2010) 
Sc
en
ar
io
 3
 
37.8 3,897,879 
36.8 3,736,368 -2.7 -161,511 10% O (Baseline 2008) 
36.7 3,727,605 -3.0 -170,274 10% O + 5% S (Baseline 2008) 
37.0 3,765,814 -2.1 -132,065 10% O (Baseline 2010) 
36.9 3,746,579 -2.4 -151,300 10% O + 40% S (Baseline 2010) 
37.9 3,847,939 -0.0 -49,940 Halt O (Baseline 2010) 
37.7 3,829,445 -0.3 -68,434 Halt O + 40% S (Baseline 2010) 
Sc
en
ar
io
 4
 
39.7 4,090,269 
36.9 3,753,832 -6.9 -336,437 10% O (Baseline 2008) 
36.8 3,745,138 -7.2 -345,131 10% O + 5% S (Baseline 2008) 
37.5 3,807,805 -5.5 -282,464 10% O (Baseline 2010) 
37.3 3,788,912 -6.0 -301,357 10% O + 40% S (Baseline 2010) 
38.3 3,892,993 -3.5 -197,276 Halt O (Baseline 2010) 
38.1 3,874,858 -4.0 -215,411 Halt O + 40% S (Baseline 2010) 
(*)10% O: 10% relative reduction of Obesity prevalence by 2022;  10% O + 5% S: 10% relative reduction of Obesity prevalence & 5% relative reduction of Smoking prevalence by 2022; 
10% O + 40% S: 10% relative reduction of Obesity prevalence & 40% relative reduction of Smoking prevalence by 2022;  
Halt O: halt the rise in Obesity prevalence by 2022; Halt O + 40% S: halt the rise in Obesity prevalence & 40% relative reduction of Smoking prevalence by 2022 
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Table  8.4. Results of the impact of reducing obesity (or obesity and smoking) on the diabetes burden in Saudi Arabia (women) using different targets 
 Baseline burden of T2DM (2022) Burden of T2DM (2022) with the “What if” policy assumption Reduction of burden of T2DM (2022) Target (What if policy 
assumption)* Prevalence 
(%) Number (T2DM cases) 
Prevalence 
(%) Number (T2DM cases) 
Prevalence 
(%) Number (T2DM cases) 
Sc
en
ar
io
 1
 
39.8 2,914,899 
36.6 2,680,031 -8.1 -234,868 10% O (Baseline 2008) 
36.6 2,679,991 -8.1 -234,907 10% O + 5% S (Baseline 2008) 
37.1 2,723,059 -6.8 -191,840 10% O (Baseline 2010) 
37.1 2,722,838 -6.8 -192,061 10% O + 40% S (Baseline 2010) 
38.9 2,849,991 -2.3 -64,908 Halt O (Baseline 2010) 
38.9 2,849,792 -2.3 -65,107 Halt O + 40% S (Baseline 2010) 
Sc
en
ar
io
 2
 
47.7 3,494,444 
37.1 2,719,453 -22.2 -774,991 10% O (Baseline 2008) 
37.1 2,719,415 -22.2 -775,029 10% O + 5% S (Baseline 2008) 
38.6 2,830,028 -19.1 -664,416 10% O (Baseline 2010) 
38.6 2,829,829 -19.1 -664,615 10% O + 40% S (Baseline 2010) 
40.5 2,965,412 -15.1 -529,032 Halt O (Baseline 2010) 
40.4 2,965,236 -15.3 -529,208 Halt O + 40% S (Baseline 2010) 
Sc
en
ar
io
 3
 
39.7 3,174,935 
36.1 2,887,686 -9.0 -287,249 10% O (Baseline 2008) 
36.1 2,887,642 -9.0 -287,293 10% O + 5% S (Baseline 2008) 
36.7 2,937,299 -7.6 -237,636 10% O (Baseline 2010) 
36.7 2,937,053 -7.6 -237,882 10% O + 40% S (Baseline 2010) 
38.4 3,074,947 -3.3 -99,988 Halt O (Baseline 2010) 
38.4 3,074,723 -3.3 -100,212 Halt O + 40% S (Baseline 2010) 
Sc
en
ar
io
 4
 
46.9 3,754,481 
36.6 2,927,109 -22.0 -827,372 10% O (Baseline 2008) 
36.6 2,927,067 -22.0 -827,414 10% O + 5% S (Baseline 2008) 
38.0 3,044,268 -19.0 -710,213 10% O (Baseline 2010) 
38.0 3,044,044 -19.0 -710,437 10% O + 40% S (Baseline 2010) 
39.9 3,190,368 -14.9 -564,113 Halt O (Baseline 2010) 
39.9 3,190,167 -14.9 -564,314 Halt O + 40% S (Baseline 2010) 
(*)10% O: 10% relative reduction of Obesity prevalence by 2022;  10% O + 5% S: 10% relative reduction of Obesity prevalence & 5% relative reduction of Smoking prevalence by 2022; 
10% O + 40% S: 10% relative reduction of Obesity prevalence & 40% relative reduction of Smoking prevalence by 2022;  
Halt O: halt the rise in Obesity prevalence by 2022; Halt O + 40% S: halt the rise in Obesity prevalence & 40% relative reduction of Smoking prevalence by 2022 
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Figure  8.5. (Scenario 1) Results of the impact of reducing obesity on the diabetes 
burden in Saudi Arabia (Men) using different targets 
(Scenario 1: population aged 25-64 years with capped obesity trends) 
 
 
Figure  8.6. (Scenario 1) Results of the impact of reducing obesity on the diabetes 
burden in Saudi Arabia (Women) using different targets 
(Scenario 1: population aged 25-64 years with capped obesity trends) 
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 Figure  8.7. (Scenario 2) Results of the impact of reducing obesity on the diabetes 
burden in Saudi Arabia (Men) using different targets 
(Scenario 2: population aged 25-64 years without capped obesity trends) 
 
Figure  8.8. (Scenario 2) Results of the impact of reducing obesity on the diabetes 
burden in Saudi Arabia (Women) using different targets 
(Scenario 2: population aged 25-64 years without capped obesity trends)
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 Figure  8.9. (Scenario 3) Results of the impact of reducing obesity on the diabetes 
burden in Saudi Arabia (Men) using different targets 
(Scenario 3: population aged 25-75+ years with capped obesity trends) 
 
Figure  8.10. (Scenario 3) Results of the impact of reducing obesity on the diabetes 
burden in Saudi Arabia (Women) using different targets 
(Scenario 3: population aged 25-75+ years with capped obesity trends)
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 Figure  8.11. (Scenario 4) Results of the impact of reducing obesity on the diabetes 
burden in Saudi Arabia (Men) using different targets 
(Scenario 4: population aged 25-75+ years without capped obesity trends) 
 
Figure  8.12. (Scenario 4) Results of the impact of reducing obesity on the diabetes 
burden in Saudi Arabia (Women) using different targets 
(Scenario 4: population aged 25-75+ years without capped obesity trends)  
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Chapter 9. Comparison of the main results of the Saudi IMPACT 
Diabetes Forecast Model against other studies of diabetes 
prevalence estimates 
9.1. Background 
In the last few decades, several estimates and projections of the global diabetes 
prevalence have been produced. Examples of such studies have been 
discussed in chapter 3.9, 14-17, 20 These studies resulted in substantial variations 
of diabetes prevalence and its projections between the world regions as well as 
between countries. As discussed in previous chapters, several factors were 
suggested to explain such variations.16 These factors include, for example, 
variations in the prevalence of some diabetes risk factors (e.g. obesity), lifestyle 
and types of foods, and ethnic and genetic susceptibility. 
The pioneer statistician George E. Box wrote “essentially, all models are wrong, 
but some are useful”.279 The reliability and accuracy of diabetes prevalence 
estimates are highly dependent on the data sources used in modelling process, 
model structure and methodology.280 Thus, comparing the results of different 
diabetes prevalence estimates may be difficult because different studies often 
utilise different data sources, apply different methodologies for estimation and 
projection, and use different assumptions. Furthermore, Danaei et al.20 
reviewed the available global diabetes estimates and reported some other 
potential reasons for variations in their results. For instance, the definition of 
diabetes varied in different studies, as diagnostic criteria have been repeatedly 
changed over time. In addition, studies were different in their populations of 
interest, and some of them used data sources with subnational samples, 
regarding them as equally representative of national populations. This could 
lead to biased results, as those specific subnational groups might differ from the 
general populations in many aspects, such as the prevalence of some risk 
factors for diabetes.  
As discussed in chapter 4, the modelling process is primarily a logical 
connection between inputs (data and assumptions) and outputs in the form of 
valued consequences (e.g. prevalence estimates) that are of interest to the 
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health care decision makers.22 It has been discussed in chapter 4 that the 
model results should never be presented as point estimates, or as unconditional 
claims of estimates and projections but, rather, the outputs should be 
represented as conditional upon the input data and assumptions. Thus, a model 
should not be a “black box” for the end-user, but be as transparent as possible, 
so that the logic behind its results can be grasped at an intuitive level.22 
This thesis used the Saudi IMPACT Diabetes Forecast Model, which integrates 
nationally representative data on the prevalence of diabetes, obesity and 
smoking in Saudi Arabia from different sources, along with various assumptions 
and literature-derived data in order to model trends of diabetes and its future 
projections during a time period of 30 years (1992–2022). Methodology and 
data sources have been described earlier in detail with their strengths and 
limitations. Also, all assumptions used in modelling have been explicitly 
discussed in chapter 5. 
Sections 9.2 and 9.3 compare the main results of diabetes prevalence in Saudi 
Arabia as estimated and projected by the Saudi IMPACT Diabetes Forecast 
Model against two of the most recent global diabetes estimates. The first is that 
of the IDF Diabetes Atlas, 20119, 280 and the second is that of the WHO Global 
Burden of Disease (GBD) project, 2011.20 These two sections discuss briefly 
the differences between these studies in terms of several aspects, such as 
study populations, data sources, methods of estimation and some assumptions 
used in modelling (summarised in Table  9.1). In addition, section 9.4 presents 
briefly a similar comparison of the model in this thesis against the relatively 
older modelling studies14-17 (summarised in Table  9.2).  
259 
 
Table  9.1. Comparison of the Saudi IMPACT Diabetes Forecast Model against the IDF (2011) model and the GBD (2011) model 
 IDF (2011)[9, 280] GBD (2011) [20] Saudi IMPACT Diabetes Forecast Model 
Estimated DM prevalence in Saudi 
Arabia (%) 
      
2011 Total: 16.2 * 2000 Males:     17.5** 
Females: 17.7 
2000 Males:    17.7† 
Females:16.4 
Total:      17.2 
2030 Total: 20.8 2008 Males:     22.0 
Females: 21.7 
2008 Males:     26.7 
Females: 24.7 
Total:       25.9 
2012 
update281 
Total: 23.4††   2011 Males:     29.8 
Females: 28.1 
Total:       29.2 
    2022 Males:     41.3 
Females: 47.7 
Total:       44.1 
      
    
Age of study population (years) 20 - 79 25+ 25 – 64† 
    
Main data sources for DM prevalence 
in Saudi Arabia 
Al-Nuaim et al. [202] 
El-Hazmi et al. [282] 
Warsy & El-Hazmi [36] 
Al-Nozha et al. [18] 
WHO STEPS [19] 
Warsy & El-Hazmi [36] 
Al-Nozha et al. [18] 
WHO STEPS [19] 
Warsy & El-Hazmi [36]  (for starting year 
prevalence) 
WHO STEPS [19]   (for validation) 
    
Estimation methodology Logistic regression modelling Complex multi-level Bayesian hierarchical 
modelling 
Markov modelling 
    
Covariates used for estimating DM 
prevalence 
 Urbanisation 
 Ageing 
 
 National income  
 Urbanisation  
 National availability of multiple food 
types 
 Age-standardised mean BMI 
 Trends in population structure 
 Trends in obesity prevalence 
 Trends in smoking prevalence 
 Estimated incidence of diabetes 
 Estimated case-fatality rate 
 Evidence-based estimates of RRs for 
transition probabilities 
* IDF estimates: prevalence adjusted to national population                 ** GBD estimates: age-standardised to the WHO reference population 
†Results of the Saudi IMPACT are based on the modelling scenario 2          †† IDF’s update for 2012 was obtained from a local study with subnational sample 
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Table  9.2. Comparison of the Saudi IMPACT Diabetes Forecast Model against four (relatively old) modelling studies 
 Shaw et al. [14] Wild et al. [15] King et al. [16] Amos et al. [17] Saudi IMPACT Diabetes Forecast Model 
Estimated DM 
prevalence in 
Saudi Arabia (%) 
          
2010 Total:   13.6 2000 Total:   6.2 1995 Total:   8.7 1995 Total:   10.0 1995 Total:      11.1 
2030 Total:   17.0 2030 Total:   8.1 2000 Total:   9.1 2000 Total:   12.0 2000 Total:      17.2 
    2025 Total:  10.1 2010 Total:   13.8 2010 Total:      28.1 
        2022 Total:      44.1 
          
        
Age of study 
population (years) 
20 – 79 20+ 20+ 20+ 25 – 64* 
      
Main data sources 
for DM prevalence 
in Saudi Arabia 
Al-Nuaim et al. [202] 
El-Hazmi et al. [282] 
Al-Nozha et al. [18] 
El-Hazmi et al. [282] 
 
Asfour et al. [178] 
(Study from Oman) 
El-Hazmi et al. [283] 
Asfour et al. [178] (study from 
Oman) 
Warsy & El-Hazmi [36]  (for 
starting year prevalence) 
WHO STEPS [19]   (for 
validation) 
      
Estimation 
methodology 
Logistic regression 
modelling 
DISMOD II Age-specific diabetes 
prevalence estimates were 
applied to UN population 
estimates and projections 
Country-specific diabetes 
prevalence data were applied 
to the corresponding national 
age distribution 
Markov modelling 
      
Covariates used 
for estimating DM 
prevalence 
 Demographic changes 
 Urbanisation 
 Demographic changes 
 Urbanisation 
 Trends in population size 
and age structure  
 Urbanisation 
 Level of economic 
development (GNP per 
capita)  
 Urbanisation 
 Trends in population 
structure 
 Trends in obesity 
prevalence 
 Trends in smoking 
prevalence 
 Estimated incidence of 
diabetes 
 Estimated case-fatality 
rate 
 Evidence-based 
estimates of RRs for 
transition probabilities 
*Results of the Saudi IMPACT are based on the modelling scenario 2          
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9.2. The IDF Diabetes Atlas (Fifth edition), 20119,280 
9.2.1. Methods 
The IDF has routinely produced global estimates of diabetes prevalence every 
three years since 2000. The most recent estimates are that of the Diabetes 
Atlas 2011 (there is a recent update for only 2012, discussed in section 9.2.3). 
In the Diabetes Atlas 2011, the IDF used a simple approach to estimate and 
project diabetes prevalence in adults aged 20-79 years in different world 
regions and countries for the years 2011 and 2030. 
Data used in the IDF study were obtained from country-level data sources, 
including peer-reviewed studies, national health statistics reports, 
commissioned studies on diabetes prevalence, and unpublished data obtained 
through personal communication. The data search was performed through a 
systematic literature review of PubMed and Google Scholar, in addition to 
relevant citations from within papers, and gathered information from the IDF 
network beginning in November 2010 and ending in April 2011. Moreover, other 
sources were used such as relevant government websites, WHO STEPS 
surveillance projects and contacts with diabetes researchers in all regions. Data 
search yielded a total of 565 studies containing prevalence data for either 
diabetes, impaired glucose tolerance, or both from the year 1980 onwards. 
These studies were reviewed and exclusion criteria were applied. Exclusion 
criteria were the following: insufficient data for characterisation or modelling, 
duplicate data, an update of a previous study, inadequate description of the 
methodology, clinic-based or hospital-based studies. Then, data sources were 
ranked by a panel of experts from each of the IDF regions using a validated 
qualification system called the Analytic Hierarchy Process (AHP). Studies were 
classified by 6 criteria (sample representation, study design, sample size, 
diagnostic criteria, study date, and type of data). AHP allows criteria from 
different domains to be compared, e.g. study size versus age of the study. 
Scores for each criterion were determined by the panel of experts. In general, 
nationally representative, population-based sources, using oral glucose 
tolerance test as the primary diagnostic criteria, that were conducted in the last 
five years received the highest score. Then, a frequency plot of the final scores 
of all the sources was generated and two thresholds, lower and upper, were 
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determined. It was found that the scores followed a bimodal distribution, with 
nearly half of all data sources scoring 0.3 and more. The data sources scoring 
above and below were examined, and the minimum threshold was then set at 
0.3, where all sources with scores below this threshold were automatically 
discarded. The upper threshold was set at 0.52, corresponding to a gap in the 
distribution, above which data sources were all of high quality and, accordingly, 
were automatically included. For each country, where there were no studies 
above the upper threshold, the top-scoring study between the lower and upper 
threshold along with any other studies with a score that was within 10 
percentage points of the top-scoring study were selected. In countries where 
more than one study was selected, a weighted average, based on the score, 
was calculated for each age-specific prevalence. In general, a total of 170 
studies from 110 countries were selected for modelling. 
If sources were selected for a particular country, these were the only studies 
used to generate prevalence estimates for that country. However, if no studies 
were selected for a country, data from countries within a ‘data region’ were used 
as a proxy. A data region was defined from a combination of IDF region, World 
Bank country income group and most common ethnicity. Estimates of the IDF 
were made for the total diabetes population, including those who were newly 
diagnosed in surveys, and those with type 1 diabetes. 
For Saudi Arabia, the IDF used five data sources for modelling. These sources 
were four published national surveys18, 36, 202, 282 (discussed in chapter 3) and 
the WHO STEPS survey in Saudi Arabia.19  
In the IDF study, prevalence was modelled for each data source using logistic 
regression, and rates were estimated separately for men and women, and for 
urban and rural populations. Where data were not available for one setting or 
for one sex, these were estimated from prevalence ratios from other sources 
within the data region. The smoothed age- and sex-specific prevalences for 
urban and rural settings were then applied to each national population 
distribution for the years 2011 and 2030 (using the UN Population estimates, as 
that used in the Saudi IMPACT Diabetes Forecast Model) to estimate national 
prevalence and numbers of adults with diabetes. The age- and sex-adjusted 
prevalences for each country were also estimated by applying the age-specific 
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prevalences to the world population distribution. The IDF methodology used 
changes in age, sex and urbanisation as covariates for estimating diabetes 
prevalence.  
9.2.2. Relevant results and comparison with the Saudi IMPACT Diabetes 
Forecast Model 
The IDF estimated the total prevalence of diabetes in Saudi Arabia at 16.2% in 
2011 and 20.8% in 2030 (both were adjusted to the Saudi population using the 
UN population estimates). According to the IDF, these estimates place Saudi 
Arabia to be the 6th country with highest prevalence of diabetes globally in 2011 
and 2030. 
In comparison, the Saudi IMPACT Diabetes Forecast Model estimated the total 
diabetes prevalence in the Kingdom in 2011 to be 28.9% (by scenario 1), 29.2% 
(by scenario 2 and scenario 3), and 29.4% (by scenario 4). In 2022, the Saudi 
IMPACT model estimated the diabetes prevalence at 39.5% (by scenario 1), 
44.1% (by scenario 2), 38.9% (by scenario 3), and 43.2% (by scenario 4).  
The substantial differences between the two studies could be attributed mainly 
to the different methods of modelling of diabetes prevalence and the covariates 
used for that purpose. According to the IDF, the estimation approach was 
deliberately kept simple and conservative.9 The model used logistic regression 
method and based its predictions for 2030 on predicted demographic changes 
(urbanisation and ageing). Moreover, the IDF model did not attempt to account 
for the effects of changes in diabetes risk factors (e.g. obesity), because the 
estimates and projections were generated for almost all countries in the world 
and not specifically for a single country. Indeed, assessing the relationship 
between risk factors and diabetes is difficult across such a very diverse global 
population. Consequently, the IDF reported this as a main limitation which was 
likely to result in underestimation of diabetes prevalence if the levels of obesity 
and other risk factors continue to rise.9 
On the other hand, as discussed in chapter 5, the Saudi IMPACT Diabetes 
Forecast Model utilised a different estimation approach (Markov modelling). It 
used only the prevalence of diabetes for the starting year (1992) along with 
demographic trends of the Saudi population (1992-2022) and the trends in 
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prevalence of two risk factors (obesity and smoking) over the same 30-year-
period. In addition, the model used a number of transition parameters in the 
process of modelling, such as the estimated incidence of diabetes, case fatality 
rate, general mortality and evidence-based RRs. The Saudi IMPACT Diabetes 
Forecast Model used published nationally representative, population-based 
studies to obtain data on the prevalence of obesity and smoking in Saudi 
Arabia, and assumed a linear increase of the prevalence of these two risk 
factors over time (1992–2022) with assuming capped versus uncapped linear 
obesity trends. 
As mentioned in chapter 2, urbanisation has been implicated in the aetiology of 
T2DM, because it is mostly associated with several risk factors for the disease. 
These risk factors include, for example, obesity, physical inactivity and 
increased consumption of high caloric foods.8 Therefore, urbanisation has been 
used by the IDF model as a proxy for these lifestyle risk factors in order to 
estimate and project the levels of T2DM, rather than the direct modelling of risk 
factors. However, quantification of the effects of urbanisation on health is 
difficult, due to difficulty in defining ‘urban’ versus ‘rural’ settings. The definitions 
of urban and rural populations are mostly made individually by each country. 
Because of national differences in the characteristics that distinguish urban from 
rural areas, the distinction between urban and rural populations is not yet 
amenable to a single definition that would be applicable to all countries, or even 
to the countries within a region.284 The majority of definitions across the world 
rely on the size of population in an area. For example, in Saudi Arabia, an urban 
area is defined as that with a population of ≥5000 inhabitants.284 Accordingly, 
the Food and Agriculture Organisation (FAO) of the UN estimated the urban 
population in Saudi Arabia to be 86.2% in 2000 and 91.8% in 2020.285 
Importantly, relying only on the population size of an area does not take into 
account the levels of infrastructures and socio-economic status of the 
population. Some low-populated areas may have as good infrastructures and 
socio-economic status as highly-populated big cities, particularly in high income 
developing countries. Therefore, significant differences in the levels of lifestyle 
risk factors (e.g. physical inactivity and obesity) become less likely to be 
informed by such a definition. However, some few countries use other criteria 
for definition, such as population density, predominant type of economic activity, 
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availability of some specific services and facilities, etc.284 A systematic review 
has revealed that the majority of studies relied mainly on these pre-existing 
measures of urbanisation using an ‘urban - rural dichotomy’.286 The IDF model 
obtained the data on the proportion of urban population for all countries from the 
UN estimates.280 
These measures of urbanisation are crude and may mask many variations in 
the levels of some important risk factors (e.g. obesity) within a country and 
between countries. In other words, using the crude dichotomy of (urban–rural) is 
likely to make it difficult to identify and track components of the urbanisation 
process that may affect diabetes risk.286 Alternatively, some studies directly use 
the levels and trends of important diabetes risk factors, such as obesity (as in 
the Saudi IMPACT Diabetes Forecast Model), or, in addition, some individual 
measures that might serve as ‘surrogates’ for the levels of urbanisation,286 such 
as national income and national availability of multiple food types (as in the 
GBD model discussed in the next sections). Therefore, again, using different 
modelling covariates might explain the discrepancy between the IDF estimates 
(which used the level of urbanisation in Saudi Arabia as a main covariate in 
modelling) and the higher IMPACT estimates (which directly used the trends in 
prevalence of obesity and smoking, assuming a linear increase over time). 
The Saudi IMPACT Diabetes Forecast Model and the IDF model were similar in 
the data sources used to obtain diabetes prevalence in Saudi Arabia. The IDF 
used five published national studies that were also covered through the 
literature review in chapter 3 of this thesis. One of these studies (Warsy and El-
Hazmi)36 was used by the IMPACT Model to obtain diabetes prevalence for the 
starting year of modelling (1992), and another study (the WHO STEPS 
survey)19 was used for validation. Also, the age of population covered by the 
two models was comparable (20-79 years in the IDF model and 25-75+ years in 
this thesis). Furthermore, both models used the UN population estimates for 
obtaining the Saudi population structure trends. However, population data in 
this thesis were obtained from local sources (national censuses) for 1992 and 
2004, and filled in the gaps within this period range by linear interpolation. It 
used the UN population estimates to obtain data for 2005–2022. 
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9.2.3. The IDF update for 2012 
The IDF has recently released on its website an update of its diabetes 
prevalence estimates for 2012, using new studies that became available in 
2011. The new studies that were reviewed came from Saudi Arabia, Japan, and 
some other countries.281 The updated estimates were reported for 2012 only, 
and there were no updated future projections of diabetes prevalence. The 
studies used for the 2012 updates were not cited on the IDF website. 
For Saudi Arabia, the IDF has updated the prevalence of diabetes in 2012 at 
23.4%. The IDF used for this update a recent local study,287 published in 2011 
(personal communication, D. Whiting and L. Guariguata, IDF). However, this 
study covered a subnational sample of population (aged 7-80 years) from the 
Riyadh Region only. The sample size was 9,149 individuals (58.6% men and 
41.4% women). Diagnosis of T2DM was based on the ADA 1997/  WHO 1999 
criteria (fasting plasma glucose ≥7.0 mmol/l). The reported overall crude 
prevalence of T2DM in the study was 23.1% (95% CI: 20.5-22.2%). 
As that study included a subnational sample from only one region of the 
Kingdom, it might be difficult to generalise its findings to the population of other 
regions. However, generally, the 2012 update has supported the suggestion 
(mentioned in the previous section) that the previous IDF’s estimates and 
projections of diabetes prevalence in Saudi Arabia were most likely 
underestimated.   
9.3. The GBD Model, 2011 - the Global Burden of Metabolic Risk Factors 
of Chronic Diseases Collaborating Group (Blood Glucose)20 
9.3.1. Methods 
In this WHO project, trends and uncertainties in mean fasting plasma glucose 
(FPG) and diabetes prevalence were estimated for the period 1980-2008 in 
adults aged 25 years and older in 199 countries and territories of the world. 
Diabetes was defined by the ADA criteria (FPG ≥7.0 mmol/l), previous 
diagnosis, or use of a glucose lowering drug. Data sources were obtained from 
health examination surveys and epidemiologic studies, review of published 
articles, in addition to unpublished data sources identified through the WHO 
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Global InfoBase. More than 3000 published articles were identified through 
searching Medline and Embase databases. After review of all articles and 
applying the exclusion criteria, a total of 128 published studies were retained. In 
brief, studies were included if they were from a representative sample, including 
from a national, subnational, or community population, and if the data were 
based on measured (vs. self reported) glucose and diabetes. On the other 
hand, studies were excluded if they contained only diagnosed diabetes, and 
self-reported diabetes status and diagnosis history with no data on measured 
glucose; had used capillary blood for postprandial glucose; used a sampling 
method that may be related to diabetes (e.g. studies on hypertensive, diabetic, 
or obese patients and populations); were not population-based or used non-
representative samples (e.g. convenience or non-random sampling); reported 
data only on children or those who were 25 of years of age or younger; or did 
not report the sampling method. 
For Saudi Arabia, the GBD used three data sources for modelling. These 
sources were two published national surveys18, 36 (discussed in chapter 3) and 
the WHO STEPS survey in Saudi Arabia.19 
The GBD model used more complicated statistical methods than that used in 
the IDF model. The model converted systematically different glycaemic metrics 
reported in studies to one metric (FPG). Although mean FPG was the most 
common metric in data, some sources reported mean postprandial glucose or 
HbA1c. The model used data sources that had mean FPG and other metrics to 
develop regression models to estimate mean FPG. The dependent variable in 
these regressions was mean FPG; while the independent variables were mean 
postprandial glucose, mean HbA1c, or diabetes prevalence, and age, sex, year 
of survey, and whether the country was high income. A similar approach was 
used to estimate diabetes prevalence, from the estimated mean FPG. The 
dependent variable of this regression was the logit of prevalence (based on the 
ADA definition), and the independent variables were the natural logarithm (Ln) 
of mean FPG, age, sex, as well as whether the country was high income (as 
classified by the Institute for Health Metrics and Evaluation). 
The GBD model estimated mean FPG by age group, country, and year, 
separately for men and women. The statistical methods were sophisticated, but 
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in brief, a multi-level statistical approach (Bayesian hierarchical modelling) was 
used. The FPG trends over time were modelled as a linear trend plus a smooth 
non-linear trend. The estimates were informed by several country-level 
covariates. These covariates were national income (Ln per-head gross 
domestic product), urbanisation (proportion of population that lived in urban 
areas), age-standardised mean BMI (from a previous GBD systematic analysis 
of country data), and national availability of multiple food types for human 
consumption (from the food balance sheets of the Food and Agriculture 
Organization (FAO) of the United Nations). 
Mean FPG and diabetes prevalence were estimated from the model for 5-10 
year age groups for adults aged ≥25 years. Estimates for subregions, regions, 
and the world were calculated as population-weighted averages of the 
constituent country estimates by age group and sex. The presented estimates 
for each country or region and year were age-standardised to the WHO 
reference population. 
9.3.2. Relevant results and comparison with the Saudi IMPACT Diabetes 
Forecast Model 
The GBD model estimated the prevalence of diabetes in Saudi Arabia among 
men and women (≥25 year-old) respectively as follows: 17.5% and 17.7% in 
2000, and 22.0% and 21.7% in 2008. On the other hand, the estimates of the 
Saudi IMPACT Diabetes Forecast Model for men and women in 2000 were 
respectively as follows: 17.7% and 16.4% (by scenario 1 and scenario 2), and 
18.3% and 17.0% (by scenario 3 and scenario 4). In 2008, the results of the 
Saudi IMPACT for men and women were respectively as follows: 26.7% and 
24.7% (by scenario 1 and scenario 2), and 27.0% and 25.2% (by scenario 3 
and scenario 4). 
Clearly, the results of the GBD model and the Saudi IMPACT Diabetes Forecast 
Model are very comparable, in spite of differences in the general methods of 
estimation. This similarity in results of the two models could be attributed 
primarily to the several covariates used in both models to estimate diabetes 
prevalence. In contrast to the IDF model that was conservative and used only 
ageing and level of urbanisation as covariates, the GBD model incorporated 
more covariates to inform its estimates. However, among all these covariates, 
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mean BMI is likely to have the most important contribution to the higher 
estimates of the GBD model than that of the IDF model; because mean BMI 
could serve as a ‘direct’ informant of the trends in obesity levels. Another GBD 
modelling study for trends in the global BMI13 showed that the estimated mean 
BMI in Saudi Arabia followed a linear increase between 1980 and 2008. The 
estimates of mean BMI (kg/m2) in men and women in Saudi Arabia were 
respectively as follows: 25.0 (UI: 23.8-26.3) and 26.3 (UI: 24.8-27.8) in 1980, 
25.9 (UI: 25.6-26.2) and 27.3 (UI: 26.9-27.8) in 1990, 27.0 (UI: 26.6-27.4) and 
28.5 (UI: 28.0-29.0) in 2000, and 27.9 (UI: 27.2-28.6) and 29.6 (UI: 28.7-30.5) in 
2008. Furthermore, the WHO’s GBD estimates showed that the region of ‘North 
Africa and Middle East’ witnessed the largest increase in mean BMI in men and 
women between 1980 and 2008 after the region of ‘Oceania’. Saudi Arabia was 
among the countries with the highest increase in mean BMI within its region.13 
Unfortunately, country-specific estimates of the prevalence of obesity (BMI ≥30 
kg/m2) were not reported. However, the region of ‘North Africa and Middle East’ 
had the seventh (among the 21 GBD regions of the world) highest prevalence of 
obesity in men, and the second highest in women between 1980 and 2008. In 
men, the estimated prevalence of obesity in that region increased substantially 
from <10% in 1980 to 20-30% in 2008. On the other hand, obesity prevalence in 
women increased from 10-20% in 1980 to 30-40% in 2008.13 
As discussed earlier, the Saudi IMPACT Diabetes Forecast Model assumed a 
linear increase in obesity prevalence during the period of 1992-2022 based on 
the estimated annual rate of increase, as informed by the available national 
studies (with assuming capped versus uncapped trends).  
One of the advantages of the GBD model is its use of a single definition of 
diabetes across all studies included in modelling process. The three Saudi 
studies used in the GBD model had different definitions of diabetes. For 
instance, Warsy and El-Hazmi36 used the WHO 1985 diagnostic criteria with the 
OGTT, while the WHO STEPS study19 and the study of Al-Nozha et al.18 used 
the ADA 1997 criteria with measuring only the fasting plasma glucose (FPG). 
As mentioned earlier, the GBD model systematically converted all data that 
were reported in other glucose metrics (e.g. mean postprandial glucose or 
HbA1c) to mean FPG, and then estimated the diabetes prevalence from mean 
FPG. This use of a single definition for diabetes could be a good solution to 
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improve the comparability of results. As discussed in detail in chapter 7, using 
different diagnostic criteria for diabetes was reported to have an impact on the 
results of diabetes prevalence.  
The GBD study modelled only the available local data on diabetes prevalence, 
and did not make future projections. In comparison, the Saudi IMPACT 
Diabetes Forecast Model estimated the past trends in diabetes prevalence from 
1992 and also projected the estimates up to 2022, based on the predicted 
trends in obesity and smoking. This ‘logical’ prediction of future might be more 
useful to the health care planners and decision makers for proper allocation of 
resources. In addition, the model in this thesis could also serve as a helpful tool 
for decision makers, through conducting a series of “what if” analyses in order 
to quantify the impact of reducing the prevalence of obesity and/ or smoking on 
the levels of diabetes in Saudi Arabia. 
9.4. Comparison of results in this thesis against other modelling studies 
Table  9.2 summarises a comparison of the results of the Saudi IMPACT 
Diabetes Forecast Model against four modelling studies14-17 that provided global 
and a large number of country-specific estimates and projections of diabetes 
prevalence. These modelling studies are older than the IDF and GBD models, 
and have been discussed in detail in chapter 3. 
For Saudi Arabia, Shaw et al.14 and Wild et al.15 used for estimation local 
population-based surveys (also used by the IDF and GBD models). On the 
other hand, the oldest two studies (King et al.16 and Amos et al.17) used old data 
from Oman178 and extrapolated such data to Saudi Arabia. 
In general, all these four models produced much lower estimates and 
projections of diabetes prevalence than the Saudi IMPACT Diabetes Forecast 
Model. Again, as with the IDF model, the most likely reason for such large 
discrepancies is the use of only demographic changes and/ or urbanisation in 
these models as covariates to inform the future projections. 
Overall, this chapter discusses in detail the variations and similarities of the 
model outputs in this thesis and the estimates of the IDF, GBD project, and 
other existing modelling studies. The next final chapter presents the overall 
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discussion and conclusions. It presents a summary of the main findings, 
strengths and limitations of the thesis, implications of the results, 
recommendations for policy action and further research, and conclusion. 
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Chapter 10. Discussion 
10.1. Summary of the main findings 
This thesis developed and validated the Saudi IMPACT Diabetes Forecast 
Model to estimate the prevalence of T2DM in Saudi Arabia during the period 
1992-2022. The model used, as a baseline, local data on the prevalence of 
T2DM in 1992, and combined several other types of data to inform its estimates 
and projections. These data include the prevalence of obesity (BMI ≥30 kg/m2) 
and smoking, assuming linear increasing trends, population structure trends, 
and a number of parameters of the disease epidemiology (incidence, case 
fatality, RRs of T2DM if obese or smoker, and total mortality). The results of 
model validation against local observed data and another model (the GBD 
model 2011) were generally consistent. 
The thesis used data for 1992 as a baseline for modelling (rather than using the 
more recent WHO STEPS in 2005) in order to provide an overall picture of the 
disease trends in Saudi Arabia since the earliest time point at which diabetes 
data were available. In addition, the model was capable of reproducing the 
prevalence of T2DM at a time point ‘forward’ (i.e. WHO STEPS, 2005), and this 
could result in gaining the acceptance of policy makers that the model forecasts 
for the ‘more forward’ time points (till 2022) are most likely reliable.  
Based on the projections in this thesis, T2DM prevalence in Saudi Arabia is set 
to rise substantially in the next decade, even considering more ‘optimistic’ future 
obesity trends. In those aged 25-64 years, the T2DM prevalence is estimated to 
increase from 8.5% (UI: 6.8–10.2%) in 1992 to 39.5% (UI: 32.5–45.9%) in 2022, 
assuming capped obesity trends, and 44.1% (UI: 35.4–52.5%), assuming 
uncapped increasing obesity trends. As discussed in chapter 5, the assumed 
capping points of the projected obesity prevalence were 35% in men and 60% 
in women. 
The huge and accelerated elevation in the estimated T2DM prevalence in Saudi 
Arabia was found to be driven mainly by high and steep estimated increases of 
the disease prevalence among the young adult men aged 25-44 years, and 
women aged 25-64 years. This can be attributed primarily to the markedly high 
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observed and projected relative increases in the prevalence of obesity (the main 
driver of T2DM projections in the model) in these particular age groups. In 
addition, the estimated incidence of T2DM (by DISMOD) in these age groups 
was relatively high, with low estimated case fatality and total mortality rates. 
Hence, the ‘pool’ of cases of T2DM in these age groups increases progressively 
over time, as it receives a large inflow of incident cases with a relatively smaller 
outflow of disease-specific deaths and other mortality competing risks. 
Generally, the higher estimated incidence and rapid increases in prevalence of 
T2DM among young/ middle-aged adults in Saudi Arabia is consistent with the 
findings of other studies regarding the T2DM projections in developing 
countries.15, 16, 57 As discussed in chapters 2 and 3, evidence has revealed that 
the disease in developing countries has been found to start at relatively younger 
age groups,57 and the majority of people with T2DM in these countries are aged 
45-64 years (compared to ≥65 years in developed countries).15, 16 
The overall prevalence of T2DM during 1992-2022 was estimated in this thesis 
to show higher relative increases in women than men. In men, the estimated 
relative increase was around 351% (assuming capped obesity trends) and 
375% (assuming uncapped obesity trends). On the other hand, in women, the 
estimated relative increase was approximately 385% (assuming capped obesity 
trends) and 481% (assuming uncapped obesity trends). It is important to note 
that the DISMOD-derived incidence rates of T2DM in this thesis for men were 
higher than that for women in almost all age groups. However, the higher 
predicted relative increases in T2DM prevalence in women could be explained 
primarily by the substantially higher trends in obesity prevalence than that in 
men. This is generally consistent with data from the WHO’s Regional Office for 
the Eastern Mediterranean114, 288, which clearly showed a much higher 
prevalence of obesity in adult women across almost all countries of the region.  
The large sex differences in the prevalence of obesity in Saudi Arabia (and 
other EMR countries) have been attributed mainly to the greater sedentary 
lifestyle patterns among women than men. For instance, Mabry et al.289 
reviewed the studies on prevalence and sex differences in adults’ physical 
activity participation in the GCC countries. They reported that the prevalence of 
‘sufficient’ physical activity (at least 150 minutes per week) in the GCC countries 
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is significantly lower among adult women (prevalence ranges from 26.3-28.4%) 
than men (prevalence ranges from 39.0-42.1%). According to the reviewers, 
these prevalence rates of sufficient physical activity are much lower than that 
reported in developed countries, such as Australia (60% for men and 54% for 
women) and the US (49.7% for men and 46.7% for women). Moreover, the 
prevalence rates of sufficient physical activity in the GCC countries are even 
lower than that reported in other neighbouring countries of the EMR. For 
example, in Egypt, the reported prevalence was 54.9% for men and 42.6% in 
women.289 This can be explained by the unique socioeconomic and cultural 
context of the GCC countries, which poses special constraints on the physical 
activity of women. Most women have restricted movement outside home, limited 
opportunities to attend gyms and health clubs, as well as high dependency on 
automobiles and domestic maids.289 
The obesity prevalence rates in the two oldest age groups of the Saudi 
population (65-74 and 75+ years) were extrapolated using data from Oman, as 
discussed in chapter 5. If such a method of extrapolation was valid, these two 
age groups would have almost a stable/ flat pattern of trends in the estimated 
T2DM prevalence in men during 1992-2022. In women, the age group (65-74 
years) would have a relative increase of around 85%, while the age group (75+ 
years) would also have flat trends in T2DM prevalence. This finding is in 
agreement with that reported by Wild et al.,15 who used DISMOD 2 models to 
estimate the global prevalence of diabetes (all ages) for 2000 and 2030. They 
reported a flattened trend pattern or modest reduction of diabetes prevalence in 
the oldest ages.  
However, in this thesis, the starting year prevalence of T2DM and the trends in 
obesity prevalence over time were based on cross-sectional data. These cross-
sectional data reflect only the situation at a specific time across the age groups. 
Importantly, however, age plays an important role in the aetiology of T2DM. If a 
group of individuals was followed from birth, their risk for the disease would vary 
as the birth cohort aged. So, different birth cohorts may have different levels of 
exposure to a particular risk factor, which might be expected to produce a 
change in disease incidence and prevalence for individuals born at a particular 
time.290 These effects are known as the 'age and birth cohort effects', which are 
recognised as potential limitations in all prevalence forecasting models that 
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mostly utilise cross-sectional data for prevalence predictions. In this thesis, 
obesity trends suggest that obesity prevalence peaks between the ages of 35-
64 years in men and women, and then, a drop of the prevalence rates is 
projected in the oldest age groups (65-74 and 75+ years). However, this drop in 
the prevalence does not necessarily mean that elderly people lose weight. 
Instead, it could be the result of age and birth cohort effects and reflect the fact 
that older birth cohorts had not gained similar weight with age as birth cohorts 
being born in a later time period.291 Moreover, beside age and birth cohort 
effects, prevalence forecasting models can also be constrained by potential 
'period effects'. A period effect specifies that time trend patterns of a disease 
could be influenced by some specific circumstances at the date (period) the 
disease was diagnosed (e.g. war famines, changes to some diagnostic 
technologies/ tests, etc), so that there might be unique effects that are produced 
by inducing a similar change in the disease risk for all individuals alive at a 
particular point in calendar time, regardless of age.290 
These age-period-cohort effects have been suggested to probably explain the 
plateau or declining trends in obesity prevalence292 and lung cancer mortality293 
in the oldest age groups over time, as projected by two prediction models. Such 
age-period-cohort effects might also have some influence on the findings in this 
thesis regarding the projected flat trends in T2DM prevalence for the oldest age 
groups versus increasing trends in younger age groups, which converge at 
some point in time and then invert. However, it is difficult to disentangle these 
potential effects with cross sectional data. Therefore, longitudinal data (such as 
multiple sequential cross-sectional surveys with several birth cohorts and 
several specific ages or preferably prospective cohort studies) are better 
sources of data for prevalence forecasting models. However, longitudinal data 
on T2DM and obesity trends are very rarely found in the literature compared to 
cross-sectional data.291 
The assumed capping of the projected obesity prevalence trends (at 35% in 
men and 60% in women) was found to have some impact on the future 
projections of T2DM prevalence. As a result of capping, the overall prevalence 
of T2DM by 2022 is predicted to reduce by around 10.4% (from 44.1% to 
39.5%) in population aged 25-64 years, and by approximately 10.0% (from 
43.2% to 38.9%) in population aged 25-75+ years. Such an impact of capped 
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obesity was found to be more prominent in women than men. For instance, in 
population aged 25-64 years, the prevalence of T2DM is predicted to reduce by 
16.6% in women (from 47.7% to 39.8%), compared to 5.1% in men (from 41.3% 
to 39.2%). These prominent differences in the predicted diabetes prevalence for 
women with and without capping of obesity trends are expected, since the 
uncapped projected obesity prevalence in most age groups of women are 
substantially higher than the assumed level of capping (60%). However, it is 
important to note that the “extrapolated” prevalence rates of obesity in the two 
oldest age groups of men and women were relatively low, and did not reach the 
assumed levels of capping. Hence, there was no effect of capping on the results 
of these two age groups in both sexes. 
Comparison of the results of the Saudi IMPACT Diabetes Forecast Model 
against other modelling studies has been extensively discussed in chapter 9, as 
such a comparison requires a detailed and long discussion of the estimation 
methodology, study population, data inputs, assumptions, and covariates used 
to generate the projections. In general, the large differences between the results 
in this thesis and the other modelling studies are primarily attributed to the 
different variables used to inform T2DM prevalence trends and projections. The 
majority of models9, 14-17 have relied only on demographic trends and 
urbanisation, and produced much lower projected prevalence rates of T2DM in 
Saudi Arabia than the local ‘observed’ data and those predicted in this thesis. In 
contrast, the model in this thesis was validated against the observed data and it 
produced consistent results. In the literature, the APHO Diabetes Prevalence 
Model30 is a recent consistent example that reported similar variations in the 
estimated prevalence of diabetes when compared to other models. As 
discussed in chapter 4, the APHO Diabetes Prevalence Model used the trends 
in overweight and obesity in England to estimate diabetes prevalence, which 
was approximately one third higher than that estimated by the IDF. For Saudi 
Arabia, the only modelling study (GBD model 2011)20 that used the BMI trends 
in the Kingdom as an informant of projections has produced very comparable 
results to the model in this thesis, in spite of the different modelling 
methodology. However, the Saudi IMPACT Diabetes Forecast Model has the 
advantage of providing future projections of T2DM prevalence (the GBD model 
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has only reported the results for 1980, 2000, and 2008), in addition to 
presenting several ‘what if’ policy scenarios. 
10.2. Strengths and limitations of the Saudi IMPACT Diabetes Forecast 
Model 
The Saudi IMPACT Diabetes Forecast Model has several strengths. First, as 
previously discussed in chapter 5, the model was originally designed to use a 
relatively limited number of data inputs that should be obtainable from a 
developing country. This is an advantage over the other diabetes models 
(reviewed in chapter 4), which require more types of data inputs that may not be 
available from Saudi Arabia. 
Second, the model is based in a very common spreadsheet package (MS 
Excel), and is user-friendly. 
Third, modelling data were obtained from the best available sources, and the 
strengths and limitations of such sources were explicitly documented. Missing 
and incomplete data were handled by appropriate inter- and extrapolation, as 
well as explicit assumptions. 
Fourth, different types of extensive sensitivity analyses (e.g. scenario analysis 
and analysis of extremes) were conducted to test the potential uncertainties 
around data inputs and assumptions. All modelling results were presented in 
different scenarios and with uncertainty intervals. 
Fifth, the model was well validated against both local observed data and an 
external model. 
Sixth, the model directly incorporated data on trends in adult obesity and 
smoking to inform the projections of future T2DM prevalence in Saudi Arabia. 
This is a big advantage over other models, and is the most likely reason for the 
large differences in the estimates and projections of T2DM. 
Seventh, the section of ‘what if policy analyses’ in the Saudi IMPACT Diabetes 
Forecast Model involved several useful and comprehensive policy scenarios. A 
number of reduction targets were incorporated, as set by local and leading 
international authorities. The ‘what if’ analyses in this thesis can form a useful 
platform for policy planning and decision making. 
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However, the model has some limitations. First, as discussed in chapter 4, 
modelling studies mostly require data inputs from several sources, which may 
differ in the data quantity and/or quality. In this thesis, as mentioned earlier, 
these issues were managed through applying a number of appropriate explicit 
assumptions, inter-/ extrapolation, and rigorous sensitivity analyses. 
Second, the DISMOD-derived transition parameters (incidence, case fatality, 
and total mortality) were assumed to be constant over the whole modelling 
period (1992-2022). Globally, data on the trends in diabetes-related mortality 
are inconsistent. Evidence from many developed countries has showed 
decreasing trends over the past 4-6 decades.294-299 However, the most recent 
IDF Diabetes Atlas reported that the number of deaths attributable to diabetes 
in 2011 shows a 13.3% increase over the estimates for 2010, which has been 
attributed to increases in the number of diabetes-related deaths in the South 
and Central America, Western Pacific, North America and Caribbean, and 
Middle East and North Africa Regions.10 In Saudi Arabia (and most other 
developing countries), such trend data are not available, and, therefore, if the 
true incidence of T2DM in Saudi Arabia has increased (or the diabetes-related 
mortality decreased) since 1992, the future projections of T2DM prevalence in 
this thesis would most likely underestimate the true burden. 
Third, the Saudi IMPACT Diabetes Forecast Model used the trends in only 
obesity (BMI ≥30 kg/m2) and current smoking as risk factors to inform the 
projections of T2DM prevalence. The model did not include other risk factors for 
T2DM (e.g. physical inactivity and diet). As discussed in chapter 1, the available 
local data on the prevalence of other risk factors are not sufficient to predict the 
likely trends, as there is only one national study19 measuring the prevalence of 
physical inactivity and dietary patterns. In addition, the model did not include 
overweight as a risk factor, mainly because lack of data to inform the required 
transitions. Also, it would be difficult to predict the linear future trends in both 
overweight and obesity simultaneously, as the obesity trends are increasing 
mainly at the expense of overweight trends. This might complicate the 
interpretation of the ‘what if’ policy options, making them confusing to the policy 
makers and other potential users. The model also did not include ex-smokers in 
the smoking pool, but this does not appear to have a significant impact on the 
model predictions, as the recent evidence (discussed in chapter 2) showed that 
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the risk of developing T2DM among ex-smokers is considerably lower than that 
among current smokers.140 However, the model validation results were 
reassuring and the model appears to capture well the trends in the most 
important determinant of T2DM (obesity). 
Fourth, the model covered the adult population (aged 25-75+ years) only, and 
did not include the younger age groups of children and adolescents, in whom 
the incidence and prevalence of T2DM are increasing worldwide.10 
Fifth, the model used only BMI ≥30 kg/m2 for definition of obesity, and did not 
use other measures of central/ abdominal obesity (such as waist circumference) 
as those data were not available from national surveys. It has been mentioned 
in chapter 3 that a considerable proportion of population in Saudi Arabia is 
composed of expatriates from different ethnic origins, with South and Southeast 
Asians comprising the majority of foreign population. As discussed in chapter 2, 
evidence revealed that Asians are more prone to abdominal obesity, and they 
mostly develop adverse health consequences (such as T2DM) at lower BMI 
than other ethnicities.89 Therefore, the modelled projections of obesity 
prevalence might be underestimated, which could result in underestimation of 
diabetes prevalence in Saudi Arabia. However, such potential uncertainties 
could be handled by the extensive sensitivity analyses, which provide higher 
and lower uncertainty limits of obesity and diabetes prevalence rates. 
Sixth, the ‘what if’ policy scenarios presented in this thesis did not consider a 
lag time between reducing the prevalence of obesity/ smoking and the 
subsequent potential reduction of T2DM prevalence. In addition, the 
achievability of the targeted reductions during a relatively short period of 12 
years (2010-2022) is not known. Evidence is not clear in this regard, particularly 
at the population-wide level. However, data from Norway300 and Cuba301 
revealed that rapid and short-term declines in diabetes burden occurred as a 
result of significant reductions of the lifestyle risk factors (particularly obesity) 
during the critical periods of World War II (6-years long) and an economic crisis 
(25-years long). 
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10.3. Implications 
The modelling work in this thesis offers very useful information to the health 
policy makers in Saudi Arabia, which has been constantly classified by the IDF 
to be among the top 10 countries with the highest diabetes prevalence 
globally.10 Policy makers need not only data on the current magnitude of T2DM, 
but also credible data on the likely future projections in order to make proper 
policy planning and allocation of resources. Currently, there are no local data on 
the future projections of T2DM in Saudi Arabia, and the available relevant 
international studies clearly underestimated the disease trends.9, 14-17 This 
thesis demonstrates for the health policy planners that T2DM prevalence in the 
Kingdom is predicted to increase substantially during the period 1992-2022. The 
major factors contributing to such a huge elevation in T2DM levels are the rapid 
population ageing and the increasing trends in the disease’s risk factors 
(particularly obesity). This thesis also revealed that the largest part of the 
growing problem of T2DM in Saudi Arabia is predicted to affect women and 
young adults of the productive age.  
Furthermore, as extensively discussed in chapter 8, this thesis quantifies for the 
health policy makers in Saudi Arabia the potential impact of achieving the local 
reduction targets set for obesity and smoking prevalence (the GCC Action 
Plan198) on T2DM prevalence trends. Also, the thesis provides additional future 
policy options and intervention scenarios (which are in line with current 
international recommendations) to reduce the burden of T2DM. It has been 
found that T2DM prevalence could be reduced if effective primary preventive 
measures are applied to reduce the prevalence of adult obesity and/or smoking. 
If the local Saudi target for obesity prevalence (10% reduction of that in 2008) 
would be achieved, a relative reduction of approximately 15% (1.1 million 
individuals) in T2DM prevalence could be attained by 2022. Furthermore, a 
relative reduction of around 10% in T2DM prevalence (around 740,000 
individuals) could be attained by 2022 if the rise in adult obesity prevalence is 
halted at 2010 levels (as recommended by the WHO275). Such a reduction in 
T2DM prevalence could increase to 13% (around 960,000 individuals) if the 
adult obesity prevalence is reduced by 10% of that in 2010 (HP 2020 target270). 
Additional reduction of smoking prevalence was estimated to yield some small 
improvements of the reduction of T2DM prevalence. However, in terms of 
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absolute numbers, this additional reduction of smoking could prevent T2DM in a 
considerable additional number of individuals. 
It is unknown if any of the additional international policy targets is effectively 
applicable to the Saudi context. However, at least for the WHO targets, they 
were established after analysing the current situation and trends of the targeted 
conditions in the member states. In addition, the WHO undertook a critical 
assessment of feasibility of such policy targets based on demonstrated country 
achievement.275 Still, the probably ‘ambitious’ nature of these policy targets 
should be taken into consideration. Generally, policy makers in Saudi Arabia 
could compare between the different policy targets offered by this thesis and 
determine the most suitable/ feasible one, based upon their experience of the 
local situation and the existing financial and other resources. The progress 
toward achieving the applied policy target should be monitored periodically 
through representative population-based surveys. 
10.4. Recommendations for policy actions 
Based on the findings from this thesis, several recommendations can be 
suggested to reduce the prevalence of T2DM in Saudi Arabia and to improve 
the availability and quality of relevant national data. These recommendations 
are generally compatible with the prevention guidelines of the WHO302, the 
WHO’s Regional Office for the Eastern Mediterranean162, 288, the IDF’s office in 
MENA303, and the GCC Action Plan for prevention and control of diabetes.198 
Relevant recommendations are briefly summarised in this section. 
The comprehensive review undertaken in this thesis (chapter 3) showed that 
the local data on prevalence of T2DM, obesity and smoking are most likely 
credible and representative of the Saudi population. However, such data are 
limited in terms of the number of available surveys and the variations in 
reporting the results. Thus, it would be important to conduct periodic/ regular 
nationwide epidemiological studies to measure the prevalence of T2DM and its 
risk factors (e.g. obesity, physical inactivity, dietary patterns, and smoking). 
These studies should include all age groups of population, preferably measure 
the prevalence of all conditions simultaneously, and report the results in 
consistent age-group-intervals to facilitate future comparison and analysis. 
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Furthermore, the availability and quality of sex- and age-specific data on 
population structure and mortality should be improved by the Saudi CDSI. 
This thesis illustrates the enormous challenge and urgency of addressing the 
epidemics of obesity and diabetes in the Kingdom. The political commitment to 
the prevention of diabetes should be urgently increased if the proposed 
reduction targets are to be attained. Such a political commitment can be 
achieved through making diabetes one of the top priorities within the national 
health care framework. Also, the strength of the national Saudi economy should 
be exploited by allocating a considerable budget for the prevention and 
monitoring of T2DM. Furthermore, governmental support should be gained for 
the approval of some legislation that may help in reducing some of the risk 
factors for T2DM (discussed below). 
A multi-sectoral collaboration of the relevant parties should be increased and 
maintained. There is urgent need for action at all levels, including regulatory/ 
policy changes in sectors beyond health. The Saudi Ministry of Health (MOH) 
should actively involve in the prevention strategy the relevant governmental 
authorities, in addition to some non-governmental organisations (NGOs). 
Examples of relevant governmental authorities include the ministries of 
Education, Information, Transport, Commerce and Industry. NGOs can play 
several roles, such as providing financial support and helping in producing 
public educational programmes and materials regarding T2DM and its risk 
factors. 
Appropriate preventive measures at the community level, which aim to reduce 
the prevalence of obesity, should be an urgent action. These preventive 
measures should focus mainly on promoting healthy diet and physical activity. 
There should be an adequate budget and resources allocated for the recently 
established ‘Diet and Physical Activity Programme’199 (discussed in chapter 3). 
However, as the Programme is still relatively recent, there are no currently 
available data on the levels of patterns of diet and physical activity to monitor 
the progress in implementing the national strategy on physical activity and diet. 
Therefore, it is strongly recommended that such a progress should be carefully 
monitored and maintained. Examples of some urgent recommended measures 
include the following: 
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a) Promoting healthy diet. This can be achieved through intensifying health 
education to public, in order to increase the population knowledge of the 
health risks of diet-related NCDs including diabetes, and the benefits of 
healthy and diverse diets. The public should be educated to restrict 
consumption of fats and sugar and increase consumption of fruit and 
vegetables. Attractive concentrated information should be delivered to the 
whole population via different channels, such as primary health care centres, 
schools, media (e.g. television, internet, magazines), and field public 
campaigns. Importantly, a special focus should be directed on women, who 
have prominently higher rates of obesity than men. In addition, the 
government should be encouraged to establish strict legislation to enforce 
the food industry to develop healthier products and to make clear product 
labelling. Moreover, the relative price and taxes of unhealthy food choices 
can be increased in favour of healthy and less energy-dense foods.  
 
b) Promoting physical activity. This can be achieved through increasing and 
improving the outdoor sport and recreational spaces. However, the weather 
in Saudi Arabia is extremely hot for around six months a year, and this has 
been documented as a major barrier to the outdoor physical activity at that 
period.304 So, alternative measures could be establishment of convenient 
public (non-private) indoor exercise venues or encouraging the use of indoor 
walking trails.  
Physical activity programmes should be implemented and monitored in 
schools and universities. In addition, the community awareness of the 
importance of physical activity should be increased through the different 
channels indicated above, with a special focus on women. Furthermore, 
there should be changes in the transport system and urban planning policy 
toward implementation of a widespread and efficient public transport. This 
could help in promoting physical activity and reducing the currently high 
dependency on private automobiles. 
Appropriate preventive measures at the community level, which aim to reduce 
the prevalence of smoking, should be an urgent action. The awareness of the 
hazards of smoking should be continually increased through the various ways 
indicated above. The recently approved legislations to prohibit smoking at public 
spaces and workplaces201 should be monitored and strictly applied. 
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Governmental support is also required to restrict tobacco imports and 
advertisement, raise its prices, and strictly ban its selling to children and 
adolescents. The existing ‘Tobacco Control Clinics’, which offer free  help and 
advice to people who want to quit tobacco smoking,201 should be strongly 
supported by allocating a sufficient financial budget and manpower. 
Nevertheless, policy makers should take into consideration some potential 
barriers/ challenges that might have an influence on the prevention strategies. 
These challenges could be cultural, political, economic, etc. Generally, it is 
difficult to change a population’s behaviours and dietary beliefs and practices, 
which are mostly traditional and deeply-rooted. In Saudi Arabia, for example, 
preventive strategies should consider the unique cultural and religious nature of 
population, particularly regarding the social restrictions on women’s work and 
physical activity patterns. In addition to establishment of ‘females only’ gyms 
and health clubs, another important starting point could be incorporating 
physical education into the school curriculum for females. Moreover, as 
mentioned in chapter 3, little is known about the regional disparities/ inequalities 
in Saudi Arabia, which probably is a politically sensitive issue. It is 
recommended to make some policy changes in order to provide more detailed 
information on any regional inequalities for proper planning of prevention 
strategies and resource allocation. 
It is important to indicate that the recommendations above focus only on 
primary preventive measures (to reduce the prevalence of T2DM, obesity and 
smoking) as one of the main initial objectives of this thesis, as mentioned in 
chapter 1. However, the findings are also important for the healthcare planning 
in Saudi Arabia. It is strongly recommended to plan the diabetes healthcare 
services properly for the currently large number of ‘patients’ and the further 
projected increase of cases in the next decade. These services should include 
effective and large-scale screening tests for early detection of T2DM in both 
high-risk groups and those with undiagnosed (occult) disease. Regular 
screening of high risk individuals should be implemented in primary health care 
centres and out-patient departments in hospitals. In addition, mass screening 
campaigns should be conducted periodically in other public places, such as 
universities, shopping centres/ malls, etc. It is important to offer the early and 
appropriate treatment to those diagnosed with T2DM by screening tests in order 
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to delay or prevent progression of the disease. In patients with existing T2DM, 
screening programmes for the early detection of complications such as 
retinopathy, nephropathy, coronary heart disease and foot problems are needed 
to reduce resulting morbidity and mortality. In addition to screening, it is 
recommended to ensure the adequate financial and manpower resources 
needed for effective treatment and rehabilitation healthcare services. Diabetes 
healthcare teams should be multidisciplinary comprising physicians, nurses, 
pharmacists, and other diabetes specialists such as dieticians and podiatrists. 
The national treatment guidelines of diabetes, along with an effective referral 
and feedback system should be strictly implemented. Furthermore, sufficient 
supplies of insulin and hypoglycaemic drugs should be continuously maintained 
in primary health care centres and hospitals. 
However, it is crucial for the health policy makers in Saudi Arabia to balance 
action based on the cost effectiveness of different intervention approaches for 
prevention and treatment of T2DM. There is considerable evidence 
investigating the cost effectiveness of different diabetes interventions (mainly in 
developed countries).26, 210, 231, 233, 305, 306 Li et al.307 have conducted a recent 
comprehensive systematic review of 56 studies to synthesise the cost-
effectiveness of interventions to prevent and control diabetes, its complications, 
and comorbidities from 20 countries. They have concluded that many 
interventions intended to prevent and/or treat diabetes are ‘cost saving’ (more 
health benefit at a lower cost) or ‘very cost-effective’ (US$ 25,000 per life per 
LYG or QALY) and supported by ‘strong’ evidence. However, overall, studies 
suggest that prevention (e.g. lifestyle modifications ‘diet, physical activity and 
smoking cessation’ and metformin) is more cost-effective than intensive 
treatment of diabetes.308-310 On the other hand, the higher intervention costs of 
intensive therapy are offset by measured reductions in hospitalisation and 
treatment costs.26, 306 
In terms of diabetes screening, studies showed different findings in different 
countries. For example, the IDF has reported that identifying each case of 
undiagnosed diabetes in Taiwan costs just US$ 17,800 per QALY gained, which 
compares favourably to the US where the cost is US$ 56,000 per QALY gained. 
This comparison between Taiwan and the US highlights that the cost-
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effectiveness of population screening is sensitive to the prevalence of 
undiagnosed diabetes.306 
Information on the cost effectiveness of diabetes interventions is limited from 
developing countries. In Saudi Arabia, for example, a recent interest in diabetes 
health economics research has emerged revealing the massive economic 
burden of diabetes on the healthcare system in the Kingdom. A recent study 
has estimated that diabetic people have medical healthcare expenditures that 
are 10 times higher (US$3,686 vs. US$380) than what expenditures would be in 
the absence of diabetes.311 However, there are no national studies evaluating 
the cost effectiveness of the different approaches of prevention and treatment/ 
control of diabetes in Saudi Arabia. Hence, it is strongly recommended to 
conduct and support such research in order to obtain evidence from the local 
context, which is required for proper healthcare planning and resource 
allocation. A starting point could be, for instance, piloting different preventive 
approaches (primary, secondary and tertiary) in different regions of the country 
and assessing the cost effectiveness accordingly. Also, using the approach of 
modelling for studying the health economics of diabetes should be supported, 
and collaboration between MOH and academic/ research institutions should be 
established for this purpose. 
10.5. Potential future developments of the Saudi IMPACT Diabetes 
Forecast Model 
A number of prospective developments can be undertaken to the model in this 
thesis, provided that the availability of relevant local data will improve in the 
future. 
The model can be improved to involve more risk factors for T2DM in Saudi 
Arabia (e.g. physical inactivity and diet). Incorporation of such risk factors may 
produce more accurate predictions of T2DM prevalence, and provide the 
decision makers with more policy intervention options. 
The model can also be developed to involve ‘dynamic’ transition parameters 
(incidence, case fatality, and total mortality), that change over the modelling 
period. This may also result in more accurate predictions, as these parameters 
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are important to describe the disease epidemiology, and are most likely variable 
over time. 
The population covered by the model can be expanded to include younger age 
groups, which, as previously mentioned, have growing trends of obesity and 
T2DM. This could result in providing more comprehensive policy options in 
terms of prevention of obesity in children (not only adults). Evidence shows that 
obese children are likely to stay obese into adulthood and are more likely to 
develop diabetes at a younger age.312 
The model can be developed to be broader in terms of the modelling outcomes. 
In addition to the predicted prevalence of T2DM, it may be worthwhile to study 
parameters that consider the quality of life of diabetic individuals, such as the 
Quality Adjusted Life Years (QALYs). 
More health states can be added to model the disease epidemiology (e.g. 
involving some common complications of T2DM, such as cardiovascular 
disease, retinopathy, and nephropathy). 
10.6. Potential areas of future research 
Currently, there are no nationwide data on the prevalence of T2DM by 
socioeconomic status (SES). It has been discussed in chapter 2 that the 
prevalence of T2DM is known to vary across different SES strata in developed 
and developing countries. Therefore, it may be useful to include SES as a main 
variable in future national surveys, in order to examine if the local distribution of 
T2DM would be compatible with what has been found in other developing 
countries.135 Furthermore, the current national censuses and surveys do not 
account for ethnicity. As discussed in chapter 3, the Saudi population has a 
large proportion of expatriates of different ethnicities (particularly South and 
Southeast Asians), who probably have higher risk of developing abdominal 
obesity and T2DM at lower ages and BMIs. So, it would be important to include 
ethnicity in censuses and surveys, and to use additional measures of obesity 
(WC and WHR).  
In this thesis, the incidence of diabetes was estimated by DISMOD, and the 
RRs of the disease in obese and in smokers were obtained from literature. It 
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may be important to conduct well designed and monitored prospective studies 
to produce reliable country-specific values for such parameters. 
Moreover, it may be very useful to establish collaboration with the concerned 
departments in the neighbouring GCC countries, in order to test the suitability of 
using the model to predict the trends in T2DM prevalence in these countries. 
These countries are similar to Saudi Arabia in having marked prevalence rates 
(and limited data) of T2DM and its risk factors. This potential collaboration, of 
course, requires the permission of and ongoing coordination with the principal 
developers of the model. 
10.7. Conclusion 
T2DM is a major public health challenge in Saudi Arabia, imposing a massive 
burden on individuals and the health care system. Information on the 
prevalence rates and trends in T2DM and its risk factors in Saudi Arabia are 
currently scarce and patchy. Thus, the availability and quality of population-
based data on the disease and its risk factors should be effectively improved. It 
would be essential to conduct regular nationally-representative studies with 
standardised methods in order to evaluate and monitor the trends in prevalence 
of T2DM and its risk factors. 
The Saudi IMPACT Diabetes Forecast Model is a very useful and validated tool 
to forecast the prevalence of T2DM in Saudi Arabia. In contrast to other models 
that underestimated the true prevalence trends of T2DM in the Kingdom, the 
model in this thesis uses relatively few data requirements, explicitly incorporates 
trends in obesity and smoking prevalence as risk factors, and provides health 
policy makers with a number of useful policy options for prevention. 
The trends and future levels of T2DM in Saudi Arabia are projected in this 
thesis to be substantially high in both sexes, if the current alarming levels of 
obesity and smoking continue to increase, or even are capped at the observed 
prevalence rates. Compared to around 555,000 diabetic people aged 25-64 
years (8.5%) in 1992, there would be nearly 7.4 million diabetic people (44.1%) 
in 2022, assuming a continuing increase of obesity levels, and approximately 
6.6 million (39.5%), assuming capped obesity levels. 
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If the current local policy target for obesity prevalence (10% relative reduction 
from that in 2008) and smoking prevalence (5% relative reduction from that in 
2008) would be successfully achieved, the T2DM prevalence in 2022 could be 
reduced by around 15% (1.1 million individuals). In addition, reducing the 
prevalence of obesity by 10% of that in 2010, or at least halting its rise, can 
result in considerable relative reduction of T2DM prevalence of around 10-13% 
by 2022. This is equivalent to preventing the disease in approximately 740,000 - 
970,000 individuals. Additional reduction of smoking prevalence by 40% of that 
in 2010 can lead to preventing the disease in a reasonable additional number of 
people.  
Overall, this thesis highlights the need for an urgent action to ensure the 
effective implementation, monitoring and maintaining of the existing national 
strategy of prevention of T2DM in Saudi Arabia. Appropriate and effective 
preventive measures should be aggressively implemented at the population 
level to promote physical activity, healthy diet, and smoking cessation.   
290 
 
References 
1 Reece EA. The history of diabetes mellitus. In: Reece EA, Coustan DR, 
eds. Diabetes Mellitus in Pregnancy. New York: Churchill Livingstone 
1995. 
2 Ahmed AM. History of Diabetes Mellitus. Saudi Medical Journal. 
2002;23(4):373-8. 
3 Report of the Expert Committee on the diagnosis and classification of 
diabetes mellitus. Diabetes Care. 1997;20:1183-97. 
4 Narayan KMV, Zhang P, Kanaya AM, Williams DE, Engelgau MM, 
Imperatore G, et al. Diabetes: The Pandemic and Potential Solutions. In: 
Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans 
DB, et al., eds. Disease Control Priorities in Developing Countries. 2nd 
ed. New York: Oxford University Press 2006. 
5 IDF Diabetes Atlas. 4th ed: International Diabetes Federation 2009. 
6 Ekoe J-M, Zimmet P. Diabetes Mellitus: Diagnosis and Classification. In: 
Ekoe J-M, Zimmet P, Williams R, eds. The Epidemiology of Diabetes 
Mellitus: An International Perspective. New York: John Wiley & Sons, 
Ltd. 2001:11-29. 
7 World Health Organization. Global health risks: mortality and burden of 
disease attributable to selected major risks; 2009. [last accessed 
February 2012]. Available from: 
http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_
report_full.pdf. 
8 Rewers M, Hamman RF. Risk Factors for Non-Insulin-Dependent 
Diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, 
Bennett PH, eds. Diabetes in America. 2nd ed: National Institutes of 
Health 1995:179-220. 
9 Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global 
estimates of the prevalence of diabetes for 2011 and 2030. Diabetes 
Research and Clinical Practice. 2011;94(3):311-21. 
10 IDF Diabetes Atlas 2011. 5th edition: International Diabetes Federation. 
[last accessed March 2013]. Available from: 
http://www.idf.org/diabetesatlas/5e/. 
11 Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden 
and costs of chronic diseases in low-income and middle-income 
countries. Lancet. 2007;370:1929-38. 
12 Reddy KS. Cardiovascular diseases in the developing countries: 
dimensions, determinants, dynamics and directions for public health 
action. Public Health Nutrition. 2002;5(1a):231-7. 
291 
 
13 Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, 
et al. National, regional, and global trends in body-mass index since 
1980: systematic analysis of health examination surveys and 
epidemiological studies with 960 country-years and 9· 1 million 
participants. Lancet. 2011;377(9765):557-67. 
14 Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of 
diabetes for 2010 and 2030. Diabetes Research and Clinical Practice. 
2010;87:4-14. 
15 Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of 
Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes 
Care. 2004;27(5):1047-53. 
16 King H, Aubert RE, Herman WH. Global Burden of Diabetes, 1995-2025: 
Prevalence, numerical estimates, and projections. Diabetes Care. 
1998;21(9):1414-31. 
17 Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes 
and its complications: estimates and projections to the year 2010. 
Diabetic Medicine. 1997;14(S5):S7-S85. 
18 Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, 
Khalil MZ, et al. Diabetes mellitus in Saudi Arabia. Saudi Medical 
Journal. 2004;25:1603 - 10. 
19 WHO STEPwise Approach to NCD Surveillance, Country-Specific 
Standard Report, Saudi Arabia; 2005. [last accessed March 2013]. 
Available from: 
www.who.int/chp/steps/2005_SaudiArabia_STEPS_Report_EN.pdf. 
20 Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. 
National, regional, and global trends in fasting plasma glucose and 
diabetes prevalence since 1980: systematic analysis of health 
examination surveys and epidemiological studies with 370 country-years 
and 2·7 million participants. Lancet. 2011;378(9785):31-40. 
21 Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz 
KM, et al. Modeling for Health Care and Other Policy Decisions: Uses, 
Roles, and Validity. Value in Health. 2001;4(5):348-61. 
22 Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, 
McCabe C, et al. Principles of good practice of decision analytic 
modeling in health care evaluation: Report of the ISPOR Task Force on 
Good Research Practices-Modeling Studies. Value Health. 2003;6:9-17. 
23 Davies R, Roderick P, Raftery J. The evaluation of disease prevention 
and treatment using simulation models. European Journal of Operational 
Research. 2003;150(1):53-66. 
24 Yi Y, Philips Z, Bergman G, Burslem K. Economic models in type 2 
diabetes. Current Medical Research and Opinion. 2010;26(9):2105-18. 
292 
 
25 Tucker DMD, Palmer AJ. The cost-effectiveness of interventions in 
diabetes: A review of published economic evaluations in the UK setting, 
with an eye on the future. Primary Care Diabetes. 2011;5(1):9-17. 
26 Clarke P, Gray A, Briggs A, Farmer A, Fenn P, Stevens R, et al. A model 
to estimate the lifetime health outcomes of patients with Type 2 diabetes: 
the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes 
Model (UKPDS no. 68). Diabetologia. 2004;47(10):1747-59. 
27 Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Freemantle N, 
Mathieu C, et al. Development and validation of the Economic 
Assessment of Glycemic Control and Long-Term Effects of diabetes 
(EAGLE) model. Diabetes technology & therapeutics. 2006;8(2):219-36. 
28 Brandle M, Herman WH. The CORE Diabetes Model. Current Medical 
Research and Opinion. 2004;20(1):S1-S3. 
29 Brown JB, Russell A, Chan W, Pedula K, Aickin M. The global diabetes 
model: user friendly version 3.0. Diabetes Research and Clinical 
Practice. 2000;50, Supplement 3(0):S15-S46. 
30 Holman N, Forouhi NG, Goyder E, Wild SH. The Association of Public 
Health Observatories (APHO) Diabetes Prevalence Model: estimates of 
total diabetes prevalence for England, 2010–2030. Diabetic Medicine. 
2011;28(5):575-82. 
31 Boyle J, Thompson T, Gregg E, Barker L, Williamson D. Projection of the 
year 2050 burden of diabetes in the US adult population: dynamic 
modeling of incidence, mortality, and prediabetes prevalence. Population 
Health Metrics. 2010;8(1):29. 
32 Lau RS, Ohinmaa A, Johnson JA. Predicting the Future Burden of 
Diabetes in Alberta from 2008 to 2035. Canadian Journal of Diabetes. 
2011;35(3):274-81. 
33 O'Flaherty M, Critchley J, Wild S, Unwin N, Capewell S. Forecasting 
Diabetes Prevalence: validation of a simple model with few data 
requirements. Journal of Epidemiology and Community Health. 
2011;65(suppl 1):A17. 
34 Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, Arafah MR, Khalil MZ, 
Khan NB, et al. Obesity in Saudi Arabia. Saudi Medical Journal. 
2005;26(5):824-9. 
35 Osman AK, Al-Nozha MM. Risk factors of coronary artery disease in 
different regions of Saudi Arabia. Eastern Mediterranean Health Journal. 
2000;6(2/3):465-74. 
36 Warsy AS, El-Hazmi MAF. Diabetes mellitus, hypertension and obesity- 
common multifactorial disorders in Saudis. Eastern Mediterranean Health 
Journal. 1999;5(6):1236-42. 
293 
 
37 Al-Nuaim AA, Bamgboye EA, Al-Rubeaan KA, Al-Mazrou Y. Overweight 
and Obesity in Saudi Arabian Adult Population, Role of Socio-
demographic Variables. Journal of Community Health. 1997;22(3):211-
23. 
38 Al-Nozha MM, Arafah MR, Al-Mazrou YY, Al-Maatouq MA, Khan NB, 
Khalil MZ, et al. Coronary artery disease in Saudi Arabia. Saudi Medical 
Journal. 2004;25(9):1165-71. 
39 Jarallah JS, Al-Rubeaan KA, Al-Nuaim ARA, Al-Ruhaily AA, Kalantan 
KA. Prevalence and determinants of smoking in three regions of Saudi 
Arabia. Tobacco Control. 1999;8:53-6. 
40 National Obesity Observatory (NOO). Measuring diet and physical 
activity in weight management interventions. March 2011. [last accessed 
March 2013]. Available from: http://www.noo.org.uk/gsf.php5?f=9915. 
41 Definition and Diagnosis of Diabetes Mellitus and Intermediate 
Hyperglycemia/ Report of a WHO/IDF Consultation. Geneva; 2006. [last 
accessed January 2013]. Available from: 
http://www.who.int/diabetes/publications/Definition%20and%20diagnosis
%20of%20diabetes_new.pdf. 
42 Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo 
R. Insulin secretion and action in subjects with impaired fasting glucose 
and impaired glucose tolerance. Diabetes 2006;55:1430-5. 
43 Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes 
Mellitus; Abbreviated Report of a WHO Consultation. Geneva; 2011.  
Available at: http://www.who.int/diabetes/publications/report-
hba1c_2011.pdf  
44 United Nations, Development Policy and Analysis Division, World 
Economic Situation and Prospects (WESP). [last accessed June 2013]. 
Available from: 
http://www.un.org/en/development/desa/policy/wesp/index.shtml. 
45 Zimmet PZ, McCarty DJ, deCourten MP. The Global Epidemiology of 
Non-Insulin Dependent Diabetes Mellitus and the Metabolic Syndrome. 
Journal of Diabetes and Its Complications. 1997;11:60-8. 
46 Boutayeb A, Boutayeb S. The burden of non communicable diseases in 
developing countries. International Journal for Equity in Health. 
2005;4(1):2. 
47 Nielsen JV. Diabetes in the Arab World: Prevalence and risk factors. 
Practical Diabetes International. 1999;16(3):82-6. 
48 Yach D, Hawkes C, Gould CL, Hofman KJ. The Global Burden of 
Chronic Diseases: Overcoming Impediments to Prevention and Control. 
JAMA. 2004 June 2, 2004;291(21):2616-22. 
294 
 
49 Zimmet P. Type 2 (Non-insulin-dependent) diabetes: an epidemiological 
review. Diabetologia. 1982;22:399 - 411. 
50 Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO. Obesity, 
Inactivity, and the Prevalence of Diabetes-Related Cardiovascular 
Comorbidities in the U.S., 2000-2002. Diabetes Care. 2005;28(7):1599-
603. 
51 Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. 
Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk 
Factors, 2001. Journal of American Medical Association (JAMA). 
2003;289(1):76-9. 
52 Hussain A, Rahim MA, Khan AKA, Ali SMK, Vaaler S. Type 2 diabetes in 
rural and urban population: diverse prevalence and associated risk 
factors in Bangladesh. Diabet Med. 2005;22(7):931-6. 
53 Al-Moosa S, Allin S, Jemiai N, Al-Lawati J, Mossialos E. Diabetes and 
urbanization in the Omani population: an analysis of national survey 
data. Population Health Metrics. 2006;4(5). 
54 El-Hazmi MAF, Al-Swailem A, Warsy AS, Sulimani R, Al-Swailem A. 
Prevalence of Diabetes Mellitus in Saudi Arabia. Saudi Medical Journal. 
1995;16(4):294-9. 
55 World Health Organization. Global Burden of Disease 2004 update; 
2008. [last accessed October 2012]. Available at: 
http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004u
pdate_full.pdf. 
56 Manton KG. The global impact of noncommunicable diseases: estimates 
and projections. World health statistics quarterly. 1988;41(3-4):255-66. 
57 Chan JCN, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon K-H, et al. 
Diabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology. 
JAMA. 2009 May 27, 2009;301(20):2129-40. 
58 Weber MB, Oza-Frank R, Staimez LR, Ali MK, Venkat Narayan KM. 
Type 2 Diabetes in Asians: Prevalence, Risk Factors, and Effectiveness 
of Behavioral Intervention at Individual and Population Levels. Annual 
Review of Nutrition. 2012;32(1):417-39. 
59 Voskuhl R. Sex differences in autoimmune diseases. Biol Sex Differ. 
2011;2(1):1. 
60 Gale EAM, Gillespie KM. Diabetes and gender. Diabetologia. 
2001;44(1):3-15. 
61 Spiegelman M, Marks HH. Age and sex variations in the prevalence and 
onset of diabetes mellitus. Am J Public Health. 1946;36:26-33. 
62 Satman I, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, et al. 
Population-based study of diabetes and risk characteristics in Turkey. 
Diabetes Care. 2002;25(9):1551. 
295 
 
63 Malins JM, FitzGerald MG, Wall M. A change in the sex incidence of 
diabetes mellitus. Diabetologia. 1965;1:121-4. 
64 Tull ES, Roseman JM. Diabetes in African Americans. In: Harris MI, 
Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes 
in America. 2nd ed: National Institutes of Health 1995:613-30. 
65 Carulli L, Rondinella S, Lombardini S, Canedi I, Loria P, Carulli N. 
Review article: diabetes, genetics and ethnicity. Alimentary 
pharmacology & therapeutics. 2005;22:16-9. 
66 Schulz LO, Bennett PH, Ravussin E, Kidd JR, Kidd KK, Esparza J, et al. 
Effects of Traditional and Western Environments on Prevalence of Type 
2 Diabetes in Pima Indians in Mexico and the U.S. Diabetes Care. 
2006;29(8):1866-71. 
67 Jaber LA, Brown MB, Hammad A, Nowak SN, Zhu Q, Ghafoor A, et al. 
Epidemiology of Diabetes Among Arab Americans. Diabetes Care. 
2003;26(2):308-13. 
68 Omar M, Seedat M, Dyer R, Rajput M, Motala A, Joubert S. The 
prevalence of diabetes mellitus in a large group of South African Indians. 
South African Medical Journal. 1985;67(23):924-6  
69 Tan CE, Emmanuel SC, Tan BY, Jacob E. Prevalence of diabetes and 
ethnic differences in cardiovascular risk factors. The 1992 Singapore 
National Health Survey. Diabetes Care. 1999 February 1, 
1999;22(2):241-7. 
70 Haffner SM, Hazuda HP, Mitchell BD, Patterson JK, Stern MP. Increased 
incidence of type II diabetes mellitus in Mexican Americans. Diabetes 
Care. 1991;14(2):102. 
71 Marshall JA, Hamman RF, Baxter J, Mayer EJ, Fulton DL, Orleans M, et 
al. Ethnic Differences in Risk Factors Associated with the Prevalence of 
Non-insulin-dependent Diabetes Mellitus: The San Luis Valley Diabetes 
Study. Am J Epidemiol. 1993;137(7):706-18. 
72 Velho G, Froguel P. Type 2 Diabetes: Genetic Factors. In: Ekoe J-M, 
Zimmet P, Williams R, eds. The Epidemiology of Diabetes Mellitus: An 
International Perspective. Chichester: John Wiley & Sons Ltd 2001:141-
53. 
73 Thompson GS. Genetic factors in diabetes mellitus studied by the oral 
glucose tolerance test. Journal of Medical Genetics. 1965;2(4):221. 
74 Hamman RF. Genetic and environmental determinants of non-insulin 
dependent diabetes mellitus (NIDDM). Diabetes Metab Rev. 1993;8:287 
- 338. 
75 Barroso I. Genetics of Type 2 diabetes. Diabetic Medicine. 
2005;22(5):517-35. 
296 
 
76 Barnett AH, Eff C, Leslie RDG, Pyke DA. Diabetes in identical twins. 
Diabetologia. 1981;20(2):87-93. 
77 Mann J, Toeller M. Type 2 Diabetes: Aetiology and Environmental 
Factors. In: Ekoe J-M, Zimmet P, Williams R, eds. The Epidemiology of 
Diabetes Mellitus: An International Perspective. Chichester: John Wiley & 
Sons Ltd 2001:134-40. 
78 van Dam RM. Review: The epidemiology of lifestyle and risk for type 2 
diabetes. European Journal of Epidemiology. 2003;18(12):1115-26. 
79 Whiting D, Unwin N, Roglic G. Diabetes: equity and social determinants. 
In: Blas E, Kurup AS, eds. Equity, social determinants and public health 
programmes. WHO, Geneva 2010:77-94. 
80 Fall CHD. Non-industrialised countries and affluence: Relationship with 
Type 2 diabetes. Br Med Bull. 2001 November 1, 2001;60(1):33-50. 
81 Uusitupa M, Louheranta A, Lindström J, Valle T, Sundvall J, Eriksson J, 
et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition. 
2000;83(Supplement S1):S137-S42. 
82 Tuomilehto J, Lindstrom J, Silventoinen K. Obesity and prevention of 
type 2 diabetes. In: Barnett AH, Kumar S, eds. Obesity and Diabetes. 
Second ed. West Sussex, UK: John Wiley & Sons, Ltd 2009:67-85. 
83 Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, et 
al. Weight Management Through Lifestyle Modification for the Prevention 
and Management of Type 2 Diabetes: Rationale and Strategies. 
Diabetes Care. 2004;27(8):2067-73. 
84 Deurenberg P, Yap M. The assessment of obesity: methods for 
measuring body fat and global prevalence of obesity. Best Practice & 
Research Clinical Endocrinology & Metabolism. 1999;13(1):1-11. 
85 Low S, Chin MC, Deurenberg M. Review on Epidemic of Obesity. Annals 
Academy of Medicine Singapore. 2009;38:57-65. 
86 James PT. Obesity: The Worldwide Epidemic. Clinics in Dermatology 
2004;22:276-80. 
87 WHO Fact Sheet No. 311. Obesity and Overweight. ; September 2006. 
[last accessed January 2013]. Available from: 
http://www.who.int/mediacentre/factsheets/fs311/en/. 
88 Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The Epidemiology of 
Obesity. Gastroenterology. 2007;132(6):2087-102. 
89 WHO expert consultation. Appropriate body-mass index for Asian 
populations and its implications for policy and intervention strategies. 
Lancet. 2004;363:157-63. 
90 World Health Organization, Western Pacific Region. The Asia-Pacific 
perspective: Redefining obesity and its treatment [Document coordinated 
297 
 
by the International Diabetes Institute]; February 2000. [last accessed 
December 2012]. Available from: 
http://www.wpro.who.int/entity/nutrition/documents/docs/Redefiningobesit
y.pdf. 
91 Leong KS, Wilding JP. Obesity and diabetes. Best Practice & Research 
Clinical Endocrinology & Metabolism. 1999;13(2):221-37. 
92 Shelgikar K, Yajnik C, Hockaday T. Central Rather than Generalized 
Obesity is Related to Hyperglycaemia in Asian Indian Subjects. Diabetic 
Medicine. 1991;8(8):712-7. 
93 Knowler WC, Pettitt DJ, Saad MF, Charles MA, Nelson RG, Howard BV, 
et al. Obesity in the Pima Indians: its magnitude and relationship with 
diabetes. Am J Clin Nutr. 1991;53(6):1543S-51. 
94 Cassano PA, Rosner B, Vokonas PS, Weiss ST. Obesity and Body Fat 
Distribution in Relation to the Incidence of Non-lnsulin-dependent 
Diabetes Mellitus: A Prospective Cohort Study of Men in the Normative 
Aging Study. Am J Epidemiol. 1992;136(12):1474-86. 
95 Hodge AM, Collins VR, Zimmet P, Dowse GK. Type 2 Diabetes and 
Obesity. In: Ekoe J-M, Zimmet P, Williams R, eds. The Epidemiology of 
Diabetes Mellitus: An International Perspective. Chichester: John Wiley 
and Sons Ltd. 2001:273-83. 
96 Lazar MA. How Obesity Causes Diabetes: Not a Tall Tale. Science. 
2005;307:373-5. 
97 Guh D, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis A. The 
incidence of co-morbidities related to obesity and overweight: a 
systematic review and meta-analysis. BMC Public Health. 2009;9(1):88. 
98 Everhart JE, Pettitt DJ, Bennett PH, Knowler WC. Duration of obesity 
increases the incidence of NIDDM. Diabetes. 1992;41(2):235. 
99 Sakurai Y, Teruya K, Shimada N, Umeda T, Tanaka H, Muto T, et al. 
Association between duration of obesity and risk of non-insulin-
dependent diabetes mellitus. American Journal of Epidemiology. 
1999;149(3):256. 
100 Vazquez G, Duval S, Jacobs DR, Silventoinen K. Comparison of body 
mass index, waist circumference, and waist/hip ratio in predicting 
incident diabetes: a meta-analysis. Epidemiologic reviews. 
2007;29(1):115. 
101 McKeigue PM, Shah B, Marmot MG. Relation of central obesity and 
insulin resistance with high diabetes prevalence and cardiovascular risk 
in South Asians. Lancet. 1991;337(8738):382-6. 
102 U.S. Department of Health and Human Services. Physical Activity and 
Health: A Report of the Surgeon General. Atlanta, GA, U.S. Department 
of Health and Human Services, Centers for Disease Control and 
298 
 
Prevention, National Center for Chronic Disease Prevention and Health 
Promotion; 1996. [last accessed January 2013]. Available from: 
http://www.cdc.gov/nccdphp/sgr/pdf/sgrfull.pdf. 
103 Bassuk SS, Manson JE. Epidemiological evidence for the role of physical 
activity in reducing risk of type 2 diabetes and cardiovascular disease. 
Journal of Applied Physiology. 2005;99(3):1193-204. 
104 Jakicic JM, Otto AD. Physical activity considerations for the treatment 
and prevention of obesity. The American journal of clinical nutrition. 
2005;82(1):226S. 
105 Kriska AM, Saremi A, Hanson RL, Bennett PH, Kobes S, Williams DE, et 
al. Physical activity, obesity, and the incidence of type 2 diabetes in a 
high-risk population. American Journal of Epidemiology. 
2003;158(7):669. 
106 Seidell JC. Dietary fat and obesity: an epidemiologic perspective. The 
American journal of clinical nutrition. 1998;67(3):546S. 
107 Jebb SA. Aetiology of obesity. British Medical Bulletin. 1997;53(2):264. 
108 Vögele C. Etiology of obesity. In: Munsch S, Beglinger C, eds. Obesity 
and binge eating disorder. Basel: Karger 2005:62-73. 
109 Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK, Ferrannini 
E. Parental history of diabetes is associated with increased 
cardiovascular risk factors. Arteriosclerosis, Thrombosis, and Vascular 
Biology. 1989;9(6):928-33. 
110 Fujimoto WY, Leonetti DL, Newell-Morris L, Shuman WP, Wahl PW. 
Relationship of absence or presence of a family history of diabetes to 
body weight and body fat distribution in type 2 diabetes. International 
Journal of Obesity. 1991;15(2):111. 
111 Cederholm J, Wibell L. Impaired glucose tolerance: influence by 
environmental and hereditary factors. Diabète & métabolisme. 
1991;17(2):295. 
112 Frenk J, Bobadilla JL, SepuuLveda J, Cervantes ML. Health transition in 
middle-income countries: new challenges for health care. Health Policy 
and Planning. 1989;4(1):29-39. 
113 Lumey LH, Van Poppel FWA. The Dutch Famine of 1944-45: Mortality 
and Morbidity in Past and Present Generations. Soc Hist Med. 
1994;7(2):229-46. 
114 Khatib O. Noncommunicable diseases: risk factors and regional 
strategies for prevention and care. Eastern Mediterranean Health 
Journal. 2004;10( 6):778-88. 
115 Ludwig DS, Peterson KE, Gortmaker SL. Relation between consumption 
of sugar-sweetened drinks and childhood obesity: a prospective, 
observational analysis. Lancet. 2001;357:505-8. 
299 
 
116 Tsunehara CH, Leonetti DL, Fujimoto WY. Animal fat and cholesterol 
intake is high in men with IGT progressing to NIDDM. Diabetes. 
1991;40:427A. 
117 Peterson DB, Lambert J, Gerring S, Darling P, Carter RD, Jelfs R, et al. 
Sucrose in the diet of diabetic patients - just another carbohydrate? 
Diabetologia. 1986;29:216-20. 
118 Lundgren H, Bengtsson C, Blohme G, Isaksson B, Lapidus L, A.Lenner 
R, et al. Dietary habits and incidence of noninsulin-dependent diabetes 
mellitus in a population study of women in Gothenburg, Sweden. 
American Journal of Clinical Nutrition. 1989;49:708-12. 
119 Marshall JA, Hamman RF, Baxter J. High-fat, low-carbohydrate diet and 
the etiology of non-insulin-dependent diabetes mellitus: the San Luis 
Valley Diabetes Study. American Journal of Epidemiology. 
1991;134(6):590. 
120 Colditz GA, Manson JE, Stampfer MJ, Rosner B, Willett WC, Speizer FE. 
Diet and risk of clinical diabetes in women. The American journal of 
clinical nutrition. 1992;55(5):1018. 
121 Perry IJ, Wannamethee SG, Walker MK, Thomson AG, Whincup PH, 
Shaper AG. Prospective study of risk factors for development of non-
insulin dependent diabetes in middle aged British men. BMJ. 
1995;310(6979):560-4. 
122 Uchimoto S, Tsumura K, Hayashi T, Suematsu C, Endo G, Fujii S, et al. 
Impact of cigarette smoking on the incidence of Type 2 diabetes mellitus 
in middle‐aged Japanese men: the Osaka Health Survey. Diabetic 
Medicine. 1999;16(11):951-5. 
123 Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective 
study of cigarette smoking, alcohol use, and the risk of diabetes in men. 
BMJ. 1995;310(6979):555-9. 
124 Ko GTC, Chan JCN, Tsang LWW, Critchley J, Cockram CS. Smoking 
and diabetes in Chinese men. Postgraduate medical journal. 
2001;77(906):240-3. 
125 Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, 
et al. Cigarette smoking and the risk of diabetes in women. American 
Journal of Public Health. 1993;83(2):211. 
126 Hu FB, Manson JAE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. 
Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. New 
England Journal of Medicine. 2001;345(11):790-7. 
127 Chiolero A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for 
body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 
2008 April 1, 2008;87(4):801-9. 
300 
 
128 Eliasson B. Cigarette smoking and diabetes. Progress in Cardiovascular 
Diseases. 2003;45(5):405-13. 
129 Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes 
Care. 1999 November 1, 1999;22(11):1887-98. 
130 Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active Smoking 
and the Risk of Type 2 Diabetes: A Systematic Review and Meta-
analysis. JAMA. 2007;298(22):2654-64. 
131 Kim JK. Hyperinsulinemic–Euglycemic Clamp to Assess Insulin 
Sensitivity In Vivo. Methods in Molecular Biology. 2009;560:221-38. 
132 Monzillo LU, Hamdy O. Evaluation of Insulin Sensitivity in Clinical 
Practice and in Research Settings. Nutrition Reviews. 2003;61(12):397-
412. 
133 Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for 
assessing insulin sensitivity and resistance in vivo: advantages, 
limitations, and appropriate usage. American Journal of Physiology - 
Endocrinology And Metabolism. 2008;294(1):E15-E26. 
134 Eliasson B, Attvall S, Taskinen MR, Smith U. The insulin resistance 
syndrome in smokers is related to smoking habits. Arteriosclerosis, 
Thrombosis, and Vascular Biology. 1994;14(12):1946-50. 
135 Monteiro CA, Moura EC, Conde WL, Popkin BM. Socioeconomic status 
and obesity in adult populations of developing countries: a review. 
Bulletin of the World Health Organization. 2004;82:940-6. 
136 Cunningham J, O’Dea K, Dunbar T, Weeramanthri T, Shaw J, Zimmet P. 
Socioeconomic status and diabetes among urban Indigenous Australians 
aged 15-64 years in the DRUID study. Ethnicity & Health. 2008;13(1):23-
37. 
137 Rabi DM, Edwards AL, Southern DA, Svenson LW, Sargious PM, Norton 
P, et al. Association of socio-economic status with diabetes prevalence 
and utilization of diabetes care services. BMC Health Services Research. 
2006;6:124. 
138 Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, 
Walker EA, et al. Reduction in the Incidence of Type 2 Diabetes with 
Lifestyle Intervention or Metformin. New England Journal of Medicine. 
2002;346(6):393-403. 
139 Warburton DER, Nicol CW, Bredin SSD. Health benefits of physical 
activity: the evidence. Canadian medical association journal. 
2006;174(6):801-9. 
140 Hur NW, Kim HC, Nam CM, Jee SH, Lee HC, Suh I. Smoking cessation 
and risk of type 2 diabetes mellitus: Korea Medical Insurance 
Corporation Study. European Journal of Cardiovascular Prevention & 
Rehabilitation. 2007;14(2):244-9. 
301 
 
141 Eriksson K, Lindgärde F. Prevention of Type 2 (non-insulin-dependent) 
diabetes mellitus by diet and physical exercise The 6-year Malmö 
feasibility study. Diabetologia. 1991;34(12):891-8. 
142 Pan X-R, Li G-W, Hu Y-H, Wang J-X, Yang W-Y, An Z-X, et al. Effects of 
Diet and Exercise in Preventing NIDDM in People With Impaired Glucose 
Tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care. 
1997;20(4):537-44. 
143 Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention 
or Metformin. New England Journal of Medicine. 2002;346(6):393-403. 
144 Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. 
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM 
randomised trial. Lancet. 2002;359(9323):2072-7. 
145 Azen PSP, Peters DRK, Berkowitz MDK, Kjos MDS, Xiang PA, 
Buchanan MDTA. TRIPOD (TRoglitazone In the Prevention Of 
Diabetes): A Randomized, Placebo-Controlled Trial of Troglitazone in 
Women with Prior Gestational Diabetes Mellitus. Controlled Clinical 
Trials. 1998;19(2):217-31. 
146 Sartor G, Scherstén B, Carlström S, Melander A, Nordén Å, Persson G. 
Ten-year Follow-up of Subjects with Impaired Glucose Tolerance: 
Prevention of Diabetes by Tolbutamide and Diet Regulation. Diabetes. 
1980;29(1):41-9. 
147 Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC. The 
fasting hyperglycaemia study: II. Randomized controlled trial of 
reinforced healthy-living advice in subjects with increased but not 
diabetic fasting plasma glucose. Metabolism. 1997;46, Supplement 
1(0):50-5. 
148 Yang W, Lin L, Qi J, Yu Z, Pei H, He G, et al. The preventive effect of 
acarbose and metformin on the progression to diabetes mellitus in the 
IGT population: a 3-year multicenter prospective study. Chin J Endocrinol 
Metab. 2001;17:131-6. 
149 Tonstad S. Cigarette smoking, smoking cessation, and diabetes. 
Diabetes Research and Clinical Practice. 2009;85(1):4-13. 
150 Yeh HC, Duncan BB, Schmidt Mis WNY, Brancati FL. Smoking, smoking 
cessation, and risk for type 2 diabetes mellitus. Annals of Internal 
Medicine. 2010;152(1):10-7. 
151 Wannamethee SG, Shaper AG, Perry IJ. Smoking as a Modifiable Risk 
Factor for Type 2 Diabetes in Middle-Aged Men. Diabetes Care. 
2001;24(9):1590-5. 
152 Hinman AR. Global progress in infectious disease control. Vaccine. 
1998;16(11-12):1116-21. 
302 
 
153 Diabetes cases could double in developing countries in next 30 years 
(WHO Press Release). Saudi Medical Journal. 2004;25(1):126-7. 
154 Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the 
diabetes epidemic. Nature. 2001;414:782-7. 
155 Songer T. The economic costs of NIDDM. Diabetes/Metabolism 
Reviews. 1992;8:389-404. 
156 Economic Costs of Diabetes in the U.S. in 2007. Diabetes Care. 2008 
March 2008;31(3):596-615. 
157 Barendregt JJ, Baan CA, Bonneux L. An Indirect Estimate of the 
Incidence of Non-Insulin Dependent Diabetes Mellitus. Epidemiology. 
2000;11(3):274-9. 
158 Marmot MG, Kogevinas M, Elston MA. Social/economic status and 
disease. Annual Review of Public Health. 1987;8:111-35. 
159 Swai ABM, McLarty DG, Kitange HM, Kilima PM, Tatalla S, Keen N, et 
al. Low prevalence of risk factors for coronary heart disease in rural 
Tanzania. International Journal of Epidemiology. 1993;22(4):651-9. 
160 Pérez-Bravo F, Carrasco E, Santos JL, Calvillán M, Larenas G, Albala C. 
Prevalence of type 2 diabetes and obesity in rural Mapuche population 
from Chile. Nutrition. 2001;17(3):236-8. 
161 Campos H, Mata L, Siles X, Vives M, Ordovas JM, Schaefer EJ. 
Prevalence of cardiovascular risk factors in rural and urban Costa Rica. 
Circulation. 1992;85(2):648-58. 
162 Khatib OMN. Guidelines for the prevention, management and care of 
diabetes mellitus: World Health Organization, Regional Office for the 
Eastern Mediterranean [EMRO Technical Publication Series, No. 32]; 
2006. 
163 Boutayeb A. The double burden of communicable and non-
communicable diseases in developing countries. Transactions of the 
Royal Society of Tropical Medicine and Hygiene. 2006;100(3):191-9. 
164 Wandell PE, Johansson SE, Gafvels C, Hellenius ML, deFaire U, 
Sundquist J. Estimation of diabetes prevalence among immigrants from 
the Middle East in Sweden by using three different data sources. 
Diabetes and Metabolism. 2008;34:328-33. 
165 Musaiger AO. Overweight and obesity in the Eastern Mediterranean 
Region: can we control it? Eastern Mediterranean Health Journal. 
2004;10(6):789-93. 
166 Taylor J, Musaiger AO. The changing health of the Middle Esat 
population through oil and automobiles. European Heart Journal. 
2009;30:1291-300. 
303 
 
167 International Diabetes Federation. IDF Diabetes Atlas 5th Edition 2012 
Update: Country specific factsheets (MENA Region). [last accessed 
February 2013]. Available from: 
http://www.idf.org/sites/default/files/MENA_5E_Update_Country.pdf. 
168 Gulf Cooperation Council, Secretary General (Official website). [last 
accessed January 2013]  Available from: http://www.gcc-sg.org/. 
169 Al-Hamdan N, Ravichandraan K, Al-Sayyad J, Al-Lawati J, Khazal Z, Al-
Khateeb F. Incidence of cancer in Gulf Cooperation Council countries, 
1998-2001. Eastern Mediterranean Health Journal. 2009;15(3):600-11. 
170 The World Bank. World Development Indicators database; 2009. [last 
accessed December 2012]. Available from: 
http://databank.worldbank.org. 
171 Mabry RM, Reevest MM, Eakint EG, Owent N. Gender differences in 
prevalence of the metabolic syndrome in Gulf Cooperation Council 
Countries: a systematic review. Diabetic Medicine. 2010;27:593-7. 
172 Al-Rashdan I, Al-Nesef Y. Prevalence of Overweight, Obesity, and 
Metabolic Syndrome Among Adult Kuwaitis: Results From Community-
based National Survey. Angiology. 2010;61(1):42-8. 
173 Bener A, Zirie M, Janahi IM, Al-Hamaq AOAA, Musallam M, Wareham 
NJ. Prevalence of diagnosed and undiagnosed diabetes mellitus and its 
risk factors in a population-based study of Qatar. Diabetes Research and 
Clinical Practice. 2009;84(1):99-106. 
174 Malik M, Bakir A, Saab BA, Roglic G, King H. Glucose intolerance and 
associated factors in the multi-ethnic population of the United Arab 
Emirates: results of a national survey. Diabetes Research and Clinical 
Practice. 2005;69:188-95. 
175 Al-Lawati JA, Al Riyami AM, Mohammed AJ, Jousilahti P. Increasing 
prevalence of diabetes mellitus in Oman. Diabet Med. 2002;19:954 - 7. 
176 Abdella N, Arouj MA, Nakhi AA, Assoussi AA, Moussa M. Non-insulin-
dependent diabetes in Kuwait: prevalence rates and associated risk 
factors. Diabetes Research and Clinical Practice. 1998;42:187-96. 
177 Al-Mahroos F, McKeigue PM. High prevalence of diabetes in Bahrainis: 
Associations with ethnicity and raised plasma cholesterol. Diabetes Care. 
1998;21(6):936-42. 
178 Asfour MG, Lambourne A, Soliman A, Al-Behlani S, Al-Asfoor D, Bold A, 
et al. High Prevalence of Diabetes Mellitus and Impaired Glucose 
Tolerance in the Sultanate of Oman: Results of the 1991 National 
Survey. Diabet Med. 1995;12:1122 - 5. 
179 Al-Lawati J, Jousilahti P. Prevalence and 10-year Secular Trend of 
Obesity in Oman. Saudi Medical Journal. 2004;25:346 - 51. 
304 
 
180 Al-Riyami AA, Afifi MM. Prevalence and correlates of obesity and central 
obesity among Omani adults. Saudi Medical Journal. 2003;24(6):641-6. 
181 Musaiger AO, Al-Mannai MA. Weight, height, body mass index and 
prevalence of obesity among the adult population in Bahrain. Annals of 
Human Biology. 2001;28(3):346-50. 
182 Al-Mahroos F, Al-Roomi K. Obesity among adult Bahraini population: 
impact of physical activity and educational level. Annals of Saudi 
Medicine. 2001;21(3-4):183-7. 
183 Riyami AAA, Afifi M. Smoking in Oman: prevalence and characteristics of 
smokers. Eastern Mediterranean Health Journal. 2004;10(4/5):600-9. 
184 Hamadeh RR, McPherson K, Doll R. Prevalence of smoking in Bahrain. 
Tobacco Control. 1992;1:102-6. 
185 Memon A, Moody PM, Sugathan TN, el-Gerges N, al-Bustan M, al-Shatti 
A, et al. Epidemiology of smoking among Kuwaiti adults: prevalence, 
characteristics, and attitudes. Bulletin of the World Health Organization. 
2000;78:1306-15. 
186 World Health Organization. Country brief - Saudi Arabia. [last accessed 
October 2012]. Available from: 
http://www.who.int/countryfocus/cooperation_strategy/ccsbrief_sau_en.p
df. 
187 Central Department of Statistics and Information, Saudi Arabia. Detailed 
Results: Population & Housing Census, 2004 (Arabic). [last accessed 
December 2012]. Available from: 
http://www.cdsi.gov.sa/pdf/Detail_Census_1425.pdf. 
188 Ministry of Health, Saudi Arabia (Official website). MOH Statistical Year 
Books [cited January 2013]. Available from: http://www.moh.gov.sa/. 
189 Al-Yousuf M, Akerele TM, Al-Mazrou YY. Organization of the Saudi 
health system. Eastern Mediterranean Health Journal. 2002;8(4 and 
5):645-53. 
190 U.S. Department of State. Electronic Information and Publications, 
Background Notes, Saudi Arabia. [last accessed November 2012]. 
Available from: http://www.state.gov/r/pa/ei/bgn/3584.htm. 
191 The Central Intelligence Agency (Official website). The World Factbook. 
[last accessed June 2013]. Available from: 
https://www.cia.gov/library/publications/the-world-
factbook/fields/2112.html. 
192 WHO Regional Health Systems Observatory- EMRO. Health System 
Profile, Saudi Arabia. Cairo; 2006. [last accessed January 2013].  
Available from: 
http://gis.emro.who.int/HealthSystemObservatory/PDF/Saudi%20Arabia/
Full%20Profile.pdf 
305 
 
 193 Almalki M, Fitzgerald G, Clark M. Health care system in Saudi Arabia: an 
overview. Eastern Mediterranean Health Journal. 2011;17(10):784-93. 
194 Ministry of Finance, Saudi Arabia (Official website). [last accessed 
January 2013]. Available from: http://www.mof.gov.sa/. 
195 Country Cooperation Strategy for WHO and Saudi Arabia 2006–2011. 
World Health Organization, Regional Office for the Eastern 
Mediterranean. Cairo; 2006. 
196 Kumosani TA, Alama MN, Iyer A. Cardiovascular diseases in Saudi 
Arabia. Prime Research on Medicine (PROM). 2011;1:1-6. 
197 General Directorate of Non-communicable Diseases, Ministry of Health, 
Saudi Arabia (Arabic).   [cited January 2013; Available from: http://moh-
ncd.gov.sa/ 
198 The GCC action plan for prevention and control of diabetes (2008-2018) 
(Arabic). [last accessed February 2013]. Available from: 
http://sgh.org.sa/Portals/0/PDF/Conventions/gcc_plane_DM.pdf. 
199 Diet and Physical Activity Programme, the General Directorate of Non-
communicable Diseases (Arabic). [last accessed January 2013]. 
Available from: http://www.dietpa.org/ar/index.php. 
200 World Health Organization. Global Strategy on Diet, Physical Activity and 
Health. [last accessed January 2013]. Available from: 
http://www.who.int/entity/dietphysicalactivity/strategy/eb11344/strategy_e
nglish_web.pdf. 
201 Al-Munif MA. Report On Tobacco Control Program of Ministry Of Health 
In Saudi Arabia. Ministry of Health, Assisting Agency to the Preventive 
Medicine, Tobacco Control Program; 2009. [last accessed February 
2013]. Available from: www.tcp-
sa.info/photos/files/REPORT_ON_TCP.pdf. 
202 Al-Nuaim AR. Prevalence of Glucose Intolerance in Urban and Rural 
Communities in Saudi Arabia. Diabetic Medicine. 1997;14:595-602. 
203 Elhadd TA, Al-Amoudi AA, Alzahrani AS. Epidemiology, Clinical and 
Complications Profile of Diabetes in Saudi Arabia: A Review. Annals of 
Saudi Medicine. 2007;27(4):241-50. 
204 Bassiony MM. Smoking in Saudi Arabia. Saudi Medical Journal. 
2009;30(7):876-81. 
205 Azhar A, Alsayed N. Prevalence of Smoking among Female Medical 
Students in Saudai Arabia. Asian Pacific Journal of Cancer Prevention. 
2012;13(9):4245-8. 
206 Wali SO. Smoking habits among medical students in Western Saudi 
Arabia. Saudi Medical Journal. 2011;32(8):843-8. 
306 
 
207 Critchley JA, Capewell S. Why model coronary heart disease? European 
Heart Journal. 2002;23(2):110-6. 
208 National Research Council: Improving Information for Social Policy 
Decisions: The Uses of Microsimulation Modeling, Vol. 1, Review and 
Recommendations. Washington: National Academy Press, 1991. 
209 Rutter CM, Zaslavsky AM, Feuer EJ. Dynamic Microsimulation Models 
for Health Outcomes. Medical Decision Making. 2011;31(1):10-8. 
210 Coyle D, Lee KM, O'Brien BJ. The Role of Models Within Economic 
Analysis: Focus on Type 2 Diabetes Mellitus. Pharmacoeconomics. 
2002;20(1):11-9. 
211 Bagust A, Hopkinson PK, Maier W, Currie CJ. An economic model of the 
long-term health care burden of Type II diabetes. Diabetologia. 
2001;44:2140-55. 
212 Mainous A, Baker R, Koopman R, Saxena S, Diaz V, Everett C, et al. 
Impact of the population at risk of diabetes on projections of diabetes 
burden in the United States: an epidemic on the way. Diabetologia. 
2007;50(5):934-40. 
213 Sonnenberg FA, Roberts MS, Tsevat J, Wong JB, Barry M, Kent DL. 
Toward a peer review process for medical decision analysis models. 
Medical Care. 1994;32:JS52-JS64. 
214 Sonnenberg FA, Beck JR. Markov Models in Medical Decision Making: A 
Practical Guide. Med Decis Making. 1993;13:322-38. 
215 O'Flaherty M. Simulating cohorts with Markov models (Power Point 
Presentation) (Unpublished); 2010. 
216 Briggs A, Sculpher M. An Introduction to Markov Modelling for Economic 
Evaluation. Pharmacoeconomics. 1998;13(4):397-409. 
217 Beck JR, Pauker SG. The Markov Process in Medical Prognosis. Medical 
Decision Making. 1983;3(4):419-58. 
218 Xin S. Markov Modelling in Healthcare Economic Evaluations. Chin J 
Evid-based Med. 2007;7(10):750-6. 
219 O'Flaherty M, Capewell S, Critchley J, Unwin N. The MEDCHAMPS 
IMPACT Diabetes model: A brief description, WP3/4 Technical Paper 1 
(Unpublished); November 2009. 
220 Honeycutt AA, Boyle JP, Broglio KR, Thompson TJ, Hoerger TJ, Geiss 
LS, et al. A Dynamic Markov Model for Forecasting Diabetes Prevalence 
in the United States through 2050. Health Care Management Science. 
2003;6(3):155-64. 
221 Chubb MC, Jacobsen KH. Mathematical modeling and the 
epidemiological research process. European Journal of Epidemiology. 
2010;25:13-9. 
307 
 
222 Walker D, Fox-Rushby J. Allowing for uncertainty in economic 
evaluations: qualitative sensitivity analysis. Health Policy and Planning. 
2001;16(4):435-43. 
223 Briggs A. Probabilistic analysis of cost-effectiveness models: statistical 
representation of parameter uncertainty. Value Health. 2005;8:1-2. 
224 Baio G, Dawid AP. Probabilistic sensitivity analysis in health economics. 
Statistical Methods in Medical Research; Published online 18 September 
2011. 
225 Oakley JE, O'Hagan A. Probabilistic sensitivity analysis of complex 
models: a Bayesian approach. Journal of the Royal Statistical Society: 
Series B (Statistical Methodology). 2004;66(3):751-69. 
226 Palmer AJ, Rozea S, Valentinea WJ, Minshallb ME, Foosa V, Luratia 
FM, et al. Validation of the CORE Diabetes Model Against 
Epidemiological and Clinical Studies. Current Medical Research and 
Opinion. 2004;20(s1):S27-S40. 
227 Unal B. Modeling coronary heart disease in the UK: past trends and 
future implications [PhD thesis]: University of Liverpool; November 2003. 
228 Computer Modeling of Diabetes and Its Complications. Diabetes Care. 
2007 June 2007;30(6):1638-46. 
229 American Diabetes Association Consensus Panel. Guidelines for 
Computer Modeling of Diabetes and Its Complications. Diabetes Care; 
2004; 27(9): 2262-2265. 
230 Knezevic M. Estimating the long-term costs of diabetic kidney disease: 
an economic approach. Applied Economics Letters. 2009;16(10):1059-
64. 
231 Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. 
The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, 
Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 
1 and 2) to Support Clinical and Reimbursement Decision-making. 
Current Medical Research and Opinion. 2004;20(s1):S5-S26. 
232 Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, 
et al. Model of complications of NIDDM: I. Model construction and 
assumptions. Diabetes Care. 1997;20(5):725-34. 
233 Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, 
Maier W, et al. Model of complications of NIDDM: II. Analysis of the 
health benefits and cost-effectiveness of treating NIDDM with the goal of 
normoglycemia. Diabetes Care. 1997;20(5):735-44. 
234 Chen J, Alemao E, Yin D, Cook J. Development of a diabetes treatment 
simulation model: with application to assessing alternative treatment 
intensification strategies on survival and diabetes-related complications. 
Diabetes, Obesity and Metabolism. 2008;10:33-42. 
308 
 
235 Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. 
Projection of diabetic retinopathy and other major eye diseases among 
people with diabetes mellitus: United States, 2005-2050. Archives of 
ophthalmology. 2008;126(12):1740. 
236 McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs 
and outcomes from changes in risk factors in type 2 diabetes using the 
Cardiff stochastic simulation cost-utility model (DiabForecaster). Current 
Medical Research and Opinion. 2006;22(1):121-9. 
237 The CDC Diabetes Cost-effectiveness Group . Cost-effectiveness of 
intensive glycemic control, intensified hypertension control, and serum 
cholesterol level reduction for type 2 diabetes. JAMA. 
2002;287(19):2542-2551. 
238 Zhou H, Isaman DJM, Messinger S, Brown MB, Klein R, Brandle M, et al. 
A Computer Simulation Model of Diabetes Progression, Quality of Life, 
and Cost. Diabetes Care. 2005 December 2005;28(12):2856-63. 
239 Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the Future 
Diabetes Population Size and Related Costs for the U.S. Diabetes Care. 
2009;32(12):2225-9. 
240 Magliano DJ, Shaw JE, Shortreed SM, Nusselder WJ, Liew D, Barr ELM, 
et al. Lifetime risk and projected population prevalence of diabetes. 
Diabetologia. 2008;51(12):2179-86. 
241 Martinsen N, Jorgensen ME, Bjerregaard P, Krasnik A, Carstensen B, 
Borch-Johnsen K. Predictions of type 2 diabetes and complications in 
Greenland in 2014. International Journal of Circumpolar Health. 
2006;65(3):243. 
242 Narayan KMV, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact 
of Recent Increase in Incidence on Future Diabetes Burden: U.S., 2005-
2050. Diabetes Care. 2006;29(9):2114-6. 
243 Bagust A, Hopkinson PK, Maslove L, Currie CJ. The projected health 
care burden of Type 2 diabetes in the UK from 2000 to 2060. Diabetic 
Medicine. 2002;19:1-5. 
244 Ruwaard D, Hoogenveen RT, Verkleij H, Kromhout D, Casparie AF, Van 
der Veen EA. Forecasting the number of diabetic patients in The 
Netherlands in 2005. American Journal of Public Health. 1993;83(7):989-
95. 
245 Helms RB. Implications of population growth on prevalence of diabetes: 
a look at the future. Diabetes Care. 1992;15(Suppl 1):6-9. 
246 Unal B, Critchley JA, Capewell S. Explaining the decline in coronary 
heart disease mortality in England and Wales between 1981 and 2000. 
Circulation. 2004;109(9):1101-7. 
309 
 
247 Laatikainen T, Critchley J, Vartiainen E, Salomaa V, Ketonen M, 
Capewell S. Explaining the Decline in Coronary Heart Disease Mortality 
in Finland between 1982 and 1997. American Journal of Epidemiology. 
2005;162(8):764-73. 
248 Capewell S, Ford ES, Croft JB, Critchley JA, Greenlund KJ, Labarthe 
DR. Cardiovascular risk factor trends and potential fir reducing coronary 
heart disease mortality in the United States of America. Bulletin of the 
World Health Organization. 2010;88:120-30. 
249 Critchley J, Liu J, Zhao D, Wei W, Capewell S. Explaining the increase in 
coronary heart disease mortality in Beijing between 1984 and 1999. 
Circulation. 2004;110(10):1236-44. 
250 O'Flaherty M, Critchley J, Unwin N, Capewell S. The  IMPACT Diabetes 
Forecast Model (unpublished). October 2009. 
251 Central Department of Statistics and Information, Kingdom of Saudi 
Arabia (Official website). [last accessed February 2013]. Available from: 
http://www.cdsi.gov.sa/english/. 
252 The United Nations; Department of Economic and Social Affairs. 
Population Division, Population Estimates and Projections Section. 
Detailed indicators. [cited 2011; Available from: 
http://esa.un.org/unpd/wpp/unpp/panel_indicators.htm   
253 Al-Baghli NA, Al-Ghamdi AJ, Al-Turki KA, El-Zubaier AG, Al-Ameer MM, 
Al-Baghli FA. Overweight and obesity in the eastern province of Saudi 
Arabia. Saudi Medical Journal. 2008;29(9):1319-25. 
254 Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of Obesity and 
Trends in the Distribution of Body Mass Index Among US Adults, 1999-
2010. JAMA: The Journal of the American Medical Association. 2012 
February 1, 2012;307(5):491-7. 
255 National Obesity Observatory (NOO). [last accessed March 2013]. 
Available from: www.noo.org.uk  
256 Rokholm B, Baker JL, Sørensen TIA. The levelling off of the obesity 
epidemic since the year 1999–a review of evidence and perspectives. 
obesity reviews. 2010;11(12):835-46. 
257 Kruijshaar ME, Barendregt JJ, Hoeymans N. The use of models in the 
estimation of disease epidemiology. Bulletin of the World Health 
Organization. 2002;80(8):622-8. 
258 Barendregt JJ, Oortmarssen GJv, Vos T, Murray CJ. A generic model for 
the assessment of disease epidemiology: the computational basis of 
DisMod II. Population Health Metrics 2003;1:4. 
259 Baan CA, Nusselder WJ, Barendregt JJ, Ruwaard D, Bonneux L, 
Feskens EJM. The burden of mortality of diabetes mellitus in The 
Netherlands. Epidemiology. 1999:184-7. 
310 
 
260 Muggeo M, Verlato G, Bonora E, Bressan F, Girotto S, Corbellini M, et al. 
The Verona diabetes study: a population-based survey on known 
diabetes mellitus prevalence and 5-year all-cause mortality. Diabetologia. 
1995;38(3):318-25. 
261 Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et 
al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic 
Review and Meta-analysis. The American Journal of Medicine. 
2009;122(3):248-56.e5. 
262 World Health Organization. WHO Global Health Observatory Data 
Repository. [cited 2011; Available from: 
http://apps.who.int/ghodata/?vid=61440. 
263 Szklo M, Nieto FJ. Epidemiology: beyond the basics: Jones & Bartlett 
Learning 2007. 
264 Hennekens CH, Buring JE. Epidemiology in Medicine. First ed. United 
States of America: Little, Brown and Company 1987. 
265 Kopec J, Fines P, Manuel D, Buckeridge D, Flanagan W, Oderkirk J, et 
al. Validation of population-based disease simulation models: a review of 
concepts and methods. BMC Public Health. 2010;10(1):710. 
266 Shaw JE, de Courten M, Boyko EJ, Zimmet PZ. Impact of new diagnostic 
criteria for diabetes on different populations. Diabetes Care. 
1999;22(5):762-6. 
267 Al-Lawati JA, Mohammed AJ. Diabetes in Oman: comparison of 1997 
American Diabetes Association classification of diabetes mellitus with 
1985 WHO classification. Annals of Saudi Medicine. 2000;20(1):12-5. 
268 Musingarimi P. Obesity in the UK: A Review and Comparative Analysis 
of Policies within the Devolved Regions. The International Longevity 
Centre - UK (ILC-UK), February 2008. [last accessed January 2013]. 
Available at: http://www.ilcuk.org.uk/files/pdf_pdf_45.pdf. 
269 Milstein B, Jones A, Homer JB, Murphy D, Essien J, Seville D. Charting 
Plausible Futures for Diabetes Prevalence in the United States: A Role 
for System Dynamics Simulation Modeling. Preventing chronic disease. 
2007;4(3):A52. 
270 The U.S. Department of Health and Human Services. Healthy People 
2020 Summary of Objectives, Nutrition and Weight Status. [last 
accessed February 2013]. Available from: 
http://www.healthypeople.gov/2020/topicsobjectives2020/pdfs/Nutritionan
dWeight.pdf   
271 National Center for Health Statistics. Healthy People 2000 Review, 1994. 
Hyattsville, Maryland: Public Health Service; 1995. [last accessed 
February 2013]. Available from: 
http://www.cdc.gov/nchs/data/hp2000/hp2k94.pdf. 
311 
 
272 Ogden CL, Carroll MD. Prevalence of Overweight, Obesity, and Extreme 
Obesity Among Adults: United States, Trends 1960–1962 Through 
2007–2008. Centers for Disease Control and Prevention, National Center 
for Health Statistics. [last accessed February 2013]. Available from: 
http://www.cdc.gov/nchs/data/hestat/obesity_adult_07_08/obesity_adult_
07_08.pdf. 
273 The U.S. Department of Health and Human Services. Healthy People 
2010 Summary of Objectives, Nutrition and Weight Status. [last 
accessed February 2013]. Available from: 
http://www.healthypeople.gov/2010/document/html/volume2/19Nutrition.h
tm. 
274 Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of Obesity in the 
United States, 2009–2010. NCHS Data Brief (No. 82); January 2012. 
[last accessed February 2013]. Available from: 
http://www.cdc.gov/nchs/data/databriefs/db82.pdf. 
275 World Health Organization. Targets to monitor progress in reducing the 
burden of noncommunicable diseases, Recommendations from a WHO 
Technical Working Group on Noncommunicable Disease Targets 
(version dated 15 July 2011 for a web-based consultation with Member 
States); 2011. [last accessed February 2013]. Available from: 
http://www.who.int/nmh/events/moscow_ncds_2011/twg_targets_to_mon
itor_progress_reducing_ncds.pdf. 
276 The U.S. Department of Health and Human Services. Healthy People 
2020 Summary of Objectives,Tobacco Use. [last accessed February 
2013]. Availabe from: 
http://www.healthypeople.gov/2020/topicsobjectives2020/pdfs/TobaccoU
se.pdf. 
277 Department of Health (DH), England. Healthy Lives, Healthy People: A 
Tobacco Control Plan for England. Published 9 March 2011. [last 
accessed January 2013]. Available at: 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/docume
nts/digitalasset/dh_124960.pdf. 
278 Australian Government; Department of Health and Ageing. National 
Tobacco Campaign – Targeting high-need and hard to reach groups 
(National Health and Hospitals Network - Fact Sheet). [last accessed 
January 2013]. Available from: 
http://www.yourhealth.gov.au/internet/yourhealth/publishing.nsf/Content/
726AA9322809A5C6CA2579540005F1EB/$File/HEALTH%20REFORM
%20FACT%20SHEET%20National%20Tobacco%20Campaign%20-
%20%20FINAL.pdf. 
279 Box GEP, Hunter WG, Hunter SJ. Statistics for Experimenters. New 
York: John Wiley & Sons Inc 1978. 
280 Guariguata L, Whiting D, Weil C, Unwin N. The International Diabetes 
Federation diabetes atlas methodology for estimating global and national 
312 
 
prevalence of diabetes in adults. Diabetes Research and Clinical 
Practice. 2011;94(3):322-32. 
281 International Diabetes Federation. IDF Diabetes Atlas 5th Edition 2012 
Update (poster update). [last accessed March 2013]. Available from: 
http://www.idf.org/sites/default/files/5E_IDFAtlasPoster_2012_EN.pdf. 
282 El-Hazmi MAF, Warsy AS, Al-Swailem AR, Al-Swailem AM, Sulaimani R. 
Diabetes mellitus as a health problem in Saudi Arabia. Eastern 
Mediterranean Health Journal. 1998;4(1):58-67. 
283 El-Hazmi MAF, Al-Swailem A, Warsy AS, Al-Sudairy F, Sulaimani R, Al-
Swailem A, et al. The prevalence of diabetes mellitus and impaired 
glucose tolerance in the population of Riyadh. Annals of Saudi Medicine. 
1995;15(6):598-601. 
284 United Nations; Department of Economic and Social Affairs. United 
Nations Demographic Yearbook 2009-2010. New York; 2011. [last 
accessed January 2013]. Available at: 
http://unstats.un.org/unsd/demographic/products/dyb/dybsets/2009-
2010.pdf. 
285 Åkerlund U, Knuth L, Randrup TB, Schipperijn J. Urban and peri-urban 
forestry and greening in west and Central Asia: Experiences, constraints 
and prospects. Food and Agriculture Organization of the United Nations, 
Livelihood Support Programme (LSP); 2006. [last accessed January 
2013]. Available from: 
ftp://ftp.fao.org/docrep/fao/009/ah238e/ah238e00.pdf. 
286 Allender S, Foster C, Hutchinson L, Arambepola C. Quantification of 
Urbanization in Relation to Chronic Diseases in Developing Countries: A 
Systematic Review. Journal of Urban Health. 2008;85(6):938-51. 
287 Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Yousef M, Sabico 
SL, et al. Diabetes mellitus type 2 and other chronic non-communicable 
diseases in the central region, Saudi Arabia (riyadh cohort 2): a decade 
of an epidemic. BMC medicine. 2011;9(1):76. 
288 World Health Organization; Regional Office for the Eastern 
Mediterranean. Regional strategy on nutrition 2010–2019 and Plan of 
action; 2011. [last accessed March 2013]. Available from: 
http://www.emro.who.int/dsaf/dsa1230.pdf. 
289 Mabry RM, Reeves MM, Eakin EG, Owen N. Evidence of physical 
activity participation among men and women in the countries of the Gulf 
Cooperation Council: a review. obesity reviews. 2009;11(6):457-64. 
290 Holford TR. Understanding the Effects of Age, Period, and Cohort on 
Incidence and Mortality Rates. Annual Review of Public Health. 
1991;12(1):425-57. 
291 von Ruesten A, Steffen A, Floegel A, Masala G, Tjønneland A, Halkjaer 
J, et al. Trend in obesity prevalence in European adult cohort populations 
313 
 
during follow-up since 1996 and their predictions to 2015. PLoS One. 
2011;6(11):e27455. 
292 Grinker JA, Tucker K, Vokonas PS, Rush D. Body habitus changes 
among adult males from the normative aging study: relations to aging, 
smoking history and alcohol intake. Obesity research. 1995;3(5):435-46. 
293 Korteweg R. The age curve in lung cancer. British Journal of Cancer. 
1951;5(1):21. 
294 Gregg EW, Gu Q, Cheng YJ, Narayan KMV, Cowie CC. Mortality trends 
in men and women with diabetes, 1971 to 2000. Annals of Internal 
Medicine. 2007;147(3):149-55. 
295 Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and 
mortality in Ontario, Canada 1995-2005: a population-based study. 
Lancet. 2007;369(9563):750-6. 
296 Preis SR, Hwang S-J, Coady S, Pencina MJ, D'Agostino Sr RB, Savage 
PJ, et al. Trends in all-cause and cardiovascular disease mortality among 
women and men with and without diabetes mellitus in the Framingham 
Heart Study, 1950 to 2005. Circulation. 2009;119(13):1728-35. 
297 Thomas RJ, Palumbo PJ, Melton Iii LJ, Roger VL, Ransom J, O'Brien 
PC, et al. Trends in the mortality burden associated with diabetes 
mellitus: a population-based study in Rochester, Minn, 1970-1994. 
Archives of internal medicine. 2003;163(4):445. 
298 Dale AC, Vatten LJ, Nilsen TI, Midthjell K, Wiseth R. Secular decline in 
mortality from coronary heart disease in adults with diabetes mellitus: 
cohort study. BMJ: British Medical Journal. 2008;337(7661):99. 
299 Tierney EF, Cadwell BL, Engelgau MM, Shireley L, Parsons SL, Moum 
K, et al. Declining mortality rate among people with diabetes in North 
Dakota, 1997–2002. Diabetes Care. 2004;27(11):2723-5. 
300 Westlund K. Incidence of Diabetes Mellitus in Oslo, Norway 1925 to 1954 
Report No. 11 of the Life Insurance Companies' Institute for Medical 
Statistics at the Oslo City Hospitals. British Journal of Preventive and 
Social Medicine. 1966;20(3):105-16. 
301 Franco M, Orduñez P, Caballero B, Granados JAT, Lazo M, Bernal JL, et 
al. Impact of energy intake, physical activity, and population-wide weight 
loss on cardiovascular disease and diabetes mortality in Cuba, 1980–
2005. American Journal of Epidemiology. 2007;166(12):1374-80. 
302 World Health Organization. 2008-2013 Action Plan for the Global 
Strategy for the Prevention and Control of Noncommunicable Diseases; 
2008. [last accessed January 2013]. Available from: 
http://whqlibdoc.who.int/publications/2009/9789241597418_eng.pdf. 
303 International Diabetes Federation. Middle East and North Africa (MENA) 
Regional Meeting: Supporting the Implementation of the United Nations 
314 
 
Resolution (UNR) on Diabetes (61/225) in Middle East and North Africa. 
Alexandria, Egypt; 18 April 2009. 
304 AlQuaiz AM, Tayel SA. Barriers to a healthy lifestyle among patients 
attending primary care clinics at a university hospital in Riyadh Annals of 
Saudi Medicine. 2009;29(1):30-6. 
305 Brandle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of 
insulin glargine compared with NPH insulin based on a 10-year 
simulation of long-term complications with the Diabetes Mellitus Model in 
patients with type 2 diabetes in Switzerland. International journal of 
clinical pharmacology and therapeutics. 2007;45(4):203-20. 
306 Cosgrove P, Engelgau M, Islam I. Cost-effectiveness approaches to 
diabetes care and prevention. Diabetes Voice. 2002;47(4):13-6. 
307 Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-Effectiveness 
of Interventions to Prevent and Control Diabetes Mellitus: A Systematic 
Review. Diabetes Care. 2010;33(8):1872-94. 
308 Caro JJ, Getsios D, Caro I, Klittich WS, O'Brien JA. Economic evaluation 
of therapeutic interventions to prevent type 2 diabetes in Canada. 
Diabetic medicine. 2004;21(11):1229-36. 
309 Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-
effectiveness of strategies for managing people at high risk for diabetes. 
Annals of Internal Medicine. 2005;143(4):251-64. 
310 Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. 
Intensive lifestyle changes or metformin in patients with impaired glucose 
tolerance: modeling the long-term health economic implications of the 
diabetes prevention program in Australia, France, Germany, Switzerland, 
and the United Kingdom. Clinical therapeutics. 2004;26(2):304-21. 
311 Alhowaish AK. Economic costs of diabetes in Saudi Arabia. Journal of 
Family and Community Medicine. 2013;20(1):1. 
312 World Health Organization. Global Strategy on Diet, Physical Activity and 
Health - Childhood overweight and obesity [last accessed January 2013]. 
Available from: http://www.who.int/dietphysicalactivity/childhood/en/. 
 
 
 
  
315 
 
Appendices 
Appendix 1. Search strategy results for studies on prevalence of type 2 
diabetes, obesity and active smoking in the GCC countries and Saudi 
Arabia 
Table. Search strategy - prevalence studies on type 2 diabetes in the GCC countries 
MEDLINE (Search Dates: 1950-week 45, 2011) 
Search history Results 
1. Diabetes mellitus.mp. or diabetes mellitus/ 237,483 
2. hypergly$.mp. 37,708 
3. 1 or 2 256,480 
4. Prevalence.mp. or prevalence/ 317,992 
5. Exp Kuwait/ or Kuwait.mp. 2,405 
6. Exp Qatar/ or Qatar.mp. 418 
7. Exp Bahrain/ or Bahrain.mp. 473 
8. Exp United Arab Emirates/ or United Arab Emirates.mp. 1,126 
9. UAE.mp. 1,440 
10. Exp Oman/ or Oman.mp. 951 
11. 5 or 6 or 7 or 8 or 9 or 10 6,131 
12. 3 and 4 and 11 184 
13. After title review, keep 26 
14. After abstract/article review, keep 5 
      plus 2 studies through cross referencing  
Table. Search strategy - prevalence studies on obesity in the GCC countries 
MEDLINE (Search Dates: 1950-week 45, 2011) 
Search history Results 
1. obesity.mp. or obesity/ 132,344 
2. fatness.mp. 2,443 
3. Overweight.mp. or overweight/ 23,447 
4. Body weight.mp. or body weight/ 228,976 
5. Central obesity.mp. 1,794 
6. Abdominal obesity.mp. or abdominal obesity/ 2,460 
7. Body mass index.mp. or body mass index/ 89,092 
8. BMI.mp. 42,669 
9. Waist circumference.mp. or waist circumference/ 7,056 
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 398,049 
11. Prevalence.mp. or prevalence/ 317,537 
12. Exp Kuwait/ or Kuwait.mp. 2,404 
13. Exp Qatar/ or Qatar.mp. 418 
14. Exp Bahrain/ or Bahrain.mp. 473 
15. Exp United Arab Emirates/ or United Arab Emirates.mp. 1,122 
16. UAE.mp. 1,438 
17. Exp Oman/ or Oman.mp. 951 
18. 12 or 13 or 14 or 15 or 16 or 17 6,125 
19. 10 and 11 and 18 170 
20. After title review, keep 34 
21. After abstract/article review, keep 5 
     plus 2 studies through cross referencing  
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Table. Search strategy - prevalence studies on active smoking in the GCC countries 
MEDLINE (Search Dates: 1950-week 45, 2011) 
Search history Results 
1. smoking.mp. or smoking/ 157,746 
2. cigarette.mp. 33,117 
3. cigarette smoking.mp. 19,692 
4. tobacco.mp. or tobacco/ 68,156 
5. tobacco smoking.mp. 4,260 
6. active smoking.mp. 660 
7. 1 or 2 or 3 or 4 or 5 or 6  195,114 
8. Prevalence.mp. or prevalence/ 317,992 
9. Exp Kuwait/ or Kuwait.mp. 2,405 
10. Exp Qatar/ or Qatar.mp. 418 
11. Exp Bahrain/ or Bahrain.mp. 473 
12. Exp United Arab Emirates/ or United Arab Emirates.mp. 1,126 
13. UAE.mp. 1,440 
14. Exp Oman/ or Oman.mp. 951 
15. 9 or 10 or 11 or 12 or 13 or 14 6,131 
16. 7 and 8 and 15 83 
17. After title review, keep 29 
18. After abstract/article review, keep 3 
Table. Search strategy - prevalence studies on type 2 diabetes in Saudi Arabia 
MEDLINE (Search Dates: 1950-week 36, 2011) 
Search history Results 
1. Diabetes mellitus.mp. or diabetes mellitus/ 236,149 
2. hypergly$.mp. 37,428 
3. 1 or 2 255,008 
4. Prevalence.mp. or prevalence/ 289,714 
5. Exp Saudi Arabia/ or Saudi Arabia.mp. 7,254 
6. 3 and 4 and 5 98 
7. After title review, keep 13 
8. After abstract/article review, keep 4 
   plus 1 study obtained from the Saudi MOH   
Table. Search strategy - prevalence studies on obesity in Saudi Arabia 
MEDLINE (Search Dates: 1950-week 36, 2011) 
Search history Results 
1. obesity.mp. or obesity/ 131,492 
2. fatness.mp. 2,438 
3. Overweight.mp. or overweight/ 23,275 
4. Body weight.mp. or body weight/ 227,238 
5. Central obesity.mp. or central obesity/ 1,775 
6. Abdominal obesity.mp. or abdominal obesity/ 2,437 
7. Body mass index.mp. or body mass index/ 88,440 
8. BMI.mp. 42,332 
9. Waist circumference.mp. or waist circumference/ 6,977 
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 395,143 
11. Prevalence.mp. or prevalence/ 314,928 
12. Exp Saudi Arabia/ or Saudi Arabia.mp. 7,254 
13. 10 and 11 and 12 141 
14. After title review, keep 22 
15. After abstract/article review, keep 4 
     plus 1 study obtained from the Saudi MOH  
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Table. Search strategy - prevalence studies on active smoking in Saudi Arabia 
MEDLINE (Search Dates: 1950-week 36, 2011) 
Search history Results 
1. smoking.mp. or smoking/ 156,258 
2. cigarette.mp. 32,670 
3. cigarette smoking.mp. 19,459 
4. tobacco.mp. or tobacco/ 65,437 
5. tobacco smoking.mp. 4,196 
6. active smoking.mp. 646 
7. 1 or 2 or 3 or 4 or 5 or 6  191,248 
8. Prevalence.mp. or prevalence/ 314,928 
9. Exp Saudi Arabia/ or Saudi Arabia.mp. 7,254 
10. 7 and 8 and 9 97 
11. After title review, keep 10 
12. After abstract/article review, keep 2 
     plus 1 study obtained from the Saudi MOH  
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Appendix 2. Papers submitted to scientific journals 
 Title of the submitted paper Journal 
1 Comparison of diabetes prevalence estimates in 
Saudi Arabia from a validated Markov model 
against the International Diabetes Federation 
Diabetes Atlas and other modelling studies 
Diabetes Research and 
Clinical Practice 
   
2 Trends and future projections of diabetes 
prevalence in Saudi Arabia during 1992 – 2022 
using a validated epidemiological Markov model 
Bulletin of the World 
Health Organisation 
   
3 Obesity and type 2 diabetes: a complex 
association 
Journal of Family and 
Community Medicine 
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